DCTPep_ID,Cell_Line,Disease,Cancer_Classified,Assay,Activity,Testing_Time,Literature
DCTPep00001,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30 µM,2 days,2
DCTPep00002,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=15.8 µM,72 h,2
DCTPep00002,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=15.8 µM,72 h,2
DCTPep00002,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=16.1 µM,72 h,2
DCTPep00002,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=30 µM,3 days,1
DCTPep00002,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=44 µM,3 days,1
DCTPep00002,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=60 µM,3 days,1
DCTPep00002,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=65 µM,3 days,1
DCTPep00003,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=75 µM,3 days,1
DCTPep00003,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,3 days,1
DCTPep00003,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50>100 µM,3 days,1
DCTPep00003,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,3 days,1
DCTPep00004,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=100 µM,3 days,1
DCTPep00004,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=100 µM,3 days,1
DCTPep00004,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=65 µM,3 days,1
DCTPep00004,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=85.3 µM,3 days,1
DCTPep00005,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=20 µM,3 days,1
DCTPep00005,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=25 µM,3 days,1
DCTPep00005,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=28 µM,3 days,1
DCTPep00005,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=35.1 µM,3 days,1
DCTPep00006,Brain tumor cell (NCI),Brain tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Breast tumor cell (NCI),Breast tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Lung tumor cell (NCI),Lung tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Ovary tumor cell (NCI),Ovary tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Prostate tumor cell (NCI),Prostate tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Renal tumor cell (NCI),Renal tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Skin tumor cell (NCI),Skin tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00006,Colon tumor cell (NCI),Colon tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00006,Leukemia tumor cell (NCI),Leukemia tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00007,Brain tumor cell (NCI),Brain tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Breast tumor cell (NCI),Breast tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Colon tumor cell (NCI),Colon tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Lung tumor cell (NCI),Lung tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Ovary tumor cell (NCI),Ovary tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Prostate tumor cell (NCI),Prostate tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Renal tumor cell (NCI),Renal tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Skin tumor cell (NCI),Skin tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00007,Leukemia tumor cell (NCI),Leukemia tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00008,Colon tumor cell (NCI),Colon tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00008,Leukemia tumor cell (NCI),Leukemia tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00008,Lung tumor cell (NCI),Lung tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00008,Prostate tumor cell (NCI),Prostate tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00008,Brain tumor cell (NCI),Brain tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00008,Breast tumor cell (NCI),Breast tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00008,Ovary tumor cell (NCI),Ovary tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00008,Renal tumor cell (NCI),Renal tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00008,Skin tumor cell (NCI),Skin tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00009,Brain tumor cell (NCI),Brain tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Breast tumor cell (NCI),Breast tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Leukemia tumor cell (NCI),Leukemia tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Lung tumor cell (NCI),Lung tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Ovary tumor cell (NCI),Ovary tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Prostate tumor cell (NCI),Prostate tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Renal tumor cell (NCI),Renal tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Skin tumor cell (NCI),Skin tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00009,Colon tumor cell (NCI),Colon tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00010,Brain tumor cell (NCI),Brain tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Breast tumor cell (NCI),Breast tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Colon tumor cell (NCI),Colon tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Lung tumor cell (NCI),Lung tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Ovary tumor cell (NCI),Ovary tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Prostate tumor cell (NCI),Prostate tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Renal tumor cell (NCI),Renal tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Skin tumor cell (NCI),Skin tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00010,Leukemia tumor cell (NCI),Leukemia tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00011,Brain tumor cell (NCI),Brain tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Breast tumor cell (NCI),Breast tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Lung tumor cell (NCI),Lung tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Ovary tumor cell (NCI),Ovary tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Prostate tumor cell (NCI),Prostate tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Renal tumor cell (NCI),Renal tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Skin tumor cell (NCI),Skin tumor,Carcinoma,Not available,LC50=10 µM,Not available,1
DCTPep00011,Colon tumor cell (NCI),Colon tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00011,Leukemia tumor cell (NCI),Leukemia tumor,Carcinoma,Not available,LC50=10-100 µM,Not available,1
DCTPep00012,Jurkat E6.1,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16 µM,3 days,1
DCTPep00012,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=22 µM,3 days,1
DCTPep00012,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL14 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=28 µM,3 days,1
DCTPep00013,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL15 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,26% Killing=30 µM,15 h,1
DCTPep00014,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL16 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,12% Killing=30 µM,15 h,1
DCTPep00015,C8166,Adult T acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15.3 µg/ml,48 h,1
DCTPep00015,BIU-87,Bladder carcinoma,Carcinoma,MTT assay,IC50=20.5 µg/ml,48 h,1
DCTPep00015,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=24.3 µg/ml,48 h,1
DCTPep00015,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50=35.4 µg/ml,48 h,1
DCTPep00016,C8166,Adult T acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11.4 µg/ml,48 h,1
DCTPep00016,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50=18 µg/ml,48 h,1
DCTPep00016,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=25.2 µg/ml,48 h,1
DCTPep00016,BIU-87,Bladder carcinoma,Carcinoma,MTT assay,IC50=28 µg/ml,48 h,1
DCTPep00017,C8166,Adult T acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=24.2 µg/ml,48 h,1
DCTPep00017,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=35.4 µg/ml,48 h,1
DCTPep00017,BIU-87,Bladder carcinoma,Carcinoma,MTT assay,IC50>50 µg/ml,48 h,1
DCTPep00017,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>50 µg/ml,48 h,1
DCTPep00018,C8166,Adult T acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=34.4 µg/ml,48 h,1
DCTPep00018,BIU-87,Bladder carcinoma,Carcinoma,MTT assay,IC50>50 µg/ml,48 h,1
DCTPep00018,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>50 µg/ml,48 h,1
DCTPep00018,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>50 µg/ml,48 h,1
DCTPep00019,A549,Lung adenocarcinoma,Carcinoma,MTT assay,33.2% Cytotoxicity=200 µg/ml,20h,1
DCTPep00019,ME-180,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,33.2% Cytotoxicity=200 µg/ml,20h,1
DCTPep00020,ME-180,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,100% Cytotoxicity=200 µg/ml,20h,1
DCTPep00020,A549,Lung adenocarcinoma,Carcinoma,MTT assay,99.7% Cytotoxicity=200 µg/ml,20h,1
DCTPep00021,A549,Lung adenocarcinoma,Carcinoma,MTT assay,81.5% Cytotoxicity=200 µg/ml,20h,1
DCTPep00021,ME-180,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,81.5% Cytotoxicity=200 µg/ml,20h,1
DCTPep00022,"RCCs (A-498, Caki-2, 786-0, 769-P, ACHN, LE 9211-RCC, TW33, N43)",Renal Cell Carcinoma,Carcinoma,WST-1 assay ,"At higher concentrations than 25 μg/ml, HNPs-1, -2, and -3 exerted cytotoxic effects on all tested RCC lines in an in vitro serum-free culture system (at lower concentrations they stimulated cell grow",40 h,1
DCTPep00023,"RCCs (A-498, Caki-2, 786-0, 769-P, ACHN, LE 9211-RCC, TW33, N43)",Renal Cell Carcinoma,Carcinoma,WST-1 assay ,"At higher concentrations than 25 μg/ml, HNPs-1, -2, and -3 exerted cytotoxic effects on all tested RCC lines in an in vitro serum-free culture system (at lower concentrations they stimulated cell grow",40 h,1
DCTPep00024,"RCCs (A-498, Caki-2, 786-0, 769-P, ACHN, LE 9211-RCC, TW33, N43)",Renal Cell Carcinoma,Carcinoma,WST-1 assay ,"At higher concentrations than 25 μg/ml, HNPs-1, -2, and -3 exerted cytotoxic effects on all tested RCC lines in an in vitro serum-free culture system (at lower concentrations they stimulated cell grow",40 h,1
DCTPep00026,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.5 µM,3 days,1
DCTPep00026,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=4 µM,3 days,1
DCTPep00026,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=8 µM,3 days,1
DCTPep00027,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3 µM,3 days,1
DCTPep00027,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=3 µM,3 days,1
DCTPep00027,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9 µM,3 days,1
DCTPep00028,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3 µM,3 days,1
DCTPep00028,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=4 µM,3 days,1
DCTPep00028,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=7 µM,3 days,1
DCTPep00029,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12 µM,3 days,1
DCTPep00029,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=6 µM,3 days,1
DCTPep00029,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=9.5 µM,3 days,1
DCTPep00030,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11 µM,3 days,1
DCTPep00030,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=11 µM,3 days,1
DCTPep00030,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7 µM,3 days,1
DCTPep00031,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=11 µM,3 days,1
DCTPep00031,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=17 µM,3 days,1
DCTPep00031,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=17 µM,3 days,1
DCTPep00032,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=23 µM,3 days,1
DCTPep00032,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=24 µM,3 days,1
DCTPep00032,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=32 µM,3 days,1
DCTPep00033,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00033,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00033,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00034,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=4 µM,3 days,1
DCTPep00034,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=4.2 µM,3 days,1
DCTPep00034,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=5 µM,3 days,1
DCTPep00035,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3 µM,3 days,1
DCTPep00035,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=5 µM,3 days,1
DCTPep00035,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=6 µM,3 days,1
DCTPep00036,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=10 µM,3 days,1
DCTPep00036,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=14 µM,3 days,1
DCTPep00036,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=17 µM,3 days,1
DCTPep00037,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=26 µM,3 days,1
DCTPep00037,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=31 µM,3 days,1
DCTPep00037,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=32 µM,3 days,1
DCTPep00038,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=23 µM,3 days,1
DCTPep00038,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=26 µM,3 days,1
DCTPep00038,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=38 µM,3 days,1
DCTPep00039,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=62 µM,3 days,1
DCTPep00039,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=74 µM,3 days,1
DCTPep00039,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=79 µM,3 days,1
DCTPep00040,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=25 µM,3 days,1
DCTPep00040,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=31 µM,3 days,1
DCTPep00040,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=54 µM,3 days,1
DCTPep00041,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=100 µM,3 days,1
DCTPep00041,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=67 µM,3 days,1
DCTPep00041,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=81 µM,3 days,1
DCTPep00042,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=21 µM,3 days,1
DCTPep00042,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=27 µM,3 days,1
DCTPep00042,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=47 µM,3 days,1
DCTPep00043,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00043,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00043,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00044,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=30 µM,3 days,1
DCTPep00044,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=54 µM,3 days,1
DCTPep00044,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=83 µM,3 days,1
DCTPep00045,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00045,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00045,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00046,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00046,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00046,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=100.0< µM,3 days,1
DCTPep00047,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=1.8 µM,72h,1
DCTPep00047,ACHN,Papillary renal cell carcinoma,Carcinoma,FMCA assay,IC50=3.2 µM,72h,1
DCTPep00048,Hut-78,Sezary syndrome ,Lymphoma,Trypan blue assay,100% Killing=10 µM,Not available,1
DCTPep00048,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,20% Killing=10 µM,Not available,1
DCTPep00048,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL9 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,60% Killing=10 µM,Not available,1
DCTPep00049,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,no cytotoxic effects up to 23 μM,24h,1
DCTPep00050,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,no cytotoxic effects up to 23 μM,24h,1
DCTPep00051,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Not available,lower doses of cancer cells could be eliminated after administration of 25 μg of alloferon,Not available,1
DCTPep00052,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Not available,lower doses of cancer cells could be eliminated after administration of 25 μg of alloferon,Not available,1
DCTPep00053,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>404 µM,4 h,1
DCTPep00053,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50>404 µM,4 h,1
DCTPep00053,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50>404 µM,4 h,1
DCTPep00054,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=144 µM,4 h,1
DCTPep00054,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50>254 µM,4 h,1
DCTPep00054,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>440 µM,4 h,1
DCTPep00055,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=141 µM,4 h,1
DCTPep00055,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=18 µM,4 h,1
DCTPep00055,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=32 µM,4 h,1
DCTPep00056,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=16 µM,4 h,1
DCTPep00056,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=31 µM,4 h,1
DCTPep00056,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=57 µM,4 h,1
DCTPep00057,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=14 µM,4 h,1
DCTPep00057,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3 ± 1 μM(pH=7.4); IC50=4 ± 1 μM(pH=5.5),2 h,2
DCTPep00057,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=6.6 µM,4 h,1
DCTPep00057,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=8 µM,4 h,1
DCTPep00058,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=11 µM,4 h,1
DCTPep00058,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=12 µM,4 h,1
DCTPep00058,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=15 µM,4 h,1
DCTPep00059,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=11 µM,4 h,1
DCTPep00059,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=16 µM,4 h,1
DCTPep00059,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=16 µM,4 h,1
DCTPep00060,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=110 µM,4 h,1
DCTPep00060,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=180 µM,4 h,1
DCTPep00060,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=87 µM,4 h,1
DCTPep00061,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=32 µM,4 h,1
DCTPep00061,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=35 µM,4 h,1
DCTPep00061,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=52 µM,4 h,1
DCTPep00062,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=20 µM,4 h,1
DCTPep00062,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=24 µM,4 h,1
DCTPep00062,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35 µM,4 h,1
DCTPep00063,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=116 µM,4 h,1
DCTPep00063,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=248 µM,4 h,1
DCTPep00063,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=75 µM,4 h,1
DCTPep00064,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=10 µM,4 h,1
DCTPep00064,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=25 µM,4 h,1
DCTPep00064,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=7.9 µM,4 h,1
DCTPep00065,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=12 µM,4 h,1
DCTPep00065,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=14 µM,4 h,1
DCTPep00065,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=29 µM,4 h,1
DCTPep00066,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=125 µM,4 h,1
DCTPep00066,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=141 µM,4 h,1
DCTPep00066,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=423 µM,4 h,1
DCTPep00067,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=178 µM,4 h,1
DCTPep00067,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,IC50=87 µM,4 h,1
DCTPep00067,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=92 µM,4 h,1
DCTPep00068,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,30-40% viablity=100 µM ,24 h,1
DCTPep00069,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,80-90% viablity=100 µM ,24 h,1
DCTPep00070,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,55-65% viablity=100 µM ,24 h,1
DCTPep00071,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=16.1±0.4 μM,"2, 24 h",4
DCTPep00071,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50=17.9±0.7 μM,"2, 24 h",4
DCTPep00071,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=9.5±0.2 μM,"2, 24 h",4
DCTPep00071,CLL (Primary Human Cells),Chronic lymphocytic leukemia,leukemia,FMCA assay,IC50=1.34  µM,72h,1
DCTPep00071,OVCA (Primary Human Cells),Ovarian carcinoma,Carcinoma,FMCA assay,IC50=11.03  µM,72h,1
DCTPep00071,RPMI-8226/Dox40,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=2.73 µM,72h,1
DCTPep00071,RPMI-8226/LR-5,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=3.19 µM,72h,1
DCTPep00071,RPMI-8226/s ,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=3.24 µM,72h,1
DCTPep00071,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,FMCA assay,IC50=3.56 µM,72h,1
DCTPep00071,U251,Astrocytoma,Carcinoma,SRB assay,IC50=37.18 µg/ml,48h,2
DCTPep00071,ACHN ,Papillary renal cell carcinoma; Papillary renal cell carcinoma,Carcinoma,FMCA assay,IC50=4.19 µM,72h,1
DCTPep00071,U-937/Vcr,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=4.84 µM,72h,1
DCTPep00071,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,FMCA assay,IC50=4.88 µM,72h,1
DCTPep00071,NCI-H69AR,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,FMCA assay,IC50=4.89 µM,72h,1
DCTPep00071,CCRF-CEM/VM-1,Not available,Not available,FMCA assay,IC50=4.97 µM,72h,1
DCTPep00071,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=6.35 µM,72h,1
DCTPep00071,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00071,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00071,DU145,Prostate carcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00071,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00072,ACHN ,Papillary renal cell carcinoma; Papillary renal cell carcinoma,Carcinoma,FMCA assay,IC50=2.63 µM,72h,1
DCTPep00072,RPMI-8226/Dox40,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=3.14 µM,72h,1
DCTPep00072,U251,Astrocytoma,Carcinoma,SRB assay,IC50=44.49 µg/ml,48h,2
DCTPep00072,RPMI-8226/s ,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=5.90 µM,72h,1
DCTPep00072,RPMI-8226/LR-5,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=6.31 µM,72h,1
DCTPep00072,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=7.07 µM,72h,1
DCTPep00072,NCI-H69AR,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,FMCA assay,IC50=7.12 µM,72h,1
DCTPep00072,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,FMCA assay,IC50=7.13 µM,72h,1
DCTPep00072,CCRF-CEM/VM-1,Not available,Not available,FMCA assay,IC50=7.15 µM,72h,1
DCTPep00072,U-937/Vcr,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=7.45 µM,72h,1
DCTPep00072,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,FMCA assay,IC50=7.49 µM,72h,1
DCTPep00072,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00072,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00072,DU145,Prostate carcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00072,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,2
DCTPep00073,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=0.64±0.02 µM ,24h,4
DCTPep00073,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=0.82±0.20 µM ,24h,4
DCTPep00073,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=1.77±0.10 µM ,24h,4
DCTPep00073,CLL (Primary Human Cells),Chronic lymphocytic leukemia,leukemia,FMCA assay,IC50=0.1 µM,72h,1
DCTPep00073,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,FMCA assay,IC50=0.11 µM,72h,1
DCTPep00073,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,FMCA assay,IC50=0.12 µM,72h,1
DCTPep00073,RPMI-8226/Dox40,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=0.12 µM,72h,1
DCTPep00073,RPMI-8226/LR-5,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=0.12 µM,72h,1
DCTPep00073,RPMI-8226/s ,Plasma cell myeloma; Multiple myeloma,Carcinoma,FMCA assay,IC50=0.12 µM,72h,1
DCTPep00073,CCRF-CEM/VM-1,Not available,Not available,FMCA assay,IC50=0.14 µM,72h,1
DCTPep00073,U-937/Vcr,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=0.20 µM,72h,1
DCTPep00073,ACHN ,Papillary renal cell carcinoma; Papillary renal cell carcinoma,Carcinoma,FMCA assay,IC50=0.22 µM,72h,1
DCTPep00073,NCI-H69AR,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,FMCA assay,IC50=0.26 µM,72h,1
DCTPep00073,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=0.26 µM,72h,1
DCTPep00073,OVCA (Primary Human Cells),Ovarian carcinoma,Carcinoma,FMCA assay,IC50=1.32  µM,72h,1
DCTPep00073,U251,Astrocytoma,Carcinoma,SRB assay,IC50=17.05 µg/ml,48h,2
DCTPep00073,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=4.81 µg/ml,48h,2
DCTPep00073,DU145,Prostate carcinoma,Carcinoma,SRB assay,IC50=5.08 µg/ml,48h,2
DCTPep00073,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=5.99 µg/ml,48h,2
DCTPep00073,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=6.07 µg/ml,48h,2
DCTPep00074,U251,Astrocytoma,Carcinoma,SRB assay,IC50=44.70 µg/ml,48h,1
DCTPep00074,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00074,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00074,DU145,Prostate carcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00074,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00075,U251,Astrocytoma,Carcinoma,SRB assay,IC50=46.62 µg/ml,48h,1
DCTPep00075,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00075,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00075,DU145,Prostate carcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00075,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00076,U251,Astrocytoma,Carcinoma,SRB assay,IC50=38.84 µg/ml,48h,1
DCTPep00076,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00076,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00076,DU145,Prostate carcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00076,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48h,1
DCTPep00077,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,60% Cytotoxicity at 0.5 µg/ml,6 h,2
DCTPep00077,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00077,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00077,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00078,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00078,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00079,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00079,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=28 ± 1 μM(pH=7.4); IC50=25 ± 2 μM(pH=5.5),2 h,2
DCTPep00079,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50>1 μM,Not available,1
DCTPep00080,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00080,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00080,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50>100 μM,Not available,1
DCTPep00081,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00081,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00081,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00082,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00082,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00083,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00083,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00084,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00084,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00085,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00085,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00086,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00086,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00087,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00087,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00088,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50>10 μM,Not available,1
DCTPep00089,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00089,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=1 μM,Not available,1
DCTPep00089,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00089,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00089,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00089,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50=10 μM,Not available,1
DCTPep00089,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00089,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00089,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00090,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50>10 μM,Not available,1
DCTPep00090,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50>10 μM,Not available,1
DCTPep00091,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00091,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50>10 μM,Not available,1
DCTPep00092,CNS cancer group (NCI),CNS Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00092,Lung cancer group (NCI),Lung Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00092,Melanoma cancer group (NCI),Melanoma cancer group (NCI),Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00092,Prostate cancer group (NCI),Prostate Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00092,Renal cancer group (NCI),Renal Carcinoma,Carcinoma,Not available,IC50=10 μM,Not available,1
DCTPep00092,Breast cancer group (NCI),Breast Carcinoma,Carcinoma,Not available,IC50>10 μM,Not available,1
DCTPep00092,Colon cancer group (NCI),Colon Carcinoma,Carcinoma,Not available,IC50>10 μM,Not available,1
DCTPep00092,Leukemia group (NCI),Leukemia,Leukemia,Not available,IC50>10 μM,Not available,1
DCTPep00092,Ovarian cancer group (NCI),Ovarian Carcinoma,Carcinoma,Not available,IC50>10 μM,Not available,1
DCTPep00093,B16-F10,Mouse melanoma,Carcinoma,XTT assay,LC50=100 µM,24h,1
DCTPep00093,D122,Malignant tumors of the mouse pulmonary system,Carcinoma,XTT assay,LC50>50 µM,24h,1
DCTPep00094,B16-F10,Mouse melanoma,Carcinoma,XTT assay,LC50=2.5 µM,24h,1
DCTPep00094,D122,Malignant tumors of the mouse pulmonary system,Carcinoma,XTT assay,LC50=4.5 µM,24h,1
DCTPep00095,EL4 T-lymphoma,T-cell lymphoma,Lymphoma,Trypan blue assay,LC50=14 μM,1 h,1
DCTPep00096,NCI-H735,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=10.4 µM,24 h,1
DCTPep00096,NCI-H526,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=11.7 µM,24 h,1
DCTPep00096,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,IC50=16 µg/ml,72 h,3
DCTPep00096,RPMI-8402,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,leukemia,Trypan blue assay,IC50=18 µg/ml,72 h,3
DCTPep00096,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=20 µg/ml,72 h,3
DCTPep00096,SSKT-1,Leukemia,Leukemia,Trypan blue assay,IC50=23 µg/ml,72 h,3
DCTPep00096,Daudi,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=30 µg/ml,72 h,3
DCTPep00096,MLA,Leukemia,Leukemia,Trypan blue assay,IC50=34 µg/ml,72 h,3
DCTPep00096,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,IC50=40 µg/ml,72 h,3
DCTPep00096,CHP-100,Ewing sarcoma,Sarcoma,Trypan blue assay,IC50=45 µg/ml,72 h,3
DCTPep00096,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Trypan blue assay,IC50=49 µg/ml,72 h,3
DCTPep00096,PC-3,Prostate carcinoma,Carcinoma,Trypan blue assay,IC50=53 µg/ml,72 h,3
DCTPep00096,NCI-H678,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=6.23 µM,24 h,1
DCTPep00096,NCI-H889,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=6.56 µM,24 h,1
DCTPep00096,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=7.28 µM,24 h,1
DCTPep00096,NCI-H841,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=9.7 µM,24 h,1
DCTPep00097,NCI-H526,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=10.5 µM,24 h,1
DCTPep00097,NCI-H841,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=11.7 µM,24 h,1
DCTPep00097,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=12.5 µM,24 h,1
DCTPep00097,RPMI-8402,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,leukemia,Trypan blue assay,IC50=16 µg/ml,72 h,3
DCTPep00097,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,IC50=19 µg/ml,72 h,3
DCTPep00097,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=25 µg/ml,72 h,3
DCTPep00097,SSKT-1,Leukemia,Leukemia,Trypan blue assay,IC50=29 µg/ml,72 h,3
DCTPep00097,MLA,Leukemia,Leukemia,Trypan blue assay,IC50=33 µg/ml,72 h,3
DCTPep00097,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,IC50=37 µg/ml,72 h,3
DCTPep00097,Daudi,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=38 µg/ml,72 h,3
DCTPep00097,CHP-100,Ewing sarcoma,Sarcoma,Trypan blue assay,IC50=39 µg/ml,72 h,3
DCTPep00097,NCI-H678,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=4.44 µM,24 h,1
DCTPep00097,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Trypan blue assay,IC50=42 µg/ml,72 h,3
DCTPep00097,PC-3,Prostate carcinoma,Carcinoma,Trypan blue assay,IC50=47 µg/ml,72 h,3
DCTPep00097,NCI-H889,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=6.57 µM,24 h,1
DCTPep00097,NCI-H735,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=7.23 µM,24 h,1
DCTPep00098,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.88±0.53 µg/ml,96 h,1
DCTPep00098,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50=4.91±0.80 µg/ml,96 h,1
DCTPep00098,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=5.75±1.17 µg/ml,96 h,1
DCTPep00098,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=6.49 ± 1.39 µg/ml,96 h,1
DCTPep00099,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00099,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00099,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00099,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00100,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00100,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00100,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00100,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 µg/ml,96 h,1
DCTPep00101,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=13.71 ± 2.12 µg/ml,96 h,1
DCTPep00101,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=18.10 ± 2.13 µg/ml,96 h,1
DCTPep00101,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50=18.18 ± 3.31 µg/ml,96 h,1
DCTPep00101,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=18.63 ± 0.99 µg/ml,96 h,1
DCTPep00102,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.43±0.15 µg/ml,96 h,1
DCTPep00102,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9.09 ± 3.95 µg/ml,96 h,1
DCTPep00103,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=13.27 ± 4.27 µg/ml,96 h,1
DCTPep00103,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=13.94 ± 3.96 µg/ml,96 h,1
DCTPep00103,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50=15.07 ± 1.59 µg/ml,96 h,1
DCTPep00103,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=17.56 ± 6.23 µg/ml,96 h,1
DCTPep00104,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=11 μM ,2 h,2
DCTPep00104,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=5.01±0.42 µg/ml,96 h,1
DCTPep00104,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.25±0.63 µg/ml,96 h,1
DCTPep00104,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50=5.40 ± 0.91 µg/ml,96 h,1
DCTPep00104,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=8.01 ± 1.32 µg/ml,96 h,1
DCTPep00105,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=24.58 ± 3.24 µg/ml,96 h,1
DCTPep00105,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=28.90 ± 5.19 µg/ml,96 h,1
DCTPep00105,Hep 3B,Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma ,Carcinoma,MTT assay,IC50=30.79 ± 3.11 µg/ml,96 h,1
DCTPep00105,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=32.23 ± 9.12 µg/ml,96 h,1
DCTPep00106,HepG2,Hepatoblastoma,Blastoma,MTT assay,37±4% Reduction in viability=50.0 µM,72h,1
DCTPep00106,L1210,Mouse leukemia,Leukemia,MTT assay,40±3% Reduction in viability=50.0 µM,72h,1
DCTPep00106,M1,Mouse myeloid leukemia ,Leukemia,MTT assay,49±3% Reduction in viability=50.0 µM,72h,1
DCTPep00107,N202.A2,Spontaneous tumor in A2×neu mice, -- ,Not available,"Animals immunized three times with DC pulsed with p369–377 or p773–782 peptide showed ~25–30% tumor growth inhibition, while two immunizations induced ~12–15% tumor growth inhibition and one injection",Not available,1
DCTPep00108,N202.A2,Spontaneous tumor in A2×neu mice, -- ,Not available,"Animals immunized three times with DC pulsed with p369–377 or p773–782 peptide showed ~25–30% tumor growth inhibition, while two immunizations induced ~12–15% tumor growth inhibition and one injection",Not available,1
DCTPep00109,L1210,Mouse leukemia,Leukemia,MTT assay,IC50=0.1 µM,48h,1
DCTPep00109,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=0.2 µM,48h,1
DCTPep00110,SAS-H1,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,Trypan blue assay,88 ± 7.2% cytotoxicity=40 mg/ml,24-96 h,1
DCTPep00111,3LL,Lewis lung carcinoma,Carcinoma,Syngeneic tumor models,The 50 mg/kg dose in the 3LL model significantly inhibited tumor growth by 48%,Not available,1
DCTPep00111,B16-F1,Mouse melanoma,Carcinoma,Syngeneic tumor models,The 50 mg/kg dose in the 3LL model significantly inhibited tumor growth by 48%,Not available,1
DCTPep00112,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=45 µM,1 h,1
DCTPep00113,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=5660 µM,1 h,1
DCTPep00114,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=42 µM,1 h,1
DCTPep00115,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=88 µM,1 h,1
DCTPep00116,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=140 µM,1 h,1
DCTPep00117,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=45 µM,1 h,1
DCTPep00118,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,IC50=85 µM,1 h,1
DCTPep00119,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTS assay,IC50=135±10 µmol/L,72 h,1
DCTPep00119,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=136±16  µmol/L,72 h,1
DCTPep00119,3LL,Malignant tumors of the mouse pulmonary system,Carcinoma,MTT assay,IC50=143±4 µmol/L,72 h,2
DCTPep00119,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=171±12 µmol/L,72 h,2
DCTPep00119,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTS assay,IC50=182±6  µmol/L,72 h,1
DCTPep00119,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTS assay,IC50=20±3 µmol/L,72 h,1
DCTPep00119,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=201±16 µmol/L,72 h,2
DCTPep00119,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=30±3 µmol/L,72 h,2
DCTPep00119,NCI-H125,Lung adenosquamous carcinoma,Carcinoma,MTS assay,IC50=36±9  µmol/L,72 h,1
DCTPep00119,TC-1,Human renal cell carcinoma,Carcinoma,MTS assay,IC50=71±15  µmol/L,72 h,1
DCTPep00119,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTS assay,IC50=89±3  µmol/L,72 h,1
DCTPep00120,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,FITC fluorophore assay,"rendered all the tested cancer cell lines sensitive to doses of cisplatin, adriamycin, and mitoxantrone ",20 h,1
DCTPep00120,H-Meso-1 ,Human malignant mesothelomia,Carcinoma,FITC fluorophore assay,"rendered all the tested cancer cell lines sensitive to doses of cisplatin, adriamycin, and mitoxantrone ",20 h,1
DCTPep00120,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,FITC fluorophore assay,"rendered all the tested cancer cell lines sensitive to doses of cisplatin, adriamycin, and mitoxantrone ",20 h,1
DCTPep00120,U2OS,Human osteosarcoma,Sarcoma,FITC fluorophore assay,"rendered all the tested cancer cell lines sensitive to doses of cisplatin, adriamycin, and mitoxantrone ",20 h,1
DCTPep00121,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=30 µM,72 h,1
DCTPep00121,L1210,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=40 µM,72 h,1
DCTPep00122,HepG2,Hepatoblastoma,Blastoma,Radioactive precursor assay,Not active up to 110 µM,48 h,1
DCTPep00123,PC-3,Prostate carcinoma,Carcinoma,MTT assay,30% Cell viability at 5 µg/ml,48 h,1
DCTPep00124,MKN7,Gastric tubular adenocarcinoma,Carcinoma,MTT assay,35 % Cytotoxity at 40 µg/ml,4 h,1
DCTPep00124,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,55 % Cytotoxity at 40 µg/ml,4 h,1
DCTPep00124,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,55 % Cytotoxity at 40 µg/ml,4 h,1
DCTPep00124,MKN1,Gastric adenosquamous carcinoma,Carcinoma,MTT assay,60 % Cytotoxity at 40 µg/ml,4 h,1
DCTPep00124,COLO 201,Colon adenocarcinoma,Carcinoma,MTT assay,65 % Cytotoxity at 40 µg/ml,4 h,1
DCTPep00125,P388,Mouse lymphoma,Lymphoma,Cell Viability assay,IC50=10.1 µg/ml,Not available,1
DCTPep00126,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,39% inhibition at 7 mg/kg/d,672 h,1
DCTPep00127,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,19% inhibition at 7 mg/kg/d,672 h,1
DCTPep00128,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,No inhibition at 7 mg/kg/d,672 h,1
DCTPep00129,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,No inhibition at 7 mg/kg/d,672 h,1
DCTPep00130,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,29% inhibition at 7 mg/kg/d,672 h,1
DCTPep00131,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,No inhibition at 7 mg/kg/d,672 h,1
DCTPep00132,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,No inhibition at 7 mg/kg/d,672 h,1
DCTPep00133,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,Matrigel Assay,No inhibition at 7 mg/kg/d,672 h,1
DCTPep00134,CEM/VM-1,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Cell Viability assay,40% inhibition at 1 µM,96 h,1
DCTPep00134,CEM-VLB,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Cell Viability assay,40% inhibition at 1 µM,96 h,1
DCTPep00134,CEM-WT,human lymphoblastic cancer,Lymphoma,Cell Viability assay,40% inhibition at 1 µM,96 h,1
DCTPep00134,CEM/VM-1,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Cell Viability assay,44% inhibition at 1 µM,96 h,1
DCTPep00134,CEM-VLB,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Cell Viability assay,44% inhibition at 1 µM,96 h,1
DCTPep00134,CEM-WT,human lymphoblastic cancer,Lymphoma,Cell Viability assay,44% inhibition at 1 µM,96 h,1
DCTPep00134,CEM-WT,human lymphoblastic cancer,Lymphoma,Cell Viability assay,50% inhibition at 1 µM,96 h,1
DCTPep00135,CEM/VM-1,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Cell Viability assay,No inhibition at 4 µM,96 h,1
DCTPep00135,CEM-VLB,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Cell Viability assay,No inhibition at 4 µM,96 h,1
DCTPep00135,CEM-WT,human lymphoblastic cancer,Lymphoma,Cell Viability assay,No inhibition at 4 µM,96 h,1
DCTPep00136,M1,Mouse myeloid leukemia ,Leukemia,MTT assay,70%Inhibition=0.5mg/ml,24 h,1
DCTPep00136,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,85%Inhibition=0.5mg/ml,24 h,1
DCTPep00137,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=37 µM,18.67 min,1
DCTPep00137,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=47 µM,18.67 min,1
DCTPep00137,OCI-AML-2,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=50 µM,18.67 min,1
DCTPep00137,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=53 µM,18.67 min,1
DCTPep00137,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=55 µM,18.67 min,1
DCTPep00138,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50<10 µM,22.5 min,1
DCTPep00138,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=20 µM,22.5 min,1
DCTPep00138,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=23 µM,22.5 min,1
DCTPep00138,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=25 µM,22.5 min,1
DCTPep00138,OCI-AML-2,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=29 µM,22.5 min,1
DCTPep00139,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=38 µM,20.08 min,1
DCTPep00139,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=50 µM,20.08 min,1
DCTPep00139,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=50 µM,20.08 min,1
DCTPep00139,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=52 µM,20.08 min,1
DCTPep00139,OCI-AML-2,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=67 µM,20.08 min,1
DCTPep00140,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=29 µM,19.15 min,1
DCTPep00140,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=37 µM,19.15 min,1
DCTPep00140,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=46 µM,19.15 min,1
DCTPep00140,OCI-AML-2,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=50 µM,19.15 min,1
DCTPep00140,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=51 µM,19.15 min,1
DCTPep00141,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50>70 µM,19.17 min,1
DCTPep00141,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>70 µM,19.17 min,1
DCTPep00141,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>70 µM,19.17 min,1
DCTPep00141,OCI-AML-2,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50>70 µM,19.17 min,1
DCTPep00141,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50>70 µM,19.17 min,1
DCTPep00142,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50>70 µM,14.54 min,1
DCTPep00142,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>70 µM,14.54 min,1
DCTPep00142,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>70 µM,14.54 min,1
DCTPep00142,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50>70 µM,14.54 min,1
DCTPep00143,L1210,Mouse leukemia,Leukemia,Radioactive precursor assay,IC50=3.6 µM,48h,1
DCTPep00144,Human nasopharyngeal carcinoma,Nasopharyngeal carcinoma,Carcinoma,Methylene Blue colourimetric assay,IC50=0.017 µM,72h,1
DCTPep00145,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20.8% cytotoxic at 1 µg/ml,96 h,1
DCTPep00145,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,33.8% cytotoxic at 10 µg/ml,96 h,1
DCTPep00145,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,35.6% cytotoxic at 100 µg/ml,96 h,1
DCTPep00145,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,39.0% cytotoxic at 0.1 µg/ml,96 h,1
DCTPep00145,B16-F10,Mouse melanoma,Carcinoma,MTT assay,49.4% cytotoxic at 0.1 µg/ml,96 h,1
DCTPep00145,B16-F10,Mouse melanoma,Carcinoma,MTT assay,51.2% cytotoxic at 1 µg/ml,96 h,1
DCTPep00145,B16-F10,Mouse melanoma,Carcinoma,MTT assay,53.0% cytotoxic at 10 µg/ml,96 h,1
DCTPep00145,B16-F10,Mouse melanoma,Carcinoma,MTT assay,61.2% cytotoxic at 100 µg/ml,96 h,1
DCTPep00146,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=23.7±2.9 µM,24h,1
DCTPep00146,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=25.2±1.8 µM,24h,1
DCTPep00146,EJ,Endometrial Adenocarcinoma,Carcinoma,MTT assay,IC50=25±1.9 µM,24h,1
DCTPep00146,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL10 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=5.06±0.1 µM,24h,1
DCTPep00146,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=5.86±0.18 µM,24h,1
DCTPep00146,L1210,Mouse leukemia,Leukemia,MTT assay,IC50=6.18±0.53 µM,24h,1
DCTPep00146,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL17 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.01±1.4 µM,24h,1
DCTPep00147,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,28.7 ± 9.3% Cytotoxicity=100 μg/ml,24 h,3
DCTPep00147,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=~40 µM,24 h,2
DCTPep00147,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=~50 µM,2 h,2
DCTPep00147,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=~50 µM,4 h,2
DCTPep00147,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=~70 µM,30 min,2
DCTPep00147,LA-N-1,Neuroblastoma,Blastoma,PI-uptake assay,LD50=1-4 µM,Not available,1
DCTPep00147,SH-SY5Y,Neuroblastoma,Blastoma,PI-uptake assay,LD50=1-4 µM,Not available,1
DCTPep00147,SW480,Colon adenocarcinoma,Carcinoma,PI-uptake assay,LD50=1-4 µM,Not available,1
DCTPep00147,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI-uptake assay,LD50=30 µM,Not available,1
DCTPep00148,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.71 µM,4 h,1
DCTPep00149,RT-4(G2),Prostate tumor,Carcinoma,Cell Viability assay,IC50=135.3 µM,48 h,1
DCTPep00149,486P,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=28.6 µM,48 h,1
DCTPep00149,647V,Bladder carcinoma,Carcinoma,Cell Viability assay,IC50=31 µM,48 h,1
DCTPep00149,RT-4(G2),Prostate tumor,Carcinoma,LDH leakage assay,IC50=32.3 µM,48 h,1
DCTPep00149,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=4.5 µM,Not available,1
DCTPep00149,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=4.6 µM,Not available,1
DCTPep00149,RT-4(G2),Prostate tumor,Carcinoma,WST-1 assay,IC50=484 µM,48 h,1
DCTPep00149,647V,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=52.4 µM,48 h,1
DCTPep00149,647V,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=54.1 µM,48 h,1
DCTPep00149,486P,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=57.8 µM,48 h,1
DCTPep00149,486P,Bladder carcinoma,Carcinoma,Cell Viability assay,IC50=59.4 µM,48 h,1
DCTPep00149,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=6.4 µM,Not available,1
DCTPep00149,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=9.1 µM,Not available,1
DCTPep00149,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=9.5 µM,Not available,1
DCTPep00150,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,>50% apoptosis at 20 µM,8 h,1
DCTPep00150,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,0% apoptosis at 10 µM,8 h,1
DCTPep00150,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,10% apoptosis at 20 µM,8 h,1
DCTPep00150,IMR-5,Neuroblastoma,Blastoma,MTT assay,15% apoptosis at 10 µM,8 h,1
DCTPep00150,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,20% apoptosis at 10 µM,8 h,1
DCTPep00150,IMR-5,Neuroblastoma,Blastoma,MTT assay,20% apoptosis at 20 µM,8 h,1
DCTPep00150,NB69,Neuroblastoma,Blastoma,MTT assay,30% apoptosis at 10 µM,8 h,1
DCTPep00150,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,30% apoptosis at 50 µM,8 h,1
DCTPep00150,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,30% apoptosis at 50 µM,8 h,1
DCTPep00150,IMR-5,Neuroblastoma,Blastoma,MTT assay,50% apoptosis at 50 µM,8 h,1
DCTPep00150,NB69,Neuroblastoma,Blastoma,MTT assay,80% apoptosis at 20 µM,8 h,1
DCTPep00150,NB69,Neuroblastoma,Blastoma,MTT assay,80% apoptosis at 50 µM,8 h,1
DCTPep00151,IMR-5,Neuroblastoma,Blastoma,MTT assay,23% apoptosis at 10 µM,8 h,1
DCTPep00151,NB69,Neuroblastoma,Blastoma,MTT assay,25% apoptosis at 10 µM,8 h,1
DCTPep00151,IMR-5,Neuroblastoma,Blastoma,MTT assay,35% apoptosis at 20 µM,8 h,1
DCTPep00151,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,43% apoptosis at 10 µM,8 h,1
DCTPep00151,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,45% apoptosis at 20 µM,8 h,1
DCTPep00151,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,46% apoptosis at 20 µM,8 h,1
DCTPep00151,IMR-5,Neuroblastoma,Blastoma,MTT assay,55% apoptosis at 50 µM,8 h,1
DCTPep00151,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,65% apoptosis at 50 µM,8 h,1
DCTPep00151,NB69,Neuroblastoma,Blastoma,MTT assay,66% apoptosis at 20 µM,8 h,1
DCTPep00151,NB69,Neuroblastoma,Blastoma,MTT assay,68% apoptosis at 50 µM,8 h,1
DCTPep00151,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,79% apoptosis at 50 µM,8 h,1
DCTPep00151,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,8% apoptosis at 10 µM,8 h,1
DCTPep00152,IMR-5,Neuroblastoma,Blastoma,MTT assay,0% apoptosis at 10 µM,8 h,1
DCTPep00152,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,1% apoptosis at 10 µM,8 h,1
DCTPep00152,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,1% apoptosis at 10 µM,8 h,1
DCTPep00152,IMR-5,Neuroblastoma,Blastoma,MTT assay,1% apoptosis at 20 µM,8 h,1
DCTPep00152,NB69,Neuroblastoma,Blastoma,MTT assay,1% apoptosis at 20 µM,8 h,1
DCTPep00152,NB69,Neuroblastoma,Blastoma,MTT assay,2% apoptosis at 10 µM,8 h,1
DCTPep00152,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,2% apoptosis at 20 µM,8 h,1
DCTPep00152,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,2% apoptosis at 20 µM,8 h,1
DCTPep00152,IMR-5,Neuroblastoma,Blastoma,MTT assay,2% apoptosis at 50 µM,8 h,1
DCTPep00152,NGP,NeuroblastomaDerived from metastatic site: Lung.,Blastoma,MTT assay,3% apoptosis at 50 µM,8 h,1
DCTPep00152,SK-N-AS,Neuroblastoma; Neuroblastoma,Blastoma,MTT assay,3% apoptosis at 50 µM,8 h,1
DCTPep00152,NB69,Neuroblastoma,Blastoma,MTT assay,5% apoptosis at 50 µM,8 h,1
DCTPep00153,Kelly,Neuroblastoma,Blastoma,MTT assay,IC50=15.5 µM,48 h,1
DCTPep00153,IMR-32,Neuroblastoma,Blastoma,MTT assay,IC50=29 µM,48 h,1
DCTPep00153,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=37 µM,48 h,1
DCTPep00153,SHEP-12,Neuroblastoma,Blastoma,MTT assay,IC50=45 µM,48 h,1
DCTPep00153,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,IC50=60 µM,48 h,1
DCTPep00154,KBv,Human oral carcinoma,Carcinoma,MTT assay,LC50=25±1 µM,24 h,1
DCTPep00154,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LC50=30 µM,24 h,1
DCTPep00155,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=20.1 μg/ml,24 h,2
DCTPep00155,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LC50=57 µM,24 h,1
DCTPep00155,KBv,Human oral carcinoma,Carcinoma,MTT assay,LC50=60 µM,24 h,1
DCTPep00156,KBv,Human oral carcinoma,Carcinoma,MTT assay,LC50=39 µM,24 h,1
DCTPep00156,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LC50=40 µM,24 h,1
DCTPep00157,CL-1,Canine leukemia,Leukemia,ELISA assay,LC50=3 μmol/L,Not available,1
DCTPep00157,MDA-MB-231,Breast adenocarcinoma,Carcinoma,ELISA assay,LC50=3 μmol/L,Not available,1
DCTPep00157,22Rv1,Prostate carcinoma,Carcinoma,ELISA assay,LC50=6 μmol/L,Not available,1
DCTPep00158,HBL,Melanoma,Carcinoma,MTT assay,"0.4% inhibition at 1μM, 1% inhibition at 10μM, 4.5% inhibition at 100μM, 10.8% inhibition at 1000μM",72 h,1
DCTPep00158,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"14% inhibition at 1μM, 15.9% inhibition at 10μM, 16.1% inhibition at 100μM, 19.3% inhibition at 1000μM",72 h,1
DCTPep00158,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"18.9% inhibition at 1μM, 12.7% inhibition at 10μM, 15.3% inhibition at 100μM, 19.1% inhibition at 1000μM",72 h,1
DCTPep00158,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"2.3% inhibition at 1μM, 11.4% inhibition at 10μM, 12% inhibition at 100μM, 22.3% inhibition at 1000μM",72 h,1
DCTPep00158,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"3.6% inhibition at 1μM, 4.1% inhibition at 10μM, 7.6% inhibition at 100μM, 15.4% inhibition at 1000μM",72 h,1
DCTPep00158,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"4.2% inhibition at 1μM, 6.4% inhibition at 10μM, 8.4% inhibition at 100μM, 3.2% inhibition at 1000μM",72 h,1
DCTPep00158,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"5.2% inhibition at 1μM, 4.5% inhibition at 10μM, 2.4% inhibition at 100μM, 3.3% inhibition at 1000μM",72 h,1
DCTPep00159,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"10% inhibition at 10μM, 8.2% inhibition at 100μM, 36.1% inhibition at 1000μM",72 h,1
DCTPep00159,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"12.9% inhibition at 1μM, 16.5% inhibition at 10μM, 28.1% inhibition at 100μM, 58.2% inhibition at 1000μM",72 h,1
DCTPep00159,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"14.2% inhibition at 1μM, 19.7% inhibition at 10μM, 24.9% inhibition at 100μM, 30.4% inhibition at 1000μM",72 h,1
DCTPep00159,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"2.4% inhibition at 10μM, 7.5% inhibition at 1000μM",72 h,1
DCTPep00159,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"3.5% inhibition at 1μM, 22.7% inhibition at 10μM, 18.9% inhibition at 100μM, 26.4% inhibition at 1000μM",72 h,1
DCTPep00159,HBL,Melanoma,Carcinoma,MTT assay,"6.5% inhibition at 1μM, 14% inhibition at 10μM, 7.5% inhibition at 100μM, 14% inhibition at 1000μM",72 h,1
DCTPep00159,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"9.8% inhibition at 1μM, 1.6% inhibition at 10μM, 5.4% inhibition at 100μM, 26.5% inhibition at 1000μM",72 h,1
DCTPep00160,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"1.1% inhibition at 10μM, 1.2% inhibition at 100μM, 17.8% inhibition at 1000μM",72 h,1
DCTPep00160,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"10.5% inhibition at 1μM, 21.9% inhibition at 10μM, 11.8% inhibition at 100μM, 17.9% inhibition at 1000μM",72 h,1
DCTPep00160,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"3.7% inhibition at 1μM, 16.5% inhibition at 10μM, 8.4% inhibition at 100μM, 14.5% inhibition at 1000μM",72 h,1
DCTPep00160,HBL,Melanoma,Carcinoma,MTT assay,"3.9% inhibition at 10μM, 7.3% inhibition at 1000μM",72 h,1
DCTPep00160,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"4.9% inhibition at 1μM, 8.9% inhibition at 10μM, 3.4% inhibition at 100μM, 20.8% inhibition at 1000μM",72 h,1
DCTPep00160,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"6.2% inhibition at 1μM, 6.4% inhibition at 10μM, 8.2% inhibition at 100μM, 21.2% inhibition at 1000μM",72 h,1
DCTPep00160,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"7.5% inhibition at 1μM, 6.1% inhibition at 10μM, 3.1% inhibition at 100μM, 14.8% inhibition at 1000μM",72 h,1
DCTPep00161,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"0.7% inhibition at 1μM, 8.3% inhibition at 10μM, 10.5% inhibition at 100μM, 21.8% inhibition at 1000μM",72 h,1
DCTPep00161,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"1.6% inhibition at 1μM, 2.6% inhibition at 10μM, 7.7% inhibition at 100μM, 18.7% inhibition at 1000μM",72 h,1
DCTPep00161,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"10.7% inhibition at 1μM, 10% inhibition at 10μM, 9.4% inhibition at 100μM, 18.7% inhibition at 1000μM",72 h,1
DCTPep00161,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"2.7% inhibition at 1μM, 2% inhibition at 10μM, 18.8% inhibition at 100μM, 26.7% inhibition at 1000μM",72 h,1
DCTPep00161,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"22.2% inhibition at 1μM, 21.4% inhibition at 10μM, 17.5% inhibition at 100μM, 16% inhibition at 1000μM",72 h,1
DCTPep00161,HBL,Melanoma,Carcinoma,MTT assay,"3% inhibition at 1μM, 4.7% inhibition at 10μM, 2.7% inhibition at 100μM, 7.3% inhibition at 1000μM",72 h,1
DCTPep00161,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"7.2% inhibition at 1μM, 17.1% inhibition at 10μM, 11% inhibition at 100μM, 20.5% inhibition at 1000μM",72 h,1
DCTPep00162,HBL,Melanoma,Carcinoma,MTT assay,"1.6% inhibition at 1μM, 2.9% inhibition at 10μM, 5.9% inhibition at 100μM, 17.9% inhibition at 1000μM",72 h,1
DCTPep00162,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"13.6% inhibition at 1μM, 20.4% inhibition at 10μM, 14.4% inhibition at 100μM, 23.4% inhibition at 1000μM",72 h,1
DCTPep00162,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"2.2% inhibition at 1μM, 4.2% inhibition at 10μM, 6.4% inhibition at 100μM, 6.2% inhibition at 1000μM",72 h,1
DCTPep00162,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"2.7% inhibition at 1μM, 2% inhibition at 10μM, 18.8% inhibition at 100μM, 26.7% inhibition at 1000μM",72 h,1
DCTPep00162,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,21.2% inhibition at 100μM,72 h,1
DCTPep00162,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"5.4% inhibition at 1μM, 7.4% inhibition at 10μM, 9.5% inhibition at 100μM, 15.7% inhibition at 1000μM",72 h,1
DCTPep00162,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"9.8% inhibition at 1μM, 7.3% inhibition at 10μM, 9.9% inhibition at 100μM, 28.2% inhibition at 1000μM",72 h,1
DCTPep00163,HBL,Melanoma,Carcinoma,MTT assay,"1.2% inhibition at 10μM, 3.3% inhibition at 100μM, 19.4% inhibition at 1000μM",72 h,1
DCTPep00163,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"11% inhibition at 1μM, 11.7% inhibition at 10μM, 11.6% inhibition at 100μM, 28.2% inhibition at 1000μM",72 h,1
DCTPep00163,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,15.6% inhibition at 100μM,72 h,1
DCTPep00163,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"17% inhibition at 1μM, 13.5% inhibition at 10μM, 13.5% inhibition at 100μM, 25.3% inhibition at 1000μM",72 h,1
DCTPep00163,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"4.6% inhibition at 1μM, 4.9% inhibition at 10μM, 12.6% inhibition at 100μM, 26.4% inhibition at 1000μM",72 h,1
DCTPep00163,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"7.6% inhibition at 1μM, 3.8% inhibition at 10μM, 12.4% inhibition at 100μM, 22.4% inhibition at 1000μM",72 h,1
DCTPep00163,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"8.1% inhibition at 1μM, 6.9% inhibition at 10μM, 8.1% inhibition at 100μM, 8.6% inhibition at 1000μM",72 h,1
DCTPep00164,HBL,Melanoma,Carcinoma,MTT assay,"0.8% inhibition at 1μM, 1.4% inhibition at 10μM, 2.4% inhibition at 100μM, 18.3% inhibition at 1000μM",72 h,1
DCTPep00164,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"1% inhibition at 1μM, 10.1% inhibition at 10μM, 16.8% inhibition at 100μM, 36.1% inhibition at 1000μM",72 h,1
DCTPep00164,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"12.2% inhibition at 1μM, 15.5% inhibition at 10μM, 24.7% inhibition at 100μM, 29% inhibition at 1000μM",72 h,1
DCTPep00164,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,22.8% inhibition at 1000μM,72 h,1
DCTPep00164,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"3% inhibition at 1μM, 8.4% inhibition at 10μM, 18.5% inhibition at 100μM, 10.6% inhibition at 1000μM",72 h,1
DCTPep00164,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"3.3% inhibition at 1μM, 11% inhibition at 10μM, 7.9% inhibition at 100μM, 23.7% inhibition at 1000μM",72 h,1
DCTPep00164,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"4.9% inhibition at 1μM, 10.2% inhibition at 10μM, 13.3% inhibition at 100μM, 28% inhibition at 1000μM",72 h,1
DCTPep00165,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"13.7% inhibition at 1μM, 25.8% inhibition at 10μM, 34.7% inhibition at 100μM, 44.5% inhibition at 1000μM",72 h,1
DCTPep00165,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,"16.2% inhibition at 1μM, 6.6% inhibition at 10μM, 5.1% inhibition at 100μM, 14.5% inhibition at 1000μM",72 h,1
DCTPep00165,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"17.7% inhibition at 1μM, 10.9% inhibition at 10μM, 12.1% inhibition at 100μM, 8.1% inhibition at 1000μM",72 h,1
DCTPep00165,HBL,Melanoma,Carcinoma,MTT assay,"2.4% inhibition at 1μM, 4.5% inhibition at 10μM, 11.4% inhibition at 100μM, 23.2% inhibition at 1000μM",72 h,1
DCTPep00165,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,"26.4% inhibition at 1μM, 13.1% inhibition at 10μM, 14.6% inhibition at 100μM, 38.4% inhibition at 1000μM",72 h,1
DCTPep00165,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"8.5% inhibition at 1μM, 9.5% inhibition at 10μM, 15.4% inhibition at 100μM, 24.1% inhibition at 1000μM",72 h,1
DCTPep00165,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"9.6% inhibition at 100μM, 29.9% inhibition at 100μM",72 h,1
DCTPep00166,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,"11.8% inhibition at 10μM, 47.0% inhibition at 1000μM",72 h,1
DCTPep00166,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"2.2% inhibition at 1μM, 7.1% inhibition at 10μM, 6.9% inhibition at 100μM, 25.9% inhibition at 1000μM",72 h,1
DCTPep00166,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"3.9% inhibition at 10μM, 45.0% inhibition at 1000μM",72 h,1
DCTPep00166,HBL,Melanoma,Carcinoma,MTT assay,"4.1% inhibition at 1μM, 70.7% inhibition at 10μM, 34.2% inhibition at 1000μM",72 h,1
DCTPep00166,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,9.2% inhibition at 1000μM,72 h,1
DCTPep00166,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,9.3% inhibition at 1000μM,72 h,1
DCTPep00167,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=113.31 µg/ml,3 days,1
DCTPep00167,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=138.06 µg/ml,3 days,1
DCTPep00167,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=145.72 µg/ml,3 days,1
DCTPep00167,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=183.74 µg/ml,3 days,1
DCTPep00167,MKN 45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=34.96 µg/ml,3 days,1
DCTPep00167,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,MTT assay,IC50=38.28 µg/ml,3 days,1
DCTPep00167,NCI-H630,Rectal carcinoma,Carcinoma,MTT assay,IC50=41.85 µg/ml,3 days,1
DCTPep00167,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=43.64 µg/ml,3 days,1
DCTPep00167,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=47.47 µg/ml,3 days,1
DCTPep00168,NCI-H630,Rectal carcinoma,Carcinoma,MTT assay,IC50=129.54 µg/ml,3 days,1
DCTPep00168,MKN 45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=142.72 µg/ml,3 days,1
DCTPep00168,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=144.37 µg/ml,3 days,1
DCTPep00168,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,MTT assay,IC50=150.45 µg/m,3 days,1
DCTPep00168,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=174.15 µg/ml,3 days,1
DCTPep00168,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=198.87 µg/ml,3 days,1
DCTPep00168,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=214.33 µg/ml,3 days,1
DCTPep00168,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=418.15 µg/ml,3 days,1
DCTPep00169,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=106.27 µg/ml,3 days,1
DCTPep00169,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=123.81 µg/ml,3 days,1
DCTPep00169,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=30.48 µg/ml,3 days,1
DCTPep00169,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=30.48 µg/ml,3 days,1
DCTPep00169,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=73.26 µg/ml,3 days,1
DCTPep00169,NCI-H630,Rectal carcinoma,Carcinoma,MTT assay,IC50=75.92 µg/ml,3 days,1
DCTPep00169,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=77.29 µg/ml,3 days,1
DCTPep00169,MKN 45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=82.70 µg/ml,3 days,1
DCTPep00169,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,MTT assay,IC50=92.15 µg/ml,3 days,1
DCTPep00170,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=58 µg/ml,48h,1
DCTPep00171,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=6.7μg/ml,24h,1
DCTPep00171,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=8.9μg/ml,24h,1
DCTPep00172,RPMI-8402,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,leukemia,Trypan blue assay,IC50=12 µg/ml,72 h,1
DCTPep00172,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,IC50=17 µg/ml,72 h,1
DCTPep00172,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=23 µg/ml,72 h,1
DCTPep00172,SSKT-1,Leukemia,Leukemia,Trypan blue assay,IC50=27 µg/ml,72 h,1
DCTPep00172,Daudi,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=28 µg/ml,72 h,1
DCTPep00172,MLA,Leukemia,Leukemia,Trypan blue assay,IC50=30 µg/ml,72 h,1
DCTPep00172,CHP-100,Ewing sarcoma,Sarcoma,Trypan blue assay,IC50=32 µg/ml,72 h,1
DCTPep00172,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,IC50=32 µg/ml,72 h,1
DCTPep00172,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Trypan blue assay,IC50=37 µg/ml,72 h,1
DCTPep00172,PC-3,Prostate carcinoma,Carcinoma,Trypan blue assay,IC50=41 µg/ml,72 h,1
DCTPep00172,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=125 µg/ml,24 h,Patent
DCTPep00172,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=130 µg/ml,24 h,Patent
DCTPep00172,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=22 µg/ml,24 h,Patent
DCTPep00172,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=45 µg/ml,24 h,Patent
DCTPep00172,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep00172,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep00175,SSKT-1,Leukemia,Leukemia,Trypan blue assay,IC50=107 µg/ml,72 h,1
DCTPep00175,Daudi,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=115 µg/ml,72 h,1
DCTPep00175,RPMI-8402,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,leukemia,Trypan blue assay,IC50=60 µg/ml,72 h,1
DCTPep00175,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=64 µg/ml,72 h,1
DCTPep00175,MLA,Leukemia,Leukemia,Trypan blue assay,IC50=80 µg/ml,72 h,1
DCTPep00175,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,IC50=97 µg/ml,72 h,1
DCTPep00175,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,IC50=98 µg/ml,72 h,1
DCTPep00176,MLA,Leukemia,Leukemia,Trypan blue assay,IC50=102 µg/ml,72 h,1
DCTPep00176,SSKT-1,Leukemia,Leukemia,Trypan blue assay,IC50=109 µg/ml,72 h,1
DCTPep00176,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,IC50=112 µg/ml,72 h,1
DCTPep00176,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,IC50=123 µg/ml,72 h,1
DCTPep00176,Daudi,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=143 µg/ml,72 h,1
DCTPep00176,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50=72 µg/ml,72 h,1
DCTPep00176,RPMI-8402,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,leukemia,Trypan blue assay,IC50=83 µg/ml,72 h,1
DCTPep00177,Daudi,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,MLA,Leukemia,Leukemia,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,RPMI-8402,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,leukemia,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,SSKT-1,Leukemia,Leukemia,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,IC50>150 µg/ml,72 h,1
DCTPep00177,CHP-100,Ewing sarcoma,Sarcoma,Trypan blue assay,IC50>200 µg/ml,72 h,1
DCTPep00177,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Trypan blue assay,IC50>200 µg/ml,72 h,1
DCTPep00177,PC-3,Prostate carcinoma,Carcinoma,Trypan blue assay,IC50>200 µg/ml,72 h,1
DCTPep00178,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=27.31 µM,24h,1
DCTPep00178,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=41.21 µM,24h,1
DCTPep00178,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=52.83 µM,24h,1
DCTPep00178,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=55.22 µM,24h,1
DCTPep00179,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µg/ml,24h,1
DCTPep00180,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,(38.4±10.3)% Cytotoxicity=100 µg/ml,24h,1
DCTPep00181,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,(6.5±17.3)% Cytotoxicity=100 µg/ml,24h,1
DCTPep00182,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µg/ml,24h,1
DCTPep00183,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=7.4 µM,24h,1
DCTPep00183,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=7.5 µM,24h,1
DCTPep00184,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,10.4 % inhibition of cell proliferation at 1 nM,24 h,1
DCTPep00184,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,10.6 % inhibition of cell proliferation at 1 nM,24 h,1
DCTPep00184,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,14.2 % inhibition of cell proliferation at 10 nM,24 h,1
DCTPep00184,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,16.5 % inhibition of cell proliferation at 1 nM,24 h,1
DCTPep00184,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,16.8 % inhibition of cell proliferation at 100 nM,24 h,1
DCTPep00184,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,18.2 % inhibition of cell proliferation at 10 nM,24 h,1
DCTPep00184,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,18.7 % inhibition of cell proliferation at 10 nM,24 h,1
DCTPep00184,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,21.7 % inhibition of cell proliferation at 1 µM,24 h,1
DCTPep00184,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,24.2 % inhibition of cell proliferation at 1 nM,24 h,1
DCTPep00184,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,27.9 % inhibition of cell proliferation at 10 µM,24 h,1
DCTPep00184,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,28.2 % inhibition of cell proliferation at 10 nM,24 h,1
DCTPep00184,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,29.7 % inhibition of cell proliferation at 1 nM,24 h,1
DCTPep00184,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,30.7 % inhibition of cell proliferation at 100 nM,24 h,1
DCTPep00184,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,34.7 % inhibition of cell proliferation at 100 nM,24 h,1
DCTPep00184,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,35.3 % inhibition of cell proliferation at 100 nM,24 h,1
DCTPep00184,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,37.8 % inhibition of cell proliferation at 10 nM,24 h,1
DCTPep00184,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,43.1 % inhibition of cell proliferation at 1 µM,24 h,1
DCTPep00184,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,48.2 % inhibition of cell proliferation at 100 nM,24 h,1
DCTPep00184,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,54.3 % inhibition of cell proliferation at 1 µM,24 h,1
DCTPep00184,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,59.4 % inhibition of cell proliferation at 1 µM,24 h,1
DCTPep00184,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,59.6 % inhibition of cell proliferation at 1 µM,24 h,1
DCTPep00184,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,84.5 % inhibition of cell proliferation at 10 µM,24 h,1
DCTPep00184,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,85.4 % inhibition of cell proliferation at 10 µM,24 h,1
DCTPep00184,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,94.5 % inhibition of cell proliferation at 10 µM,24 h,1
DCTPep00184,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,98.3 % inhibition of cell proliferation at 10 µM,24 h,1
DCTPep00185,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LC50=45 μM,1 h,1
DCTPep00186,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LC50=35 μM,1 h,1
DCTPep00187,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL11 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=17.9 µM,24h,2
DCTPep00187,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Alamar blue assay,LD50=4 µM,30 min,1
DCTPep00188,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Fluorometric microculture cytotoxicity assay,IC50=0.96 μM,72 h,1
DCTPep00189,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Fluorometric microculture cytotoxicity assay,IC50=1.6 μM,72 h,1
DCTPep00190,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Fluorometric microculture cytotoxicity assay,IC50=3.2 μM,72 h,1
DCTPep00191,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Fluorometric microculture cytotoxicity assay,IC50>30 μM,72 h,1
DCTPep00192,647V,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=185.39 µg/ml,48 h,1
DCTPep00192,647V,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=200.7 µg/ml,48 h,1
DCTPep00192,J82,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=212.07 µg/ml,48 h,1
DCTPep00192,RT-4,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=231.26 µg/ml,48 h,1
DCTPep00192,486P,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=251.47 µg/ml,48 h,1
DCTPep00192,647V,Bladder carcinoma,Carcinoma,BrdU assay,IC50=28.74 µg/ml,48 h,1
DCTPep00192,RT-4,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=289.3 µg/ml,48 h,1
DCTPep00192,J82,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=319.2 µg/ml,48 h,1
DCTPep00192,486P,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=373.3/ µg/ml,48 h,1
DCTPep00192,486P,Bladder carcinoma,Carcinoma,BrdU assay,IC50=69.2 µg/ml,48 h,1
DCTPep00192,RT-4,Bladder carcinoma,Carcinoma,BrdU assay,IC50=96.22 µg/ml,48 h,1
DCTPep00192,J82,Bladder carcinoma,Carcinoma,BrdU assay,IC50=99.01 µg/ml,48 h,1
DCTPep00193,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11.7±1.3 µM,48 h,4
DCTPep00193,647V,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=115.12 µg/ml,48 h,1
DCTPep00193,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=15.5 µM,96 h,3
DCTPep00193,486P,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=161.76 µg/ml,48 h,1
DCTPep00193,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=18.5±1.7 µM,48 h,4
DCTPep00193,647V,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=181.1 µg/ml,48 h,1
DCTPep00193,RT-4,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=184.81 µg/ml,48 h,1
DCTPep00193,J82,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=196.3 µg/ml,48 h,1
DCTPep00193,486P,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=232.4 µg/ml,48 h,1
DCTPep00193,MCF-7R,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=24.5 µM,96 h,3
DCTPep00193,BTS-30,Breast Cancer,Carcinoma,MTT assay,IC50=24.8 µM,96 h,3
DCTPep00193,RT-4,Bladder carcinoma,Carcinoma,LDH leakage assay,IC50=240.4 µg/ml,48 h,1
DCTPep00193,HRT-18,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=25.5 µM,96 h,3
DCTPep00193,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=30.6 µM,96 h,3
DCTPep00193,CHO-K1,Ovary tumor,Carcinoma,MTT assay,IC50=32 µM,96 h,3
DCTPep00193,HCLO,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=33.5 µM,96 h,3
DCTPep00193,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=34.5 µM,96 h,3
DCTPep00193,MAC 15A,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=37 µM,96 h,3
DCTPep00193,WEHI-3B,Mouse leukemia,Leukemia,MTT assay,IC50=4.4 µM,96 h,3
DCTPep00193,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=42.5 µM,96 h,3
DCTPep00193,NCI-H520,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=58.8±2.0 µM,48 h,4
DCTPep00193,647V,Bladder carcinoma,Carcinoma,Cell Viability assay,IC50=61.86 µg/ml,48 h,1
DCTPep00193,J82,Bladder carcinoma,Carcinoma,Cell Viability assay,IC50=77.51 µg/ml,48 h,1
DCTPep00193,486P,Bladder carcinoma,Carcinoma,Cell Viability assay,IC50=87.47 µg/ml,48 h,1
DCTPep00193,RT-4,Bladder carcinoma,Carcinoma,Cell Viability assay,IC50=92.9 µg/ml,48 h,1
DCTPep00193,J82,Bladder carcinoma,Carcinoma,WST-1 assay,IC50=97.93 µg/ml,48 h,1
DCTPep00193,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,96 h,3
DCTPep00193,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,96 h,3
DCTPep00193,NCI-H661,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50>100 µM,48 h,4
DCTPep00193,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50>50 µM,48 h,4
DCTPep00194,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTS assay,IC50=77 µM,24 h,1
DCTPep00195,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTS assay,IC50=8 µM,24 h,1
DCTPep00196,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=10-15μg/ml,4h,1
DCTPep00196,Jurkat ,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,LD50=20-25μg/ml,4h,1
DCTPep00196,BJAB,Burkitt lymphoma ,Lymphoma,MTT assay,LD50=30-40μg/ml,4h,1
DCTPep00197,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=10 µg/ml,48 h,1
DCTPep00197,RPMI-8226,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,IC50=10.5 µg/ml,48 h,1
DCTPep00197,MDA-N,Amelanotic melanoma,Carcinoma,MTT assay,IC50=10.6 µg/ml,48 h,1
DCTPep00197,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=10.6 µg/ml,48 h,1
DCTPep00197,UACC-62,Melanoma,Carcinoma,MTT assay,IC50=10.6 µg/ml,48 h,1
DCTPep00197,UO-31,Renal cell carcinoma,Carcinoma,MTT assay,IC50=10.6 µg/ml,48 h,1
DCTPep00197,NCI-H322M,Minimally invasive lung adenocarcinoma,Carcinoma,MTT assay,IC50=10.7 µg/ml,48 h,1
DCTPep00197,NCI-H23,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10.8 µg/ml,48 h,1
DCTPep00197,Malme-3M,Melanoma,Carcinoma,MTT assay,IC50=10.9 µg/ml,48 h,1
DCTPep00197,RXF 393L,Renal cell carcinoma,Carcinoma,MTT assay,IC50=11 µg/ml,48 h,1
DCTPep00197,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=11.1 µg/ml,48 h,1
DCTPep00197,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.2 µg/ml,48 h,1
DCTPep00197,NCI-H522,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.2 µg/ml,48 h,1
DCTPep00197,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=11.3 µg/ml,48 h,1
DCTPep00197,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=11.3 µg/ml,48 h,1
DCTPep00197,MDA-MB-435,Amelanotic melanoma,Carcinoma,MTT assay,IC50=11.3 µg/ml,48 h,1
DCTPep00197,SN12C,Renal cell carcinoma,Carcinoma,MTT assay,IC50=11.4 µg/ml,48 h,1
DCTPep00197,NCI-ADR-RES,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=11.5 µg/ml,48 h,1
DCTPep00197,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.7 µg/ml,48 h,1
DCTPep00197,Hs 578T,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.7 µg/ml,48 h,1
DCTPep00197,ACHN,Papillary renal cell carcinoma,Carcinoma,MTT assay,IC50=12 µg/ml,48 h,1
DCTPep00197,KM12,Colon carcinoma,Carcinoma,MTT assay,IC50=12 µg/ml,48 h,1
DCTPep00197,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=12 µg/ml,48 h,1
DCTPep00197,EKVX,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12.1 µg/ml,48 h,1
DCTPep00197,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=12.1 µg/ml,48 h,1
DCTPep00197,786-O,Renal cell carcinoma,Carcinoma,MTT assay,IC50=12.2 µg/ml,48 h,1
DCTPep00197,SF268,Astrocytoma,Carcinoma,MTT assay,IC50=12.4 µg/ml,48 h,1
DCTPep00197,UACC-257,Melanoma,Carcinoma,MTT assay,IC50=12.5 µg/ml,48 h,1
DCTPep00197,HOP-62,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12.6 µg/ml,48 h,1
DCTPep00197,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=12.6 µg/ml,48 h,1
DCTPep00197,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.7 µg/ml,48 h,1
DCTPep00197,BT-549,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12.9 µg/ml,48 h,1
DCTPep00197,SF295,Glioblastoma,Blastoma,MTT assay,IC50=12.9 µg/ml,48 h,1
DCTPep00197,OVCAR-8,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=13 µg/ml,48 h,1
DCTPep00197,TK-10,Clear cell renal cell carcinoma; Clear cell renal carcinoma,Carcinoma,MTT assay,IC50=13.1 µg/ml,48 h,1
DCTPep00197,HCT 15,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=13.2 µg/ml,48 h,1
DCTPep00197,NCI-H226,Pleural epithelioid mesothelioma; Pleural mesothelioma,Carcinoma,MTT assay,IC50=13.3 µg/ml,48 h,1
DCTPep00197,OVCAR-5,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=13.8 µg/ml,48 h,1
DCTPep00197,SNB-19,Astrocytoma,Carcinoma,MTT assay,IC50=13.8 µg/ml,48 h,1
DCTPep00197,Caki-1,Clear cell renal cell carcinoma; Clear cell renal carcinoma,Carcinoma,MTT assay,IC50=14.1 µg/ml,48 h,1
DCTPep00197,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=14.6 µg/ml,48 h,1
DCTPep00197,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=14.7 µg/ml,48 h,1
DCTPep00197,M14,Amelanotic melanoma,Carcinoma,MTT assay,IC50=15.1 µg/ml,48 h,1
DCTPep00197,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.1 µg/ml,48 h,1
DCTPep00197,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=15.2 µg/ml,48 h,1
DCTPep00197,DU145,Prostate carcinoma,Carcinoma,MTT assay,IC50=15.3 µg/ml,48 h,1
DCTPep00197,SNB-75,Glioblastoma,Blastoma,MTT assay,IC50=15.5 µg/ml,48 h,1
DCTPep00197,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=17 µg/ml,48 h,1
DCTPep00197,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=17.6 µg/ml,48 h,1
DCTPep00197,OVCAR-4,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=17.6 µg/ml,48 h,1
DCTPep00197,SR,"Anaplastic large cell lymphoma, ALK-positive; ALK-positive anaplastic large cell lymphoma",Lymphoma,MTT assay,IC50=20.2 µg/ml,48 h,1
DCTPep00197,T-47D,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=23.9 µg/ml,48 h,1
DCTPep00197,HOP-92,Lung non-small cell carcinoma,Carcinoma,MTT assay,IC50=7.2 µg/ml,48 h,1
DCTPep00197,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=8.2 µg/ml,48 h,1
DCTPep00197,SK-MEL-5,Cutaneous melanoma,Carcinoma,MTT assay,IC50=8.9 µg/ml,48 h,1
DCTPep00197,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=9 µg/ml,48 h,1
DCTPep00197,LOX-IMVI,Amelanotic melanoma,Carcinoma,MTT assay,IC50=9.5 µg/ml,48 h,1
DCTPep00197,SF539,Gliosarcoma,Sarcoma,MTT assay,IC50=9.5 µg/ml,48 h,1
DCTPep00199,HCT 116,Colon carcinoma,Carcinoma,MTT assay,~80% Cytotoxicity at 100 µM,24 h,1
DCTPep00200,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=80 µg/ml,Not available,1
DCTPep00200,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=90 µg/ml,Not available,1
DCTPep00201,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=10 µg/ml,Not available,1
DCTPep00201,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=15 µg/ml,Not available,1
DCTPep00201,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=17 µg/ml,Not available,1
DCTPep00201,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=17 µg/ml,Not available,1
DCTPep00203,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,100% Cytotoxicity=75μM,48 h,1
DCTPep00204,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µM,4h,1
DCTPep00205,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LD50=12 μM,Not available,1
DCTPep00206,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LD50=6 μM,Not available,1
DCTPep00207,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LD50=16 μM,Not available,1
DCTPep00208,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LD50=11 μM,Not available,1
DCTPep00209,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LD50=14 μM,Not available,1
DCTPep00210,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,Cytolytic assays,LD50=20 μM,Not available,1
DCTPep00211,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=54 µM,24 h,1
DCTPep00212,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12 µM,24 h,1
DCTPep00212,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=27.84 μM,6 h,2
DCTPep00212,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=31.78 μM,1 h,2
DCTPep00212,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=31.91 μM,24 h,2
DCTPep00212,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=34.5 μM,48 h,2
DCTPep00212,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=36.31 μM,24 h,2
DCTPep00212,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=36.9 μM,1 h,2
DCTPep00212,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=37.1 μM,6 h,2
DCTPep00212,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=37.33 μM,1 h,2
DCTPep00212,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.39 μM,48 h,2
DCTPep00212,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.5 μM,6 h,2
DCTPep00212,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.96 μM,48 h,2
DCTPep00212,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.98 μM,24 h,2
DCTPep00212,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=39.42 μM,24 h,2
DCTPep00212,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=40.16 μM,48 h,2
DCTPep00212,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=40.6 μM,6 h,2
DCTPep00212,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=43.87 μM,1 h,2
DCTPep00212,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=44.92 μM,1 h,2
DCTPep00212,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=46.73 μM,6 h,2
DCTPep00212,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=47.73 μM,48 h,2
DCTPep00212,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=50.32 μM,24 h,2
DCTPep00212,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=52.09 μM,48 h,2
DCTPep00212,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=52.82 μM,1 h,2
DCTPep00212,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=53.12 μM,6 h,2
DCTPep00212,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=53.31 μM,24 h,2
DCTPep00212,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=54.95 μM,48 h,2
DCTPep00212,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=55.16 μM,6 h,2
DCTPep00212,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=56.47 μM,1 h,2
DCTPep00212,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=57.94 μM,24 h,2
DCTPep00212,LK-2,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=58.32 μM,1 h,2
DCTPep00212,NCI-H446,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=59.45 μM,1 h,2
DCTPep00212,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=60.38 μM,6 h,2
DCTPep00212,LK-2,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=61.57 μM,48 h,2
DCTPep00212,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=61.63 μM,24 h,2
DCTPep00212,LK-2,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=61.73 μM,6 h,2
DCTPep00212,HO-8910,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=62.84 μM,1 h,2
DCTPep00212,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=63.2 μM,48 h,2
DCTPep00212,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=63.26 μM,1 h,2
DCTPep00212,LK-2,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=63.4 μM,24 h,2
DCTPep00212,HO-8910,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=64.75 μM,24 h,2
DCTPep00212,NCI-H446,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=64.81 μM,6 h,2
DCTPep00212,NCI-H446,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=65.29 μM,48 h,2
DCTPep00212,HO-8910,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=66.55 μM,48 h,2
DCTPep00212,HO-8910,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=66.68 μM,6 h,2
DCTPep00212,NCI-H446,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=67.66 μM,24 h,2
DCTPep00212,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=88.91 μM,1 h,2
DCTPep00212,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,6 h,2
DCTPep00212,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,2
DCTPep00212,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48 h,2
DCTPep00213,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=56 µM,24 h,1
DCTPep00214,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>200 µM,24 h,1
DCTPep00215,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=0.15±0.08nM,72h,1
DCTPep00215,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.20±0.02nM,72h,1
DCTPep00215,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=15.80±0.09nM,72h,1
DCTPep00215,PC-12,Lung papillary adenocarcinoma,Carcinoma,MTT assay,IC50=7.71±0.24nM,72h,1
DCTPep00216,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=0.15±0.08nM,72h,1
DCTPep00216,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.20±0.02nM,72h,1
DCTPep00216,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=15.80±0.09nM,72h,1
DCTPep00216,PC-12,Lung papillary adenocarcinoma,Carcinoma,MTT assay,IC50=7.71±0.24nM,72h,1
DCTPep00218,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=10 µM,24 h,1
DCTPep00218,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=13 µM,24 h,1
DCTPep00218,Kelly,Neuroblastoma,Blastoma,MTT assay,IC50=141 ± 3 µM,30 min,2
DCTPep00218,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=148±8 µM,24 h,1
DCTPep00218,SU-DHL-4,Diffuse large B-cell lymphoma germinal center B-cell type; Diffuse large B-cell lymphoma,Lymphoma,MTT assay,IC50=16 µM,24 h,1
DCTPep00218,KMS-5,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,IC50=38 µM,24 h,1
DCTPep00218,FEMX-I,Melanoma,Carcinoma,MTT assay,IC50=40±7 µM,24 h,1
DCTPep00218,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,IC50=55 µM,24 h,1
DCTPep00218,KMM-1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,IC50=57 µM,24 h,1
DCTPep00218,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50>160 µM,30 min,2
DCTPep00219,FEMX-I,Melanoma,Carcinoma,MTT assay,IC50=30±3 µM,30 min,1
DCTPep00219,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=55±14 µM,30 min,1
DCTPep00220,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=20.3±1.0µM,24h,1
DCTPep00220,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=21.2±0.8µM,24h,1
DCTPep00220,EJ,Endometrial Adenocarcinoma,Carcinoma,MTT assay,IC50=21.6±1.2µM,24h,1
DCTPep00221,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL7 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50>36 µM,3h,1
DCTPep00222,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL6 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50>36 µM,3h,1
DCTPep00223,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL8 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50>36 µM,3h,1
DCTPep00224,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL5 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50=0.7 µM,3h,1
DCTPep00225,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL4 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50=18 µM,3h,1
DCTPep00226,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL3 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50=18 µM,3h,1
DCTPep00227,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Hoechst 33342 and PI assay,EC50=12 µM,3h,1
DCTPep00228,HT-29,Colon adenocarcinoma,Carcinoma,NR uptake assay ,IC50=48.3±3.5µM,24-96h,1
DCTPep00229,A-375,Amelanotic melanoma,Carcinoma,MTT assay,"86 ± 0.57% cell viability at 10 µM, 63.8 ± 0.8% cell viability at 20 µM, 47.5 ± 1.66% cell viability at 40 µM, 26.9 ± 0.5% cell viability at 60 µM, 6.5 ± 1.07% cell viability at 80 µM",Not available,1
DCTPep00229,M14,Amelanotic melanoma,Carcinoma,MTT assay,"92.2 ± 1.02% cell viability at 10 µM, 71.1 ± 2.84% cell viability at 20 µM, 50 ± 3.09% cell viability at 40 µM, 31.5 ± 1.49% cell viability at 60 µM, 13.8 ± 1.44% cell viability at 80 µM",Not available,1
DCTPep00231,RenCa,Mouse kidney carcinoma,Carcinoma,MTT assay,LC50=1.3 µM,24 h,1
DCTPep00231,B16-F10,Mouse melanoma,Carcinoma,MTT assay,LC50=1.75 µM,24 h,1
DCTPep00231,WM1158,Melanoma,Carcinoma,MTT assay,LC50=4.1 µM,24 h,1
DCTPep00231,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,MTT assay,LC50=6.2 µM,24 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,35.2 % Cell viability at 100 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,41.1 % Cell viability at 75 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,48.6 % Cell viability at 100 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,49.7 % Cell viability at 50 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,54.2 % Cell viability at 100 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,54.3 % Cell viability at 100 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,62.8 % Cell viability at 75 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,63.3 % Cell viability at 25 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,71.5 % Cell viability at 75 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,72.1 % Cell viability at 12.5 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,75.6 % Cell viability at 50 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,76.3% Cell viability at 50 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,84.1% Cell viability at 25 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,87.3 % Cell viability at 25 µM,48 h,1
DCTPep00232,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,91.8% Cell viability at 12.5 µM,48 h,1
DCTPep00233,B16-F10,Mouse melanoma,Carcinoma,MTT assay,40% inhibition at 5µg/ml,72 h,1
DCTPep00233,B16-F10,Mouse melanoma,Carcinoma,MTT assay,50% inhibition at 2.5µg/ml,72 h,1
DCTPep00233,B16-F10,Mouse melanoma,Carcinoma,MTT assay,75% inhibition at 10µg/ml,72 h,1
DCTPep00234,B16-F10,Mouse melanoma,Carcinoma,MTT assay,40% inhibition at 2.5µg/ml,72 h,1
DCTPep00234,B16-F10,Mouse melanoma,Carcinoma,MTT assay,42% inhibition at 5µg/ml,72 h,1
DCTPep00234,B16-F10,Mouse melanoma,Carcinoma,MTT assay,52% inhibition at 10µg/ml,72 h,1
DCTPep00235,B16-F10,Mouse melanoma,Carcinoma,MTT assay,60% inhibition at 11µg/ml,73 h,1
DCTPep00236,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Nonclonogenic fluorometric microculture cytotoxicity assay,IC50=26 μM,72 h,1
DCTPep00237,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Nonclonogenic fluorometric microculture cytotoxicity assay,IC50=0.76 μM,72 h,1
DCTPep00238,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Nonclonogenic fluorometric microculture cytotoxicity assay,IC50=3.5 μM,72 h,1
DCTPep00239,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=0.39µM,72h,1
DCTPep00239,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,ED50=3.4µM,72h,1
DCTPep00239,PC-12,Lung papillary adenocarcinoma,Carcinoma,MTT assay,ED50=3.8µM,72h,1
DCTPep00240,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,ED50>9µM,72h,1
DCTPep00240,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50>9µM,72h,1
DCTPep00240,PC-12,Lung papillary adenocarcinoma,Carcinoma,MTT assay,ED50>9µM,72h,1
DCTPep00241,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=3.03µM,72h,1
DCTPep00242,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=0.48µM,72h,1
DCTPep00243,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=0.41µM,72h,1
DCTPep00243,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,ED50=4.43µM,72h,1
DCTPep00243,PC-12,Lung papillary adenocarcinoma,Carcinoma,MTT assay,ED50>8µM,72h,1
DCTPep00244,A2058,Amelanotic melanoma,Carcinoma,MTT assay,30% viablity=100 µM,48 h,1
DCTPep00244,SK-MEL-28,Cutaneous melanoma,Carcinoma,MTT assay,35-40% viablity=100 µM,48 h,1
DCTPep00244,B16-F10,Mouse melanoma,Carcinoma,MTT assay,50% viablity=100 µM,48 h,1
DCTPep00244,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% viablity=100 µM,48 h,1
DCTPep00244,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,55% viablity=100 µM,48 h,1
DCTPep00244,SK-MEL-25,Melanoma,Carcinoma,MTT assay,55-60% viablity=100 µM,48 h,1
DCTPep00244,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,90% viablity=100 µM,48 h,1
DCTPep00245,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,35-40% viablity=10 µM,Not available,1
DCTPep00245,PC-3,Prostate carcinoma,Carcinoma,MTT assay,60% viablity=10 µM,Not available,1
DCTPep00247,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,B16,Mouse melanoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00247,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=37.7 μmol/L,36 h,1
DCTPep00248,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,B16,Mouse melanoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00248,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=16.4 μmol/L,36 h,1
DCTPep00249,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,B16,Mouse melanoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00249,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00250,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=15.6 μmol/L,36 h,1
DCTPep00250,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=59.8 μmol/L,36 h,1
DCTPep00250,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=63.5 μmol/L,36 h,1
DCTPep00250,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=64.7 μmol/L,36 h,1
DCTPep00250,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=70.8 μmol/L,36 h,1
DCTPep00250,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=71 μmol/L,36 h,1
DCTPep00250,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00250,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00251,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=14 μmol/L,36 h,1
DCTPep00251,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=53 μmol/L,36 h,1
DCTPep00251,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=58.6 μmol/L,36 h,1
DCTPep00251,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=58.7 μmol/L,36 h,1
DCTPep00251,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=62.3 μmol/L,36 h,1
DCTPep00251,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=62.5 μmol/L,36 h,1
DCTPep00251,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00251,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>83.6 μmol/L,36 h,1
DCTPep00252,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.4 μmol/L,36 h,1
DCTPep00252,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.1 μmol/L,36 h,1
DCTPep00252,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=11.5 μmol/L,36 h,1
DCTPep00252,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.8 μmol/L,36 h,1
DCTPep00252,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=17.8 μmol/L,36 h,1
DCTPep00252,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50=25.2 μmol/L,36 h,1
DCTPep00252,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=33 μmol/L,36 h,1
DCTPep00252,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=4.7 μmol/L,36 h,1
DCTPep00253,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.1 μmol/L,36 h,1
DCTPep00253,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.8 μmol/L,36 h,1
DCTPep00253,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=4.3 μmol/L,36 h,1
DCTPep00253,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=4.4 μmol/L,36 h,1
DCTPep00253,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5 μmol/L,36 h,1
DCTPep00253,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=5.2 μmol/L,36 h,1
DCTPep00253,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=6.4 μmol/L,36 h,1
DCTPep00253,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50=7.5 μmol/L,36 h,1
DCTPep00254,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=2.9 μmol/L,36 h,1
DCTPep00254,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.3 μmol/L,36 h,1
DCTPep00254,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=5 μmol/L,36 h,1
DCTPep00254,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.1 μmol/L,36 h,1
DCTPep00254,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=6.5 μmol/L,36 h,1
DCTPep00254,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=7.8 μmol/L,36 h,1
DCTPep00254,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=8.7 μmol/L,36 h,1
DCTPep00254,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50=9.8 μmol/L,36 h,1
DCTPep00255,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2 μmol/L,36 h,1
DCTPep00255,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=4.1 μmol/L,36 h,1
DCTPep00255,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=4.3 μmol/L,36 h,1
DCTPep00255,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=4.4 μmol/L,36 h,1
DCTPep00255,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=6.2 μmol/L,36 h,1
DCTPep00255,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50=6.4 μmol/L,36 h,1
DCTPep00255,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=8.7 μmol/L,36 h,1
DCTPep00255,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9.7 μmol/L,36 h,1
DCTPep00256,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.2 μmol/L,36 h,1
DCTPep00256,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=2.7 μmol/L,36 h,1
DCTPep00256,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=3.5 μmol/L,36 h,1
DCTPep00256,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=4.6 μmol/L,36 h,1
DCTPep00256,RD,Embryonal rhabdomyosarcoma,Sarcoma,MTT assay,IC50=5.5 μmol/L,36 h,1
DCTPep00256,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.7 μmol/L,36 h,1
DCTPep00256,A-375,Amelanotic melanoma,Carcinoma,MTT assay,IC50=7.2 μmol/L,36 h,1
DCTPep00256,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9.2 μmol/L,36 h,1
DCTPep00257,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=15.32 µM,24h,1
DCTPep00257,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=37.23 µM,24h,1
DCTPep00257,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=45.25 µM,24h,1
DCTPep00257,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=59.78 µM,24h,1
DCTPep00258,MDA-MB-231,Breast adenocarcinoma,Carcinoma,ELISA assay,IC50=0.12 µM,60 min,1
DCTPep00258,MDA-MB-231,Breast adenocarcinoma,Carcinoma,ELISA assay,IC50=0.46 µM,15 min,1
DCTPep00259,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 2000µg/ml,24h,1
DCTPep00259,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 2000µg/ml,24h,1
DCTPep00260,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 2000µg/ml,24h,1
DCTPep00260,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 2000µg/ml,24h,1
DCTPep00261,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 2000µg/ml,24h,1
DCTPep00261,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 2000µg/ml,24h,1
DCTPep00262,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,5% Cytotoxicity at 0.5 µg/ml,6 h,1
DCTPep00264,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,15% Cytotoxicity at 0.5 µg/ml,6 h,1
DCTPep00265,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,27% Cytotoxicity at 0.5 µg/ml,6 h,1
DCTPep00266,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,75% Cytotoxicity at 0.5 µg/ml,6 h,1
DCTPep00266,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTS assay,LC50=13 at 100 µM,72 h,3
DCTPep00266,LNCaP,Prostate carcinoma,Carcinoma,MTS assay,LC50=6 at 100 µM,72 h,3
DCTPep00266,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTS assay,LC50=8 at 100 µM,72 h,3
DCTPep00266,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep00266,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep00266,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=31 µg/ml,24 h,Patent
DCTPep00266,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=34 µg/ml,24 h,Patent
DCTPep00266,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=66 µg/ml,24 h,Patent
DCTPep00267,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,61% Cytotoxicity at 0.5 µg/ml,6 h,1
DCTPep00268,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,15% Cytotoxicity at 0.5 µg/ml,6 h,1
DCTPep00269, --, --, --,ELISA assay,IC50 for MDM2=0.29 µM,Not available,1
DCTPep00269, --, --, --,ELISA assay,IC50 for MDMX-p53=1.6 µM,Not available,1
DCTPep00270, --, --, --,ELISA assay,IC50 for MDM2>100 µM,Not available,1
DCTPep00270, --, --, --,ELISA assay,IC50 for MDMX-p53>100 µM,Not available,1
DCTPep00271, --, --, --,ELISA assay,IC50 for MDM2=4.7 µM,Not available,1
DCTPep00271, --, --, --,ELISA assay,IC50 for MDMX-p53=30 µM,Not available,1
DCTPep00272, --, --, --,ELISA assay,IC50 for MDM2=0.57 µM,Not available,1
DCTPep00273, --, --, --,ELISA assay,IC50 for MDM2>100 µM,Not available,1
DCTPep00274, --, --, --,ELISA assay,IC50 for MDM2>100 µM,Not available,1
DCTPep00275, --, --, --,ELISA assay,IC50 for MDM2=0.02 µM,Not available,1
DCTPep00276, --, --, --,ELISA assay,IC50 for MDM2=1.14 µM,Not available,1
DCTPep00277, --, --, --,ELISA assay,IC50 for MDM2=0.4 µM,Not available,1
DCTPep00278, --, --, --,ELISA assay,IC50 for MDM2=0.01 µM,Not available,1
DCTPep00278, --, --, --,ELISA assay,IC50 for MDMX-p53=0.12 µM,Not available,1
DCTPep00279,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Fluorometric microculture cytotoxicity assay,IC50=7.6 μM,72 h,1
DCTPep00280,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Fluorometric microculture cytotoxicity assay,IC50=2.6 μM,72 h,1
DCTPep00281,HL-60/ADR,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=10.5 ± 3.1 µM,4 h,2
DCTPep00281,MCF-7/mdr,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.0 ± 4.4 µM,4 h,2
DCTPep00281,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=16.0 ± 3.0 µM,4 h,2
DCTPep00281,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=19.6 ± 8.7 µM,4 h,2
DCTPep00281,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=21.0 ± 1.7 µM,4 h,2
DCTPep00281,Kelly,Neuroblastoma,Blastoma,MTT assay,IC50=28 ± 0 µM,30 min,1
DCTPep00281,IGROV-1/CDDP,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=6.4 ± 2.6 µM,4 h,2
DCTPep00281,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=73 ± 2 µM,30 min,1
DCTPep00281,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=75 ± 5 µM,30 min,1
DCTPep00281,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=8.0 ± 1.1 µM,4 h,2
DCTPep00281,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=8.2 ± 1.3 µM,4 h,2
DCTPep00281,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.9 ± 2.8 µM,4 h,2
DCTPep00281,K562/Gleevec,"Blast phase chronic myelogenous leukemia, BCR-ABL6 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=9.0 ± 2.1 µM,4 h,2
DCTPep00282,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=11.0 ± 0 µM,4 h,2
DCTPep00282,Kelly,Neuroblastoma,Blastoma,MTT assay,IC50=14 ± 1 µM,30 min,1
DCTPep00282,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=2.1 ± 0.4 µM,4 h,2
DCTPep00282,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.2 ± 0.6 µM,4 h,2
DCTPep00282,MCF-7/mdr,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.5 ± 1.0 µM,4 h,2
DCTPep00282,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.0 ± 0.3 µM,4 h,2
DCTPep00282,K562/Gleevec,"Blast phase chronic myelogenous leukemia, BCR-ABL2 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.0 ± 0.3 µM,4 h,2
DCTPep00282,HL-60/ADR,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=3.0 ± 0.9 µM,4 h,2
DCTPep00282,IGROV-1/CDDP,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=3.2 ± 1.6 µM,4 h,2
DCTPep00282,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=31 ± 3 µM,30 min,1
DCTPep00282,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=38 ± 3 µM,30 min,1
DCTPep00282,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=6.4 ± 2.0 µM,4 h,2
DCTPep00282,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=8.3 ± 1.2 µM,4 h,2
DCTPep00283,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=21.7 ± 2.5 µM,4 h,2
DCTPep00283,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,IC50=216 ± 36 µM,30 min,1
DCTPep00283,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=23.0 ± 3.6 µM,4 h,2
DCTPep00283,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=248 ± 5 µM,30 min,1
DCTPep00283,Kelly,Neuroblastoma,Blastoma,MTT assay,IC50=78 ± 7 µM,30 min,1
DCTPep00284,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=7.59 µM ,72 h,2
DCTPep00284,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8.0 μM,72 h,1
DCTPep00285,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.21 µM ,72 h,2
DCTPep00285,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=0.6 μM,72 h,1
DCTPep00286,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=0.6 μM,72 h,1
DCTPep00287,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.0 μM,72 h,1
DCTPep00288,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=1.75±0.05µM,48h,1
DCTPep00288,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15.5±0.06µM,5h,1
DCTPep00288,MM96L,Melanoma,Carcinoma,MTT assay,IC50=4.91±0.04µM,5h,1
DCTPep00289,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=1.75±0.05µM,48h,1
DCTPep00289,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15.5±0.06µM,5h,1
DCTPep00289,MM96L,Melanoma,Carcinoma,MTT assay,IC50=4.91±0.04µM,5h,1
DCTPep00290,MM96L,Melanoma,Carcinoma,MTT assay,IC50=2.51±0.03µM,5h,1
DCTPep00290,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5.24±0.40µM,5h,1
DCTPep00291,MM96L,Melanoma,Carcinoma,MTT assay,IC50=2.51±0.03µM,5h,1
DCTPep00291,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5.24±0.40µM,5h,1
DCTPep00292,MM96L,Melanoma,Carcinoma,MTT assay,IC50=1.03±0.03µM,5h,1
DCTPep00292,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=2.91±0.06µM,48h,1
DCTPep00292,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.35±0.31µM,5h,1
DCTPep00293,MM96L,Melanoma,Carcinoma,MTT assay,IC50=1.03±0.03µM,5h,1
DCTPep00293,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=2.91±0.06µM,48h,1
DCTPep00293,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.35±0.31µM,5h,1
DCTPep00294,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=1.32±0.15µM,48h,1
DCTPep00294,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.21±0.43µM,5h,1
DCTPep00294,MM96L,Melanoma,Carcinoma,MTT assay,IC50=3.10±0.06µM,5h,1
DCTPep00295,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=1.32±0.15µM,48h,1
DCTPep00295,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.21±0.43µM,5h,1
DCTPep00295,MM96L,Melanoma,Carcinoma,MTT assay,IC50=3.10±0.06µM,5h,1
DCTPep00296,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL2 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,50% Cell death=13.1±0.4µM,"2, 24h",3
DCTPep00296,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=1.32±0.15µM,48h,1
DCTPep00296,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.21±0.43µM,5h,1
DCTPep00296,MM96L,Melanoma ,Carcinoma,MTT assay,IC50=3.10±0.06µM,5h,1
DCTPep00296,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=6.9µM,72h,2
DCTPep00297,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=8 µg/ml,2h,1
DCTPep00298,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2h,1
DCTPep00299,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2h,1
DCTPep00300,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=128 µg/ml,2h,1
DCTPep00301,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=32 µg/ml,2h,1
DCTPep00302,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=64 µg/ml,2h,1
DCTPep00303,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=128 µg/ml,2h,1
DCTPep00304,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=18 µg/ml,2h,1
DCTPep00305,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=128 µg/ml,2h,1
DCTPep00306,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=64 µg/ml,2h,1
DCTPep00307,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2h,1
DCTPep00308,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=16 µg/ml,2h,1
DCTPep00309,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=16 µg/ml,2h,1
DCTPep00310,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=64 µg/ml,2h,1
DCTPep00311,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2h,1
DCTPep00312,COLO 587,Colon adenocarcinoma,Carcinoma,WST-1 assay,IC50=13.5 µM,72 h,1
DCTPep00312,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=14.1 µM,72 h,1
DCTPep00312,LNCaP,Prostate carcinoma,Carcinoma,WST-1 assay,IC50=15.8 µM,72 h,1
DCTPep00312,LNCaP,Prostate carcinoma,Carcinoma,WST-8 assay,IC50=16±2.5μM,72h,Patent
DCTPep00312,U-251MG,Astrocytoma,Carcinoma,WST-1 assay,IC50=17.0 µM,72 h,1
DCTPep00312,HuCC-T1,Intrahepatic cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,WST-1 assay,IC50=17.1 µM,72 h,1
DCTPep00312,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-1 assay,IC50=18.5 μmol/L,24 h,2
DCTPep00312,SF295,Glioblastoma,Blastoma,WST-1 assay,IC50=19.1 µM,72 h,1
DCTPep00312,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=19.4 µM,72 h,1
DCTPep00312,BT-20,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=20.0 µM,72 h,1
DCTPep00312,H460,Lung large cell carcinoma,Carcinoma,WST-8 assay,IC50=20±1.6μM,72h,Patent
DCTPep00312,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=20±2.5μM,72h,Patent
DCTPep00312,BT-20 ,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=20±2.9μM,72h,Patent
DCTPep00312,SN19,Glioblastoma,Blastoma,WST-1 assay,IC50=21.9 µM,72 h,1
DCTPep00312,H322,Minimally invasive lung adenocarcinoma,Carcinoma,WST-8 assay,IC50=21±3.2μM,72h,Patent
DCTPep00312,SK-BR-3,Breast adenocarcinoma,Carcinoma,WST-1 assay,IC50=25.7 µM,72 h,1
DCTPep00312,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-1 assay,IC50=27.0 µM,72 h,1
DCTPep00312,NCI-H322,Minimally invasive lung adenocarcinoma,Carcinoma,WST-1 assay,IC50=27.1 μmol/L,24 h,2
DCTPep00312,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=27.1±1.5μM,72h,Patent
DCTPep00312,KCCT873,Not available,Not available,WST-8 assay,IC50=27.7±1.4μM,72h,Patent
DCTPep00312,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-1 assay,IC50=28.0 μmol/L,24 h,2
DCTPep00312,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=28±0.5μM,48h,Patent
DCTPep00312,A172,Glioblastoma,Blastoma,WST-1 assay,IC50=30.5 μmol/L,24 h,2
DCTPep00312,A172,Glioblastoma,Blastoma,WST-8 assay,IC50=30.5±0.9μM,72h,Patent
DCTPep00312,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=32±1.6μM,48h,Patent
DCTPep00312,BT-474,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=34.5 µM,72 h,1
DCTPep00312,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,WST-1 assay,IC50=37.1 μmol/L,24 h,2
DCTPep00312,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-1 assay,IC50=37.4 μmol/L,24 h,2
DCTPep00312,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,WST-8 assay,IC50=67±0.9μM,48h,Patent
DCTPep00312,T98G,Glioblastoma,Blastoma,WST-1 assay,IC50=77.3 μmol/L,24 h,2
DCTPep00312,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-8 assay,IC50>100μM,48h,Patent
DCTPep00313,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=4.0 µM,72 h,1
DCTPep00313,BT-20,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=4.8 µM,72 h,1
DCTPep00313,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=4.8μM,72h,Patent
DCTPep00313,SK-BR-3,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=5.3μM,72h,Patent
DCTPep00313,LNCaP,Prostate carcinoma,Carcinoma,WST-1 assay,IC50=6.2 µM,72 h,1
DCTPep00313,LNCaP,Prostate carcinoma,Carcinoma,WST-8 assay,IC50=6.2μM,72h,Patent
DCTPep00313,SF295,Glioblastoma,Blastoma,WST-1 assay,IC50=6.3 µM,72 h,1
DCTPep00313,COLO 587,Colon adenocarcinoma,Carcinoma,WST-1 assay,IC50=6.4 µM,72 h,1
DCTPep00313,SK-BR-3,Breast adenocarcinoma,Carcinoma,WST-1 assay,IC50=6.5 µM,72 h,1
DCTPep00313,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=6.7μM,72h,Patent
DCTPep00313,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=6.8μM,72h,Patent
DCTPep00313,COLO 587,Colon adenocarcinoma,Carcinoma,WST-8 assay,IC50=6.9μM,72h,Patent
DCTPep00313,U-251MG,Astrocytoma,Carcinoma,WST-1 assay,IC50=7.0 µM,72 h,1
DCTPep00313,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-1 assay,IC50=7.8 µM,72 h,1
DCTPep00313,SN19,Glioblastoma,Blastoma,WST-1 assay,IC50=7.8 µM,72 h,1
DCTPep00313,SN19,Glioblastoma,Blastoma,WST-8 assay,IC50=8.2μM,72h,Patent
DCTPep00313,HuCC-T1,Intrahepatic cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,WST-1 assay,IC50=8.3 µM,72 h,1
DCTPep00313,BT-474,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=8.8 µM,72 h,1
DCTPep00313,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,WST-1 assay,IC50=9.3 µM,72 h,1
DCTPep00314,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=49.3±7.2 µM,1h,1
DCTPep00314,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=50.2±4.6 µM,1h,1
DCTPep00315,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,IC50=0.8 mM,72 h,1
DCTPep00315,HCT 15,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=1.0 mM,72 h,1
DCTPep00316,HCT 15,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=0.8 mM,72 h,1
DCTPep00316,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,IC50=1.5 mM,72 h,1
DCTPep00319,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-1 assay,IC50=160 µM,Not available,1
DCTPep00319,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,WST-1 assay,IC50>500 µM,Not available,1
DCTPep00320,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-1 assay,IC50=15 µM,Not available,1
DCTPep00320,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,WST-1 assay,IC50=25 µM,Not available,1
DCTPep00321,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,WST-1 assay,IC50=10 µM,Not available,1
DCTPep00321,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-1 assay,IC50=4 µM,Not available,1
DCTPep00323,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=16 µg/ml,2h,1
DCTPep00324,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00324,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00324,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00325,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=13 µM,Not available,1
DCTPep00325,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=16 µM,Not available,1
DCTPep00325,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50=9 µM,Not available,1
DCTPep00326,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=14 µM,Not available,1
DCTPep00326,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50=19 µM,Not available,1
DCTPep00326,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=23 µM,Not available,1
DCTPep00327,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50=155 µM,Not available,1
DCTPep00327,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=173 µM,Not available,1
DCTPep00327,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=68 µM,Not available,1
DCTPep00328,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50=15 µM,Not available,1
DCTPep00328,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=15 µM,Not available,1
DCTPep00328,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=21 µM,Not available,1
DCTPep00329,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=128 µM,Not available,1
DCTPep00329,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00329,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00330,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=28 µM,Not available,1
DCTPep00330,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50=42 µM,Not available,1
DCTPep00330,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=67 µM,Not available,1
DCTPep00331,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=186 µM,Not available,1
DCTPep00331,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00331,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00332,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=173 µM,Not available,1
DCTPep00332,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00332,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50>211 µM,Not available,1
DCTPep00333,MT-1,Human mammary carcinoma,Carcinoma,MTT assay,EC50=16 µM,Not available,1
DCTPep00333,Meth A,Mouse fibrosarcoma,Sarcoma,MTT assay,EC50=17 µM,Not available,1
DCTPep00333,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=31 µM,Not available,1
DCTPep00334,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,~70% Cytotoxicity=25 mg/L,6 h,2
DCTPep00334,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,~90% Cytotoxicity=25 mg/L,6 h,2
DCTPep00334,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,IC50=14.51 µg/ml,12 h,1
DCTPep00334,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,IC50=14.52 µg/ml,24 h,1
DCTPep00334,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,IC50=15.40 µg/ml,6 h,1
DCTPep00334,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,IC50=15.74 µg/ml,3 h,1
DCTPep00335,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=2.17 µM,3 h,1
DCTPep00335,NCI-H358,Minimally invasive lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.63 mM,3 h,1
DCTPep00336,NCI-H358,Minimally invasive lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.19 µM,3 h,1
DCTPep00336,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=2.64 µM,3 h,1
DCTPep00337,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=6.24 µM,3 h,1
DCTPep00337,NCI-H358,Minimally invasive lung adenocarcinoma,Carcinoma,MTT assay,IC50=8.41 µM,3 h,1
DCTPep00339,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-1 assay,IC50=13.2 μmol/L,24 h,1
DCTPep00339,T98G,Glioblastoma,Blastoma,WST-1 assay,IC50=18.5 μmol/L,24 h,1
DCTPep00339,NCI-H322,Minimally invasive lung adenocarcinoma,Carcinoma,WST-1 assay,IC50=3.6 μmol/L,24 h,1
DCTPep00339,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-1 assay,IC50=5.7 μmol/L,24 h,1
DCTPep00339,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=5.7±0.4μM,72h,Patent
DCTPep00339,KCCT873,Not available,Not available,WST-8 assay,IC50=5.9±0.6μM,72h,Patent
DCTPep00339,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=6.6±0.4μM,72h,Patent
DCTPep00339,A172,Glioblastoma,Blastoma,WST-1 assay,IC50=6.8 μmol/L,24 h,1
DCTPep00339,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,WST-1 assay,IC50=6.8 μmol/L,24 h,1
DCTPep00339,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=6.8±0.3μM,72h,Patent
DCTPep00339,A172,Glioblastoma,Blastoma,WST-8 assay,IC50=6.8±0.4μM,72h,Patent
DCTPep00339,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-1 assay,IC50=7.5 μmol/L,24 h,1
DCTPep00340,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=16 µM,48 h,1
DCTPep00340,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=16±3 µM,48 h,1
DCTPep00340,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=17 µM,48 h,1
DCTPep00341,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=18 ± 1 µM,48 h,1
DCTPep00341,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8±2 µM,48 h,1
DCTPep00341,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9±2 µM,48 h,1
DCTPep00342,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12±2 µM,48 h,1
DCTPep00342,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=14 ± 1 µM,48 h,1
DCTPep00342,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=7±1 µM,48 h,1
DCTPep00343,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11 µM,48 h,1
DCTPep00343,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=16 ± 1 µM,48 h,1
DCTPep00343,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8±2 µM,48 h,1
DCTPep00344,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10±4 µM,48 h,1
DCTPep00344,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12±6 µM,48 h,1
DCTPep00344,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=23±4 µM,48 h,1
DCTPep00345,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11 µM,48 h,1
DCTPep00345,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=12±4 µM,48 h,1
DCTPep00345,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=19±2 µM,48 h,1
DCTPep00346,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=32±2 µM,48 h,1
DCTPep00346,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=70 µM,48 h,1
DCTPep00346,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00347,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=21±4 µM,48 h,1
DCTPep00347,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=43±11 µM,48 h,1
DCTPep00347,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=68±2 µM,48 h,1
DCTPep00348,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15±5 µM,48 h,1
DCTPep00348,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=29 µM,48 h,1
DCTPep00348,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=49±9 µM,48 h,1
DCTPep00349,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15 µM,48 h,1
DCTPep00349,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=29±3 µM,48 h,1
DCTPep00349,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8±2 µM,48 h,1
DCTPep00350,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10±1 µM,48 h,1
DCTPep00350,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=25±3 µM,48 h,1
DCTPep00350,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35±4 µM,48 h,1
DCTPep00351,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=17±2 µM,48 h,1
DCTPep00351,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=22±4 µM,48 h,1
DCTPep00351,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9±3 µM,48 h,1
DCTPep00352,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15±6 µM,48 h,1
DCTPep00352,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16 µM,48 h,1
DCTPep00353,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=13±3 µM,48 h,1
DCTPep00353,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=14±4 µM,48 h,1
DCTPep00353,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8±1 µM,48 h,1
DCTPep00354,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=34 µM,48 h,1
DCTPep00354,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep00355,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00355,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00356,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30±3 µM,48 h,1
DCTPep00356,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00357,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14±2 µM,48 h,1
DCTPep00357,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00357,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>40 µM,48 h,1
DCTPep00358,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14±3 µM,48 h,1
DCTPep00358,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=40 µM,48 h,1
DCTPep00359,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35±5 µM,48 h,1
DCTPep00359,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6±1 µM,48 h,1
DCTPep00359,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>40 µM,48 h,1
DCTPep00360,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14±2 µM,48 h,1
DCTPep00360,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep00360,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>40 µM,48 h,1
DCTPep00361,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=32 µM,48 h,1
DCTPep00361,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00361,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00362,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=35±3 µM,48 h,1
DCTPep00362,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00363,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=11±7 µM,48 h,1
DCTPep00363,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=25±4 µM,48 h,1
DCTPep00363,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00364,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9 µM,48 h,1
DCTPep00364,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9±4 µM,48 h,1
DCTPep00365,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3 µM,48 h,1
DCTPep00365,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=7±2 µM,48 h,1
DCTPep00366,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11±1 µM,48 h,1
DCTPep00366,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=22 µM,48 h,1
DCTPep00366,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9±2 µM,48 h,1
DCTPep00367,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=37 µM,48 h,1
DCTPep00367,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5±2 µM,48 h,1
DCTPep00367,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=5±3 µM,48 h,1
DCTPep00368,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11 µM,48 h,1
DCTPep00368,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=7±2 µM,48 h,1
DCTPep00369,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=42 µM,48 h,1
DCTPep00369,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=7±1 µM,48 h,1
DCTPep00369,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9±3 µM,48 h,1
DCTPep00370,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6±1 µM,48 h,1
DCTPep00371,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=28 µM,48 h,1
DCTPep00371,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3±1 µM,48 h,1
DCTPep00371,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=8±2 µM,48 h,1
DCTPep00372,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=4±1 µM,48 h,1
DCTPep00372,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=48 µM,48 h,1
DCTPep00372,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8±1 µM,48 h,1
DCTPep00373,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12± 3 µM,48 h,1
DCTPep00373,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=3±1 µM,48 h,1
DCTPep00373,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3±1 µM,48 h,1
DCTPep00375,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=18±4 µM,48 h,1
DCTPep00375,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4±1 µM,48 h,1
DCTPep00375,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=5±3 µM,48 h,1
DCTPep00376,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=20 µM,48 h,1
DCTPep00376,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=5±2 µM,48 h,1
DCTPep00376,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6±2 µM,48 h,1
DCTPep00377,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=13 µM,48 h,1
DCTPep00377,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=4±1 µM,48 h,1
DCTPep00377,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=5±1 µM,48 h,1
DCTPep00378,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=12±1 µM,48 h,1
DCTPep00378,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9 µM,48 h,1
DCTPep00379,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=25± 5 µM,48 h,1
DCTPep00379,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3±1 µM,48 h,1
DCTPep00380,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=18 µM,48 h,1
DCTPep00380,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=7±1 µM,48 h,1
DCTPep00380,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep00381,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep00382,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=6±3 µM,48 h,1
DCTPep00382,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep00383,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=15 µM,48 h,1
DCTPep00383,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4 µM,48 h,1
DCTPep00383,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=6 µM,48 h,1
DCTPep00385,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=20 µM,48 h,1
DCTPep00385,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=4 µM,48 h,1
DCTPep00385,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4±2 µM,48 h,1
DCTPep00386,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13±2 µM,48 h,1
DCTPep00386,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=18 µM,48 h,1
DCTPep00386,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep00387,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=20 µM,48 h,1
DCTPep00387,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3±1 µM,48 h,1
DCTPep00387,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=5±2 µM,48 h,1
DCTPep00388,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9 µM,48 h,1
DCTPep00390,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=30 µM,48 h,1
DCTPep00390,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5±1 µM,48 h,1
DCTPep00390,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=6 µM,48 h,1
DCTPep00391,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.9±0.6µM,24h,1
DCTPep00391,MDA-MB-436,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.6±0.5µM,24h,1
DCTPep00391,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.3±0.7µM,24h,1
DCTPep00391,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.1±0.8µM,24h,1
DCTPep00392,MDA-MB-436,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.2±0.4µM,24h,1
DCTPep00392,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3.2±0.6µM,24h,1
DCTPep00392,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.5±0.5µM,24h,1
DCTPep00392,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.7±0.4µM,24h,1
DCTPep00393,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100µM,24h,1
DCTPep00393,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100µM,24h,1
DCTPep00393,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100µM,24h,1
DCTPep00393,MDA-MB-436,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100µM,24h,1
DCTPep00394,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1 μM,Not available,1
DCTPep00395,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9.8 μM,Not available,1
DCTPep00396,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5 μM,Not available,1
DCTPep00397,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.4 μM,Not available,1
DCTPep00398,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>15 μM,Not available,1
DCTPep00399,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9.8μM,Not available,1
DCTPep00400,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.2 μM,Not available,1
DCTPep00401,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>15 μM,Not available,1
DCTPep00402,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.2 μM,Not available,1
DCTPep00403,B16-F10,Mouse melanoma,Carcinoma,WST-1 assay,IC50=1 µM,48 h,1
DCTPep00404,MEC,Cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,MTT assay,24.15Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,HL-7702(L-02),Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,37.22 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,A549,Lung adenocarcinoma,Carcinoma,MTT assay,45.62 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,48.19 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,50.90 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,52.32 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,52.77 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00404,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,57.62 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,MEC,Cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,MTT assay,27.99 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,HL-7702(L-02),Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,37.00 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,A549,Lung adenocarcinoma,Carcinoma,MTT assay,50.64 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50.85 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,55.98 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,56.81 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,59.37 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00405,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,62.73 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,MEC,Cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,MTT assay,19.76 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,HL-7702(L-02),Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,36.25 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,A549,Lung adenocarcinoma,Carcinoma,MTT assay,47.26Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,60.22 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,62.49 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,70.39 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,72.69 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00406,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,73.09 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,MEC,Cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,MTT assay,29.33 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,HL-7702(L-02),Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,38.13 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,A549,Lung adenocarcinoma,Carcinoma,MTT assay,52.50 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,73.07 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,73.705 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,78.045 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,SW1116,Colon adenocarcinoma,Carcinoma,MTT assay,81.465 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00407,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,86.175 Inhibition ratio at 50 µg/ml,24 h,1
DCTPep00408,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=24.76 µM,72 h,1
DCTPep00408,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=25.20 µM,72 h,1
DCTPep00408,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=26.70 µM,72 h,1
DCTPep00408,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=27.00 µM,72 h,1
DCTPep00408,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=27.39 µM,72 h,1
DCTPep00408,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=41.21 µM,72 h,1
DCTPep00408,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=47.69 µM,72 h,1
DCTPep00409,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=13.97 µM,72 h,1
DCTPep00409,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=20.36 µM,72 h,1
DCTPep00409,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=22.06 µM,72 h,1
DCTPep00409,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=22.88 µM,72 h,1
DCTPep00409,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=24.31 µM,72 h,1
DCTPep00409,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=24.63 µM,72 h,1
DCTPep00409,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=46.51 µM,72 h,1
DCTPep00410,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=12.55 µM,72 h,1
DCTPep00410,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=14.53 µM,72 h,1
DCTPep00410,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=14.8 µM,72 h,1
DCTPep00410,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=21.48 µM,72 h,1
DCTPep00410,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=22.25 µM,72 h,1
DCTPep00410,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=22.51 µM,72 h,1
DCTPep00410,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=29.10 µM,72 h,1
DCTPep00411,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=13.16 µM,72 h,1
DCTPep00411,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=13.77 µM,72 h,1
DCTPep00411,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=14.58 µM,72 h,1
DCTPep00411,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=14.80 µM,72 h,1
DCTPep00411,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=15.88 µM,72 h,1
DCTPep00411,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=22.59 µM,72 h,1
DCTPep00411,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=24.32 µM,72 h,1
DCTPep00412,SNU-1,Gastric adenocarcinoma,Carcinoma,Cell Viability assay,<100% cell viability at 5 µM,24 h,1
DCTPep00412,SNU-1,Gastric adenocarcinoma,Carcinoma,Cell Viability assay,<40% cell viability at 50 µM,24 h,1
DCTPep00412,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Cell Viability assay,<60% cell viability at 50 µM,24 h,1
DCTPep00412,SW480,Colon adenocarcinoma,Carcinoma,Cell Viability assay,>100% cell viability at 5 µM,24 h,1
DCTPep00412,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Cell Viability assay,100% cell viability at 5 µM,24 h,1
DCTPep00412,SW480,Colon adenocarcinoma,Carcinoma,Cell Viability assay,60% cell viability at 50 µM,24 h,1
DCTPep00413,SNU-1,Gastric adenocarcinoma,Carcinoma,Cell Viability assay,<100% cell viability at 5 µM,24 h,1
DCTPep00413,SNU-1,Gastric adenocarcinoma,Carcinoma,Cell Viability assay,<20% cell viability at 50 µM,24 h,1
DCTPep00413,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Cell Viability assay,<40% cell viability at 50 µM,24 h,1
DCTPep00413,SW480,Colon adenocarcinoma,Carcinoma,Cell Viability assay,100% cell viability at 5 µM,24 h,1
DCTPep00413,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Cell Viability assay,100% cell viability at 5 µM,24 h,1
DCTPep00413,SW480,Colon adenocarcinoma,Carcinoma,Cell Viability assay,40% cell viability at 50 µM,24 h,1
DCTPep00414,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=1.52±0.05 µmol/L,1 h,1
DCTPep00415,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=1.40±0.09 µmol/L,1 h,1
DCTPep00416,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=18.07±0.48 µmol/L,1 h,1
DCTPep00417,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=1.39±0.02 µmol/L,1 h,1
DCTPep00418,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=20.41±0.64 µmol/L,1 h,1
DCTPep00419,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=1.29±0.03 µmol/L,1 h,1
DCTPep00420,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=4.79±0.23 µmol/L,1 h,1
DCTPep00421,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=2.06±0.01 µmol/L,1 h,1
DCTPep00422,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=4.45±0.19 µmol/L,1 h,1
DCTPep00423,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=2.63±0.07 µmol/L,1 h,1
DCTPep00424,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=3.14±0.06 µmol/L,1 h,1
DCTPep00425,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=2.33±0.06 µmol/L,1 h,1
DCTPep00426,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=2.23±0.10 µmol/L,1 h,1
DCTPep00427,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=3.01±0.08 µmol/L,1 h,1
DCTPep00428,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=9.69±0.38 µmol/L,1 h,1
DCTPep00429,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=12.88±0.15 µmol/L,1 h,1
DCTPep00430,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=7.80±0.26 µmol/L,1 h,1
DCTPep00431,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=1.71±0.07 µmol/L,1 h,1
DCTPep00433,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,LDH leakage assay,EC50=3.3μM,Not available,1
DCTPep00434,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=10±2 μM,Not available,1
DCTPep00434,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=22±5 μM,Not available,1
DCTPep00435,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=11±2 μM,Not available,1
DCTPep00435,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=23±3 μM,Not available,1
DCTPep00436,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=15±2 μM,Not available,1
DCTPep00436,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=92±2 μM,Not available,1
DCTPep00437,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=157±30 μM,Not available,1
DCTPep00437,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=16±5 μM,Not available,1
DCTPep00438,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=12.6±0.6 μM,Not available,1
DCTPep00438,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=99±15 μM,Not available,1
DCTPep00439,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=20±2 μM,Not available,1
DCTPep00439,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=226±21 μM,Not available,1
DCTPep00440,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=1.71±0.6 μM,Not available,1
DCTPep00440,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=7.9±0.3 μM,Not available,1
DCTPep00441,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=26±2 μM,Not available,1
DCTPep00441,Ramos,Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=8±1 μM,Not available,1
DCTPep00442,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=28 µM,Not available,1
DCTPep00442,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=57 μM ,2 h,2
DCTPep00443,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=32 µM,Not available,1
DCTPep00443,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=77 μM ,2 h,2
DCTPep00444,J774A.1,Mouse reticulum cell sarcoma,Sarcoma,MTT assay,IC50=12 µM,96 h,1
DCTPep00444,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=16 µM,48 h,1
DCTPep00444,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=23 µM,24 h,1
DCTPep00444,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=25 µM,96 h,1
DCTPep00444,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=28 µM,48 h,1
DCTPep00444,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=29 µM,24 h,1
DCTPep00444,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=36 µM,72 h,1
DCTPep00444,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=37 µM,48 h,1
DCTPep00444,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=39 µM,24 h,1
DCTPep00444,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=39 µM,2 h,1
DCTPep00444,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=44 µM,2 h,1
DCTPep00444,J774A.1,Mouse reticulum cell sarcoma,Sarcoma,MTT assay,IC50=47 µM,24 h,1
DCTPep00444,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=93 µM,2 h,1
DCTPep00445,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=10 µM,48 h,1
DCTPep00445,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=12 µM,24 h,1
DCTPep00445,J774A.1,Mouse reticulum cell sarcoma,Sarcoma,MTT assay,IC50=17 µM,96 h,1
DCTPep00445,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=18 µM,2 h,1
DCTPep00445,J774A.1,Mouse reticulum cell sarcoma,Sarcoma,MTT assay,IC50=26 µM,24 h,1
DCTPep00445,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=26 µM,2 h,1
DCTPep00445,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=36 µM,96 h,1
DCTPep00445,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=38 µM,2-h,1
DCTPep00445,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=43 µM,24 h,1
DCTPep00445,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=43 µM,48 h,1
DCTPep00445,HuT 102,Mycosis fungoides; Classic mycosis fungoides,Lymphoma,MTT assay,IC50=45 µM,72 h,1
DCTPep00445,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=8 µM,48 h,1
DCTPep00445,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=9 µM,24 h,1
DCTPep00446,LNCaP,Prostate carcinoma,Carcinoma,LDH leakage assay,GI50=0.31±0.15 µM,24 h,1
DCTPep00446,DU145,Prostate carcinoma,Carcinoma,LDH leakage assay,GI50=0.91±0.04 µM,24 h,1
DCTPep00446,PC-3,Prostate carcinoma,Carcinoma,LDH leakage assay,GI50=1.24±0.23 µM,24 h,1
DCTPep00446,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,LDH leakage assay,GI50=2.57±0.75 µM,24 h,1
DCTPep00446,MDA-MB-231,Breast adenocarcinoma,Carcinoma,LDH leakage assay,GI50=8.06±0.50 µM,24 h,1
DCTPep00447,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13.4 µg/ml,24h,1
DCTPep00447,LNCaP C4-2,Prostate carcinoma,Carcinoma,MTT assay,IC50=30 µg/ml,24 h,2
DCTPep00447,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=30 µg/ml,24 h,2
DCTPep00447,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=31 µg/ml,24 h,2
DCTPep00448,HT-29,Colon adenocarcinoma,Carcinoma,Resazurin assay,IC50=132±12µM ,48h,1
DCTPep00448,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,IC50=143±21µM ,48h,1
DCTPep00448,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,IC50=159±7µM ,48h,1
DCTPep00449,L1210,Mouse leukemia,Leukemia,Radioactive precursor assay,IC50=8.33 µM,48h,1
DCTPep00449,HepG2,Hepatoblastoma,Blastoma,Radioactive precursor assay,NA at 40 µM,48h,1
DCTPep00450,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Alamar blue assay,EC50=0.15 µM,72h,1
DCTPep00450,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,Alamar blue assay,EC50=0.19 µM,72h,1
DCTPep00450,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Alamar blue assay,EC50=0.23 µM,72h,1
DCTPep00450,Sup T1,,,Alamar blue assay,EC50=0.23 µM,72h,1
DCTPep00450,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Alamar blue assay,EC50=0.33 µM,72h,1
DCTPep00450,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Alamar blue assay,EC50=0.35 µM,72h,1
DCTPep00451,AZ-97,Colon carcinoma,Carcinoma,MTT assay,Inhibition at 24-28 g/l,Not available,1
DCTPep00452,AZ-97,Colon carcinoma,Carcinoma,MTT assay,Inhibition at 12-15 g/l,Not available,1
DCTPep00453,AZ-97,Colon carcinoma,Carcinoma,MTT assay,Inhibition at 9-11 g/l,Not available,1
DCTPep00454,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,~70% Cytotoxicity=25 mg/L,6 h,1
DCTPep00454,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,~85% Cytotoxicity=25 mg/L,6 h,1
DCTPep00455,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,~72% Cytotoxicity=25 mg/L,6 h,1
DCTPep00455,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,~84% Cytotoxicity=25 mg/L,6 h,1
DCTPep00457,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,~70% Cytotoxicity=25 mg/L,6 h,1
DCTPep00457,HT-1080,Fibrosarcoma,Sarcoma,MTS assay,~90% Cytotoxicity=25 mg/L,6 h,1
DCTPep00458,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=44.7µM,24h,1
DCTPep00458,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=83.49µM,24h,1
DCTPep00458,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=894.7µM,24h,1
DCTPep00459,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=224.8µM,24h,1
DCTPep00459,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=25.04µM,24h,1
DCTPep00459,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=27.72µM,24h,1
DCTPep00460,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=18.7µM,24h,1
DCTPep00460,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=20.97µM,24h,1
DCTPep00460,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=66.4µM,24h,1
DCTPep00461,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.54µM,24h,1
DCTPep00461,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=18.9µM,24h,1
DCTPep00461,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=85.41µM,24h,1
DCTPep00462,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11µM,24h,1
DCTPep00462,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=41.55µM,24h,1
DCTPep00462,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9.39µM,24h,1
DCTPep00463,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.52µM,24h,1
DCTPep00463,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=34.74µM,24h,1
DCTPep00463,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=9.01µM,24h,1
DCTPep00464,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay; cell invasion assay kit(cell invasion),10% Killing=50µM; 25% Inhibition=5µM(In a cell invasion assay); 30% Killing=100µM; 47% Inhibition=50µM(In a cell invasion assay),24h,1
DCTPep00465,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=32 µg/ml,2h,1
DCTPep00466,NCI-H838,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.0μM,24h,1
DCTPep00466,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=13.3μM,24h,1
DCTPep00466,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=15.4μM,24h,1
DCTPep00466,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=4.1μM,24h,1
DCTPep00466,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=6.4μM,24h,1
DCTPep00467,NCI-H838,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=52.5μM,24h,1
DCTPep00467,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=55.9μM,24h,1
DCTPep00468,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=1.4 ± 0.1 µM,24 h,1
DCTPep00468,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=1.8 ± 0.1 µM,4 h,1
DCTPep00468,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=2.1 ± 0.1 µM,2 h,1
DCTPep00468,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50=3.2 ± 0.1 µM,30 min,1
DCTPep00468,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=13 µg/ml,24 h,Patent
DCTPep00468,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=18 µg/ml,24 h,Patent
DCTPep00468,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=23 µg/ml,24 h,Patent
DCTPep00468,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=25 µg/ml,24 h,Patent
DCTPep00468,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep00468,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep00469,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>200 µM,48 h,1
DCTPep00469,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50>200 µM ,48 h,1
DCTPep00470,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=24.2 ± 7.2 µM ,48 h,1
DCTPep00470,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=40.0 ± 3.4 µM,48 h,1
DCTPep00471,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=22.7 ± 1.5 µM,48 h,1
DCTPep00471,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=29.2 ± 4.2 µM,48 h,1
DCTPep00472,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=35.7 ± 1.5 µM,48 h,1
DCTPep00472,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=64.7 ± 12.5 µM,48 h,1
DCTPep00473,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12.0 ± 2.7 µM,48 h,1
DCTPep00473,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=13.7 ± 2.4 µM,48 h,1
DCTPep00473,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50>>100 µM,30 min,1
DCTPep00473,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50>>100 µM,2 h,1
DCTPep00473,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50>>100 µM,4 h,1
DCTPep00473,E42/02,Horse sarcoid,Sarcoma,MTT assay,IC50>>100 µM,24 h,1
DCTPep00474,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,IC50>50 µM,2h,1
DCTPep00475,HT-29,Colon adenocarcinoma,Carcinoma,Crystal violet assay,IC50=4.5µM,48h,1
DCTPep00475,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Crystal violet assay,IC50=4.7µM,48h,1
DCTPep00476,HepG2,Hepatoblastoma,Blastoma,Not available,Not active up to 600 µg/ml,Not available,1
DCTPep00476,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Not available,Not active up to 601 µg/ml,Not available,1
DCTPep00477,LNCaP,Prostate carcinoma,Carcinoma,Trypan blue assay,"At 20 μM,  about 30% Trypan blue-negative cells",18 h,1
DCTPep00477,PC-3-TR,Prostate carcinoma,Carcinoma,Trypan blue assay,"At 20 μM,  about 30% Trypan blue-negative cells",18 h,1
DCTPep00477,RS4;11,Adult B acute lymphoblastic leukemia; B acute lymphoblastic leukemia with t(v;11q23.3) MLL rearranged; B-lymphoblastic leukemia/lymphoma with t(v;11q23.3),Leukemia,Trypan blue assay,"At 20 μM, 10.4% Trypan blue-negative cells",18 h,1
DCTPep00477,MV4-11,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,"At 20 μM, 10.8% Trypan blue-negative cells",18 h,1
DCTPep00477,HCT 115,Human colon cancer,Carcinoma,Trypan blue assay,"At 20 μM, 40% Trypan blue-negative cells",18 h,1
DCTPep00477,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Trypan blue assay,"At 20 μM, 7.7% Trypan blue-negative cells",18 h,1
DCTPep00477,PC-3,Prostate carcinoma,Carcinoma,Trypan blue assay,"At 20 μM, about 50% Trypan blue-negative cells",18 h,1
DCTPep00477,HCT 116,Colon carcinoma,Carcinoma,Trypan blue assay,"At 20 μM, about 70% Trypan blue-negative cells",18 h,1
DCTPep00478,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,100% Cytotoxicity at 5 µM Approx,24 h,1
DCTPep00478,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,99% Cytotoxicity at 4 µM Approx,24 h,1
DCTPep00479,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,90% Cytotoxicity at 5 µM Approx,24 h,1
DCTPep00479,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,95% Cytotoxicity at 4 µM Approx,24 h,1
DCTPep00480,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,70% Cytotoxicity at 5 µM Approx,24 h,1
DCTPep00480,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,80% Cytotoxicity at 4 µM Approx,24 h,1
DCTPep00481,Raji,EBV-related Burkitt lymphoma; Burkitt lymphoma,Lymphoma,MTT assay,IC50=15 µg/ml,Not available,1
DCTPep00481,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=18 µg/ml,Not available,1
DCTPep00481,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=4 µg/ml,Not available,1
DCTPep00482,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=74.7±8.8µM,48h,1
DCTPep00482,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=76.2±0.8µM,48h,1
DCTPep00483,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=148.2±8.8µM,48h,1
DCTPep00483,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=97.0±15.4µM,48h,1
DCTPep00484,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=23.5±7.0 µM,48h,1
DCTPep00484,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=26.3±7.5 µM,48h,1
DCTPep00485,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=24.12 µg/ml,"0.5, 3, 6h",1
DCTPep00486,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=28.51 µg/ml,"0.5, 3, 6h",1
DCTPep00487,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,CC50=27.92 µg/ml,"0.5, 3, 6h",1
DCTPep00488,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=28.11 µg/ml,"0.5, 3, 6h",1
DCTPep00489,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=103.11 µg/ml,"0.5, 3, 6h",1
DCTPep00490,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=2.06 μg/mL,24-72h,1
DCTPep00491,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=45-50µM,24h,1
DCTPep00492,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10-20 μmol/L,12h,1
DCTPep00494,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTS assay,LC50=21 at 100 µM,72 h,1
DCTPep00494,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTS assay,LC50=24 at 100 µM,72 h,1
DCTPep00494,LNCaP,Prostate carcinoma,Carcinoma,MTS assay,LC50=27 at 100 µM,72 h,1
DCTPep00495,PC-3,Prostate carcinoma,Carcinoma,MTT assay,At 200 µg/ml induced 2.5% cell death,48h,1
DCTPep00495,HepG2,Hepatoblastoma,Blastoma,MTT assay,At 200 µg/ml induced 4.3% cell death,48h,1
DCTPep00496,FEMX-I,Melanoma,Carcinoma,MTT assay,IC50>350 µM,6 h,1
DCTPep00497,DU145,Prostate carcinoma,Carcinoma,MTS assay,~87%Inhibit=5 µg/mL,24 h,1
DCTPep00497,DU145,Prostate carcinoma,Carcinoma,MTS assay,~87%Inhibit=5 µg/mL,24 h,1
DCTPep00497,DU145,Prostate carcinoma,Carcinoma,MTS assay,~87%Inhibit=5 µg/mL,24 h,1
DCTPep00498,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,67.2% maximum inhibitory rate at 8 mg/kg,48 h,1
DCTPep00498,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,69.6% maximum inhibitory rate at 8 mg/kg,48 h,1
DCTPep00498,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,70% maximum inhibitory rate at 8 mg/kg,48 h,1
DCTPep00499,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=27 µM,Not available,1
DCTPep00500,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.7 µM,Not available,1
DCTPep00501,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=16.3 µM,Not available,1
DCTPep00502,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.1 µM,Not available,1
DCTPep00503,HepG2,Hepatoblastoma,Blastoma,Non-Radioactive Cell Proliferation assay,50% Cell death=52.51±3.6 µM,72h,1
DCTPep00504,HCT 116,Colon carcinoma,Carcinoma,Cell Viability assay,Cell viability >40% at 12.5μM approx,24 h,1
DCTPep00504,HROC40,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >45% at 12.5μM approx,24 h,1
DCTPep00504,HROC107,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 12.5μM approx,24 h,1
DCTPep00504,HCT 116,Colon carcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00504,HROC60,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00504,HROC18,Cecum adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >55% at 12.5μM approx,24 h,1
DCTPep00504,HROC24,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >55% at 12.5μM approx,24 h,1
DCTPep00504,HROC32,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >55% at 12.5μM approx,24 h,1
DCTPep00504,HROC24,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >60% at 25μM approx,1 h,1
DCTPep00504,HROC32,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >60% at 25μM approx,1 h,1
DCTPep00504,HROC40,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >60% at 25μM approx,1 h,1
DCTPep00504,HROC60,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >70% at 12.5μM approx,24 h,1
DCTPep00504,HROC113,Colon adenocarcinoma; Lynch syndrome,Carcinoma,Cell Viability assay,Cell viability >80% at 12.5μM approx,24 h,1
DCTPep00505,HCT 116,Colon carcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 12.5μM approx,24 h,1
DCTPep00505,HCT 116,Colon carcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 12.5μM approx.,1 h,1
DCTPep00505,HROC40,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00505,HROC60,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00505,HROC24,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >60% at 25μM approx,1 h,1
DCTPep00505,HROC107,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >70% at 12.5μM approx,24 h,1
DCTPep00505,HROC113,Colon adenocarcinoma; Lynch syndrome,Carcinoma,Cell Viability assay,Cell viability >70% at 12.5μM approx,24 h,1
DCTPep00505,HROC24,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >70% at 12.5μM approx,24 h,1
DCTPep00505,HROC60,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >70% at 12.5μM approx,24 h,1
DCTPep00505,HROC18,Cecum adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >75% at 12.5μM approx,24 h,1
DCTPep00505,HROC32,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >85% at 12.5μM approx,24 h,1
DCTPep00505,HROC40,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >85% at 12.5μM approx,24 h,1
DCTPep00505,HROC32,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability=50% at 12.5μM approx.,1 h,1
DCTPep00506,HCT 116,Colon carcinoma,Carcinoma,Cell Viability assay,Cell viability >40% at 12.5μM approx,24 h,1
DCTPep00506,HROC24,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00506,HROC40,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00506,HROC60,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >50% at 25μM approx,1 h,1
DCTPep00506,HROC18,Cecum adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >55% at 12.5μM approx,24 h,1
DCTPep00506,HROC24,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >55% at 12.5μM approx,24 h,1
DCTPep00506,HROC60,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >60% at 12.5μM approx,24 h,1
DCTPep00506,HROC107,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >65% at 12.5μM approx,24 h,1
DCTPep00506,HROC113,Colon adenocarcinoma; Lynch syndrome,Carcinoma,Cell Viability assay,Cell viability >65% at 12.5μM approx,24 h,1
DCTPep00506,HROC32,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >80% at 12.5μM approx,24 h,1
DCTPep00506,HROC40,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability >80% at 12.5μM approx,24 h,1
DCTPep00506,HCT 116,Colon carcinoma,Carcinoma,Cell Viability assay,Cell viability=50% at 12.5μM approx.,1 h,1
DCTPep00506,HROC32,Colon adenocarcinoma,Carcinoma,Cell Viability assay,Cell viability=50% at 12.5μM approx.,1 h,1
DCTPep00507,A549,Lung adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=106±5 μg/mL  ,24h,1
DCTPep00507,HT-29,Colon adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50>300 μg/mL,24h,1
DCTPep00507,MDA-MB-231,Breast adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50>300 μg/mL,24h,1
DCTPep00508,HT-29,Colon adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=110±4 μg/mL,24h,1
DCTPep00508,A549,Lung adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=56±4 μg/mL,24h,1
DCTPep00508,MDA-MB-231,Breast adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=62±2 μg/mL,24h,1
DCTPep00509,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Colorimetric detection assay,25% Cytotoxicity=80µM,24h,1
DCTPep00509,DU145,Prostate carcinoma,Carcinoma,MTS assay,CC50>30µM,48h,2
DCTPep00509,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,CC50>30µM,48h,2
DCTPep00509,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTS assay,CC50>30µM,48h,2
DCTPep00510,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Colorimetric detection assay,28% Cytotoxicity=40µM; 62% Cytotoxicity=80µM,24h,1
DCTPep00510,DU145,Prostate carcinoma,Carcinoma,MTS assay,CC50=18µM,48h,2
DCTPep00510,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,CC50=30µM,48h,2
DCTPep00510,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTS assay,CC50>30µM,48h,2
DCTPep00510,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=12.8±1.1µg/ml,24h,3
DCTPep00511,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=1.2±0.2 μM,24h,1
DCTPep00511,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=12.3±4.7 μM,24h,1
DCTPep00511,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=3.1±0.2 μM,24h,1
DCTPep00512,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=0.9±0.3 μM,24h,1
DCTPep00512,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=2.4±0.1 μM,24h,1
DCTPep00512,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=3.9±0.4 μM,24h,1
DCTPep00513,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=2.5±0.3 μM,24h,1
DCTPep00513,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=5.4±0.4 μM,24h,1
DCTPep00513,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay ,LC50=6.3±1.9 μM,24h,1
DCTPep00514,A2058,Amelanotic melanoma,Carcinoma,MTT assay,IC50=140 µM ,24h,1
DCTPep00514,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,IC50=172.1 µM ,24h,1
DCTPep00514,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=251.25 µM ,24h,1
DCTPep00514,U-87MG ATCC,Glioblastoma,Blastoma,MTT assay,IC50=311.7 µM ,24h,1
DCTPep00514,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=320.3 µM ,24h,1
DCTPep00514,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=432.5 µM ,24h,1
DCTPep00514,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=77.9 µM ,24h,1
DCTPep00515,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=11.5±2.6 μM,24h,1
DCTPep00515,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6.0±0.6 μM,24h,1
DCTPep00515,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6.2±0.6 μM,24h,1
DCTPep00516,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=2.5±0.2 μM,24h,1
DCTPep00516,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6.6±0.3 μM,24h,1
DCTPep00516,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=9.5±1.3 μM,24h,1
DCTPep00517,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=8.6 µM,48h,1
DCTPep00517,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.9 µM,48h,1
DCTPep00518,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=19.9 µM,48h,1
DCTPep00518,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=44.7 µM,48h,1
DCTPep00519,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=36.6 µM,48h,1
DCTPep00519,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=38.9 µM,48h,1
DCTPep00520,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=1.3 µM,48h,1
DCTPep00520,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.7 µM,48h,1
DCTPep00521,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=14.8 µM,48h,1
DCTPep00521,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.8 µM,48h,1
DCTPep00522,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=10.5 µM,48h,1
DCTPep00522,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.0 µM,48h,1
DCTPep00523,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=5.5 µM,48h,1
DCTPep00523,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=5.5 µM,48h,1
DCTPep00523,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.3 µM,48h,1
DCTPep00523,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.6 µM,48h,1
DCTPep00524,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=1.1 µM,48h,1
DCTPep00524,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=3.3. µM,48h,1
DCTPep00524,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.6 µM,48h,1
DCTPep00524,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.4 µM,48h,1
DCTPep00525,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=14.5 µM,48h,1
DCTPep00525,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=16.2 µM,48h,1
DCTPep00526,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.5 µM,48h,1
DCTPep00526,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=8.7 µM,48h,1
DCTPep00527,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=22.2±1.3 μM,48h,1
DCTPep00527,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=24.6±3.7 μM,48h,1
DCTPep00527,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=27.0±2.1 μM,48h,1
DCTPep00527,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=45.1±3.7 μM,48h,1
DCTPep00527,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=57.6±6.3 μM,48h,1
DCTPep00528,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=17.0 µM,48h,1
DCTPep00528,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=19.1 µM,48h,1
DCTPep00529,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.9 µM,48h,1
DCTPep00529,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=5.0 µM,48h,1
DCTPep00530,MM1.S,Plasma cell myeloma; Multiple myeloma,Carcinoma,Not available,25% Inhibition=10µM,Not available,1
DCTPep00531,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>200µg/ml,1h,1
DCTPep00532,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=199µg/ml,1h,1
DCTPep00533,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=131µg/ml,1h,1
DCTPep00534,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=173µg/ml,1h,1
DCTPep00535,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=106µg/ml,1h,1
DCTPep00536,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>200µg/ml,1h,1
DCTPep00537,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=97µg/ml,1h,1
DCTPep00538,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>200µg/ml,1h,1
DCTPep00539,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=37µg/ml,1h,1
DCTPep00540,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=47µg/ml,1h,1
DCTPep00541,A549,Lung adenocarcinoma,Carcinoma,CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay,IC50>250µg/ml,24h,1
DCTPep00542,A549,Lung adenocarcinoma,Carcinoma,CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay,IC50=97.0±9.8µg/ml,24h,1
DCTPep00543,A549,Lung adenocarcinoma,Carcinoma,CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay,IC50=93.3±5.1µg/ml,24h,1
DCTPep00544,A549,Lung adenocarcinoma,Carcinoma,CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay,IC50=56.0±9.3µg/ml,24h,1
DCTPep00545,A549,Lung adenocarcinoma,Carcinoma,CellTiter 96® AQueous Non-Radioactive Cell Proliferation assay,IC50=215.3±19.7µg/ml,24h,1
DCTPep00546,PC-12,Lung papillary adenocarcinoma,Carcinoma,WST-1 assay,IC50=225µg/ml,Not available,1
DCTPep00547,PC-12,Lung papillary adenocarcinoma,Carcinoma,WST-1 assay,IC50=595µg/ml,Not available,1
DCTPep00548,PC-12,Lung papillary adenocarcinoma,Carcinoma,WST-1 assay,IC50=629µg/ml,Not available,1
DCTPep00549,PC-3,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=2.24 μM,72h,1
DCTPep00549,DU145,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=3.32 μM,72h,1
DCTPep00549,LNCaP,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=5.03 μM,72h,1
DCTPep00550,PC-3,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=2.65 μM,72h,1
DCTPep00550,DU145,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=3.11 μM,72h,1
DCTPep00550,LNCaP,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=4.31 μM,72h,1
DCTPep00551,LNCaP,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=0.21 μM,72h,1
DCTPep00551,DU145,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=0.55 μM,72h,1
DCTPep00551,PC-3,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=0.76 μM,72h,1
DCTPep00552,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=60 mg/ml,24h,1
DCTPep00553,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=50 mg/ml,24h,1
DCTPep00553,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=50 mg/ml,24h,1
DCTPep00554,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=100 mg/ml,24h,1
DCTPep00555,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=110 mg/ml,24h,1
DCTPep00556,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=70 mg/ml,24h,1
DCTPep00557,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=60 mg/ml,24h,1
DCTPep00558,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=2.92µM,72h,2
DCTPep00558,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50>100µM; IC90>100µM,48h,1
DCTPep00559,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=4.14µM,72h,2
DCTPep00559,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,ED50>8µM,72h,2
DCTPep00559,PC-12,Lung papillary adenocarcinoma,Carcinoma,MTT assay,ED50>8µM,72h,2
DCTPep00559,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=5µM; IC90=30µM,48h,1
DCTPep00560,L5178Y,Mouse leukemia,Leukemia,MTT assay,ED50=3.61µM,72h,2
DCTPep00560,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=30µM; IC90=50µM,48h,1
DCTPep00561,A-375,Amelanotic melanoma,Carcinoma,MTS assay,LC50=9.3±0.8 µM ,24h,1
DCTPep00561,SBcl-2,Serum B cell lymphoma 2,Lymphoma,MTS assay,LC50=9.4±0.5 µM ,24h,1
DCTPep00562,SBcl-2,Serum B cell lymphoma 2,Lymphoma,MTS assay,LC50>100 µM ,24h,1
DCTPep00563,SBcl-2,Serum B cell lymphoma 2,Lymphoma,MTS assay,LC50=10.4±0.7 µM ,24h,1
DCTPep00563,A-375,Amelanotic melanoma,Carcinoma,MTS assay,LC50=23.3±1.7 µM ,24h,1
DCTPep00564,SBcl-2,Serum B cell lymphoma 2,Lymphoma,MTS assay,LC50=5.0±0.4 µM ,24h,1
DCTPep00564,A-375,Amelanotic melanoma,Carcinoma,MTS assay,LC50=61.8±0.1 µM ,24h,1
DCTPep00565,SBcl-2,Serum B cell lymphoma 2,Lymphoma,MTS assay,LC50=16.0±0.5 µM ,24h,1
DCTPep00565,A-375,Amelanotic melanoma,Carcinoma,MTS assay,LC50=21.0±1.2 µM ,24h,1
DCTPep00566,A-375,Amelanotic melanoma,Carcinoma,MTS assay,LC50=13.9±0.4 µM ,24h,1
DCTPep00566,SBcl-2,Serum B cell lymphoma 2,Lymphoma,MTS assay,LC50=4.6±0.2 µM ,24h,1
DCTPep00567,HepG2,Hepatoblastoma,Blastoma,Cell Proliferation Kit II (XTT) assay,Not active up to 40 µM,24h,1
DCTPep00568,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=18.73±1.82µM,24h,1
DCTPep00568,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.04±0.26µM,24h,1
DCTPep00569,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=18.73±1.82µM,24h,1
DCTPep00569,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.04±0.26µM,24h,1
DCTPep00570,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.30±0.44µM,24h,1
DCTPep00570,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=19.26±1.37µM,24h,1
DCTPep00571,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.09±0.18µM,24h,1
DCTPep00571,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=9.83±0.78µM,24h,1
DCTPep00572,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.58±0.48µM,24h,1
DCTPep00572,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=11.42±1.00µM,24h,1
DCTPep00573,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.58±0.48µM,24h,1
DCTPep00573,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=11.42±1.00µM,24h,1
DCTPep00574,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=21.94±1.90µM,24h,1
DCTPep00574,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=36.92±3.25µM,24h,1
DCTPep00575,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=21.94±1.90µM,24h,1
DCTPep00575,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=36.92±3.25µM,24h,1
DCTPep00576,A549,Lung adenocarcinoma,Carcinoma,CyQuant stain assay (cell invasion),28% Inhibition=5µM(In a cell invasion assay); 56% Inhibition=50µM(In a cell invasion assay),36h,1
DCTPep00577,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.5±0.03 μM,24h,1
DCTPep00577,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5.2±0.14 μM,24h,1
DCTPep00577,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=6.1±0.02 μM,24h,1
DCTPep00577,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=7.7±0.23 μM,24h,1
DCTPep00578,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.8±0.02 μM,24h,1
DCTPep00578,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=3.5±0.03 μM,24h,1
DCTPep00578,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.8±0.08 μM,24h,1
DCTPep00578,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=5.8±0.36 μM,24h,1
DCTPep00579,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.42±0.30 μM ,24h,1
DCTPep00579,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=19.16±0.38 μM ,24h,1
DCTPep00579,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=21.38±0.56 μM ,24h,1
DCTPep00579,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8.65 ±0.38 μM ,24h,1
DCTPep00580,HeLa S3,Breast cancer,Carcinoma,Resazurin assay,IC50>10 µM,4h,1
DCTPep00581,HeLa S3,Breast cancer,Carcinoma,Resazurin assay,IC50=1 µM,4h,1
DCTPep00581,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=25 µM,4h,1
DCTPep00581,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=6.25 µM,4h,1
DCTPep00582,HeLa S3,Breast cancer,Carcinoma,Resazurin assay,IC50 < 1 µM ,4h,1
DCTPep00582,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50 < 1 µM ,4h,1
DCTPep00582,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=1.56 µM ,4h,1
DCTPep00582,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,IC50>12.5 µM ,4h,1
DCTPep00582,Jurkat E6.1,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Resazurin assay,IC50>12.5 µM ,4h,1
DCTPep00583,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=104.05 μg/mL,48h,1
DCTPep00583,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=188.23 μg/mL,48h,1
DCTPep00583,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=247.32 μg/mL,48h,1
DCTPep00583,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=446.72 μg/mL,48h,1
DCTPep00584,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=0.60±0.17 mg/mL ,48h,1
DCTPep00584,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=0.65±0.42 mg/mL ,48h,1
DCTPep00585,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,IC50=2.5±0.5µM,24h,1
DCTPep00585,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,IC50=4.3±0.2µM,24h,1
DCTPep00585,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,IC50=5.6±0.4µM,24h,1
DCTPep00586,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,IC50=11±2µM,24h,1
DCTPep00586,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,IC50=2.1±0.7µM,24h,1
DCTPep00586,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,IC50=3.6±0.5µM,24h,1
DCTPep00587,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=1.8µM,24h,1
DCTPep00587,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=2.9µM,24h,1
DCTPep00587,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=4.3µM,24h,1
DCTPep00588,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=1.8 μM,24h,1
DCTPep00588,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=2.9 μM,24h,1
DCTPep00588,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=4.3 μM,24h,1
DCTPep00589,A549,Lung adenocarcinoma,Carcinoma,Trypan Blue exclusion assay,Not active up to 170 µM,24h,1
DCTPep00590,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.3±0.4 μM ,24h,1
DCTPep00591,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=34.5±1.6 μM,24h,1
DCTPep00592,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.3±0.2 μM,24h,1
DCTPep00592,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.5±0.3 μM,24h,1
DCTPep00592,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.8±0.6 μM,24h,1
DCTPep00593,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.5±0.3 μM ,24h,1
DCTPep00593,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.7±0.1 μM,24h,1
DCTPep00593,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.3±0.2 μM ,24h,1
DCTPep00594,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=141.7±12.2 µM,6h,1
DCTPep00594,SACC-83,Salivary gland adenoid cystic carcinoma,Carcinoma,MTT assay,IC50=27.9±7.7 µM,6h,1
DCTPep00594,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=62.6±8.4 µM,6h,1
DCTPep00594,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=69.1±1.6 µM,6h,1
DCTPep00594,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=77.9±0.9 µM,6h,1
DCTPep00595,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=14.2±0.5 µM,2h,1
DCTPep00595,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=14.8±1.6 μM ,2h,2
DCTPep00595,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=7.5±1.2 µM,2h,1
DCTPep00595,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8.1±1.6 µM,2h,1
DCTPep00595,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8.1±1.6 μM ,2h,2
DCTPep00595,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=8.4±1.1 µm,2h,1
DCTPep00595,SACC-83,Salivary gland adenoid cystic carcinoma,Carcinoma,MTT assay,IC50=9.9±1.7 µM,2h,1
DCTPep00596,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>600µg/ml,24h,1
DCTPep00597,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>600µg/ml,24h,1
DCTPep00598,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=640±150µg/ml,24h,1
DCTPep00599,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=230 ± 90µg/ml,24h,1
DCTPep00600,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.33 µM,24h,1
DCTPep00600,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=3.62 µM,24h,1
DCTPep00600,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5.52 µM,24h,1
DCTPep00600,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=6.83 µM,24h,1
DCTPep00601,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=109.68µM,24h,1
DCTPep00601,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=92.04µM,24h,1
DCTPep00602,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.0 µM,24h,1
DCTPep00602,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.80 µM,24h,1
DCTPep00602,B16,Mouse melanoma,Carcinoma,MTT assay,IC50=3.51 µM,24h,1
DCTPep00602,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.86 µM,24h,1
DCTPep00603,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Trypan blue assay,IC 50=141.62 μg/mL  ,48h,1
DCTPep00603,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=97.3 μg/mL (18.65 μM),24h,2
DCTPep00604,U-87MG ATCC,Glioblastoma,Blastoma,MTT assay,IC50=16.34±1.47 µg/mL,48h,1
DCTPep00604,A172,Glioblastoma,Blastoma,MTT assay,IC50=21.96±3.68 µg/mL ,48h,1
DCTPep00605,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,22.2±2.4% Cell death=10µM,30min,1
DCTPep00606,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,20.0±1.4% Cell death=10µM,30min,1
DCTPep00607,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,13.7±8.1% Cell death=10µM,30min,1
DCTPep00608,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,43.1±7.2% Cell death=10µM,30min,1
DCTPep00609,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,44.6±8.5% Cell death=10µM,30min,1
DCTPep00610,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,5.9±1.3% Cell death=10	µM,30min,1
DCTPep00611,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,PI uptake assay,7.9±2.4% Cell death=10µM,30min,1
DCTPep00612,PC-3,Prostate carcinoma,Carcinoma,MTT assay,100% Killing=25 µM,48h,1
DCTPep00612,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,100% Killing=25 µM,48h,1
DCTPep00613,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI staining assay,LD50=5.39µM,Not available,1
DCTPep00614,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI staining assay,LD50=8.79µM,Not available,1
DCTPep00615,Eca 109,Esophageal squamous cell carcinoma; Squamous cell carcinoma of the esophagus,Carcinoma,MTT assay,30% Killing=20µM,24h,1
DCTPep00616,A549,Lung adenocarcinoma,Carcinoma,Alamar blue assay,Not active up to 500µg/ml,24h,1
DCTPep00617,A549,Lung adenocarcinoma,Carcinoma,Alamar blue assay,Not active up to 500µg/ml,24h,1
DCTPep00618,A549,Lung adenocarcinoma,Carcinoma,Alamar blue assay,Not active up to 500 µg/ml,24h,1
DCTPep00619,A549,Lung adenocarcinoma,Carcinoma,Alamar blue assay,Not active up to 250 µg/ml,24h,1
DCTPep00620,A549,Lung adenocarcinoma,Carcinoma,Alamar blue assay,Not active up to 500 µg/ml,24h,1
DCTPep00621,A549,Lung adenocarcinoma,Carcinoma,Alamar blue assay,Not active up to 500µg/ml,24h,1
DCTPep00622,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=40.12±0.13 μM,48h,1
DCTPep00622,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=45.01±0.16 μM,48h,1
DCTPep00622,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00623,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=52.89±0.11 μM,48h,1
DCTPep00623,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00623,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00624,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00624,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00624,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00625,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=58.89±0.09 μM,48h,1
DCTPep00625,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=70.61±0.11 μM,48h,1
DCTPep00625,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=83.55±0.20 μM,48h,1
DCTPep00626,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35.22±0.08 μM,48h,1
DCTPep00626,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=39.11±0.07 μM,48h,1
DCTPep00626,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=53.44±0.14 μM,48h,1
DCTPep00627,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=74.13±0.07 μM,48h,1
DCTPep00627,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=85.44±0.08 μM,48h,1
DCTPep00627,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00628,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=19.75±0.07 μM,48h,1
DCTPep00628,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=35.44±0.13 μM,48h,1
DCTPep00628,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00629,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00629,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00629,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00630,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=28.72±0.15 μM,48h,1
DCTPep00630,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=82.27±0.13 μM,48h,1
DCTPep00630,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00631,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00631,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00631,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00632,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=43.29±0.04 μM,48h,1
DCTPep00632,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=55.13±0.07 μM,48h,1
DCTPep00632,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00633,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=41.84±0.07 μM,48h,1
DCTPep00633,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00633,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00634,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00634,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00634,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00635,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=45.38±0.03 μM,48h,1
DCTPep00635,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=46.07±0.05 μM,48h,1
DCTPep00635,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00636,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00636,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00636,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00637,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=83.51±0.46 μM,48h,1
DCTPep00637,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00637,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00638,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00638,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00638,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00639,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00639,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00639,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 μM,48h,1
DCTPep00640,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=58.4±13.7 μM,2h,1
DCTPep00640,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=73.9±13.6 μM,2h,1
DCTPep00641,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=43.6±7.9 μM,2h,1
DCTPep00641,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=52.0±5.8 μM,2h,1
DCTPep00642,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=74.9±13.3 μM,2h,1
DCTPep00642,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=93.5±19.4 μM,2h,1
DCTPep00643,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=35.5±3.9 μM,2h,1
DCTPep00643,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=54.4±3.0 μM,2h,1
DCTPep00644,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=22.0±2.6 μM,2h,1
DCTPep00644,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=28.0±4.6 μM,2h,1
DCTPep00646,HSC-4,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,IC50=97 μg/mL,24h,1
DCTPep00647,HSC-4,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,IC50=26 μg/mL,24h,1
DCTPep00647,HSC-4,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,IC50=29 μg/mL,24h,1
DCTPep00647,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=34 μg/mL ,24h,1
DCTPep00648,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,EC50=125µg/ml,24h,1
DCTPep00648,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,EC50=31.2µg/ml,24h,1
DCTPep00649,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50=70µM,Not available,1
DCTPep00650,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50=100µM,Not available,1
DCTPep00651,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50>100µM,Not available,1
DCTPep00652,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50=60µM,Not available,1
DCTPep00653,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>64µM,24h,1
DCTPep00654,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>64µM,24h,1
DCTPep00655,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=32µM,24h,1
DCTPep00656,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>64µM,24h,1
DCTPep00657,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=64µM,24h,1
DCTPep00658,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=64µM,24h,1
DCTPep00659,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=32µM,24h,1
DCTPep00660,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>64µM,24h,1
DCTPep00661,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurine assay,Not active up to 44 µg/ml,72h,1
DCTPep00661,HepG2,Hepatoblastoma,Blastoma,Resazurine assay,Not active up to 44 µg/ml,72h,1
DCTPep00662,Hep 3B,Childhood hepatocellular carcinoma,Carcinoma,MTT assay,85% Cytotoxicity=100µg/ml,Not available,1
DCTPep00663,Hep 3B,Childhood hepatocellular carcinoma,Carcinoma,MTT assay,90% Cytotoxicity=100µg/ml,Not available,1
DCTPep00664,Hep 3B,Childhood hepatocellular carcinoma,Carcinoma,MTT assay,80% Cytotoxicity=100µg/ml,Not available,1
DCTPep00665,Hep 3B,Childhood hepatocellular carcinoma,Carcinoma,MTT assay,85% Cytotoxicity=100µg/ml,Not available,1
DCTPep00666,A549,Lung adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µg/ml,24h,1
DCTPep00667,A549,Lung adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µg/ml,24h,1
DCTPep00668,A549,Lung adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µg/ml,24h,1
DCTPep00669,CaCo-2,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,0% Killing=12µM; 20% Killing=17µM,Not available,1
DCTPep00669,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability Assay,0% Killing=8µM; 50% Killing=17µM,Not available,1
DCTPep00670,NB4,Acute promyelocytic leukemia with PML-RARA ; Acute promyelocytic leukemia,Leukemia,MTT assay,IC50=11.479µM,48h,1
DCTPep00670,MKN 45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=4.686µM,48h,1
DCTPep00671,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50>60µM,72h,1
DCTPep00671,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>600µM,72h,1
DCTPep00672,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=184.9 µM,24h,1
DCTPep00672,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=196.1 µM,24h,1
DCTPep00672,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=223.9 µM,24h,1
DCTPep00673,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=228.5 µM,24h,1
DCTPep00673,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=303.2 µM,24h,1
DCTPep00673,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=349.5 µM,24h,1
DCTPep00674,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00675,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00676,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00677,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00678,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00679,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00680,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00681,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00682,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50=50µM,48h,1
DCTPep00683,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00684,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00685,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00686,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00687,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00688,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50=60µM,48h,1
DCTPep00689,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep0069,HCT 116,Colon carcinoma,Carcinoma,MTT assay,~10% Cytotoxicity at 100 µM,24 h,1
DCTPep00690,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00691,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00692,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00693,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50>100µM,48h,1
DCTPep00694,A549,Lung adenocarcinoma,Carcinoma,PI flow cytometric assay,IC50=59µM,24h,1
DCTPep00695,A549,Lung adenocarcinoma,Carcinoma,PI flow cytometric assay,10% Killing=96 µM,24h,1
DCTPep00695,HeLa S3,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=93 µg/ml,24h,2
DCTPep00696,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=21.4±2.7µM,48h,1
DCTPep00696,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=23.2±2.4µM,48h,1
DCTPep00696,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL17 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=27.4±3.5µM,48h,1
DCTPep00696,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL18 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=31.3±4.0µM,48h,1
DCTPep00697,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=70.7±6.3µM,48h,1
DCTPep00697,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL24 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=76.3±5.4µM,48h,1
DCTPep00697,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=77.9±6.7µM,48h,1
DCTPep00697,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL25 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=82.5±6.8µM,48h,1
DCTPep00698,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=79.5±6.9µM,48h,1
DCTPep00698,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=83.2±6.7µM,48h,1
DCTPep00698,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL23 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=89.4±7.3µM,48h,1
DCTPep00698,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL24 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50>100µM,48h,1
DCTPep00699,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=30.3±4.2µM,48h,1
DCTPep00699,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=33.5±3.3µM,48h,1
DCTPep00699,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL20 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=34.5±4.0µM,48h,1
DCTPep00699,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL21 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=36.8±3.9µM,48h,1
DCTPep00700,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.2±1.7µM,48h,1
DCTPep00700,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL26 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.6±1.8µM,48h,1
DCTPep00700,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.6±1.3µM,48h,1
DCTPep00700,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL27 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=9.9±1.4µM,48h,1
DCTPep00701,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=21.3±2.1µM,48h,1
DCTPep00701,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=21.5±1.9µM,48h,1
DCTPep00701,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL19 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=23.7±2.3µM,48h,1
DCTPep00701,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL20 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=24.6±1.6µM,48h,1
DCTPep00702,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=6.6±1.4µM,48h,1
DCTPep00702,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=7.3±0.7µM,48h,1
DCTPep00702,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL18 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.7±1.4µM,48h,1
DCTPep00702,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL19 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=9.3±1.7µM,48h,1
DCTPep00703,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=53.3±4.5µM,48h,1
DCTPep00703,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=53.6±4.2µM,48h,1
DCTPep00703,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL22 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=57.6±3.9µM,48h,1
DCTPep00703,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL23 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=58.3±6.2µM,48h,1
DCTPep00704,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=57.3±4.5µM,48h,1
DCTPep00704,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=59.4±2.9µM,48h,1
DCTPep00704,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL25 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=60.8±5.3µM,48h,1
DCTPep00704,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL26 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=71.2±4.7µM,48h,1
DCTPep00705,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL21 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=32.2±2.2µM,48h,1
DCTPep00705,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=33.7±3.9µM,48h,1
DCTPep00705,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=36.9±4.0µM,48h,1
DCTPep00705,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL22 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=39.5±3.7µM,48h,1
DCTPep00706,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=2.5 μM,24h,1
DCTPep00706,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=3.15 μM,24h,1
DCTPep00706,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.9 μM,24h,1
DCTPep00706,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=6.7 μM,24h,1
DCTPep00707,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=11 μM,24h,1
DCTPep00707,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.9 μM,24h,1
DCTPep00707,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=4.8 μM,24h,1
DCTPep00707,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=7.0 μM,24h,1
DCTPep00708,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.5 μM,24h,1
DCTPep00708,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.8 μM,24h,1
DCTPep00708,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=4.2 μM,24h,1
DCTPep00708,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=6.4 μM,24h,1
DCTPep00709,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=15 μM,24h,1
DCTPep00709,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=18.9 μM,24h,1
DCTPep00709,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=22 μM,24h,1
DCTPep00709,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=27 μM,24h,1
DCTPep00710,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=2.5 μM,24h,1
DCTPep00710,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=6.3 μM,24h,1
DCTPep00710,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=7.7 μM,24h,1
DCTPep00710,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.4 μM,24h,1
DCTPep00711,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13.8 μM,24h,1
DCTPep00711,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=15.3 μM,24h,1
DCTPep00711,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=15.4 μM,24h,1
DCTPep00711,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=5 μM,24h,1
DCTPep00712,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=73.7±6.1 μM,48h,1
DCTPep00712,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=77.3±5.6 μM,48h,1
DCTPep00712,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=97.3±11.4 μM,48h,1
DCTPep00712,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50>100 μM,48h,1
DCTPep00713,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=25.3±2.5 μM,48h,1
DCTPep00713,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=27.6±3.0 μM,48h,1
DCTPep00713,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=30.4±2.7 μM,48h,1
DCTPep00713,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=32.6±3.4 μM,48h,1
DCTPep00713,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=57.7 ± 13.3 µM,48 h,2
DCTPep00714,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.7±1.5 μM,48h,1
DCTPep00714,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=17.9±1.4 μM,48h,1
DCTPep00714,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=18.2±1.3 μM,48h,1
DCTPep00714,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=19.1±2.1 μM,48h,1
DCTPep00715,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=30.8±3.4 μM,48h,1
DCTPep00715,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=33.6±4.2 μM,48h,1
DCTPep00715,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=36.1±6.7 μM,48h,1
DCTPep00715,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=39.6±5.7 μM,48h,1
DCTPep00716,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=25.3±3.2 μM,48h,1
DCTPep00716,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=28.4±3.1 μM,48h,1
DCTPep00716,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=47.4±12.5 μM,48h,1
DCTPep00716,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50>100 μM,48h,1
DCTPep00717,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=30.6±5.7 μM,48h,1
DCTPep00717,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=38.3±2.5 μM,48h,1
DCTPep00717,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=60.7±5.4 μM,48h,1
DCTPep00717,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=83.7±5.3 μM,48h,1
DCTPep00718,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.9±1.2 μM,48h,1
DCTPep00718,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=7.6±1.4 μM,48h,1
DCTPep00718,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.7±1.2 μM,48h,1
DCTPep00718,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=8.1±0.9 μM,48h,1
DCTPep00719,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.9±0.2 μM,48h,1
DCTPep00719,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=6.3±0.4 μM,48h,1
DCTPep00719,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=6.6±0.5 μM,48h,1
DCTPep00719,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=7.7±0.4 μM,48h,1
DCTPep00720,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=26.5±1.5 μM,48h,1
DCTPep00720,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=27.3±2.4 μM,48h,1
DCTPep00720,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=28.2±2.7 μM,48h,1
DCTPep00720,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=28.3±2.3 μM,48h,1
DCTPep00721,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=18.4±1.5  μM,48h,1
DCTPep00721,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=19.2±2.3 μM,48h,1
DCTPep00721,MCF-7/ADM,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=20.7±1.6 μM,48h,1
DCTPep00721,K562/Adr,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=22.7±2.3 μM,48h,1
DCTPep00722,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,Not active up to 100 µg/ml,24h,1
DCTPep00723,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,MTT assay,IC50=0.61 μM,48h,1
DCTPep00723,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=2.83 μM,48h,1
DCTPep00723,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=3.87 μM,48h,1
DCTPep00724,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,MTT assay,IC50=0.99 μM,48h,1
DCTPep00724,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=1.81 μM,48h,1
DCTPep00724,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=2.88 μM,48h,1
DCTPep00725,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9.814µM,Not available,1
DCTPep00726,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=37180µM,Not available,1
DCTPep00727,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=90.16µM,Not available,1
DCTPep00728,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12100µM,Not available,1
DCTPep00729,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.3±0.3 μM,48h,1
DCTPep00729,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=12.9±0.3 μM,48h,1
DCTPep00729,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=15.1±1.1 μM,48h,1
DCTPep00729,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.5±0.3 μM,48h,1
DCTPep00729,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=7.0±0.2 μM,48h,1
DCTPep00730,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=14.3±0.2 μM,48h,1
DCTPep00730,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4.2±0.8 μM,48h,1
DCTPep00730,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.9±0.1 μM,48h,1
DCTPep00730,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=6.9±0.2 μM,48h,1
DCTPep00730,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=7.6±0.3 μM,48h,1
DCTPep00731,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15.4±0.1 μM,48h,1
DCTPep00731,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=22.5±3.3 μM,48h,1
DCTPep00731,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=24.4±3.3 μM,48h,1
DCTPep00731,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=54.8±6.1 μM,48h,1
DCTPep00731,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=65.2±4.2 μM,48h,1
DCTPep00733,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12.7±2.5 μM,48h,1
DCTPep00733,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=19.3±0.8 μM,48h,1
DCTPep00733,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=26.5±0.9 μM,48h,1
DCTPep00733,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=31.1±5.1 μM,48h,1
DCTPep00733,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9.8±1.5 μM,48h,1
DCTPep00734,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.2±0.8 μM,48h,1
DCTPep00734,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.5±1.2 μM,48h,1
DCTPep00734,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=20.4±3.3 μM,48h,1
DCTPep00734,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=20.7±1.1 μM,48h,1
DCTPep00734,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=30.2±2.4 μM,48h,1
DCTPep00735,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=16.5±0.4 μM,48h,1
DCTPep00735,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=31.1±2.2 μM,48h,1
DCTPep00735,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=33.4±1.1 μM,48h,1
DCTPep00735,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=43.6±1.1 μM,48h,1
DCTPep00735,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=55.6±3.3 μM,48h,1
DCTPep00736,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.5±0.5 μM,48h,1
DCTPep00736,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=19.0±1.1 μM,48h,1
DCTPep00736,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=23.2±1.7 μM,48h,1
DCTPep00736,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=35.7±1.5 μM,48h,1
DCTPep00736,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=9.46±0.5 μM,48h,1
DCTPep00737,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13.5±1.4 μM,48h,1
DCTPep00737,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=16.2±3.8 μM,48h,1
DCTPep00737,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=21.5±2.7 μM,48h,1
DCTPep00737,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=25.6±3.3 μM,48h,1
DCTPep00737,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=43.5±4.2 μM,48h,1
DCTPep00738,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.7±0.5 μM,48h,1
DCTPep00738,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=16.9±2.1 μM,48h,1
DCTPep00738,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=17.9±0.2 μM,48h,1
DCTPep00738,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=22.7±0.5 μM,48h,1
DCTPep00738,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=40.6±5.1 μM,48h,1
DCTPep00739,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=10.5±0.7 μM,48h,1
DCTPep00739,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=16.8±0.8 μM,48h,1
DCTPep00739,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=20.4±0.7 μM,48h,1
DCTPep00739,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.3±1.1 μM,48h,1
DCTPep00739,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=7.5±0.9 μM,48h,1
DCTPep00740,K562/ADM,Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia,Leukemia,MTT assay,IC50=10.3±0.3 μM,48h,1
DCTPep00740,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.1±1.0 μM,48h,1
DCTPep00740,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.8±0.4 μM,48h,1
DCTPep00740,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=7.9±0.9 μM,48h,1
DCTPep00740,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=8.5±1.1 μM,48h,1
DCTPep00741,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=8.7µM,72h,1
DCTPep00742,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50>>80µM,72h,1
DCTPep00743,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50>>32µM,72h,1
DCTPep00744,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=2.5µM,72h,1
DCTPep00745,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=0.42µM,72h,1
DCTPep00746,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=3µM,72h,1
DCTPep00747,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=3.8µM,72h,1
DCTPep00748,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50>>40µM,72h,1
DCTPep00749,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FMCA assay,IC50=0.52µM,72h,1
DCTPep00750,PC-3,Prostate carcinoma,Carcinoma,WST-1 assay ,IC50=16.5±0.7 µM,48h,1
DCTPep00751,PC-3,Prostate carcinoma,Carcinoma,WST-1 assay ,IC50=10.1±0.9 µM,48h,1
DCTPep00752,HT-29,Colon adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=100 μM,24h,1
DCTPep00752,MDA-MB-231,Breast adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=40 μM,24h,1
DCTPep00752,A549,Lung adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=45 μM,24h,1
DCTPep00753,A549,Lung adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=18 μM,24h,1
DCTPep00753,HT-29,Colon adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=18 μM,24h,1
DCTPep00753,MDA-MB-231,Breast adenocarcinoma,Carcinoma,"CellTiter-Glo Lumines-
cent Cell Viability assay",LC50=8 μM,24h,1
DCTPep00754,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=>64 µM ,18-24h,1
DCTPep00754,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=10.3 ± 1.1 µM ,18-24h,1
DCTPep00754,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=11.5 ± 0.6 µM ,18-24h,1
DCTPep00754,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=34.1 ± 3.9 µM ,18-24h,1
DCTPep00754,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=48.4 ± 0.7 µM ,18-24h,1
DCTPep00754,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50>64 µM ,18-24h,1
DCTPep00755,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=23.3 ± 0.4 µM ,18-24h,1
DCTPep00755,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=3.9 ± 0.2 µM ,18-24h,1
DCTPep00755,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=5.1 ± 0.3 µM ,18-24h,1
DCTPep00755,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=64 µM ,18-24h,1
DCTPep00756,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=15.1 ± 1.4 µM ,18-24h,1
DCTPep00756,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=3.9±0.1 µM ,18-24h,1
DCTPep00756,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=31.6 ± 1.3 µM ,18-24h,1
DCTPep00756,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=41.0 ± 4.2 µM ,18-24h,1
DCTPep00756,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=5.4 ± 0.3 µM ,18-24h,1
DCTPep00757,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.7 ± 0.1 µM ,18-24h,1
DCTPep00757,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=30.3 ± 1.1 µM ,18-24h,1
DCTPep00757,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=4.0 ± 0.1 µM ,18-24h,1
DCTPep00757,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=50.4 ± 2.4 µM ,18-24h,1
DCTPep00758,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=22.5 ± 3.3 µM ,18-24h,1
DCTPep00758,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=3.0 ± 0.1 µM ,18-24h,1
DCTPep00758,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=3.9 ± 0.2 µM ,18-24h,1
DCTPep00758,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=51.5 ± 3.9 µM ,18-24h,1
DCTPep00759,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=12.7 ± 1.1 µM ,18-24h,1
DCTPep00759,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=15.3 ± 1.4 µM ,18-24h,1
DCTPep00759,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.7 ± 0.1 µM ,18-24h,1
DCTPep00759,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.9 ± 0.1 µM ,18-24h,1
DCTPep00759,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=39.8 ± 1.0 µM ,18-24h,1
DCTPep00759,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=64 µM ,18-24h,1
DCTPep00760,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=29.4 ± 1.1 µM ,18-24h,1
DCTPep00760,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=3.1 ± 0.1 µM ,18-24h,1
DCTPep00760,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=39.4 ± 2.6 µM ,18-24h,1
DCTPep00760,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=5.0 ± 0.3 µM ,18-24h,1
DCTPep00761,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.0 ± 0.1 µM ,18-24h,1
DCTPep00761,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=17.1 ± 0.7 µM ,18-24h,1
DCTPep00761,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=18.3 ± 1.4 µM ,18-24h,1
DCTPep00761,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=4.0 ± 0.1 µM ,18-24h,1
DCTPep00762,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.4 ± 0.2 µM ,18-24h,1
DCTPep00762,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=37.5 ± 3.3 µM ,18-24h,1
DCTPep00762,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=38.5 ± 4.8 µM ,18-24h,1
DCTPep00762,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=4.6 ± 0.2 µM ,18-24h,1
DCTPep00762,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=51.0 ± 4.6 µM ,18-24h,1
DCTPep00762,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50>64 µM ,18-24h,1
DCTPep00763,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL27 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.4±0.2µM,24h,1
DCTPep00763,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=37.5±3.3µM,24h,1
DCTPep00763,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=38.5±4.8µM,24h,1
DCTPep00763,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=4.6±0.2µM,24h,1
DCTPep00763,CRL-1739,Human gastric adenocarcinoma cells,Carcinoma,Resazurin assay,CC50=51.0±4.6µM,24h,1
DCTPep00763,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50>64µM,24h,1
DCTPep00764,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.7 ± 0.1 µM ,18-24h,1
DCTPep00764,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=19.5 ± 0.5 µM ,18-24h,1
DCTPep00764,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.1 ± 0.2 µM ,18-24h,1
DCTPep00764,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=44.2 ± 2.2 µM ,18-24h,1
DCTPep00764,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=6.7 ± 0.7 µM ,18-24h,1
DCTPep00764,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=9.0 ± 1.1 µM ,18-24h,1
DCTPep00765,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.3 ± 0.1 µM ,18-24h,1
DCTPep00765,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=15.2 ± 1.9 µM ,18-24h,1
DCTPep00765,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=15.7 ± 1.1 µM ,18-24h,1
DCTPep00765,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.0 ± 0.1 µM ,18-24h,1
DCTPep00765,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=20.9 ± 1.4 µM ,18-24h,1
DCTPep00765,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=26.5 ± 2.4 µM ,18-24h,1
DCTPep00766,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.3 ± 0.2 µM ,18-24h,1
DCTPep00766,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=29.0 ± 3.7 µM ,18-24h,1
DCTPep00766,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=33.3 ± 7.4 µM ,18-24h,1
DCTPep00766,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=36.2 ± 2.8 µM ,18-24h,1
DCTPep00766,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=46.2 ± 7.6 µM ,18-24h,1
DCTPep00766,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=6.4 ± 0.6 µM ,18-24h,1
DCTPep00767,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.3±0.2µM,24h,1
DCTPep00767,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=29.0±3.7µM,24h,1
DCTPep00767,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Resazurin assay,CC50=33.3±7.4µM,24h,1
DCTPep00767,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=36.2±2.8µM,24h,1
DCTPep00767,CRL-1739,Human gastric adenocarcinoma cells,Carcinoma,Resazurin assay,CC50=46.2±7.6µM,24h,1
DCTPep00767,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL28 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=6.4±0.6µM,24h,1
DCTPep00768,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=3.7 ± 0.2 µM ,18-24h,1
DCTPep00768,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=3.8 ± 0.3 µM ,18-24h,1
DCTPep00768,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=54.1 ± 5.0 µM ,18-24h,1
DCTPep00768,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50=67.0 ± 5.0 µM ,18-24h,1
DCTPep00769,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.7 ± 0.2 µM ,18-24h,1
DCTPep00769,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=8.6 ± 0.8 µM,18-24h,1
DCTPep00769,CRL-1739,Gastric adenocarcinoma,Carcinoma,Resazurin assay,CC50>64 µM ,18-24h,1
DCTPep00769,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50>64 µM ,18-24h,1
DCTPep00770,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,26±0.9% Cell death=200µg/ml,48h,1
DCTPep00770,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,58±1.5% Cell death=200µg/ml,48h,1
DCTPep00770,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,58±1.5% Cell death=200µg/ml,48h,1
DCTPep00771,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=(50-100)µM,72h,1
DCTPep00771,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,Not active up to 100 µM,72h,1
DCTPep00772,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=25µM,72h,1
DCTPep00773,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,Not active up to 100 µM,72h,1
DCTPep00774,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=25µM,72h,1
DCTPep00775,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=23 μM ,48h,1
DCTPep00775,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=31 μM ,24h,1
DCTPep00775,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=34 μM ,6h,1
DCTPep00775,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=38 μM ,1h,1
DCTPep00776,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=24.05µM,24h,1
DCTPep00776,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,LD50=28.48µM,24h,1
DCTPep00776,U-251MG,Astrocytoma,Carcinoma,MTT assay,LD50=34.67µM,24h,1
DCTPep00776,HCT 116,Colon carcinoma,Carcinoma,MTT assay,LD50=36.64µM,24h,1
DCTPep00776,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,LD50=37.61µM,24h,1
DCTPep00776,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=37.96µM,24h,1
DCTPep00777,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=6.73µM,24h,1
DCTPep00778,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00778,CNE2,unknow,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00778,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00778,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>50µM,Not available,1
DCTPep00778,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00779,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=13.8 µM,Not available,1
DCTPep00779,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=17.4 µM,Not available,1
DCTPep00779,CNE2,unknow,Carcinoma,MTT assay,IC50=24.5 µM,Not available,1
DCTPep00779,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=7.1 µM,Not available,1
DCTPep00779,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=8.9 µm,Not available,1
DCTPep00780,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=3.2 µM,Not available,1
DCTPep00780,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.3 µM,Not available,1
DCTPep00780,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3.5 µM,Not available,1
DCTPep00780,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.5 µM,Not available,1
DCTPep00780,CNE2,unknow,Carcinoma,MTT assay,IC50=6.8 µM,Not available,1
DCTPep00781,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00781,CNE2,unknow,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00781,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00781,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>50µM,Not available,1
DCTPep00781,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00782,CNE2,unknow,Carcinoma,MTT assay,IC50=14.9 µM,Not available,1
DCTPep00782,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.9 µM,Not available,1
DCTPep00782,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.9 µM,Not available,1
DCTPep00782,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=4.9 µM,Not available,1
DCTPep00782,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=6.2 µM,Not available,1
DCTPep00783,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00783,CNE2,unknow,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00783,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00783,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>50µM,Not available,1
DCTPep00783,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>50µM,Not available,1
DCTPep00784,HepG2,Hepatoblastoma,Blastoma,MTS assay,IC50=192µg/ml,24h,1
DCTPep00784,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTS assay,IC50=280µg/ml,24h,1
DCTPep00785,A549,Lung adenocarcinoma,Carcinoma,MTT assay,Not active up to 200 µm,24h,1
DCTPep00786,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=11 μM,2h,1
DCTPep00786,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=31 μM,2h,1
DCTPep00787,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=5 μM,2h,1
DCTPep00787,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=9 μM,2h,1
DCTPep00788,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=130 μM,2h,1
DCTPep00788,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,2h,1
DCTPep00789,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=15 μM,2h,1
DCTPep00789,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=6 μM,2h,1
DCTPep00790,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=14 μM,2h,1
DCTPep00790,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=5 μM,2h,1
DCTPep00791,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=2 μM,2h,1
DCTPep00791,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=6 μM,2h,1
DCTPep00792,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>102 μM,2h,1
DCTPep00792,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>102 μM,2h,1
DCTPep00793,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>88 μM,2h,1
DCTPep00793,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>88 μM,2h,1
DCTPep00794,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>203 μM,2h,1
DCTPep00794,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>203 μM,2h,1
DCTPep00795,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>200 μM,2h,1
DCTPep00795,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>200 μM,2h,1
DCTPep00796,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>103 μM,2h,1
DCTPep00796,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>103 μM,2h,1
DCTPep00797,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=7 μM,2h,1
DCTPep00797,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>107 μM,2h,1
DCTPep00798,A549,Lung adenocarcinoma,Carcinoma,Cell Viability Assay,Not active up to 20 µM,24h,1
DCTPep00798,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL29 positive; Chronic myeloid leukemia",Leukemia,Cell Viability Assay,Not active up to 20 µM,24h,1
DCTPep00798,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Cell Viability Assay,Not active up to 20 µM,24h,1
DCTPep00799,A549,Lung adenocarcinoma,Carcinoma,Cell Viability Assay,Not active up to 20 µM,24h,1
DCTPep00799,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL30 positive; Chronic myeloid leukemia",Leukemia,Cell Viability Assay,Not active up to 20 µM,24h,1
DCTPep00799,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Cell Viability Assay,Not active up to 20 µM,24h,1
DCTPep00800,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=0.69µM,24h,1
DCTPep00800,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=11.8µM,24h,1
DCTPep00800,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=2.01µM,24h,1
DCTPep00800,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=2.36µM,24h,1
DCTPep00800,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=9.94µM,24h,1
DCTPep00801,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,MTT assay,IC50=0.76µM,"6, 24, 48h",1
DCTPep00801,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=3.75µM,"6, 24, 48h",1
DCTPep00801,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=3.91µM,"6, 24, 48h",1
DCTPep00802,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=0.76 μM,48h,1
DCTPep00802,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,MTT assay,IC50=3.75 μM,48h,1
DCTPep00802,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=3.91 μM,48h,1
DCTPep00803,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=3.61 μM,48h,1
DCTPep00803,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,MTT assay,IC50=8.08 μM,48h,1
DCTPep00803,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=8.42 μM,48h,1
DCTPep00804,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=2.85µM,24h,1
DCTPep00805,JLTRG (Jurkat LTR-GFP Cells),Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,CCK-8 assay,Not active up to 50 µg/ml,36h,1
DCTPep00806,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=25.13µM,Not available,1
DCTPep00806,MDA-MB-435s,Amelanotic melanoma,Carcinoma,MTT assay,IC50=33.23µM,Not available,1
DCTPep00806,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=34.56µM,Not available,1
DCTPep00806,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=38.56µM,Not available,1
DCTPep00807,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=3.051µM,24h,1
DCTPep00807,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=3.087µM,24h,1
DCTPep00807,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=3.464µM,24h,1
DCTPep00807,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=3.483µM,24h,1
DCTPep00808,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=27.62µM,24h,1
DCTPep00808,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=3.398µM,24h,1
DCTPep00808,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=3.520µM,24h,1
DCTPep00808,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=9.864µM,24h,1
DCTPep00809,HepG2,Hepatoblastoma,Blastoma,Not available,Not active up to 128 µg/ml,Not available,1
DCTPep00810,HepG2,Hepatoblastoma,Blastoma,Not available,IC50=45.9µg/ml,Not available,1
DCTPep00811,HepG2,Hepatoblastoma,Blastoma,Not available,IC50=24.4µg/ml,Not available,1
DCTPep00812,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=10.3 µM,Not available,1
DCTPep00812,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=10.6 µM,Not available,1
DCTPep00812,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=14.6 µM,Not available,1
DCTPep00812,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=4.1 µM,Not available,1
DCTPep00812,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=7.0 µM,Not available,1
DCTPep00813,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,FDA cytotoxicity assay,15% Killing=100 µM,72h,1
DCTPep00815,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=13.66 μM,24h,1
DCTPep00815,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=13.87 μM,24h,1
DCTPep00815,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=13.87 μM,24h,1
DCTPep00815,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=7.02 μM,24h,1
DCTPep00815,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=8.56 μM,24h,1
DCTPep00816,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=13.57 μM,24h,1
DCTPep00816,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=25.27 μM,24h,1
DCTPep00816,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=27.70 μM,24h,1
DCTPep00816,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=36.65 μM,24h,1
DCTPep00816,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=6.29 μM,24h,1
DCTPep00817,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=2.79 μM,24h,1
DCTPep00817,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=3.36 μM,24h,1
DCTPep00817,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.70 μM,24h,1
DCTPep00817,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=3.86 μM,24h,1
DCTPep00817,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=3.86 μM,24h,1
DCTPep00818,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=50.0 µmol/L,24h,1
DCTPep00819,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=50.0 µmol/L,24h,1
DCTPep00820,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=25.0 µmol/L,24h,1
DCTPep00821,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=50.0 µmol/L,24h,1
DCTPep00822,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>50 µmol/L,24h,1
DCTPep00823,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=18±1 μM,24/72 h,2
DCTPep00823,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=19±1 μM,24/72 h,2
DCTPep00823,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=28±1 μM,24/72 h,2
DCTPep00823,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=40±1 μM,24/72 h,2
DCTPep00823,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12.5 µmol/L,24h,1
DCTPep00824,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=25.0 µmol/L,24h,1
DCTPep00825,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12.5 µmol/L,24h,1
DCTPep00826,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>50 µmol/L,24h,1
DCTPep00827,N2a,Mouse neuroblastoma cells,Blastoma,CCK-8 assay,65.6% Killing=20µM,72h,1
DCTPep00827,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,73.5% Killing=20µM,72h,1
DCTPep00828,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=15.67 μM,24h,1
DCTPep00828,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=18.2 μM,24h,1
DCTPep00829,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=0.12 μM,24h,1
DCTPep00829,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=1.85 μM,24h,1
DCTPep00830,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=18.20 μM,24h,1
DCTPep00830,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=18.20 μM,24h,1
DCTPep00831,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=164.47±37.69µM,48h,1
DCTPep00831,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=193.63±13.92 µM,48h,1
DCTPep00832,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=213.4±59.59µM,48h,1
DCTPep00832,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=256.23±14.58µM,48h,1
DCTPep00833,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=135.07±32.3µM,48h,1
DCTPep00833,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=434.03±90.38µM,48h,1
DCTPep00834,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=112.9±2.21µM,48h,1
DCTPep00834,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=94.06±4.97µM,48h,1
DCTPep00835,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=218.37µM,48h,1
DCTPep00835,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=62.33µM,48h,1
DCTPep00836,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=106.4±2.72µM,48h,1
DCTPep00836,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=138.37±6.55µM,48h,1
DCTPep00837,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=366.3±119.08µM,48h,1
DCTPep00837,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=800.8±62.29µM,48h,1
DCTPep00838,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,MTT assay,IC50=0.61 μM,48h,1
DCTPep00838,U-87MG ATCC,Glioblastoma,Blastoma,MTT assay,IC50=0.92 μM,48h,1
DCTPep00839,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=35.4 μM,24h,1
DCTPep00839,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=50.1 μM ,24h,1
DCTPep00839,DKs-8,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.8 μM ,24h,1
DCTPep00840,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=104.10 μM,24h,1
DCTPep00840,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=109.30 μM,24h,1
DCTPep00840,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=283.90 μM,24h,1
DCTPep00840,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=843.40 μM,24h,1
DCTPep00840,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=872.70 μM,24h,1
DCTPep00841,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=15.44 μM,24h,1
DCTPep00841,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=16.14 μM,24h,1
DCTPep00841,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=20.19 μM,24h,1
DCTPep00841,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=5.79 μM,24h,1
DCTPep00841,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=5.90 μM,24h,1
DCTPep00842,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=179.00 μM,24h,1
DCTPep00842,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=278.30 μM,24h,1
DCTPep00842,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=316.90 μM,24h,1
DCTPep00842,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=58.18 μM,24h,1
DCTPep00842,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=792.60 μM,24h,1
DCTPep00843,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=20.1 µM,48h,1
DCTPep00844,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=26.8 µM,48h,1
DCTPep00845,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=30.4 µM,48h,1
DCTPep00846,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=19.4 µM,48h,1
DCTPep00847,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=72.9 µM,48h,1
DCTPep00848,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=38.9 µM,48h,1
DCTPep00849,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 100 µM,24h,1
DCTPep00849,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,Not active up to 100 µM,24h,1
DCTPep00849,PC-3,Prostate carcinoma,Carcinoma,MTT assay,Not active up to 100 µM,24h,1
DCTPep00850,U-373MG ATCC,Astrocytoma,Carcinoma,MTT assay,IC50=20.94±5.18 μM ,48h,1
DCTPep00850,U-87MG ATCC,Glioblastoma,Blastoma,MTT assay,IC50=29.20±7.96 μM,48h,1
DCTPep00850,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,IC50=93.80±2.17 μM ,48h,1
DCTPep00851,NCI-H460,Lung large cell carcinoma,Carcinoma,Crystal violet assay,IC50=14.97 ± 1.16 µM ,48h,1
DCTPep00852,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13.7±1.3 μM,48h,1
DCTPep00852,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=15.3±1.0 μM,48h,1
DCTPep00852,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=27.5±0.8 μM,48h,1
DCTPep00852,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=5.0±0.4 μM,48h,1
DCTPep00853,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=24.2±1.7 μM,48h,1
DCTPep00853,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=26.5±1.2 μM,48h,1
DCTPep00853,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=30.1±1.9 μM,48h,1
DCTPep00853,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=4.8±0.3 μM,48h,1
DCTPep00854,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=2.5±0.1 μM,48h,1
DCTPep00854,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.0±0.2 μM,48h,1
DCTPep00854,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=7.3±0.5 μM,48h,1
DCTPep00854,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=9.9±0.1 μM,48h,1
DCTPep00855,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10.8±1.9 μM,48h,1
DCTPep00855,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=16.4±1.3 μM,48h,1
DCTPep00855,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=17.3±0.6 μM,48h,1
DCTPep00855,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=7.2±0.5 μM,48h,1
DCTPep00856,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=12.5±0.9 μM,48h,1
DCTPep00856,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=16.0±0.6 μM,48h,1
DCTPep00856,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=7.2±0.5 μM,48h,1
DCTPep00856,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=8.8±1.3 μM,48h,1
DCTPep00857,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=24.4±3.0 μM,48h,1
DCTPep00857,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=28.1±1.7 μM,48h,1
DCTPep00857,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=34.0±1.3 μM,48h,1
DCTPep00857,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=5.6±0.5 μM,48h,1
DCTPep00858,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=13.3 µM,24h,1
DCTPep00858,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14.1 µM,24h,1
DCTPep00858,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=14.8 µM,24h,1
DCTPep00858,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.7 µM,24h,1
DCTPep00858,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=22.9 µM,24h,1
DCTPep00859,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=14.3 µM,24h,1
DCTPep00859,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=14.8 µM,24h,1
DCTPep00859,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=15.2 µM,24h,1
DCTPep00859,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=18.5 µM,24h,1
DCTPep00859,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=22.5 µM,24h,1
DCTPep00860,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=12.9 µM,24h,1
DCTPep00860,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14.8 µM,24h,1
DCTPep00860,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=15.2 µM,24h,1
DCTPep00860,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.8 µM,24h,1
DCTPep00860,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=21.6 µM,24h,1
DCTPep00861,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.1 µM,24h,1
DCTPep00861,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.8 µM,24h,1
DCTPep00861,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15.7 µM,24h,1
DCTPep00861,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=19.5 µM,24h,1
DCTPep00861,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=27 µM,24h,1
DCTPep00862,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10.8 µM,24h,1
DCTPep00862,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.8 µM,24h,1
DCTPep00862,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=14.6 µM,24h,1
DCTPep00862,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=15.6 µM,24h,1
DCTPep00862,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=8.4 µM,24h,1
DCTPep00863,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=3.39±0.15 μM,48h,1
DCTPep00863,B16-F1,Mouse melanoma,Carcinoma,MTT assay,IC50=4.82±1.01 μM,48h,1
DCTPep00863,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=5.63±1.05 μM,48h,1
DCTPep00863,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=6.49±0.09 μM,48h,1
DCTPep00864,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=108.32µM,48h,1
DCTPep00864,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=85.83µM,48h,1
DCTPep00865,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=0.70±0.07 μM,48h,1
DCTPep00865,MM170,Melanoma,Carcinoma,MTT assay,IC50=0.87±0.04 μM,48h,1
DCTPep00865,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=2.86±0.14 μM,48h,1
DCTPep00866,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.35±0.06 μM,48h,1
DCTPep00866,MM170,Melanoma,Carcinoma,MTT assay,IC50=1.75±0.06 μM,48h,1
DCTPep00866,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=6.31±0.099 μM,48h,1
DCTPep00867,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=12.41±0.14 μM,48h,1
DCTPep00867,MM170,Melanoma,Carcinoma,MTT assay,IC50=3.27±0.12 μM,48h,1
DCTPep00867,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.32±0.09 μM,48h,1
DCTPep00868,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=12.34µM,48h,1
DCTPep00868,C8166,Human T cell leukemia cells,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=19.19µM,48h,1
DCTPep00868,MT-4,Human acute lymphoblastic leukemia cell line,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=19.65µM,48h,1
DCTPep00868,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CellTiter 96 AQueous One Solution assay,50% Cytotoxicity=9.97µM,48h,1
DCTPep00869,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,34% Cytotoxicity=10 µM,24h,1
DCTPep00869,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=50 µM,24h,1
DCTPep00869,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 10 µM,24h,1
DCTPep00870,A549,Lung adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µM,2 days,1
DCTPep00870,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µM,2 days,1
DCTPep00871,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL11 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.7 µM,24h,1
DCTPep00872,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL11 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=16.2 µM,24h,1
DCTPep00873,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,2h,1
DCTPep00873,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 µM,2h,1
DCTPep00873,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 µM,2h,1
DCTPep00874,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,2h,1
DCTPep00874,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>100 µM,2h,1
DCTPep00874,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50>100 µM,2h,1
DCTPep00875,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=67.4 μM,48h,1
DCTPep00875,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=73.4 μM,48h,1
DCTPep00876,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,19% Killing=32µM,20h,1
DCTPep00877,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,5% Killing=32µM,20h,1
DCTPep00878,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,5% Killing=32µM,20h,1
DCTPep00879,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,9% Killing=32µM,20h,1
DCTPep00880,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,32% Killing=32µM,20h,1
DCTPep00881,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,10% Killing=32µM,20h,1
DCTPep00882,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,Not active up to 32 µM,20h,1
DCTPep00883,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,13% Killing=32µM,20h,1
DCTPep00884,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,5% Killing=32µM,20h,1
DCTPep00885,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,Not active up to 32 µM,20h,1
DCTPep00886,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,7% Killing=32µM,20h,1
DCTPep00887,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,20% Killing=32µM,20h,1
DCTPep00888,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,2% Killing=32µM,20h,1
DCTPep00889,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,16% Killing=32µM,20h,1
DCTPep00890,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,22% Killing=32µM,20h,1
DCTPep00891,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,28% Killing=32µM,20h,1
DCTPep00892,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,Not active up to 32 µM,20h,1
DCTPep00893,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,5% Killing=32µM,20h,1
DCTPep00894,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,5% Killing=32µM,20h,1
DCTPep00895,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,23% Killing=32µM,20h,1
DCTPep00896,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,25% Killing=32µM,20h,1
DCTPep00897,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,16% Killing=32µM,20h,1
DCTPep00898,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,11% Killing=32µM,20h,1
DCTPep00899,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,17% Killing=32µM,20h,1
DCTPep00900,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,4% Killing=32µM,20h,1
DCTPep00901,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,1% Killing=32µM,20h,1
DCTPep00902,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,1% Killing=32µM,20h,1
DCTPep00903,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,19% Killing=32µM,20h,1
DCTPep00904,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,9% Killing=32µM,20h,1
DCTPep00905,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,9% Killing=32µM,20h,1
DCTPep00906,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,22% Killing=32µM,20h,1
DCTPep00907,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,8% Killing=32µM,20h,1
DCTPep00908,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,14% Killing=32µM,20h,1
DCTPep00909,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,10% Killing=32µM,20h,1
DCTPep00910,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,27% Killing=32µM,20h,1
DCTPep00911,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,41% Killing=32µM,20h,1
DCTPep00912,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=18.9±0.9 µM ,24h,1
DCTPep00912,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=2.0±0.1 µM ,24h,1
DCTPep00912,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.7±0.2 µM ,24h,1
DCTPep00912,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=22.5±2.1 µM ,24h,1
DCTPep00912,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=3.0±0.2 µM ,24h,1
DCTPep00912,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=3.9±0.2 µM ,24h,1
DCTPep00913,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=13.4±1.9 µM ,24h,1
DCTPep00913,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.5±0.1 µM ,24h,1
DCTPep00913,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=3.5±0.4 µM ,24h,1
DCTPep00913,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=4.3±0.3 µM ,24h,1
DCTPep00914,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00914,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00914,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00914,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00914,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00914,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50>64 µM ,24h,1
DCTPep00915,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.3±0.1 µM ,24h,1
DCTPep00915,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.9±0.1 µM ,24h,1
DCTPep00915,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=2.9±0.2 µM ,24h,1
DCTPep00915,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=3.2±0.1 µM ,24h,1
DCTPep00915,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=5.1±0.3 µM ,24h,1
DCTPep00916,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.5±0.1 µM ,24h,1
DCTPep00916,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.7±0.1 µM ,24h,1
DCTPep00916,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=1.7±0.2 µM ,24h,1
DCTPep00916,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=13.1±1.2 µM ,24h,1
DCTPep00916,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=16.0±2.0 µM ,24h,1
DCTPep00916,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=2.5±0.1 µM ,24h,1
DCTPep00916,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=8.0±0.6 µM ,24h,1
DCTPep00917,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.3±0.1 µM ,24h,1
DCTPep00917,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=1.4±0.1µM ,24h,1
DCTPep00917,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.0±0.1 µM ,24h,1
DCTPep00917,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=2.7±0.1 µM ,24h,1
DCTPep00917,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=2.7±0.3 µM ,24h,1
DCTPep00917,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=6.4±0.6 µM ,24h,1
DCTPep00917,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=6.7±0.6 µM ,24h,1
DCTPep00918,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.0±0.1 µM ,24h,1
DCTPep00918,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.7±0.1 µM ,24h,1
DCTPep00918,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=2.7±0.2 µM ,24h,1
DCTPep00918,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=3.2±0.1 µM ,24h,1
DCTPep00918,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=6.7±1.1 µM ,24h,1
DCTPep00919,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=1.2±0.1 µM ,24h,1
DCTPep00919,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.8±0.1 µM ,24h,1
DCTPep00919,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=1.8±0.1 µM ,24h,1
DCTPep00919,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=12.2±0.4 µM ,24h,1
DCTPep00919,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=4.5±0.3 µM ,24h,1
DCTPep00920,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=1.7±0.1 µM ,24h,1
DCTPep00920,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=2.3±0.2 µM ,24h,1
DCTPep00920,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=2.7±0.1 µM ,24h,1
DCTPep00920,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=3.5±0.3 µM ,24h,1
DCTPep00920,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=7.5±0.3 µM ,24h,1
DCTPep00921,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=5.3±0.6 µM ,24h,1
DCTPep00922,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=11.1±0.9 µM ,24h,1
DCTPep00922,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=11.8±0.9 µM ,24h,1
DCTPep00922,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=4.8±0.3 µM ,24h,1
DCTPep00923,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=13.2±0.9 µM ,24h,1
DCTPep00923,MM96L,Melanoma ,Carcinoma,Resazurin assay,CC50=17.3±1.0 µM ,24h,1
DCTPep00923,HT-144,Melanoma,Carcinoma,Resazurin assay,CC50=27.8±2.2 µM ,24h,1
DCTPep00923,WM164,Cutaneous melanoma,Carcinoma,Resazurin assay,CC50=28.2±2.0 µM ,24h,1
DCTPep00923,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00923,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50>32 µM ,24h,1
DCTPep00923,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50>64 µM ,24h,1
DCTPep00924,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,PrestoBlue cell viability reagent,Not active up to 300 µg/ml,overnight,1
DCTPep00925,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>100µM,,1
DCTPep00926,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00927,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00928,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00929,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00930,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00931,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00932,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00933,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00934,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00935,A2058,Amelanotic melanoma,Carcinoma,MTS assay,IC50>200µM,,1
DCTPep00936,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>100 µM,24h,1
DCTPep00936,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,Not active up to 100 µM,24h,1
DCTPep00937,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>100 µM,24h,1
DCTPep00937,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,Not active up to 100 µM,24h,1
DCTPep00938,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>100 µM,24h,1
DCTPep00938,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,Not active up to 100 µM,24h,1
DCTPep00939,A2058,Amelanotic melanoma,Carcinoma,AqueousOne assay,IC50=4.1 µM,72h,1
DCTPep00940,A2058,Amelanotic melanoma,Carcinoma,AqueousOne assay,IC50=27.4 µM,72h,1
DCTPep00941,A2058,Amelanotic melanoma,Carcinoma,AqueousOne assay,IC50>50.0 µM,72h,1
DCTPep00942,A2058,Amelanotic melanoma,Carcinoma,AqueousOne assay,IC50=1.4 µM,72h,1
DCTPep00943,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9.5 µM,24h,1
DCTPep00944,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=13.7 µM,24h,1
DCTPep00944,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=200 µg/ml,24 h,Patent
DCTPep00944,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=270 µg/ml,24 h,Patent
DCTPep00944,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=290 µg/ml,24 h,Patent
DCTPep00944,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=345 µg/ml,24 h,Patent
DCTPep00944,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=345 µg/ml,24 h,Patent
DCTPep00944,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep00945,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00946,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00947,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00948,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=33.0 ± 1.0 µM,48 h,1
DCTPep00948,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=35.2 ± 1.8 µM,48 h,1
DCTPep00948,22Rv1,Prostate carcinoma,Carcinoma,MTT assay,LC50=50 µM,Not available,Patent
DCTPep00948,CL1,Prostate carcinoma,Carcinoma,MTT assay,LC50>100 µM,Not available,Patent
DCTPep00949,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9.6 µM,24h,1
DCTPep00950,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≤ 6.5 µM,24h,1
DCTPep00951,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00952,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=13.3 µM,24h,1
DCTPep00953,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=14.5 µM,24h,1
DCTPep00954,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=27.6 µM,24h,1
DCTPep00955,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15.1 µM,24h,1
DCTPep00956,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11.5 µM,24h,1
DCTPep00957,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≤ 6.5 µM,24h,1
DCTPep00958,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12.5 µM,24h,1
DCTPep00959,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16.2 µM,24h,1
DCTPep00960,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9.6 µM,24h,1
DCTPep00961,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=44.8 µM,24h,1
DCTPep00962,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16.1 µM,24h,1
DCTPep00963,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00964,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00965,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00966,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=36.5 µM,24h,1
DCTPep00967,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=24.6 µM,24h,1
DCTPep00968,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15.1 µM,24h,1
DCTPep00969,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00970,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=48.2 µM,24h,1
DCTPep00971,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=10.7 µM,24h,1
DCTPep00972,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=22.8 µM,24h,1
DCTPep00973,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=6.8 µM,24h,1
DCTPep00974,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=9.4 µM,24h,1
DCTPep00975,MDA-MB-361,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=142 µg/ml,Not available,1
DCTPep00975,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=18.3 µM,24h,1
DCTPep00975,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>200 µg/ml,Not available,1
DCTPep00976,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12.0 µM,24h,1
DCTPep00977,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11.4 µM,24h,1
DCTPep00978,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=25.6 µM,24h,1
DCTPep00979,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=19.3 µM,24h,1
DCTPep00980,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=35.4 µM,24h,1
DCTPep00981,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=32.2 µM,24h,1
DCTPep00982,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep00983,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Not available,0% Killing=32µM; 15% Killing=64µM; 95% Killing=128µM,Not available,1
DCTPep00984,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20% Killing=256	µg/ml,2h,1
DCTPep00985,HepG2,Hepatoblastoma,Blastoma,MTT assay,20% Killing=100	µg/ml,48h,1
DCTPep00986,HepG2,Hepatoblastoma,Blastoma,MTT assay,10% Killing=20µM,48h,1
DCTPep00986,Eca 109,Esophageal squamous cell carcinoma; Squamous cell carcinoma of the esophagus,Carcinoma,MTT assay,20% Killing=100µg/ml,24h,2
DCTPep00987,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo ATP assay,Not active up to 1655 µg/ml,24h,1
DCTPep00988,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo ATP assay,Not active up to 1622 µg/ml,24h,1
DCTPep00989,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo ATP assay,Not active up to 535 µg/ml,24h,1
DCTPep00990,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo ATP assay,Not active up to 1330 µg/ml,24h,1
DCTPep00991,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=0.52±0.03 µM ,24h,1
DCTPep00991,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=0.75±0.05 µM ,24h,1
DCTPep00991,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=0.88±0.05 µM ,24h,1
DCTPep00992,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.54±0.08 µM ,24h,1
DCTPep00992,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=2.00±0.04 µM ,24h,1
DCTPep00992,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=3.34±0.28 µM ,24h,1
DCTPep00993,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50>8 µM ,24h,1
DCTPep00994,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=2.64±0.09 µM ,24h,1
DCTPep00994,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=2.85±0.09 µM ,24h,1
DCTPep00994,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=3.73±0.25 µM ,24h,1
DCTPep00995,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=1.16±0.03 µM ,24h,1
DCTPep00995,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=1.34±0.04 µM ,24h,1
DCTPep00995,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=2.36±0.16 µM ,24h,1
DCTPep00996,B16-F10,Mouse melanoma,Carcinoma,MTT assay,IC50=12.8 µM,24h,1
DCTPep00996,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.3 µM,24h,1
DCTPep00996,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,Not toxic up to 25 µM,24h,1
DCTPep00997,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=1.55 μM,24h,1
DCTPep00997,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=2.47 μM,24h,1
DCTPep00997,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.92 μM,24h,1
DCTPep00997,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=4.15 μM,24h,1
DCTPep00998,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=1.67 μM,24h,1
DCTPep00998,NCI-H838,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10.3 μM,24h,1
DCTPep00998,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=13.20 μM ,24h,1
DCTPep00998,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=21.54 μM,24h,1
DCTPep00998,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=3.79 μM,24h,1
DCTPep00998,NCI-H23,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.52 μM,24h,1
DCTPep00999,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,30% Killing=256	µM,24h,1
DCTPep01000,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20% Killing=256	µM,24h,1
DCTPep01001,HCT 116,Colon carcinoma,Carcinoma,Concentration-cell number assay,IC50=0.02µM,120h,1
DCTPep01001,MDA-MB-435,Amelanotic melanoma,Carcinoma,Concentration-cell number assay,IC50=0.022µM,120h,1
DCTPep01001,NCI-H460,Lung large cell carcinoma,Carcinoma,Concentration-cell number assay,IC50=0.063µM,120h,1
DCTPep01001,N2a,Mouse neuroblastoma cells,Blastoma,Concentration-cell number assay,IC50>1.0µM,120h,1
DCTPep01002,HCT 116,Colon carcinoma,Carcinoma,Concentration-cell number assay,IC50=0.016µM,120h,1
DCTPep01002,NCI-H460,Lung large cell carcinoma,Carcinoma,Concentration-cell number assay,IC50=0.094µM,120h,1
DCTPep01002,MDA-MB-435,Amelanotic melanoma,Carcinoma,Concentration-cell number assay,IC50=0.23µM,120h,1
DCTPep01002,N2a,Mouse neuroblastoma cells,Blastoma,Concentration-cell number assay,IC50>1.0µM,120h,1
DCTPep01003,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-8 assay,10% Killing=600	µg/ml,24h,1
DCTPep01004,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,WST-8 assay,10% Killing=572	µg/ml,24h,1
DCTPep01005,A549,Lung adenocarcinoma,Carcinoma,MTT assay,50% Cell death=150 µM,24h,1
DCTPep01006,A549,Lung adenocarcinoma,Carcinoma,MTT assay,10% Cell death=150 µM,24h,1
DCTPep01007,A549,Lung adenocarcinoma,Carcinoma,MTT assay,20% Killing=64 µM,24h,1
DCTPep01008,HepG2,Hepatoblastoma,Blastoma,MTT assay,50.5% Killing=32µg/ml,24h,1
DCTPep01009,HepG2,Hepatoblastoma,Blastoma,MTT assay,80.3% Killing=32µg/ml,24h,1
DCTPep01010,HepG2,Hepatoblastoma,Blastoma,MTT assay,95.3% Killing=32µg/ml,24h,1
DCTPep01011,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=2.599 μM,24h,1
DCTPep01011,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=3.37 μM,24h,1
DCTPep01011,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=3.47 μM,24h,1
DCTPep01011,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=5.87 μM,24h,1
DCTPep01012,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=186.9 μM,24h,1
DCTPep01012,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=214.7 μM,24h,1
DCTPep01012,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=278.9 μM,24h,1
DCTPep01012,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=342.8 μM,24h,1
DCTPep01013,MDA-MB-435S,Amelanotic melanoma,Carcinoma,MTT assay,IC50=2.243 μM,24h,1
DCTPep01013,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=2.811 μM,24h,1
DCTPep01013,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=3.583 μM,24h,1
DCTPep01013,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=5.425 μM,24h,1
DCTPep01014,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,MCF-7/G11-TR1,Breast cancer,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,MCF-7/G11-TR5,Breast cancer,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,T-47D ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01014,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>131.0 µM ,24h,1
DCTPep01015,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=135.6±9.3 µM,24h,1
DCTPep01015,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=43.5±11.5 µM,24h,1
DCTPep01015,MCF-7/G11-TR5,Breast cancer,Carcinoma,MTT assay,IC50=56.4±5.0 µM,24h,1
DCTPep01015,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=58.9±2.0 µM,24h,1
DCTPep01015,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=61.8±3.9 µM,24h,1
DCTPep01015,MCF-7/G11-TR1,Breast cancer,Carcinoma,MTT assay,IC50=61.8±5.1 µM,24h,1
DCTPep01015,T-47D ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=78.5±20.9 µM,24h,1
DCTPep01015,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=83.7±20.1 µM,24h,1
DCTPep01016,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,MCF-7/G11-TR1,Breast cancer,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,MCF-7/G11-TR5,Breast cancer,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,T-47D ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01016,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>128.5 µM,24h,1
DCTPep01017,T-47D ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50 >148.5 µM,24h,1
DCTPep01017,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.1±1.8 µM,24h,1
DCTPep01017,MCF-7/G11-TR1,Breast cancer,Carcinoma,MTT assay,IC50=10.8±2.0 µM,24h,1
DCTPep01017,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=16.0±1.6 µM,24h,1
DCTPep01017,MCF-7/G11-TR5,Breast cancer,Carcinoma,MTT assay,IC50=16.1±4.9 µM,24h,1
DCTPep01017,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=16.6±1.5 µM,24h,1
DCTPep01017,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=18.1±4.7 µM,24h,1
DCTPep01017,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=18.6±2.4 µM,24h,1
DCTPep01018,MDA-MB-468,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=12.4±1.4 µM,24h,1
DCTPep01018,T-47D ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=17.5±6.5 µM,24h,1
DCTPep01018,MCF-7/G11-TR5,Breast cancer,Carcinoma,MTT assay,IC50=3.8±0.3 µM,24h,1
DCTPep01018,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.2±1.0 µM,24h,1
DCTPep01018,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.9±0.5 µM,24h,1
DCTPep01018,MCF-7/G11-TR1,Breast cancer,Carcinoma,MTT assay,IC50=6.2±0.8 µM,24h,1
DCTPep01018,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=7.2±0.8 µM,24h,1
DCTPep01018,SK-BR-3,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=7.2±1.0 µM,24h,1
DCTPep01019,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,45% Killing=12.5µM; 96% Killing=25µM,72h,1
DCTPep01020,B16-F10,Mouse melanoma,Carcinoma,MTT assay,IC50=10.5 µM (0.020 g/L),24h,1
DCTPep01020,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=11.1 µM (0.021 g/L),24h,1
DCTPep01020,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=13.7 µM (0.026 g/L),24h,1
DCTPep01021,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=25.5±2.9	µg/ml,24h,1
DCTPep01022,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30.4±2.5µg/ml,24h,1
DCTPep01023,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=21.9±4.5µg/ml,24h,1
DCTPep01024,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.8±4.4µg/ml,24h,1
DCTPep01025,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=3.6±0.5µg/ml,24h,1
DCTPep01026,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.2±2.7µg/ml,24h,1
DCTPep01027,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8.4±1.7µg/ml,24h,1
DCTPep01028,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Blue assay,IC50=5.02±1.04 µM,24h,1
DCTPep01029,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,80% killing=32μM,20h,1
DCTPep01030,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,40% Killing=32µM,20h,1
DCTPep01031,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,32% killing=32μM,20h,1
DCTPep01032,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,95% killing=32μM,20h,1
DCTPep01033,MEC-1,Chronic lymphocytic leukemia; B-cell chronic lymphocytic leukemia,Leukemia,MTT assay,90% killing=32μM,20h,1
DCTPep01034,TZM-bl,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=40.16µg/ml,48h,1
DCTPep01035,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=14.2 µM,48h,1
DCTPep01035,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=36.2 µM,48h,1
DCTPep01035,NCI/ADR-RES,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=85.6 µM,48h,1
DCTPep01035,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>100 µM,48h,1
DCTPep01036,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=53.5 µM,48h,1
DCTPep01037,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.9 µM,48h,1
DCTPep01037,NCI/ADR-RES,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=14.0 µM,48h,1
DCTPep01037,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50=15.3 µM,48h,1
DCTPep01037,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=8.6 µM,48h,1
DCTPep01038,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,48h,1
DCTPep01038,NCI/ADR-RES,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,48h,1
DCTPep01038,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,48h,1
DCTPep01038,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50>100 µM,48h,1
DCTPep01039,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,MTT assay,IC50=51.1 µM,48h,1
DCTPep01040,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>250 µg/ml,24h,1
DCTPep01041,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=80.7±6.9 µM,"24, 48, 72h",1
DCTPep01042,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=19.2±2.3 µM,"24, 48, 72h",1
DCTPep01043,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=93.5±10.7 µM,"24, 48, 72h",1
DCTPep01044,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=4.4±0.4 µM,"24, 48, 72h",1
DCTPep01045,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=0.71±0.22 µM,"24, 48, 72h",1
DCTPep01046,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=5.6±0.15 µM,"24, 48, 72h",1
DCTPep01047,CT26,Mouse colon adenocarcinoma,Carcinoma,MTT assay,IC50=1.56±0.35 µM,"24, 48, 72h",1
DCTPep01048,5637,Bladder carcinoma,Carcinoma,MTT assay,IC50=20 μg/mL,24h,1
DCTPep01048,T24,Bladder carcinoma,Carcinoma,MTT assay,IC50=20 μg/mL,24h,1
DCTPep01049,A549,Lung adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=73µM,24h,1
DCTPep01050,Molt-4,Adult T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=0.84 mM ,48h,1
DCTPep01050,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=1.57 mM ,48h,1
DCTPep01051,EC109,Esophageal cancer,Carcinoma,MTS assay,49.01% decrease=50μg/mL,24h,1
DCTPep01051,HepG2 ,Hepatoblastoma,Blastoma,MTS assay,53.26% decrease=50μg/mL,24h,1
DCTPep01051,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,70.30% decrease=50μg/mL,24h,1
DCTPep01051,EJ,Bladder carcinoma,Carcinoma,MTS assay,78.44% decrease=50μg/mL,24h,1
DCTPep01052,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,44.76±23.77% Cytotoxicity=256 µg/ml,3h,1
DCTPep01053,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,70.84±14.6% Cytotoxicity=256 µg/ml,3h,1
DCTPep01054,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,66.5±5.32% Cytotoxicity=256 µg/ml,3h,1
DCTPep01055,SW480,Colon adenocarcinoma,Carcinoma,MTS assay,IC50=10.37±0.40 µM ,48h,1
DCTPep01055,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,IC50=5.44±0.33 µM ,48h,1
DCTPep01055,A549,Lung adenocarcinoma,Carcinoma,MTS assay,IC50=5.81±0.23 µM ,48h,1
DCTPep01055,HCT 116,Colon carcinoma,Carcinoma,MTS assay,IC50=5.87±0.15 µM ,48h,1
DCTPep01055,B16-F10,Mouse melanoma,Carcinoma,MTS assay,IC50=6.65±0.33 µM ,48h,1
DCTPep01055,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=6.87±0.51 µM ,48h,1
DCTPep01056,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,0% Killing=40 µg/ml,2h,1
DCTPep01056,A549,Lung adenocarcinoma,Carcinoma,MTT assay,30% Killing=40 µg/ml,2h,1
DCTPep01057,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=23.26 µM,24h,1
DCTPep01057,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=24.01 µM,24h,1
DCTPep01057,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35.05 µM,24h,1
DCTPep01057,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=37.84 µM,24h,1
DCTPep01058,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=128 µM,24h,1
DCTPep01058,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>128 µM,24h,1
DCTPep01058,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>128 µM,24h,1
DCTPep01058,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>128 µM,24h,1
DCTPep01059,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,CC50=15.9±1.1 µM ,24h,1
DCTPep01060,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=29±6 µM,72h,1
DCTPep01060,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=47±5 µM,72h,1
DCTPep01061,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.7±0.5 µM,72h,1
DCTPep01061,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=7.7±0.2 µM,72h,1
DCTPep01062,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50>100 µM,72h,1
DCTPep01062,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,72h,1
DCTPep01063,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=23±2 µM,72h,1
DCTPep01063,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=83±9 µM,72h,1
DCTPep01064,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=15.6±1.0 µM,72h,1
DCTPep01064,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=26.7±1.3 µM,72h,1
DCTPep01065,SK-MEL-28,Cutaneous melanoma,Carcinoma,MTT assay,IC50=50.8 µM,"24, 48h",1
DCTPep01065,G-361,Melanoma,Carcinoma,MTT assay,IC50=57.8 µM,"24, 48h",1
DCTPep01066,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=114.9±1.5 µM,"24, 48, 72h",1
DCTPep01067,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=32.7±4.5 µM,72h,1
DCTPep01067,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8.9±2.1 µM,72h,1
DCTPep01068,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14.5±2.3 µM,72h,1
DCTPep01068,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=20.9±2.0 µM,72h,1
DCTPep01069,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15.5±1.2 µM,72h,1
DCTPep01069,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=30.1±5.2 µM,72h,1
DCTPep01070,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=14.5±1.3 µM,72h,1
DCTPep01070,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=17.7±6.5 µM,72h,1
DCTPep01071,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50>40 µM,72h,1
DCTPep01071,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>40 µM,72h,1
DCTPep01072,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50>40 µM,72h,1
DCTPep01072,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>40 µM,72h,1
DCTPep01073,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=31.8±2.9  µM,72h,1
DCTPep01073,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>40 µM,72h,1
DCTPep01074,HSC-4,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,IC50=10.22 μM,48h,1
DCTPep01074,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=4.5 μM,48h,1
DCTPep01075,YAC-1,Mouse lymphoma,Lymphoma,Esuspension of the cell lines in 1% Nonidet P-40,LC90=50 µg/ml,2h,1
DCTPep01076,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=28.7 µM,96 h,1
DCTPep01076,HRT-18,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=49.3 µM,96 h,1
DCTPep01076,BTS-30,Breast Cancer,Carcinoma,MTT assay,IC50=56 µM,96 h,1
DCTPep01076,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,96 h,1
DCTPep01077,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=93 µM,96 h,1
DCTPep01077,BTS-30,Breast Cancer,Carcinoma,MTT assay,IC50>100 µM,96 h,1
DCTPep01077,DLD-1,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,96 h,1
DCTPep01077,HRT-18,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,96 h,1
DCTPep01078,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Trypan blue assay,LC50=14 µM,1h,1
DCTPep01078,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,LC50=80 µM,1h,1
DCTPep01079,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,LC=50 µM,1h,1
DCTPep01079,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Trypan blue assay,LC50=8 µM,1h,1
DCTPep01080,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Trypan blue assay,LC50=60 µM,1h,1
DCTPep01080,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,LC50=80 µM,1h,1
DCTPep01081,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10 µM,48 h,1
DCTPep01082,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=6 µM,48 h,1
DCTPep01085,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=28.6 µM,72 h,1
DCTPep01085,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=28.6 µM,72 h,1
DCTPep01085,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=32.2 µM,72 h,1
DCTPep01086,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=3.4 µM,72 h,1
DCTPep01086,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=3.5 µM,72 h,1
DCTPep01086,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=4.5 µM,72 h,1
DCTPep01087,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=36.2 µM,72 h,1
DCTPep01087,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=37.9 µM,72 h,1
DCTPep01087,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=47.7 µM,72 h,1
DCTPep01088,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=10.9 µM,72 h,1
DCTPep01088,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=9.3 µM,72 h,1
DCTPep01088,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=9.3 µM,72 h,1
DCTPep01089,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=1.3 µM,72 h,1
DCTPep01089,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=1.9 µM,72 h,1
DCTPep01089,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.8 µM,72 h,1
DCTPep01090,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.9 µM,72 h,1
DCTPep01090,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.9 µM,72 h,1
DCTPep01090,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=3.2 µM,72 h,1
DCTPep01091,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=1.7 µM,72 h,1
DCTPep01091,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2 µM,72 h,1
DCTPep01091,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=3.1 µM,72 h,1
DCTPep01092,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.4 µM,72 h,1
DCTPep01092,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.4 µM,72 h,1
DCTPep01092,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=3.1 µM,72 h,1
DCTPep01093,NCI-H146,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=1.8 µM,72 h,1
DCTPep01093,NCI-H128,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.3 µM,72 h,1
DCTPep01093,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=2.6 µM,72 h,1
DCTPep01094,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Thymidine Incorporation assay,Cytotoxicity=15 µM,6 h,1
DCTPep01095,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Thymidine Incorporation assay,Cytotoxicity=12 µM,6 h,1
DCTPep01097,HSC-4,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,IC50>61.46 µM,Not available,1
DCTPep01097,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>61.46 µM,Not available,1
DCTPep01098,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,EC50=1.50 μmol/mL,72h,1
DCTPep01098,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=2.38 μmol/mL ,72h,1
DCTPep01099,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=1.99 mg/mL ,24h,1
DCTPep01099,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.54 mg/mL ,24h,1
DCTPep01099,DU145,Prostate carcinoma,Carcinoma,MTT assay,IC50=2.80 mg/mL,24h,1
DCTPep01099,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=3.3 mg/mL ,24h,1
DCTPep01100,HT-29,Colon adenocarcinoma,Carcinoma,MTS assay,"Antiproliferative acitivity (%)=38.55±1.75%,  Peptide concentration 3 mg/mL",72h,1
DCTPep01101,HT-29,Colon adenocarcinoma,Carcinoma,MTS assay,"Antiproliferative acitivity (%)=41.49±2.18%,  Peptide concentration 3 mg/mL",72h,1
DCTPep01102,HT-29,Colon adenocarcinoma,Carcinoma,CCK-8 assay,IC50=1.40±0.09 µg/mL,48h,1
DCTPep01102,SW1990,Pancreatic adenocarcinoma,Carcinoma,CCK-8 assay,IC50=13.40±0.08 µg/mL,48h,1
DCTPep01102,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=13.81±0.31 µg/mL,48h,1
DCTPep01102,SW480,Colon adenocarcinoma,Carcinoma,CCK-8 assay,IC50=17.15±0.97 µg/mL,48h,1
DCTPep01102,EC109,Esophageal cancer,Carcinoma,CCK-8 assay,IC50=2.13±0.23 µg/mL,48h,1
DCTPep01102,A498,Renal cell carcinoma,Carcinoma,CCK-8 assay,IC50=2.33±0.49 µg/mL,48h,1
DCTPep01102,DU145,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=2.56±0.23 µg/mL,48h,1
DCTPep01102,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=2.60±0.24 µg/mL,48h,1
DCTPep01102,A431,Skin squamous cell carcinoma,Carcinoma,CCK-8 assay,IC50=2.75±0.07 µg/mL,48h,1
DCTPep01102,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,CCK-8 assay,IC50=3.11±0.49 µg/mL,48h,1
DCTPep01102,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=3.14±0.07 µg/mL,48h,1
DCTPep01102,HeLa S3,Breast cancer,Carcinoma,CCK-8 assay,IC50=3.16±0.45 µg/mL,48h,1
DCTPep01102,EC9706,Esophageal squamous cell carcinoma; Squamous cell carcinoma of the esophagus,Carcinoma,CCK-8 assay,IC50=3.23±0.16 µg/mL,48h,1
DCTPep01102,A-375,Amelanotic melanoma,Carcinoma,CCK-8 assay,IC50=4.16±0.15 µg/mL,48h,1
DCTPep01102,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CCK-8 assay,IC50=4.16±0.27 µg/mL,48h,1
DCTPep01102,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,CCK-8 assay,IC50=4.26±0.25 µg/mL,48h,1
DCTPep01102,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=4.94±0.28 µg/mL,48h,1
DCTPep01102,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=5.54±0.55 µg/mL,48h,1
DCTPep01102,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=5.68±0.25 µg/mL,48h,1
DCTPep01102,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=5.73±0.21 µg/mL,48h,1
DCTPep01102,Tca8113,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=5.82±0.25 µg/mL,48h,1
DCTPep01102,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=5.86±0.66 µg/mL,48h,1
DCTPep01102,PC-3M,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=6.17±0.24 µg/mL,48h,1
DCTPep01102,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CCK-8 assay,IC50=7.40±0.36 µg/mL,48h,1
DCTPep01102,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=7.67±0.57 µg/mL,48h,1
DCTPep01102,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,CCK-8 assay,IC50=9.84±0.39 µg/mL,48h,1
DCTPep01103,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.07 μg/mL,24h,1
DCTPep01103,T-47D ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.26 μg/mL,24h,1
DCTPep01103,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=3.53 μg/mL ,24h,1
DCTPep01103,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.78  µg/mL,24h,1
DCTPep01104,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=20 μg/mL ,72h,1
DCTPep01105,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=72.00±4.51 µg/mL,24h,1
DCTPep01106,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=63.00±5.00 µg/mL,24h,1
DCTPep01107,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=53.17±1.69 µg/mL,24h,1
DCTPep01108,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50>256 µg/mL,24h,1
DCTPep01109,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=102.33±1.45 µg/mL,24h,1
DCTPep01110,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50>256 µg/mL,24h,1
DCTPep01111,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=152.17±7.73 µg/mL,24h,1
DCTPep01112,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=87.17±2.35 µg/mL ,24h,1
DCTPep01113,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=191.67±12.02 µg/mL,24h,1
DCTPep01114,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50>256 µg/mL,24h,1
DCTPep01115,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50>256 µg/mL,24h,1
DCTPep01116,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50>256 µg/mL,24h,1
DCTPep01117,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=71.2 μM (42.0 mg/mL),48h,1
DCTPep01119,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=19.0 μM (13.1 mg/mL),48h,1
DCTPep01120,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=11.1 μM (8.1 mg/mL),48h,1
DCTPep01121,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=70.79 µg/mL ,24h,1
DCTPep01123,Mouse S180 sarcoma,Mouse S180 sarcoma,Sarcoma,Antitumor in vivo,"At a dose of 4.4 mg/kg body weight, the tumor weight inhibition rate was 46%",7 days,Patent
DCTPep01124,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=6.32 μM/mL,Not available,Patent
DCTPep01126,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 79%(Duncan-test,P<0.05)",24 h,Patent
DCTPep01126,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 79%(Duncan-test,P<0.05)",24 h,Patent
DCTPep01127,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 25%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01127,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 41%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01127,BT-474,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01127,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 63%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01128,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 21%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01128,BT-474,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 39%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01128,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 39%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01128,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 59%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01129,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 35%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01129,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 41%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01129,BT-474,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01129,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 66%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01130,BT-474,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01130,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01130,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01130,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 61%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01131,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 79%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01132,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 79%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01133,BT-474,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01133,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 50%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01133,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 60%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01133,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 60%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01134,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 70%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01134,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 82%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01135,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 70%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01135,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 80%(Duncan-test,P<0.05)",24 h,Patent
DCTPep01135,ZR-75-1,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 80%(Duncan-test,P<0.05)",24 h,Patent
DCTPep01136,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 73%(Duncan-test,P<0.05)",24 h,Patent
DCTPep01137,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 72%(Duncan-test,P<0.01)",24 h,Patent
DCTPep01138,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,"At a concentration of 100μM, the 24 h cell viability is approximately 85%(Duncan-test,P<0.05)",24 h,Patent
DCTPep01139,NCI-H520,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=22.7±0.2	 µM,48 h,1
DCTPep01139,NCI-H661,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=35.9±0.2	 µM,48 h,1
DCTPep01139,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=4.4±0.3 µM,48 h,1
DCTPep01139,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=5.6±0.5 µM,48 h,1
DCTPep01139,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=6.7±1.1 µM,48 h,1
DCTPep01140,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=40.65 μg/ml,24 h,Patent
DCTPep01140,SGC-7901,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=45.06 μg/ml,24 h,Patent
DCTPep01140,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=49.45 μg/ml,24 h,Patent
DCTPep01140,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=50.37 μg/ml,24 h,Patent
DCTPep01140,MKN28,Gastric tubular adenocarcinoma,Carcinoma,MTT assay,IC50=52.51 μg/ml,24 h,Patent
DCTPep01140,KATO III,Down syndrome; Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=57.52 μg/ml,24 h,Patent
DCTPep01140,MGC-803,Gastric mucinous adenocarcinoma,Carcinoma,MTT assay,IC50=58.33 μg/ml,24 h,Patent
DCTPep01168,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CD44v6 specifically binds to assay,Kd=17.69,Not available,Patent
DCTPep01168,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,CD44v6 specifically binds to assay,Kd=29.12,Not available,Patent
DCTPep01168,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,CD44v6 specifically binds to assay,Kd=6.655,Not available,Patent
DCTPep01169,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CD44v6 specifically binds to assay,Kd=11.62,Not available,Patent
DCTPep01169,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,CD44v6 specifically binds to assay,Kd=16.68,Not available,Patent
DCTPep01169,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,CD44v6 specifically binds to assay,Kd=8.449,Not available,Patent
DCTPep01170,A549,Lung adenocarcinoma,Carcinoma,MTS assay,"The non- survival rate in the HeLa cell it exposed to the HDH-LGBP-A2 peptide of the concentration of 10 μg/ml, 25 μg/ml, 50 μg/ml are 13%, 99%, 99%",24 h,Patent
DCTPep01170,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,"The non- survival rate in the HeLa cell it exposed to the HDH-LGBP-A2 peptide of the concentration of 10 μg/ml, 25 μg/ml, 50 μg/ml are 16%, 99%, 98%",24 h,Patent
DCTPep01171,A549,Lung adenocarcinoma,Carcinoma,MTS assay,"The non- survival rate in the HeLa cell it exposed to the HDH-LGBP-A1 peptide of the concentration of 10 μg/ml, 25 μg/ml, 50 μg/ml are 25%, 99%, 97%",24 h,Patent
DCTPep01171,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,"The non- survival rate in the HeLa cell it exposed to the HDH-LGBP-A1 peptide of the concentration of 10 μg/ml, 25 μg/ml, 50 μg/ml are 35%, 99%, 95%",24 h,Patent
DCTPep01174,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 100%, 100%, 90%, 82%",24 h,Patent
DCTPep01174,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 90%, 95%, 81%, 79%",24 h,Patent
DCTPep01174,SNU-719,Gastric tubular adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 92%, 90%, 82%, 80%",24 h,Patent
DCTPep01174,HCT 116,Colon carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 95%, 89%, 82%, 70%",24 h,Patent
DCTPep01175,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 100%, 90%, 82%, 23%",24 h,Patent
DCTPep01175,SNU-719,Gastric tubular adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 100%, 95%, 82%, 10%",24 h,Patent
DCTPep01175,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 95%, 82%, 70%, 35%",24 h,Patent
DCTPep01175,HCT 116,Colon carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 95%, 93%, 62%, 8%",24 h,Patent
DCTPep01176,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 100%, 90%, 32%, 8%",24 h,Patent
DCTPep01176,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 90%, 81%, 10%, 2%",24 h,Patent
DCTPep01176,SNU-719,Gastric tubular adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 95%, 87%, 43%, 2%",24 h,Patent
DCTPep01176,HCT 116,Colon carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 μM, 10 μM, 100 μM, 300μM, the Cell viability(%)  was 97%, 89%, 45%, 8%",24 h,Patent
DCTPep01177,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,MTT assay,It could confirm that the proliferation of the ovarian cancer cell was statistically carefully reduced in the culture medium containing the peptide of the concentration more than 25mM cultivated,24 h,Patent
DCTPep01179,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.98 μM,3-5 days,Patent
DCTPep01179,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=2.11 μM,3-5 days,Patent
DCTPep01179,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.30 μM,3-5 days,Patent
DCTPep01179,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50>10 μM,3-5 days,Patent
DCTPep01179,HCT 8,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>10 μM,3-5 days,Patent
DCTPep01180,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.03 μM,3-5 days,Patent
DCTPep01180,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.94 μM,3-5 days,Patent
DCTPep01180,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.08 μM,3-5 days,Patent
DCTPep01180,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=3.79 μM,3-5 days,Patent
DCTPep01180,HCT 8,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=5.93 μM,3-5 days,Patent
DCTPep01181,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=1.03 μM,72h,Patent
DCTPep01181,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=1.08 μM,72h,Patent
DCTPep01181,Capan-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=1.21 μM,72h,Patent
DCTPep01181,MOH-1,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=1.32 μM,72h,Patent
DCTPep01182,Capan-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=1.85 μM,72h,Patent
DCTPep01182,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=1.97 μM,72h,Patent
DCTPep01182,MOH-1,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=2.10 μM,72h,Patent
DCTPep01182,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=2.33 μM,72h,Patent
DCTPep01183,MOH-1,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=1.88 μM,72h,Patent
DCTPep01183,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=1.95 μM,72h,Patent
DCTPep01183,Capan-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=2.14 μM,72h,Patent
DCTPep01183,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=3.11 μM,72h,Patent
DCTPep01184,MOH-1,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=0.33 μM,72h,Patent
DCTPep01184,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=0.36 μM,72h,Patent
DCTPep01184,Capan-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=0.45 μM,72h,Patent
DCTPep01184,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=0.68 μM,72h,Patent
DCTPep01185,MOH-1,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=1.14 μM,72h,Patent
DCTPep01185,Capan-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=1.32 μM,72h,Patent
DCTPep01185,BxPC-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=1.54 μM,72h,Patent
DCTPep01185,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=2.01 μM,72h,Patent
DCTPep01186,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=19.72±0.38 µmol/L,72h,Patent
DCTPep01186,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=30.78±0.24 µmol/L,72h,Patent
DCTPep01186,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=47.25±0.33 µmol/L,72h,Patent
DCTPep01187,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01187,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01187,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=39.57±0.12 µmol/L,72h,Patent
DCTPep01188,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01188,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01188,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=28.97±0.27 µmol/L,72h,Patent
DCTPep01189,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.48±0.15 µmol/L,72h,Patent
DCTPep01189,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.38±0.38 µmol/L,72h,Patent
DCTPep01189,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=2.67±0.29 µmol/L,72h,Patent
DCTPep01190,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=10.66±0.25 µmol/L,72h,Patent
DCTPep01190,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=18.50±0.22 µmol/L,72h,Patent
DCTPep01190,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=6.01±0.15 µmol/L,72h,Patent
DCTPep01191,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.54±0.32 µmol/L,72h,Patent
DCTPep01191,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=5.56±0.41 µmol/L,72h,Patent
DCTPep01191,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=9.70±0.50 µmol/L,72h,Patent
DCTPep01192,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=12.75±0.26 µmol/L,72h,Patent
DCTPep01192,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=5.32±0.47 µmol/L,72h,Patent
DCTPep01192,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=7.57±0.18 µmol/L,72h,Patent
DCTPep01193,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01193,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01193,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01194,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01194,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01194,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=28.32±0.28 µmol/L,72h,Patent
DCTPep01195,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.90±0.35 µmol/L,72h,Patent
DCTPep01195,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.36±0.23 µmol/L,72h,Patent
DCTPep01195,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=2.45±0.22 µmol/L,72h,Patent
DCTPep01196,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=15.17±0.34 µmol/L,72h,Patent
DCTPep01196,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=17.09±0.26 µmol/L,72h,Patent
DCTPep01196,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=19.81±0.20 µmol/L,72h,Patent
DCTPep01197,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=2.52±0.42 µmol/L,72h,Patent
DCTPep01197,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3.17±0.33 µmol/L,72h,Patent
DCTPep01197,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=3.38±0.26 µmol/L,72h,Patent
DCTPep01198,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.75±0.33 µmol/L,72h,Patent
DCTPep01198,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=7.22±0.21 µmol/L,72h,Patent
DCTPep01198,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=8.04±0.27 µmol/L,72h,Patent
DCTPep01199,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01199,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01199,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01200,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=1.36±0.35 µmol/L,72h,Patent
DCTPep01200,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.61±0.27 µmol/L,72h,Patent
DCTPep01200,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=1.67±0.25 µmol/L,72h,Patent
DCTPep01201,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=5.18±0.37 µmol/L,72h,Patent
DCTPep01201,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=7.35±0.34 µmol/L,72h,Patent
DCTPep01201,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=7.99±0.22 µmol/L,72h,Patent
DCTPep01202,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01202,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01202,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50 ＞50 µmol/L,72h,Patent
DCTPep01203,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=11.84±0.17 µmol/L,72h,Patent
DCTPep01203,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=16.80±0.34 µmol/L,72h,Patent
DCTPep01203,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=16.84±0.28 µmol/L,72h,Patent
DCTPep01204,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10.01±0.34 µmol/L,72h,Patent
DCTPep01204,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,IC50=14.71±0.42 µmol/L,72h,Patent
DCTPep01204,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=22.89±0.22 µmol/L,72h,Patent
DCTPep01205,J5 [Human hepatocellular carcinoma],Hepatocellular carcinoma,Carcinoma,MTT assay,IC50=29.9 μM,24 h,Patent
DCTPep01205,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=70.0 μM,24 h,Patent
DCTPep01206,J5 [Human hepatocellular carcinoma],Hepatocellular carcinoma,Carcinoma,MTT assay,IC50=30.8 μM,24 h,Patent
DCTPep01207,J5 [Human hepatocellular carcinoma],Hepatocellular carcinoma,Carcinoma,MTT assay,IC50=28.9 μM,24 h,Patent
DCTPep01208,J5 [Human hepatocellular carcinoma],Hepatocellular carcinoma,Carcinoma,MTT assay,IC50=128.9 μM,24 h,Patent
DCTPep01208,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=145.2 μM,24 h,Patent
DCTPep01210,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,MTT assay,IC50=107.4 μM,24 h,Patent
DCTPep01210,J5 [Human hepatocellular carcinoma],Hepatocellular carcinoma,Carcinoma,MTT assay,IC50=24.3 μM,24 h,Patent
DCTPep01211,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=16 µg/ml,2 h,3
DCTPep01211,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,IC50=58.2 ± 3.9 μg/ml,120 h,1
DCTPep01213,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=17 µM,24 h,1
DCTPep01213,J5 [Human hepatocellular carcinoma],Hepatocellular carcinoma,Carcinoma,MTT assay,IC50=20.3 μM,24 h,Patent
DCTPep01237,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=281 ± 56.5 μM ,1 h,1
DCTPep01307,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50>200 µM,48 h,1
DCTPep01307,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>200 µM,48 h,1
DCTPep01359,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=12.2μM,72h,Patent
DCTPep01359,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,WST-8 assay,IC50=3.5μM,72h,Patent
DCTPep01359,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=6.4μM,72h,Patent
DCTPep01359,OE19,Not available,Not available,WST-8 assay,IC50=7.1μM,72h,Patent
DCTPep01359,LNCaP,Prostate carcinoma,Carcinoma,WST-8 assay,IC50=8.9μM,72h,Patent
DCTPep01366,BT-20,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=11.4μM,48h,Patent
DCTPep01366,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-8 assay,IC50=14.1μM,48h,Patent
DCTPep01366,SKBR-3,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=14.5μM,48h,Patent
DCTPep01366,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=14.7μM,48h,Patent
DCTPep01366,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=3.7μM,48h,Patent
DCTPep01366,HuCC-T1,Intrahepatic cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,WST-8 assay,IC50=7.9μM,48h,Patent
DCTPep01366,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=8.0μM,48h,Patent
DCTPep01366,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=8.1μM,48h,Patent
DCTPep01366,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,WST-8 assay,IC50=9.2μM,48h,Patent
DCTPep01374,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=6.5±1.1μM,72h,Patent
DCTPep01374,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=6.7±0.4μM,72h,Patent
DCTPep01374,A172,Glioblastoma,Blastoma,WST-8 assay,IC50=7.4±0.3μM,72h,Patent
DCTPep01374,KCCT873,Not available,Not available,WST-8 assay,IC50=7.6±0.8μM,72h,Patent
DCTPep01374,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=8.1±0.4μM,72h,Patent
DCTPep01377,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=3.2±0.4μM,72h,Patent
DCTPep01377,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=3.7±0.1μM,72h,Patent
DCTPep01377,A172,Glioblastoma,Blastoma,WST-8 assay,IC50=3.8±1.1μM,72h,Patent
DCTPep01377,KCCT873,Not available,Not available,WST-8 assay,IC50=4.6±0.1μM,72h,Patent
DCTPep01377,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=5.6±0.5μM,72h,Patent
DCTPep01379,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=12.5μM,48h,Patent
DCTPep01379,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=19.5μM,48h,Patent
DCTPep01379,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,WST-8 assay,IC50=22.6μM,48h,Patent
DCTPep01379,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-8 assay,IC50=28.2μM,48h,Patent
DCTPep01379,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=29.6μM,48h,Patent
DCTPep01379,BT-20,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=38.0μM,48h,Patent
DCTPep01379,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=38.5μM,48h,Patent
DCTPep01384,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-8 assay,IC50=13±2.7μM,48h,Patent
DCTPep01384,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=5.2±0.4μM,48h,Patent
DCTPep01384,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=5.7±2.3μM,48h,Patent
DCTPep01384,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,WST-8 assay,IC50=6.7±0.1μM,48h,Patent
DCTPep01386,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,WST-8 assay,IC50=10.6μM,48h,Patent
DCTPep01386,BT-20,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=10.9μM,48h,Patent
DCTPep01386,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=11.5μM,48h,Patent
DCTPep01386,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=12.5μM,48h,Patent
DCTPep01386,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-8 assay,IC50=13.1μM,48h,Patent
DCTPep01386,HuCC-T1,Intrahepatic cholangiocarcinoma; Cholangiocarcinoma,Carcinoma,WST-8 assay,IC50=13.6μM,48h,Patent
DCTPep01386,T-47D,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=4.1μM,48h,Patent
DCTPep01386,SU.86.86,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=7.9μM,48h,Patent
DCTPep01386,SKBR-3,Breast adenocarcinoma,Carcinoma,WST-8 assay,IC50=8.0μM,48h,Patent
DCTPep01403,LNCaP,Prostate carcinoma,Carcinoma,WST-8 assay,IC50=10±1.3μM,72h,Patent
DCTPep01403,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=12±0.9μM,72h,Patent
DCTPep01403,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=12±2.0μM,72h,Patent
DCTPep01403,SU.86.86 ,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=12±2.3μM,72h,Patent
DCTPep01403,BT-20 ,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=6.5±0.7μM,72h,Patent
DCTPep01403,H322,Minimally invasive lung adenocarcinoma,Carcinoma,WST-8 assay,IC50=6.8±0.5μM,72h,Patent
DCTPep01403,H460,Lung large cell carcinoma,Carcinoma,WST-8 assay,IC50=8.9±1.6μM,72h,Patent
DCTPep01407,BT-20 ,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,IC50=1.9μM,72h,Patent
DCTPep01407,H322,Minimally invasive lung adenocarcinoma,Carcinoma,WST-8 assay,IC50=3.2μM,72h,Patent
DCTPep01407,LNCaP,Prostate carcinoma,Carcinoma,WST-8 assay,IC50=4.8μM,72h,Patent
DCTPep01407,BXPC-3 ,Pancreatic ductal adenocarcinoma,Carcinoma,WST-8 assay,IC50=6.6μM,72h,Patent
DCTPep01407,SU.86.86 ,Pancreatic adenocarcinoma,Carcinoma,WST-8 assay,IC50=7.4μM,72h,Patent
DCTPep01407,U251 ,Astrocytoma,Carcinoma,WST-8 assay,IC50=8.4μM,72h,Patent
DCTPep01525,NCI-H526,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈11 μM,Not available,Patent
DCTPep01525,NCI-H524,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈9 μM,Not available,Patent
DCTPep01526,NCI-H526,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01526,NCI-H524,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈15 μM,Not available,Patent
DCTPep01527,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01527,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01527,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01527,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01528,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01528,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01528,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01529,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈2.5 μM,Not available,Patent
DCTPep01529,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01529,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01529,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01530,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01530,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01530,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01530,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01531,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01531,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12 μM,Not available,Patent
DCTPep01531,NCI-H524,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01531,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01531,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50≈14 μM,Not available,Patent
DCTPep01531,GBM-18,Glioblastoma,Blastoma,MTT assay,EC50≈4 μM,Not available,Patent
DCTPep01531,GBM-27,Glioblastoma,Blastoma,MTT assay,EC50≈5 μM,Not available,Patent
DCTPep01531,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7 μM,Not available,Patent
DCTPep01531,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50≈9 μM,Not available,Patent
DCTPep01532,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01532,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01532,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01532,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01533,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈2.5 μM,Not available,Patent
DCTPep01533,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01533,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01533,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01534,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈2.5 μM,Not available,Patent
DCTPep01534,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01534,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01534,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01535,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01535,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01535,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01535,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01536,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈2.5 μM,Not available,Patent
DCTPep01536,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01536,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01536,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01537,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01538,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01538,"H-5B, epithelial small cell lung cancer",lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01538,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01538,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01588,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 25μM, the Cell survival rate(%)  was  0%",3 h,Patent
DCTPep01588,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 25μM, the Cell survival rate(%)  was  0%",3 h,Patent
DCTPep01588,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",3 h,Patent
DCTPep01588,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01588,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",3 h,Patent
DCTPep01588,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01588,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01588,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01588,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01588,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01588,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01588,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",24 h,Patent
DCTPep01588,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",3 h,Patent
DCTPep01588,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",3 h,Patent
DCTPep01588,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 10%",24 h,Patent
DCTPep01588,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 2%",24 h,Patent
DCTPep01588,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01588,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01589,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 25μM, the Cell survival rate(%)  was  0%",3 h,Patent
DCTPep01589,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 35μM, the Cell survival rate(%)  was  0%",3 h,Patent
DCTPep01589,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",3 h,Patent
DCTPep01589,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01589,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",3 h,Patent
DCTPep01589,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01589,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01589,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01589,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01589,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01589,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",24 h,Patent
DCTPep01589,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",3 h,Patent
DCTPep01589,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 10%",24 h,Patent
DCTPep01589,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 10%",24 h,Patent
DCTPep01589,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 2%",24 h,Patent
DCTPep01589,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 70%",3 h,Patent
DCTPep01589,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01589,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01590,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was  80%",3 h,Patent
DCTPep01590,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was  85%",3 h,Patent
DCTPep01590,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was  87%",3 h,Patent
DCTPep01590,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",3 h,Patent
DCTPep01590,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 40%",12 h,Patent
DCTPep01590,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 50%",12 h,Patent
DCTPep01590,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 65%",12 h,Patent
DCTPep01590,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 68%",24 h,Patent
DCTPep01590,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01590,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 75%",3 h,Patent
DCTPep01590,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 79%",3 h,Patent
DCTPep01590,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 79%",12 h,Patent
DCTPep01590,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 80%",24 h,Patent
DCTPep01590,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 81%",12 h,Patent
DCTPep01590,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 82%",24 h,Patent
DCTPep01590,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 82%",24 h,Patent
DCTPep01590,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 97%",24 h,Patent
DCTPep01590,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 98%",24 h,Patent
DCTPep01591,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 25μM, the Cell survival rate(%)  was  0%",3 h,Patent
DCTPep01591,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 25μM, the Cell survival rate(%)  was  0%",3 h,Patent
DCTPep01591,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",3 h,Patent
DCTPep01591,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01591,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",3 h,Patent
DCTPep01591,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01591,OECM-1,Gingival squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01591,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01591,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01591,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",12 h,Patent
DCTPep01591,PC-9G,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 0%",24 h,Patent
DCTPep01591,A549,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",24 h,Patent
DCTPep01591,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",3 h,Patent
DCTPep01591,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 1%",3 h,Patent
DCTPep01591,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 10%",24 h,Patent
DCTPep01591,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 2%",24 h,Patent
DCTPep01591,PC-9,Lung adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01591,SAS,Tongue squamous cell carcinoma; Squamous cell carcinoma of the oral tongue,Carcinoma,MTT assay,"When the peptide concentrations was 50μM, the Cell survival rate(%)  was 72%",12 h,Patent
DCTPep01592,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=26.33 ± 5.8 μM,24 h,Patent
DCTPep01592,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01592,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01593,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=29.5 ± 6.03 μM,24 h,Patent
DCTPep01593,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=37.3 ± 3.5 μM,24 h,Patent
DCTPep01593,DoHH2,Diffuse large B-cell lymphoma germinal center B-cell type; Diffuse large B-cell lymphoma (ORDO: Orphanet_544),Lymphoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01593,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01594,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=17.9 ± 1.1 μM,24 h,Patent
DCTPep01594,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01594,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01595,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=22.4 ± 2.2 μM,24 h,Patent
DCTPep01595,DoHH2,Diffuse large B-cell lymphoma germinal center B-cell type; Diffuse large B-cell lymphoma (ORDO: Orphanet_544),Lymphoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01595,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01595,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,Patent
DCTPep01596,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=16.2 ± 2.2 μM,24 h,Patent
DCTPep01596,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=22.7 ± 0.86 μM,24 h,Patent
DCTPep01596,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=24.3 ± 0.84 μM,24 h,Patent
DCTPep01597,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=14.47 ± 0.57 μM,24 h,Patent
DCTPep01597,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=18.36 ± 0.92 μM,24 h,Patent
DCTPep01597,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,IC50=34.49 ± 1.5 μM,24 h,Patent
DCTPep01598,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01598,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01598,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01598,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01598,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01598,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01598,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=285 µg/ml,24 h,Patent
DCTPep01599,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01599,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01599,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01599,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01599,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01599,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01599,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01600,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01600,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01600,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01600,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01600,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01600,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01600,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01601,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01601,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01601,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01601,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01601,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01601,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=740 µg/ml,24 h,Patent
DCTPep01601,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01602,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=23 µg/ml,24 h,Patent
DCTPep01602,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=25 µg/ml,24 h,Patent
DCTPep01602,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01602,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01602,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=51 µg/ml,24 h,Patent
DCTPep01602,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=670 µg/ml,24 h,Patent
DCTPep01602,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=83 µg/ml,24 h,Patent
DCTPep01603,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01603,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01603,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep01603,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep01603,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01603,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=80 µg/ml,24 h,Patent
DCTPep01604,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=11 µg/ml,24 h,Patent
DCTPep01604,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=26 µg/ml,24 h,Patent
DCTPep01604,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=26 µg/ml,24 h,Patent
DCTPep01604,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=27 µg/ml,24 h,Patent
DCTPep01604,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep01604,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01604,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=8 µg/ml,24 h,Patent
DCTPep01605,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01605,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01605,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01605,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01605,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01605,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01605,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01606,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01606,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01606,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=525 µg/ml,24 h,Patent
DCTPep01606,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=525 µg/ml,24 h,Patent
DCTPep01606,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=625 µg/ml,24 h,Patent
DCTPep01606,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=850 µg/ml,24 h,Patent
DCTPep01606,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01607,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01607,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01607,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01607,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01607,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01607,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01607,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01608,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01608,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01608,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01608,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01608,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=575 µg/ml,24 h,Patent
DCTPep01608,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01608,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01609,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01609,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01609,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01609,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=45 µg/ml,24 h,Patent
DCTPep01609,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep01609,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=76 µg/ml,24 h,Patent
DCTPep01609,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=77 µg/ml,24 h,Patent
DCTPep01610,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01610,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01610,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01610,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01610,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01610,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01610,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01611,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01611,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01611,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01611,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01611,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01611,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=125 µg/ml,24 h,Patent
DCTPep01611,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=125 µg/ml,24 h,Patent
DCTPep01612,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=380 µg/ml,24 h,Patent
DCTPep01612,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01612,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=675 µg/ml,24 h,Patent
DCTPep01612,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=750 µg/ml,24 h,Patent
DCTPep01612,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=750 µg/ml,24 h,Patent
DCTPep01612,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=860 µg/ml,24 h,Patent
DCTPep01612,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=970 µg/ml,24 h,Patent
DCTPep01613,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=260 µg/ml,24 h,Patent
DCTPep01613,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=340 µg/ml,24 h,Patent
DCTPep01613,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=460 µg/ml,24 h,Patent
DCTPep01613,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=460 µg/ml,24 h,Patent
DCTPep01613,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=465 µg/ml,24 h,Patent
DCTPep01613,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=660 µg/ml,24 h,Patent
DCTPep01613,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=670 µg/ml,24 h,Patent
DCTPep01614,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01614,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01614,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01614,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01614,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=180 µg/ml,24 h,Patent
DCTPep01614,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=260 µg/ml,24 h,Patent
DCTPep01614,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01615,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=17 µg/ml,24 h,Patent
DCTPep01615,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=24 µg/ml,24 h,Patent
DCTPep01615,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=24 µg/ml,24 h,Patent
DCTPep01615,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=42 µg/ml,24 h,Patent
DCTPep01615,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01615,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=74 µg/ml,24 h,Patent
DCTPep01615,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=80 µg/ml,24 h,Patent
DCTPep01616,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=190 µg/ml,24 h,Patent
DCTPep01616,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01616,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=270 µg/ml,24 h,Patent
DCTPep01616,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=320 µg/ml,24 h,Patent
DCTPep01616,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=445 µg/ml,24 h,Patent
DCTPep01616,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=445 µg/ml,24 h,Patent
DCTPep01616,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=570 µg/ml,24 h,Patent
DCTPep01617,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01617,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01617,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=290 µg/ml,24 h,Patent
DCTPep01617,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=290 µg/ml,24 h,Patent
DCTPep01617,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=63 µg/ml,24 h,Patent
DCTPep01617,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=82 µg/ml,24 h,Patent
DCTPep01617,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=93 µg/ml,24 h,Patent
DCTPep01618,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=11 µg/ml,24 h,Patent
DCTPep01618,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=28 µg/ml,24 h,Patent
DCTPep01618,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01618,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=63 µg/ml,24 h,Patent
DCTPep01618,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=82 µg/ml,24 h,Patent
DCTPep01618,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01618,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01619,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=100 µg/ml,24 h,Patent
DCTPep01619,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01619,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=38 µg/ml,24 h,Patent
DCTPep01619,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=66 µg/ml,24 h,Patent
DCTPep01619,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=73 µg/ml,24 h,Patent
DCTPep01619,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=83 µg/ml,24 h,Patent
DCTPep01619,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=83 µg/ml,24 h,Patent
DCTPep01620,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01620,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01620,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01620,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=83 µg/ml,24 h,Patent
DCTPep01621,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=125 µg/ml,24 h,Patent
DCTPep01621,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=175 µg/ml,24 h,Patent
DCTPep01621,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=52 µg/ml,24 h,Patent
DCTPep01621,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=53 µg/ml,24 h,Patent
DCTPep01621,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01621,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01621,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=96 µg/ml,24 h,Patent
DCTPep01622,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=120 µg/ml,24 h,Patent
DCTPep01622,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=180 µg/ml,24 h,Patent
DCTPep01622,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=28 µg/ml,24 h,Patent
DCTPep01622,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01622,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01622,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01622,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=95 µg/ml,24 h,Patent
DCTPep01623,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=120 µg/ml,24 h,Patent
DCTPep01623,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01623,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=185 µg/ml,24 h,Patent
DCTPep01623,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=245 µg/ml,24 h,Patent
DCTPep01623,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=290 µg/ml,24 h,Patent
DCTPep01623,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=290 µg/ml,24 h,Patent
DCTPep01623,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=98 µg/ml,24 h,Patent
DCTPep01624,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01624,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=300 µg/ml,24 h,Patent
DCTPep01625,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01625,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=210 µg/ml,24 h,Patent
DCTPep01625,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=260 µg/ml,24 h,Patent
DCTPep01625,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=280 µg/ml,24 h,Patent
DCTPep01625,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=300 µg/ml,24 h,Patent
DCTPep01626,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=155 µg/ml,24 h,Patent
DCTPep01626,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=155 µg/ml,24 h,Patent
DCTPep01626,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=180 µg/ml,24 h,Patent
DCTPep01626,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=31 µg/ml,24 h,Patent
DCTPep01626,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=42 µg/ml,24 h,Patent
DCTPep01626,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=81 µg/ml,24 h,Patent
DCTPep01627,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=130 µg/ml,24 h,Patent
DCTPep01627,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=310 µg/ml,24 h,Patent
DCTPep01627,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=420 µg/ml,24 h,Patent
DCTPep01627,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=435 µg/ml,24 h,Patent
DCTPep01627,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=510 µg/ml,24 h,Patent
DCTPep01627,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=510 µg/ml,24 h,Patent
DCTPep01627,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=620 µg/ml,24 h,Patent
DCTPep01628,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01628,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=570 µg/ml,24 h,Patent
DCTPep01628,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=620 µg/ml,24 h,Patent
DCTPep01628,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=690 µg/ml,24 h,Patent
DCTPep01628,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=690 µg/ml,24 h,Patent
DCTPep01628,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01628,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=920 µg/ml,24 h,Patent
DCTPep01629,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01629,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01629,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01629,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01629,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01629,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01629,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01630,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=100 µg/ml,24 h,Patent
DCTPep01630,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=105 µg/ml,24 h,Patent
DCTPep01630,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=127 µg/ml,24 h,Patent
DCTPep01630,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01630,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01630,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01630,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=66 µg/ml,24 h,Patent
DCTPep01631,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=14 µg/ml,24 h,Patent
DCTPep01631,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=16 µg/ml,24 h,Patent
DCTPep01631,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=27 µg/ml,24 h,Patent
DCTPep01631,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=5 µg/ml,24 h,Patent
DCTPep01631,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01631,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01631,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep01632,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=23 µg/ml,24 h,Patent
DCTPep01633,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=19 µg/ml,24 h,Patent
DCTPep01633,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01633,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=56 µg/ml,24 h,Patent
DCTPep01633,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=56 µg/ml,24 h,Patent
DCTPep01633,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=57 µg/ml,24 h,Patent
DCTPep01633,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep01634,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=10 µg/ml,24 h,Patent
DCTPep01634,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=13 µg/ml,24 h,Patent
DCTPep01634,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=17 µg/ml,24 h,Patent
DCTPep01634,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=21 µg/ml,24 h,Patent
DCTPep01634,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=21 µg/ml,24 h,Patent
DCTPep01634,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=33 µg/ml,24 h,Patent
DCTPep01634,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep01635,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01635,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=22 µg/ml,24 h,Patent
DCTPep01635,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=32 µg/ml,24 h,Patent
DCTPep01635,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=45 µg/ml,24 h,Patent
DCTPep01635,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=47 µg/ml,24 h,Patent
DCTPep01635,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=47 µg/ml,24 h,Patent
DCTPep01635,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=72 µg/ml,24 h,Patent
DCTPep01636,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01636,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01636,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01636,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01636,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=540 µg/ml,24 h,Patent
DCTPep01636,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01636,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01637,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01637,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01637,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01637,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=280 µg/ml,24 h,Patent
DCTPep01637,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=280 µg/ml,24 h,Patent
DCTPep01637,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=290 µg/ml,24 h,Patent
DCTPep01637,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=300 µg/ml,24 h,Patent
DCTPep01638,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01638,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=180 µg/ml,24 h,Patent
DCTPep01638,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=325 µg/ml,24 h,Patent
DCTPep01638,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01638,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01638,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=540 µg/ml,24 h,Patent
DCTPep01638,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=95 µg/ml,24 h,Patent
DCTPep01639,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01639,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01639,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01639,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01639,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=500 µg/ml,24 h,Patent
DCTPep01639,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01639,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01640,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01640,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01640,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=315 µg/ml,24 h,Patent
DCTPep01640,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01640,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01640,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=660 µg/ml,24 h,Patent
DCTPep01640,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01641,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01641,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01641,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01641,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01641,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01641,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01641,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01642,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01642,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01642,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01642,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01642,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=550 µg/ml,24 h,Patent
DCTPep01642,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=550 µg/ml,24 h,Patent
DCTPep01642,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=790 µg/ml,24 h,Patent
DCTPep01643,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01643,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01643,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01643,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01643,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01643,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01643,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01644,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01644,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01644,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=460 µg/ml,24 h,Patent
DCTPep01644,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=670 µg/ml,24 h,Patent
DCTPep01644,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=670 µg/ml,24 h,Patent
DCTPep01644,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=800 µg/ml,24 h,Patent
DCTPep01644,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01645,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01645,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01645,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01645,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01645,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01645,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=730 µg/ml,24 h,Patent
DCTPep01645,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01646,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=27 µg/ml,24 h,Patent
DCTPep01646,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=43 µg/ml,24 h,Patent
DCTPep01646,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=57 µg/ml,24 h,Patent
DCTPep01646,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep01646,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep01646,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep01646,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=66 µg/ml,24 h,Patent
DCTPep01647,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01647,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01647,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=33 µg/ml,24 h,Patent
DCTPep01647,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=36 µg/ml,24 h,Patent
DCTPep01647,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=36 µg/ml,24 h,Patent
DCTPep01647,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01647,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01648,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01648,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=135 µg/ml,24 h,Patent
DCTPep01648,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=135 µg/ml,24 h,Patent
DCTPep01648,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01648,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=70 µg/ml,24 h,Patent
DCTPep01648,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=74 µg/ml,24 h,Patent
DCTPep01648,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=87 µg/ml,24 h,Patent
DCTPep01649,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01649,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01649,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01649,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=70 µg/ml,24 h,Patent
DCTPep01649,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=75 µg/ml,24 h,Patent
DCTPep01649,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=75 µg/ml,24 h,Patent
DCTPep01649,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=90 µg/ml,24 h,Patent
DCTPep01650,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=14 µg/ml,24 h,Patent
DCTPep01650,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=15 µg/ml,24 h,Patent
DCTPep01650,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=16 µg/ml,24 h,Patent
DCTPep01650,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=16 µg/ml,24 h,Patent
DCTPep01650,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=16 µg/ml,24 h,Patent
DCTPep01650,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=47 µg/ml,24 h,Patent
DCTPep01650,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01651,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01651,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01651,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01651,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01651,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01651,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=340 µg/ml,24 h,Patent
DCTPep01651,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=730 µg/ml,24 h,Patent
DCTPep01652,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01652,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01652,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01652,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=180 µg/ml,24 h,Patent
DCTPep01652,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=190 µg/ml,24 h,Patent
DCTPep01652,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01652,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=50 µg/ml,24 h,Patent
DCTPep01653,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01653,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01653,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01653,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=740 µg/ml,24 h,Patent
DCTPep01653,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=740 µg/ml,24 h,Patent
DCTPep01653,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=740 µg/ml,24 h,Patent
DCTPep01653,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01654,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01654,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01654,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01654,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=615 µg/ml,24 h,Patent
DCTPep01654,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=635 µg/ml,24 h,Patent
DCTPep01654,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=635 µg/ml,24 h,Patent
DCTPep01654,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=940 µg/ml,24 h,Patent
DCTPep01655,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01655,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01655,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01655,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01655,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=820 µg/ml,24 h,Patent
DCTPep01655,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=820 µg/ml,24 h,Patent
DCTPep01655,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01656,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01656,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01656,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01656,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01656,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01656,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01656,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01657,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=210 µg/ml,24 h,Patent
DCTPep01657,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01657,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01657,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=345 µg/ml,24 h,Patent
DCTPep01657,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=450 µg/ml,24 h,Patent
DCTPep01657,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=470 µg/ml,24 h,Patent
DCTPep01657,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=475 µg/ml,24 h,Patent
DCTPep01658,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01658,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01658,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01658,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01658,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01658,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01658,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01659,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=320 µg/ml,24 h,Patent
DCTPep01659,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=690 µg/ml,24 h,Patent
DCTPep01659,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01660,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=190 µg/ml,24 h,Patent
DCTPep01660,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep01660,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=80 µg/ml,24 h,Patent
DCTPep01660,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=90 µg/ml,24 h,Patent
DCTPep01660,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=90 µg/ml,24 h,Patent
DCTPep01660,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=90 µg/ml,24 h,Patent
DCTPep01661,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01661,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01661,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01661,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01661,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01661,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01661,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01662,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01662,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=620 µg/ml,24 h,Patent
DCTPep01662,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=630 µg/ml,24 h,Patent
DCTPep01662,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=660 µg/ml,24 h,Patent
DCTPep01662,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=660 µg/ml,24 h,Patent
DCTPep01662,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=730 µg/ml,24 h,Patent
DCTPep01662,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=810 µg/ml,24 h,Patent
DCTPep01663,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01663,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01663,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01663,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01663,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=410 µg/ml,24 h,Patent
DCTPep01663,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=430 µg/ml,24 h,Patent
DCTPep01663,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=740 µg/ml,24 h,Patent
DCTPep01664,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=125 µg/ml,24 h,Patent
DCTPep01664,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=145 µg/ml,24 h,Patent
DCTPep01664,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=220 µg/ml,24 h,Patent
DCTPep01664,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=220 µg/ml,24 h,Patent
DCTPep01664,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=220 µg/ml,24 h,Patent
DCTPep01664,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=76 µg/ml,24 h,Patent
DCTPep01664,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=90 µg/ml,24 h,Patent
DCTPep01665,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=100 µg/ml,24 h,Patent
DCTPep01665,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01665,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01665,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01665,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=40 µg/ml,24 h,Patent
DCTPep01665,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=77 µg/ml,24 h,Patent
DCTPep01666,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=12 µg/ml,24 h,Patent
DCTPep01666,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=15 µg/ml,24 h,Patent
DCTPep01666,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=6 µg/ml,24 h,Patent
DCTPep01666,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01666,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01666,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep01666,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep01667,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01667,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01667,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=440 µg/ml,24 h,Patent
DCTPep01667,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=535 µg/ml,24 h,Patent
DCTPep01667,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=535 µg/ml,24 h,Patent
DCTPep01667,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=610 µg/ml,24 h,Patent
DCTPep01667,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=770 µg/ml,24 h,Patent
DCTPep01668,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=10 µg/ml,24 h,Patent
DCTPep01668,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=10 µg/ml,24 h,Patent
DCTPep01668,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=10 µg/ml,24 h,Patent
DCTPep01668,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=14 µg/ml,24 h,Patent
DCTPep01668,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=18 µg/ml,24 h,Patent
DCTPep01668,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01668,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep01669,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=130 µg/ml,24 h,Patent
DCTPep01669,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01669,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=145 µg/ml,24 h,Patent
DCTPep01669,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01669,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=200 µg/ml,24 h,Patent
DCTPep01669,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=200 µg/ml,24 h,Patent
DCTPep01669,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=90 µg/ml,24 h,Patent
DCTPep01670,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=11 µg/ml,24 h,Patent
DCTPep01670,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=11 µg/ml,24 h,Patent
DCTPep01670,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=65 µg/ml,24 h,Patent
DCTPep01670,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01671,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=445 µg/ml,24 h,Patent
DCTPep01671,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=445 µg/ml,24 h,Patent
DCTPep01671,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=470 µg/ml,24 h,Patent
DCTPep01671,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=500 µg/ml,24 h,Patent
DCTPep01671,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=640 µg/ml,24 h,Patent
DCTPep01671,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=660 µg/ml,24 h,Patent
DCTPep01671,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=800 µg/ml,24 h,Patent
DCTPep01672,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=205 µg/ml,24 h,Patent
DCTPep01672,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=205 µg/ml,24 h,Patent
DCTPep01672,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=215 µg/ml,24 h,Patent
DCTPep01672,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=300 µg/ml,24 h,Patent
DCTPep01672,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=370 µg/ml,24 h,Patent
DCTPep01672,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=435 µg/ml,24 h,Patent
DCTPep01672,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=500 µg/ml,24 h,Patent
DCTPep01673,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01673,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=155 µg/ml,24 h,Patent
DCTPep01673,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=155 µg/ml,24 h,Patent
DCTPep01673,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=215 µg/ml,24 h,Patent
DCTPep01673,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=310 µg/ml,24 h,Patent
DCTPep01673,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01673,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=80 µg/ml,24 h,Patent
DCTPep01674,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01674,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=450 µg/ml,24 h,Patent
DCTPep01674,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=500 µg/ml,24 h,Patent
DCTPep01674,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01674,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01674,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01674,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=900 µg/ml,24 h,Patent
DCTPep01675,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01675,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01675,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01675,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01675,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01675,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01675,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01676,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=27 µg/ml,24 h,Patent
DCTPep01676,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=27 µg/ml,24 h,Patent
DCTPep01676,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=41 µg/ml,24 h,Patent
DCTPep01676,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=5 µg/ml,24 h,Patent
DCTPep01676,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=62 µg/ml,24 h,Patent
DCTPep01676,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep01676,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=82 µg/ml,24 h,Patent
DCTPep01677,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01677,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01677,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01677,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01677,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01677,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01677,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01678,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01678,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01678,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01678,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01678,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01678,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=435 µg/ml,24 h,Patent
DCTPep01678,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=760 µg/ml,24 h,Patent
DCTPep01679,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=125 µg/ml,24 h,Patent
DCTPep01679,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01679,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=74 µg/ml,24 h,Patent
DCTPep01679,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=8 µg/ml,24 h,Patent
DCTPep01679,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=84 µg/ml,24 h,Patent
DCTPep01679,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01679,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=94 µg/ml,24 h,Patent
DCTPep01680,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01680,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=430 µg/ml,24 h,Patent
DCTPep01680,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=465 µg/ml,24 h,Patent
DCTPep01680,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=465 µg/ml,24 h,Patent
DCTPep01680,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=560 µg/ml,24 h,Patent
DCTPep01680,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01681,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01681,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01681,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01681,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01681,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01681,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01681,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01682,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01682,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01682,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=510 µg/ml,24 h,Patent
DCTPep01682,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01682,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01682,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=640 µg/ml,24 h,Patent
DCTPep01682,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01683,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01683,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01683,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01683,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01683,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01683,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01683,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01684,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01684,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=225 µg/ml,24 h,Patent
DCTPep01684,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01684,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01684,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=275 µg/ml,24 h,Patent
DCTPep01684,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=285 µg/ml,24 h,Patent
DCTPep01684,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=350 µg/ml,24 h,Patent
DCTPep01685,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=14 µg/ml,24 h,Patent
DCTPep01685,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01685,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01685,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01685,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=57 µg/ml,24 h,Patent
DCTPep01685,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep01686,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01686,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01686,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=6 µg/ml,24 h,Patent
DCTPep01686,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=61 µg/ml,24 h,Patent
DCTPep01686,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=72 µg/ml,24 h,Patent
DCTPep01686,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=72 µg/ml,24 h,Patent
DCTPep01686,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=95 µg/ml,24 h,Patent
DCTPep01687,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=128 µg/ml,24 h,Patent
DCTPep01687,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=128 µg/ml,24 h,Patent
DCTPep01687,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01687,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=23 µg/ml,24 h,Patent
DCTPep01687,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01687,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01687,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=50 µg/ml,24 h,Patent
DCTPep01688,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01688,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01688,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=340 µg/ml,24 h,Patent
DCTPep01688,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=360 µg/ml,24 h,Patent
DCTPep01688,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01688,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=56 µg/ml,24 h,Patent
DCTPep01689,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=10 µg/ml,24 h,Patent
DCTPep01689,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=12 µg/ml,24 h,Patent
DCTPep01689,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=12 µg/ml,24 h,Patent
DCTPep01689,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=20 µg/ml,24 h,Patent
DCTPep01689,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=36 µg/ml,24 h,Patent
DCTPep01689,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=36 µg/ml,24 h,Patent
DCTPep01689,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=37 µg/ml,24 h,Patent
DCTPep01690,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=16 µg/ml,24 h,Patent
DCTPep01690,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01690,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=59 µg/ml,24 h,Patent
DCTPep01690,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=65 µg/ml,24 h,Patent
DCTPep01690,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=80 µg/ml,24 h,Patent
DCTPep01690,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=93 µg/ml,24 h,Patent
DCTPep01690,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=93 µg/ml,24 h,Patent
DCTPep01691,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=14 µg/ml,24 h,Patent
DCTPep01691,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=16 µg/ml,24 h,Patent
DCTPep01691,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=25 µg/ml,24 h,Patent
DCTPep01691,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=26 µg/ml,24 h,Patent
DCTPep01691,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01691,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01691,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=8 µg/ml,24 h,Patent
DCTPep01692,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=145 µg/ml,24 h,Patent
DCTPep01692,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=26 µg/ml,24 h,Patent
DCTPep01692,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=38 µg/ml,24 h,Patent
DCTPep01692,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=38 µg/ml,24 h,Patent
DCTPep01692,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=72 µg/ml,24 h,Patent
DCTPep01692,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=85 µg/ml,24 h,Patent
DCTPep01692,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=85 µg/ml,24 h,Patent
DCTPep01693,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=21 µg/ml,24 h,Patent
DCTPep01693,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=24 µg/ml,24 h,Patent
DCTPep01693,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep01693,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=53 µg/ml,24 h,Patent
DCTPep01693,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=53 µg/ml,24 h,Patent
DCTPep01693,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=62 µg/ml,24 h,Patent
DCTPep01693,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=9 µg/ml,24 h,Patent
DCTPep01694,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=230 µg/ml,24 h,Patent
DCTPep01694,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01694,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01694,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=300 µg/ml,24 h,Patent
DCTPep01694,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=320 µg/ml,24 h,Patent
DCTPep01694,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=325 µg/ml,24 h,Patent
DCTPep01694,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=360 µg/ml,24 h,Patent
DCTPep01695,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01695,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01695,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01695,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=640 µg/ml,24 h,Patent
DCTPep01695,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=640 µg/ml,24 h,Patent
DCTPep01695,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=770 µg/ml,24 h,Patent
DCTPep01695,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01696,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01696,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01696,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=550 µg/ml,24 h,Patent
DCTPep01696,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01696,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01696,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=870 µg/ml,24 h,Patent
DCTPep01696,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01697,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01697,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01697,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01697,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01697,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01697,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01697,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01698,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01698,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01698,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01698,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01698,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01698,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=940 µg/ml,24 h,Patent
DCTPep01698,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01699,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01699,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=165 µg/ml,24 h,Patent
DCTPep01699,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=165 µg/ml,24 h,Patent
DCTPep01699,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=50 µg/ml,24 h,Patent
DCTPep01699,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=61 µg/ml,24 h,Patent
DCTPep01699,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep01699,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=97 µg/ml,24 h,Patent
DCTPep01700,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=305 µg/ml,24 h,Patent
DCTPep01700,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=540 µg/ml,24 h,Patent
DCTPep01700,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01700,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01700,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01700,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=770 µg/ml,24 h,Patent
DCTPep01700,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=820 µg/ml,24 h,Patent
DCTPep01701,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=120 µg/ml,24 h,Patent
DCTPep01701,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=190 µg/ml,24 h,Patent
DCTPep01701,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01701,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=310 µg/ml,24 h,Patent
DCTPep01701,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=310 µg/ml,24 h,Patent
DCTPep01701,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=310 µg/ml,24 h,Patent
DCTPep01701,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=380 µg/ml,24 h,Patent
DCTPep01702,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01702,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01702,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01702,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=590 µg/ml,24 h,Patent
DCTPep01702,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=590 µg/ml,24 h,Patent
DCTPep01702,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=630 µg/ml,24 h,Patent
DCTPep01702,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01703,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01703,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=315 µg/ml,24 h,Patent
DCTPep01703,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=375 µg/ml,24 h,Patent
DCTPep01703,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01703,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01703,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01703,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01704,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01704,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01704,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01704,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01704,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01704,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01704,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01705,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=360 µg/ml,24 h,Patent
DCTPep01705,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=570 µg/ml,24 h,Patent
DCTPep01705,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01705,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01705,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=780 µg/ml,24 h,Patent
DCTPep01705,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=800 µg/ml,24 h,Patent
DCTPep01705,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=830 µg/ml,24 h,Patent
DCTPep01706,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=106 µg/ml,24 h,Patent
DCTPep01706,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=110 µg/ml,24 h,Patent
DCTPep01706,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=110 µg/ml,24 h,Patent
DCTPep01706,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=185 µg/ml,24 h,Patent
DCTPep01706,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=340 µg/ml,24 h,Patent
DCTPep01706,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=93 µg/ml,24 h,Patent
DCTPep01706,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01707,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01707,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=315 µg/ml,24 h,Patent
DCTPep01707,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01707,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=345 µg/ml,24 h,Patent
DCTPep01707,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01707,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=530 µg/ml,24 h,Patent
DCTPep01712,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=12 µg/ml,24 h,Patent
DCTPep01712,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=180 µg/ml,24 h,Patent
DCTPep01712,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=20 µg/ml,24 h,Patent
DCTPep01712,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01712,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=31 µg/ml,24 h,Patent
DCTPep01712,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep01713,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01713,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01713,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01713,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01713,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01713,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01714,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01714,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01714,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01714,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01714,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01714,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01715,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01715,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01715,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01715,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01715,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01715,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01716,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01716,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01716,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01716,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01716,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=510 µg/ml,24 h,Patent
DCTPep01716,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=70 µg/ml,24 h,Patent
DCTPep01717,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01717,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01717,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=635 µg/ml,24 h,Patent
DCTPep01717,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01718,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01718,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01718,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=340 µg/ml,24 h,Patent
DCTPep01718,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=700 µg/ml,24 h,Patent
DCTPep01718,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=720 µg/ml,24 h,Patent
DCTPep01718,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01719,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01719,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=140 µg/ml,24 h,Patent
DCTPep01719,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=145 µg/ml,24 h,Patent
DCTPep01719,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=275 µg/ml,24 h,Patent
DCTPep01719,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=61 µg/ml,24 h,Patent
DCTPep01719,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=74 µg/ml,24 h,Patent
DCTPep01720,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=220 µg/ml,24 h,Patent
DCTPep01720,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=320 µg/ml,24 h,Patent
DCTPep01720,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=370 µg/ml,24 h,Patent
DCTPep01720,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=450 µg/ml,24 h,Patent
DCTPep01720,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=470 µg/ml,24 h,Patent
DCTPep01720,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=550 µg/ml,24 h,Patent
DCTPep01721,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01721,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=185 µg/ml,24 h,Patent
DCTPep01721,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=190 µg/ml,24 h,Patent
DCTPep01721,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=235 µg/ml,24 h,Patent
DCTPep01721,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=320 µg/ml,24 h,Patent
DCTPep01721,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=74 µg/ml,24 h,Patent
DCTPep01722,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=135 µg/ml,24 h,Patent
DCTPep01722,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=260 µg/ml,24 h,Patent
DCTPep01722,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=345 µg/ml,24 h,Patent
DCTPep01722,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=520 µg/ml,24 h,Patent
DCTPep01722,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01723,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=28 µg/ml,24 h,Patent
DCTPep01723,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=29 µg/ml,24 h,Patent
DCTPep01723,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=35 µg/ml,24 h,Patent
DCTPep01723,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=64 µg/ml,24 h,Patent
DCTPep01723,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=76 µg/ml,24 h,Patent
DCTPep01723,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=97 µg/ml,24 h,Patent
DCTPep01724,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01725,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01725,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=38 µg/ml,24 h,Patent
DCTPep01725,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=38 µg/ml,24 h,Patent
DCTPep01725,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01725,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=55 µg/ml,24 h,Patent
DCTPep01725,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=60 µg/ml,24 h,Patent
DCTPep01726,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01726,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01726,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01726,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=555 µg/ml,24 h,Patent
DCTPep01726,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01726,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01727,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=100 µg/ml,24 h,Patent
DCTPep01727,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=11 µg/ml,24 h,Patent
DCTPep01727,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=130 µg/ml,24 h,Patent
DCTPep01727,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=18 µg/ml,24 h,Patent
DCTPep01727,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=52 µg/ml,24 h,Patent
DCTPep01727,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01728,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=30 µg/ml,24 h,Patent
DCTPep01728,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=40 µg/ml,24 h,Patent
DCTPep01728,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=40 µg/ml,24 h,Patent
DCTPep01728,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=45 µg/ml,24 h,Patent
DCTPep01728,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=65 µg/ml,24 h,Patent
DCTPep01729,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=115 µg/ml,24 h,Patent
DCTPep01729,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=12 µg/ml,24 h,Patent
DCTPep01729,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=13 µg/ml,24 h,Patent
DCTPep01729,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01729,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01729,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=19 µg/ml,24 h,Patent
DCTPep01729,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=22 µg/ml,24 h,Patent
DCTPep01729,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=270 µg/ml,24 h,Patent
DCTPep01729,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=360 µg/ml,24 h,Patent
DCTPep01729,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=63 µg/ml,24 h,Patent
DCTPep01729,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=70 µg/ml,24 h,Patent
DCTPep01729,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=97 µg/ml,24 h,Patent
DCTPep01730,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=110 µg/ml,24 h,Patent
DCTPep01730,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=185 µg/ml,24 h,Patent
DCTPep01730,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=380 µg/ml,24 h,Patent
DCTPep01730,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=440 µg/ml,24 h,Patent
DCTPep01730,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=640 µg/ml,24 h,Patent
DCTPep01730,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=93 µg/ml,24 h,Patent
DCTPep01731,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01731,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01731,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01731,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=555 µg/ml,24 h,Patent
DCTPep01731,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=920 µg/ml,24 h,Patent
DCTPep01731,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01732,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=120 µg/ml,24 h,Patent
DCTPep01732,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=170 µg/ml,24 h,Patent
DCTPep01732,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=240 µg/ml,24 h,Patent
DCTPep01732,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=250 µg/ml,24 h,Patent
DCTPep01732,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=370 µg/ml,24 h,Patent
DCTPep01732,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=50 µg/ml,24 h,Patent
DCTPep01733,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01733,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01733,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01733,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01733,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01733,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01734,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=120 µg/ml,24 h,Patent
DCTPep01734,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=150 µg/ml,24 h,Patent
DCTPep01734,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=175 µg/ml,24 h,Patent
DCTPep01734,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=220 µg/ml,24 h,Patent
DCTPep01734,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=82 µg/ml,24 h,Patent
DCTPep01735,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01735,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01735,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01735,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=540 µg/ml,24 h,Patent
DCTPep01735,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=630 µg/ml,24 h,Patent
DCTPep01735,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=720 µg/ml,24 h,Patent
DCTPep01737,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=92 µg/ml,24 h,Patent
DCTPep01738,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=210 µg/ml,24 h,Patent
DCTPep01739,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=32 µg/ml,24 h,Patent
DCTPep01739,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=33 µg/ml,24 h,Patent
DCTPep01739,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=40 µg/ml,24 h,Patent
DCTPep01739,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=46 µg/ml,24 h,Patent
DCTPep01739,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=54 µg/ml,24 h,Patent
DCTPep01739,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=7 µg/ml,24 h,Patent
DCTPep01740,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=130 µg/ml,24 h,Patent
DCTPep01741,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=86 µg/ml,24 h,Patent
DCTPep01742,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=45 µg/ml,24 h,Patent
DCTPep01743,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=17 µg/ml,24 h,Patent
DCTPep01743,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=23 µg/ml,24 h,Patent
DCTPep01743,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=32 µg/ml,24 h,Patent
DCTPep01743,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=43 µg/ml,24 h,Patent
DCTPep01743,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=44 µg/ml,24 h,Patent
DCTPep01743,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=47 µg/ml,24 h,Patent
DCTPep01744,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=315 µg/ml,24 h,Patent
DCTPep01744,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=330 µg/ml,24 h,Patent
DCTPep01744,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=400 µg/ml,24 h,Patent
DCTPep01744,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=640 µg/ml,24 h,Patent
DCTPep01744,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=750 µg/ml,24 h,Patent
DCTPep01744,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01745,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=160 µg/ml,24 h,Patent
DCTPep01746,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=340 µg/ml,24 h,Patent
DCTPep01748,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01748,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01748,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01748,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=760 µg/ml,24 h,Patent
DCTPep01748,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=770 µg/ml,24 h,Patent
DCTPep01748,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=950 µg/ml,24 h,Patent
DCTPep01749,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=84 µg/ml,24 h,Patent
DCTPep01750,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=260 µg/ml,24 h,Patent
DCTPep01750,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50=302 µg/ml,24 h,Patent
DCTPep01750,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=370 µg/ml,24 h,Patent
DCTPep01750,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=440 µg/ml,24 h,Patent
DCTPep01750,PC-3,Prostate carcinoma,Carcinoma,MTT assay,LD50=570 µg/ml,24 h,Patent
DCTPep01750,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=600 µg/ml,24 h,Patent
DCTPep01751,BMKC,Skin carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01751,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01751,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01751,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,LD50=1000 µg/ml,24 h,Patent
DCTPep01751,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,LD50>1000 µg/ml,24 h,Patent
DCTPep01753,22Rv1,Prostate carcinoma,Carcinoma,MTT assay,LC50<3.125 µM,Not available,Patent
DCTPep01753,CL1,Prostate carcinoma,Carcinoma,MTT assay,LC50<3.125 µM,Not available,Patent
DCTPep01754,22Rv1,Prostate carcinoma,Carcinoma,MTT assay,LC50=3.125 µM,Not available,Patent
DCTPep01754,CL1,Prostate carcinoma,Carcinoma,MTT assay,LC50=3.125 µM,Not available,Patent
DCTPep01755,22Rv1,Prostate carcinoma,Carcinoma,MTT assay,LC50>100 µM,Not available,Patent
DCTPep01755,CL1,Prostate carcinoma,Carcinoma,MTT assay,LC50>100 µM,Not available,Patent
DCTPep01756,22Rv1,Prostate carcinoma,Carcinoma,MTT assay,LC50<3.125 µM,Not available,Patent
DCTPep01756,CL1,Prostate carcinoma,Carcinoma,MTT assay,LC50<3.125 µM,Not available,Patent
DCTPep01757,22Rv1,Prostate carcinoma,Carcinoma,MTT assay,LC50<3.125 µM,Not available,Patent
DCTPep01757,CL1,Prostate carcinoma,Carcinoma,MTT assay,LC50=3.125 µM,Not available,Patent
DCTPep01758,CT26,Mouse colon adenocarcinoma,Carcinoma,Tumor growth assay,2 μg/mouse of WRYMVm successfully inhibited tumor mass growth (50% against PBS control) on day 22. ,Not available,Patent
DCTPep01760,AsPC-1,Pancreatic ductal adenocarcinoma,Carcinoma,Xenograft experiments,Significantly inhibiting fibrosis of AsPC1 Cell,Not available,Patent
DCTPep01765,DA-3 [Mouse lymphoma],Mouse lymphoma,Lymphoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=10 nM,5 days,Patent
DCTPep01765,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=12529 nM,5 days,Patent
DCTPep01765,DLD-1,Colon adenocarcinoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=380 nM,5 days,Patent
DCTPep01765,U-118MG,Astrocytoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=49 nM,5 days,Patent
DCTPep01765,BT-549,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50>20000 nM,5 days,Patent
DCTPep01765,HT-29,Colon adenocarcinoma,Carcinoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 0 ± 2, 10 ± 8, 0 ± 10.",72 h,Patent
DCTPep01765,U-87MG ATCC,Glioblastoma,Blastoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 0 ± 4, 24 ± 5, 64 ± 8.",72 h,Patent
DCTPep01765,D-54MG,Glioblastoma,Blastoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 0 ± 5, 12 ± 6, 56 ± 5.",72 h,Patent
DCTPep01765,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 2 ± 4, 13 ± 2, 46 ± 6.",72 h,Patent
DCTPep01765,Calu-6,Lung adenocarcinoma,Carcinoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 7 ± 2, 21 ± 3, 30 ± 4.",72 h,Patent
DCTPep01766,U-118MG,Astrocytoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=12 nM,5 days,Patent
DCTPep01766,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=210 nM,5 days,Patent
DCTPep01766,DLD-1,Colon adenocarcinoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=22 nM,5 days,Patent
DCTPep01766,BT-549,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=49 nM,5 days,Patent
DCTPep01767,DA-3 [Mouse lymphoma],Mouse lymphoma,Lymphoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=13 nM,5 days,Patent
DCTPep01767,BT-549,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=14400 nM,5 days,Patent
DCTPep01767,U-118MG,Astrocytoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=20 nM,5 days,Patent
DCTPep01767,DLD-1,Colon adenocarcinoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=250 nM,5 days,Patent
DCTPep01767,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=3254 nM,5 days,Patent
DCTPep01767,HT-29,Colon adenocarcinoma,Carcinoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 0 ± 8, 10 ± 9, 0 ± 5.",72 h,Patent
DCTPep01767,U-87MG ATCC,Glioblastoma,Blastoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 12 ± 7, 45 ± 7, 82 ± 8.",72 h,Patent
DCTPep01767,Calu-6,Lung adenocarcinoma,Carcinoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 14 ± 2, 31 ± 5, 60 ± 5.",72 h,Patent
DCTPep01767,D-54MG,Glioblastoma,Blastoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 15 ± 3, 52 ± 6, 85 ± 3.",72 h,Patent
DCTPep01767,MDA-MB-231,Breast adenocarcinoma,Carcinoma,WST-8 assay,"When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 33 ± 8, 63 ± 12, 86 ± 10.",72 h,Patent
DCTPep01768,U-118MG,Astrocytoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=1.4 nM,5 days,Patent
DCTPep01768,BT-549,Invasive breast carcinoma of no special type,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=13 nM,5 days,Patent
DCTPep01768,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=7 nM,5 days,Patent
DCTPep01768,DLD-1,Colon adenocarcinoma,Carcinoma,WST-8 assay,Proliferation Inhibition (5 day) IC50=9 nM,5 days,Patent
DCTPep01769,"12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50>100 μM,72-96 h,Patent
DCTPep01769,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50>100 μM,72-96 h,Patent
DCTPep01770,"12O15, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈10 μM,72-96 h,Patent
DCTPep01770,"12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈4 μM,72-96 h,Patent
DCTPep01770,"12O89, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈5 μM,72-96 h,Patent
DCTPep01770,"RG6, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈5 μM,72-96 h,Patent
DCTPep01770,"RG5, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈50 μM,72-96 h,Patent
DCTPep01770,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈7 μM,72-96 h,Patent
DCTPep01770,"RG4, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈7 μM,72-96 h,Patent
DCTPep01770,"GMB-27, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈7.5 μM,72-96 h,Patent
DCTPep01771,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01771,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01771,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01771,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50≈16 μM,Not available,Patent
DCTPep01772,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01772,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01772,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01772,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50≈15 μM,Not available,Patent
DCTPep01773,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01773,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01773,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01773,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01774,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01774,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01774,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50≈7 μM,Not available,Patent
DCTPep01774,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50≈8 μM,Not available,Patent
DCTPep01775,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01775,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01775,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50≈7 μM,Not available,Patent
DCTPep01775,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50≈9 μM,Not available,Patent
DCTPep01776,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01776,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01776,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50≈5 μM,Not available,Patent
DCTPep01776,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50≈6 μM,Not available,Patent
DCTPep01777,"12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈10 μM,72-96 h,Patent
DCTPep01777,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈15 μM,72-96 h,Patent
DCTPep01778,"12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50>100 μM,72-96 h,Patent
DCTPep01778,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50>100 μM,72-96 h,Patent
DCTPep01778,NCI-H524,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CYTELL assay,EC50≈5 μM,72-96 h,Patent
DCTPep01779,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01779,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈15 μM,Not available,Patent
DCTPep01779,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈22.5 μM,Not available,Patent
DCTPep01780,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈10 μM,72-96 h,Patent
DCTPep01781,"12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50>100 μM,72-96 h,Patent
DCTPep01781,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50>100 μM,72-96 h,Patent
DCTPep01782,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01782,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01782,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01782,U266B1,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01783,"RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients",Glioblastoma,Blastoma,CYTELL assay,EC50≈5 μM,72-96 h,Patent
DCTPep01784,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01784,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7 μM,Not available,Patent
DCTPep01785,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈2.5 μM,Not available,Patent
DCTPep01785,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈5 μM,Not available,Patent
DCTPep01785,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈5 μM,Not available,Patent
DCTPep01786,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01786,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈15 μM,Not available,Patent
DCTPep01786,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01787,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01787,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50>100 μM,Not available,Patent
DCTPep01788,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01788,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01788,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01789,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈10 μM,Not available,Patent
DCTPep01789,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01789,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01790,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50>30 μM,Not available,Patent
DCTPep01790,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50>30 μM,Not available,Patent
DCTPep01790,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01791,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈15 μM,Not available,Patent
DCTPep01791,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈22.5 μM,Not available,Patent
DCTPep01791,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈5 μM,Not available,Patent
DCTPep01792,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈15 μM,Not available,Patent
DCTPep01792,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈22.5 μM,Not available,Patent
DCTPep01792,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈7.5 μM,Not available,Patent
DCTPep01793,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈12.5 μM,Not available,Patent
DCTPep01793,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈22.5 μM,Not available,Patent
DCTPep01793,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50≈22.5 μM,Not available,Patent
DCTPep01794,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,~20% survival rate at 10 µM,Not available,Patent
DCTPep01794,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,~60% survival rate at 10 µM,Not available,Patent
DCTPep01794,Calu-6,Lung adenocarcinoma,Carcinoma,MTT assay,0% survival rate at 100 µM,Not available,Patent
DCTPep01794,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,0% survival rate at 100 µM,Not available,Patent
DCTPep01794,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,0% survival rate at 100 µM,Not available,Patent
DCTPep01794,Calu-6,Lung adenocarcinoma,Carcinoma,MTT assay,35% survival rate at 10 µM,Not available,Patent
DCTPep01795,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM,  the Percent Cytotoxicity of the tumor was 11.0 ± 0.6",49 h,Patent
DCTPep01795,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 15.9 ± 1.0, 12.0 ± 0.3, 14.0 ± 1.0, 9.3 ± 0.4",48 h,Patent
DCTPep01795,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 18.3 ± 1.8, 22.8 ± 2.9, 21.8 ± 2.1, 20.3 ± 2.6",48 h,Patent
DCTPep01795,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 19.0 ± 1.6, 28.4 ± 1.0, 23.9 ± 2.9, 21.7 ± 1.5",48 h,Patent
DCTPep01795,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 24.8 ± 2.0, 21.0 ± 2.6, 18.5 ± 0.6, 15.0 ± 0.6",48 h,Patent
DCTPep01795,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 47.0 ± 4.8, 38.3 ± 2.0, 35.8 ± 2.4, 32.9 ± 2.6",48 h,Patent
DCTPep01796,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.7 ± 1.9,  18.0 ± 1.0, 14.8 ± 1.9, 9.6 ± 1.0",48 h,Patent
DCTPep01796,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 15.3 ± 1.6, 12.7 ± 1.6, 10.8 ± 2.9, 7.9 ± 0.1",48 h,Patent
DCTPep01796,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 22.9 ± 2.2, 25.5 ± 2.9, 22.9 ± 2.6, 19.0 ± 0.6",48 h,Patent
DCTPep01797,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM,  the Percent Cytotoxicity of the tumor was 11.2 ± 1.1, 10.7 ± 1.1",48 h,Patent
DCTPep01797,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM  the Percent Cytotoxicity of the tumor was 14.5 ± 1.8,  12.5 ± 1.9, 10.5 ± 1.2",48 h,Patent
DCTPep01797,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.8 ± 1.4, 15.8 ± 1.1, 10.4 ± 2.0, 7.9 ± 0.4",48 h,Patent
DCTPep01797,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 14.8 ± 2.9, 12.9 ± 1.5, 9.3 ± 1.1, 5.9 ± 0.0",48 h,Patent
DCTPep01797,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 20.9 ± 2.0, 21.0 ± 1.9, 18.8 ± 1.9, 14.6 ± 1.6",48 h,Patent
DCTPep01797,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 21.9 ± 2.2, 22.7 ± 2.1, 26.5 ± 2.5, 22.1 ± 2.9",48 h,Patent
DCTPep01797,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 33.5 ± 2.9, 31.9 ± 2.8, 29.5 ± 2.7, 26.0 ± 2.2",48 h,Patent
DCTPep01798,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 14.9 ± 1.9, 12.0 ± 1.7, 9.0 ± 0.6, ",48 h,Patent
DCTPep01798,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 30.5 ± 3.2, 28.0 ± 2.2, 25.6 ± 2.2, 21.8 ± 2.8",48 h,Patent
DCTPep01798,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 32.0 ± 2.5, 31.9 ± 2.9, 29.6 ± 0.7, 26.0 ± 1.8",48 h,Patent
DCTPep01798,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 35.4 ± 2.9, 32.0 ± 2.1, 31.8 ± 3.1, 28.9 ± 2.1",48 h,Patent
DCTPep01798,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 37.5 ± 3.8, 32.0 ± 2.9, 31.0 ± 2.7, 28.4 ± 2.2",48 h,Patent
DCTPep01798,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 15.2 ± 1.0, 12.9 ± 0.5, 9.4 ± 0.2",48 h,Patent
DCTPep01799,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.3 ± 0.4, 10.7 ± 0.1, 9.5 ± 1.0, 6.9 ± 0.0",48 h,Patent
DCTPep01799,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.6 ± 2.8,  15.4 ± 1.3,  13.9 ± 0.5,  10.8 ± 0.5",48 h,Patent
DCTPep01799,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.9 ± 1.3, 17.7 ± 0.5, 14.9 ± 1.1, 9.5 ± 0.1",48 h,Patent
DCTPep01799,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 16.8 ± 1.4, 18.0 ± 1.8, 12.5 ± 0.0, 10.8 ± 0.6",48 h,Patent
DCTPep01799,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 21.8 ± 2.1,  24.0 ± 2.7, 17.9 ± 1.8, 13.9 ± 0.4",48 h,Patent
DCTPep01800,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 20.2 ± 2.1, 24.6 ± 2.7, 39.3 ± 3.0, 32.1 ± 2.0",48 h,Patent
DCTPep01800,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 21.9 ± 2.9, 39.3 ± 3.2, 32.2 ± 1.9, 28.9 ± 3.2",48 h,Patent
DCTPep01800,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 23.8 ± 3.2, 30.6 ± 3.9, 21.9 ± 0.2, 13.9 ± 2.7",48 h,Patent
DCTPep01800,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 32.0 ± 3.9, 36.9 ± 3.2, 27.9 ± 2.9, 22.2 ± 2.2",48 h,Patent
DCTPep01800,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 32.9 ± 4.3, 37.4 ± 2.9, 33.2 ± 0.4, 19.9 ± 1.9",48 h,Patent
DCTPep01800,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 12.7 ± 1.8, 14.8 ± 1.9, 10.8 ± 2.0",48 h,Patent
DCTPep01801,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 23.0 ± 1.6, 21.0 ± 2.6, 18.0 ± 1.6, 12.1 ± 1.3",48 h,Patent
DCTPep01801,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 23.0 ± 2.1, 21.8 ± 1.8, 17.9 ± 1.9, 16.4 ± 0.6",48 h,Patent
DCTPep01801,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 28.5 ± 2.0, 26.0 ± 2.9, 22.8 ± 2.1, 20.8 ± 1.8",48 h,Patent
DCTPep01801,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 30.0 ± 2.8, 27.9 ± 2.1, 26.9 ± 2.1, 21.4 ± 2.1",48 h,Patent
DCTPep01801,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 44.0 ± 3.9, 41.0 ± 4.2, 38.0 ± 3.9, 35.5 ± 2.4",48 h,Patent
DCTPep01801,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 17.5 ± 1.9, 14.0 ± 0.6, 8.0 ± 0.6, ",48 h,Patent
DCTPep01802,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 28.9 ± 2.2, 26.9 ± 2.9, 21.8 ± 1.0, 15.0 ± 0.5",48 h,Patent
DCTPep01802,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 35.9 ± 3.7, 32.1 ± 2.2, 28.0 ± 2.2, 21.5 ± 2.1",48 h,Patent
DCTPep01802,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 11.0 ± 1.9, 10.6 ± 1.1, 6.0 ± 0.8, ",48 h,Patent
DCTPep01802,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 12.7 ± 0.4, 13.0 ± 0.6, 6.0 ± 0.0",48 h,Patent
DCTPep01802,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 17.0 ± 1.7, 13.9 ± 1.1, 7.0 ± 0.3, ",48 h,Patent
DCTPep01802,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, the Percent Cytotoxicity of the tumor was 14.5 ± 0.4, 12.9 ± 0.5,",48 h,Patent
DCTPep01803,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 11.0 ± 1.1, 12.8 ± 0.7, 11.4 ± 0.7, 9.8 ± 0.7",48 h,Patent
DCTPep01803,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 16.5 ± 1.6, 19.2 ± 1.6, 12.6 ± 0.5, 10.9 ± 1.1",48 h,Patent
DCTPep01803,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 24.0 ± 2.1, 22.9 ± 2.1, 19.0 ± 1.0, 16.8 ± 1.8",48 h,Patent
DCTPep01803,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, the Percent Cytotoxicity of the tumor was 9.3 ± 0.3, 9.7 ± 0.4, 3.2 ± 0.1",48 h,Patent
DCTPep01803,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, the Percent Cytotoxicity of the tumor was 9.3 ± 0.6, 7.9 ± 0.1, ",48 h,Patent
DCTPep01804,ECV-304,Bladder carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM,  the Percent Cytotoxicity of the tumor was 16.4 ± 1.9, 13.9 ± 0.5, 11.9 ± 1.1, ",48 h,Patent
DCTPep01804,PTC,Papillary thyroid carcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.0 ± 1.7, 11.9 ± 1.4, 10.4 ± 0.6, 8.4 ± 1.0",48 h,Patent
DCTPep01804,Hep-G2,Hepatoblastoma; Hepatoblastoma,Blastoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 12.8 ± 0.6, 17.9 ± 1.4, 20.9 ± 1.4, 12.0 ± 0.7",48 h,Patent
DCTPep01804,PA-1,Ovarian mixed germ cell tumor; Mixed germ cell tumor,Germ cell tumor,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 18.2 ± 1.1, 17.8 ± 1.7, 15.9 ± 0.6, 6.0 ± 0.7",48 h,Patent
DCTPep01804,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 23.0 ± 2.1, 21.8 ± 1.9, 17.0 ± 0.9, 16.0 ± 1.4",48 h,Patent
DCTPep01804,KB,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 24.9 ± 2.7, 21.9 ± 2.0, 20.5 ± 2.1, 17.9 ± 0.6",48 h,Patent
DCTPep01804,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,"When the peptide concentrations were 1 nM, 10 nM, 100 nM, and 1 μM, the Percent Cytotoxicity of the tumor was 33.6 ± 2.7, 31.7 ± 3.2, 29.0 ± 0.4, 27.9 ± 2.9",48 h,Patent
DCTPep01805,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=24.76 mM,24 h,Patent
DCTPep01805,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=25.2 mM,24 h,Patent
DCTPep01805,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=26.7 mM,24 h,Patent
DCTPep01805,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=27 mM,24 h,Patent
DCTPep01805,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=27.39 mM,24 h,Patent
DCTPep01805,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=41.21 mM,24 h,Patent
DCTPep01805,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=47.69 mM,24 h,Patent
DCTPep01806,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=13.97 mM,24 h,Patent
DCTPep01806,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=20.36 mM,24 h,Patent
DCTPep01806,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=22.06 mM,24 h,Patent
DCTPep01806,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=24.31 mM,24 h,Patent
DCTPep01806,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=24.63 mM,24 h,Patent
DCTPep01806,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=46.51 mM,24 h,Patent
DCTPep01806,NCI-H630,Rectal carcinoma,Carcinoma,MTT assay,IC50=48 mM,24 h,Patent
DCTPep01807,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=12.55 mM,24 h,Patent
DCTPep01807,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=14.53 mM,24 h,Patent
DCTPep01807,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=14.8 mM,24 h,Patent
DCTPep01807,A498,Renal cell carcinoma,Carcinoma,MTT assay,IC50=21.48 mM,24 h,Patent
DCTPep01807,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=22.25 mM,24 h,Patent
DCTPep01807,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=22.51 mM,24 h,Patent
DCTPep01807,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=29.1 mM,24 h,Patent
DCTPep01808,SK-MEL-2,Melanoma,Carcinoma,MTT assay,IC50=13.16 mM,24 h,Patent
DCTPep01808,MKN45,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=13.77 mM,24 h,Patent
DCTPep01808,SK-N-DZ,Neuroblastoma,Blastoma,MTT assay,IC50=14.58 mM,24 h,Patent
DCTPep01808,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=14.8 mM,24 h,Patent
DCTPep01808,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=14.8 mM,24 h,Patent
DCTPep01808,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=24.32 mM,24 h,Patent
DCTPep01808,NCI-H630,Rectal carcinoma,Carcinoma,MTT assay,IC50=57 mM,24 h,Patent
DCTPep01812,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35 μg/ml,Not available,Patent
DCTPep01812,QGY-7703,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38 μg/ml,Not available,Patent
DCTPep01812,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=45 μg/ml,Not available,Patent
DCTPep01812,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=52 μg/ml,Not available,Patent
DCTPep01813,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=32 μg/ml,Not available,Patent
DCTPep01813,QGY-7703,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=44 μg/ml,Not available,Patent
DCTPep01813,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=47 μg/ml,Not available,Patent
DCTPep01813,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=56 μg/ml,Not available,Patent
DCTPep01814,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=13 μg/ml,Not available,Patent
DCTPep01814,QGY-7703,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=21 μg/ml,Not available,Patent
DCTPep01814,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=25 μg/ml,Not available,Patent
DCTPep01814,LoVo,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=31 μg/ml,Not available,Patent
DCTPep01819,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"At the concentration of 40umol/L, 20umol/L and 5umol/L, the peptide can inhibit more than 80% of HeLa cells",Not available,Patent
DCTPep01820,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.97.",Not available,Patent
DCTPep01821,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.97.",Not available,Patent
DCTPep01822,JB6,Human anaplastic large cell lymphoma,Lymphoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.38.",Not available,Patent
DCTPep01822,CNE-1,Breast cancer,Carcinoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.58.",Not available,Patent
DCTPep01822,HNE-1,Nasopharyngeal carcinoma; Nasopharyngeal carcinoma,Carcinoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.6.",Not available,Patent
DCTPep01822,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.9.",Not available,Patent
DCTPep01822,HT-1080,Fibrosarcoma,Sarcoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.97.",Not available,Patent
DCTPep01823,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"When the peptide concentration is 40μmol/L, the cell growth inhibition rate is about 0.97.",Not available,Patent
DCTPep01824,MeW155,Human melanoma,Carcinoma,Cell proliferation assay,"Peptide at 0.004 mM decreased the number of tumour cells to 65% of the control, a 0.02 mMol concentration decreased the number of cells to 49%, and a concentration of 0.1 mM was toxic to melanoma cell",Not available,Patent
DCTPep01825,MeW155,Human melanoma,Carcinoma,Cell proliferation assay,"Peptide at 0.004 mM decreased the number of tumour cells to 65% of the control, a 0.02 mMol concentration decreased the number of cells to 49%, and a concentration of 0.1 mM was toxic to melanoma cell",Not available,Patent
DCTPep01828,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~20% cytotoxicity at 1 µM,24 h,Patent
DCTPep01828,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~20% cytotoxicity at 1 µM,48 h,Patent
DCTPep01828,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01828,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01828,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,~20% cytotoxicity at 10 µM,72 h,Patent
DCTPep01828,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,~30% cytotoxicity at 1 µM,72 h,Patent
DCTPep01828,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~30% cytotoxicity at 1 µM,24 h,Patent
DCTPep01828,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,~35% cytotoxicity at 10 µM,48 h,Patent
DCTPep01828,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~40% cytotoxicity at 10 µM,24 h,Patent
DCTPep01828,HCT 116,Colon carcinoma,Carcinoma,MTT assay,~40% cytotoxicity at 10 µM,72 h,Patent
DCTPep01828,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~45% cytotoxicity at 10 µM,72 h,Patent
DCTPep01828,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~45% cytotoxicity at 10 µM,72 h,Patent
DCTPep01828,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,~50% cytotoxicity at 10 µM,24 h,Patent
DCTPep01828,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~50% cytotoxicity at 10 µM,48 h,Patent
DCTPep01828,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~50% cytotoxicity at 10 µM,48 h,Patent
DCTPep01828,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~50% cytotoxicity at 10 µM,72 h,Patent
DCTPep01828,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~55% cytotoxicity at 10 µM,48 h,Patent
DCTPep01828,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,48 h,Patent
DCTPep01828,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,48 h,Patent
DCTPep01828,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,48 h,Patent
DCTPep01828,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,<30% cytotoxicity at 1 µM,48 h,Patent
DCTPep01828,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,<30% cytotoxicity at 10 µM,24 h,Patent
DCTPep01828,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,24 h,Patent
DCTPep01828,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,72 h,Patent
DCTPep01828,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 10 µM,24 h,Patent
DCTPep01828,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,>20% cytotoxicity at 1 µM,48 h,Patent
DCTPep01828,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,>20% cytotoxicity at 1 µM,24 h,Patent
DCTPep01828,HCT 116,Colon carcinoma,Carcinoma,MTT assay,>20% cytotoxicity at 10 µM,48 h,Patent
DCTPep01828,HCT 116,Colon carcinoma,Carcinoma,MTT assay,>30% cytotoxicity at 1 µM,72 h,Patent
DCTPep01828,HCT 116,Colon carcinoma,Carcinoma,MTT assay,>40% cytotoxicity at 1 µM,24 h,Patent
DCTPep01828,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,>40% cytotoxicity at 1 µM,72 h,Patent
DCTPep01828,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,>40% cytotoxicity at 10 µM,72 h,Patent
DCTPep01828,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,>40% cytotoxicity at 10 µM,24 h,Patent
DCTPep01828,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,20% cytotoxicity at 10 µM,48 h,Patent
DCTPep01828,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,40% cytotoxicity at 1 µM,24 h,Patent
DCTPep01828,HCT 116,Colon carcinoma,Carcinoma,MTT assay,50% cytotoxicity at 10 µM,24 h,Patent
DCTPep01829,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~10% cytotoxicity at 1 µM,48 h,Patent
DCTPep01829,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,~10% cytotoxicity at 10 µM,24 h,Patent
DCTPep01829,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~15% cytotoxicity at 1 µM,24 h,Patent
DCTPep01829,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,~15% cytotoxicity at 1 µM,48 h,Patent
DCTPep01829,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~15% cytotoxicity at 1 µM,24 h,Patent
DCTPep01829,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,~15% cytotoxicity at 10 µM,72 h,Patent
DCTPep01829,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~25% cytotoxicity at 1 µM,48 h,Patent
DCTPep01829,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~45% cytotoxicity at 1 µM,72 h,Patent
DCTPep01829,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~5% cytotoxicity at 10 µM,24 h,Patent
DCTPep01829,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<10% cytotoxicity at 10 µM,48 h,Patent
DCTPep01829,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<10% cytotoxicity at 10 µM,48 h,Patent
DCTPep01829,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,<10% cytotoxicity at 10 µM,24 h,Patent
DCTPep01829,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01829,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01829,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01829,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01829,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<20% cytotoxicity at 10 µM,24 h,Patent
DCTPep01829,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,<25% cytotoxicity at 10 µM,48 h,Patent
DCTPep01829,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<3% cytotoxicity at 10 µM,48 h,Patent
DCTPep01829,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<3% cytotoxicity at 10 µM,48 h,Patent
DCTPep01829,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,<45% cytotoxicity at 10 µM,72 h,Patent
DCTPep01829,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,24 h,Patent
DCTPep01829,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,72 h,Patent
DCTPep01829,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,48 h,Patent
DCTPep01829,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,48 h,Patent
DCTPep01829,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 10 µM,72 h,Patent
DCTPep01829,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,>20% cytotoxicity at 10 µM,48 h,Patent
DCTPep01829,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,10% cytotoxicity at 1 µM,48 h,Patent
DCTPep01829,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,10% cytotoxicity at 1 µM,24 h,Patent
DCTPep01829,HCT 116,Colon carcinoma,Carcinoma,MTT assay,10% cytotoxicity at 10 µM,24 h,Patent
DCTPep01829,HCT 116,Colon carcinoma,Carcinoma,MTT assay,15% cytotoxicity at 10 µM,72 h,Patent
DCTPep01829,HCT 116,Colon carcinoma,Carcinoma,MTT assay,20% cytotoxicity at 1 µM,24 h,Patent
DCTPep01829,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,20% cytotoxicity at 1 µM,24 h,Patent
DCTPep01829,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,20% cytotoxicity at 10 µM,72 h,Patent
DCTPep01829,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,20% cytotoxicity at 10 µM,72 h,Patent
DCTPep01829,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,5% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,~10% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~15% cytotoxicity at 1 µM,72 h,Patent
DCTPep01830,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~15% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,~15% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~20% cytotoxicity at 1 µM,72 h,Patent
DCTPep01830,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~25% cytotoxicity at 1 µM,24 h,Patent
DCTPep01830,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~25% cytotoxicity at 1 µM,48 h,Patent
DCTPep01830,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~25% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~40% cytotoxicity at 10 µM,72 h,Patent
DCTPep01830,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,~45% cytotoxicity at 1 µM,72 h,Patent
DCTPep01830,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,~5% cytotoxicity at 1 µM,24 h,Patent
DCTPep01830,HCT 116,Colon carcinoma,Carcinoma,MTT assay,~5% cytotoxicity at 1 µM,48 h,Patent
DCTPep01830,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<15% cytotoxicity at 1 µM,24 h,Patent
DCTPep01830,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<15% cytotoxicity at 1 µM,24 h,Patent
DCTPep01830,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<3% cytotoxicity at 1 µM,48 h,Patent
DCTPep01830,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,<3% cytotoxicity at 1 µM,48 h,Patent
DCTPep01830,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<3% cytotoxicity at 10 µM,48 h,Patent
DCTPep01830,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,<45% cytotoxicity at 10 µM,72 h,Patent
DCTPep01830,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,24 h,Patent
DCTPep01830,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,72 h,Patent
DCTPep01830,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,48 h,Patent
DCTPep01830,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 1 µM,72 h,Patent
DCTPep01830,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 10 µM,72 h,Patent
DCTPep01830,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 10 µM,48 h,Patent
DCTPep01830,HCT 116,Colon carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 10 µM,72 h,Patent
DCTPep01830,HTB-9(5637),Bladder carcinoma,Carcinoma,MTT assay,<5% cytotoxicity at 10 µM,72 h,Patent
DCTPep01830,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,>10% cytotoxicity at 1 µM,72 h,Patent
DCTPep01830,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,>10% cytotoxicity at 10 µM,48 h,Patent
DCTPep01830,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,>10% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,>20% cytotoxicity at 10 µM,48 h,Patent
DCTPep01830,Ca Ski,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,>20% cytotoxicity at 10 µM,72 h,Patent
DCTPep01830,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,>20% cytotoxicity at 10 µM,48 h,Patent
DCTPep01830,UM-UC-3,Bladder carcinoma,Carcinoma,MTT assay,>25% cytotoxicity at 10 µM,48 h,Patent
DCTPep01830,COLO 205,Colon adenocarcinoma,Carcinoma,MTT assay,10% cytotoxicity at 1 µM,48 h,Patent
DCTPep01830,HCT 116,Colon carcinoma,Carcinoma,MTT assay,15% cytotoxicity at 10 µM,24 h,Patent
DCTPep01830,SiHa,Human papillomavirus-related cervical squamous cell carcinoma; Squamous cell carcinoma of the cervix uteri,Carcinoma,MTT assay,5% cytotoxicity at 1 µM,24 h,Patent
DCTPep01831,SK-BR-3,Breast adenocarcinoma,Carcinoma,Flow cytometry,"TAT-PIER1 dose-dependently killed a breast cancer cell line, SKBR3",12 h,Patent
DCTPep01832,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,Not available,IC50=16.61 μM,Not available,Patent
DCTPep01832,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,Not available,IC50=274.6 μM,Not available,Patent
DCTPep01833,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,"Showed significant inhibition on the growth of human breast cancer Bcap-37 cells, and the optimal inhibition rate was 40.35% at the concentration of 15μg/ml.",36 h,Patent
DCTPep01833,Eca 109,Esophageal squamous cell carcinoma; Squamous cell carcinoma of the esophagus,Carcinoma,MTT assay,The growth inhibition rate of human esophageal cancer Eca-109 cells is dose-dependent. It was found that the concentration of 0.8ug/ml had the best effect on the growth inhibition of human esophageal ,36 h,Patent
DCTPep01838,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48 h,1
DCTPep01839,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48 h,1
DCTPep01840,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48 h,1
DCTPep01841,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48 h,1
DCTPep01842,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48 h,1
DCTPep01843,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50>10 µg/ml,48 h,1
DCTPep01844,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=5.36 µg/ml,48 h,1
DCTPep01845,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,SRB assay,IC50=4.94 µg/ml,48 h,1
DCTPep01846,KG-1a,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,CCK-8 assay,~45%Cellular viability=105 µM,24 h,1
DCTPep01847,HCT 15,Colon adenocarcinoma,Carcinoma,MTT assay,~40%Inhibition=5 µM,70-72 h,1
DCTPep01848,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,~90%Inhibition=5 µM,70-72 h,1
DCTPep01850,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,~88%Inhibition=5 µM,70-72 h,1
DCTPep01851,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=302.1 µM,Not available,1
DCTPep01852,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=41.6 µM,Not available,1
DCTPep01853,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=310.6 µM,Not available,1
DCTPep01854,HT-29,Colon adenocarcinoma,Carcinoma,Crystal violet assay,IC50=4.3 µM,48 h,1
DCTPep01855,Hep-G2,Hepatoblastoma,Blastoma,SRB assay,IC50=606.8 µM,Not available,1
DCTPep01856,Hep-G2,Hepatoblastoma,Blastoma,SRB assay,IC50=137.6 µM,Not available,1
DCTPep01857,Hep-G2,Hepatoblastoma,Blastoma,SRB assay,IC50>100 µM,Not available,1
DCTPep01858,Hep-G2,Hepatoblastoma,Blastoma,SRB assay,IC50>100 µM,Not available,1
DCTPep01859,Hep-G2,Hepatoblastoma,Blastoma,SRB assay,IC50>100 µM,Not available,1
DCTPep01860,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,112% Killing=500µg/ml,24 h,Patent
DCTPep01861,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,83% Killing=500µg/ml,24 h,Patent
DCTPep01862,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,77% Killing=500µg/ml,24 h,Patent
DCTPep01863,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,76% Killing=500µg/ml,24 h,Patent
DCTPep01864,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,89% Killing=500µg/ml,24 h,Patent
DCTPep01865,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,30.5% Killing=500µg/ml,24 h,Patent
DCTPep01866,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,13% Killing=500µg/ml,24 h,Patent
DCTPep01867,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,18.2% Killing=500µg/ml,24 h,Patent
DCTPep01868,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,22.1% Killing=500µg/ml,24 h,Patent
DCTPep01869,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,12.4% Killing=500µg/ml,24 h,Patent
DCTPep01870,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,9.5% Killing=500µg/ml,24 h,Patent
DCTPep01871,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,28.3% Killing=500µg/ml,24 h,Patent
DCTPep01872,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,7.3% Killing=500µg/ml,24 h,Patent
DCTPep01873,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,76.4% Killing=500µg/ml,24 h,Patent
DCTPep01874,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay, -0.7% Killing=500µg/ml,24 h,Patent
DCTPep01875,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay, -1.3% Killing=500µg/ml,24 h,Patent
DCTPep01876,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay, -0.4% Killing=500µg/ml,24 h,Patent
DCTPep01877,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,0.1% Killing=500µg/ml,24 h,Patent
DCTPep01878,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,76.8% Killing=500µg/ml,24 h,Patent
DCTPep01879,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay, -0.5% Killing=500µg/ml,24 h,Patent
DCTPep01880,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,13% Killing=500µg/ml,24 h,Patent
DCTPep01881,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,90% Killing=500µg/ml,24 h,Patent
DCTPep01882,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,>87.9% Killing=500µg/ml,24 h,Patent
DCTPep01883,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,77.8% Killing=500µg/ml,24 h,Patent
DCTPep01884,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,80.9% Killing=500µg/ml,24 h,Patent
DCTPep01885,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,84.2% Killing=500µg/ml,24 h,Patent
DCTPep01886,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,80.7% Killing=500µg/ml,24 h,Patent
DCTPep01887,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,56.8% Killing=500µg/ml,24 h,Patent
DCTPep01888,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,110.8% Killing=500µg/ml,24 h,Patent
DCTPep01889,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,103.3% Killing=500µg/ml,24 h,Patent
DCTPep01890,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,60.4% Killing=500µg/ml,24 h,Patent
DCTPep01891,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,20.9% Killing=500µg/ml,24 h,Patent
DCTPep01892,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,15% Killing=500µg/ml,24 h,Patent
DCTPep01893,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,29.6% Killing=500µg/ml,24 h,Patent
DCTPep01894,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,43.5% Killing=500µg/ml,24 h,Patent
DCTPep01895,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,46% Killing=500µg/ml,24 h,Patent
DCTPep01896,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,65% Killing=500µg/ml,24 h,Patent
DCTPep01897,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,43.8% Killing=500µg/ml,24 h,Patent
DCTPep01898,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,60% Killing=500µg/ml,24 h,Patent
DCTPep01899,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,86.5% Killing=500µg/ml,24 h,Patent
DCTPep01900,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,96.7% Killing=500µg/ml,24 h,Patent
DCTPep01901,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,66.6% Killing=500µg/ml,24 h,Patent
DCTPep01902,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC=64 µg/ml,20 h,1
DCTPep01903,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01904,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01905,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01906,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01907,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01908,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01909,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01910,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01911,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01912,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01913,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01914,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC=64 µg/ml,20 h,1
DCTPep01915,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC=64 µg/ml,20 h,1
DCTPep01916,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,LC>128 µg/ml,20 h,1
DCTPep01917,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 128 µM,20-24 h,1
DCTPep01918,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,87.5% Killing=128µM,20-24 h,1
DCTPep01919,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,80% Killing=128µM,20-24 h,1
DCTPep01920,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,20-25% Killing=16-256µM,20-24 h,1
DCTPep01921,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50>50µM,24 h,1
DCTPep01922,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50>50µM,24 h,1
DCTPep01923,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50>50µM,24 h,1
DCTPep01924,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50=50µM,24 h,1
DCTPep01925,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50>50µM,24 h,1
DCTPep01926,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50>50µM,24 h,1
DCTPep01927,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,EC50>50µM,24 h,1
DCTPep01928,U-251MG,Astrocytoma,Carcinoma,MTT assay,LD50=33.65 µM,Not available,1
DCTPep01929,U-251MG,Astrocytoma,Carcinoma,MTT assay,LD50=36.46 µM,Not available,1
DCTPep01930,U-251MG,Astrocytoma,Carcinoma,MTT assay,LD50=10.85 µM,Not available,1
DCTPep01931,U-251MG,Astrocytoma,Carcinoma,MTT assay,LD50=9.547 µM,Not available,1
DCTPep01932,U-251MG,Astrocytoma,Carcinoma,MTT assay,LD50=4.059 µM,Not available,1
DCTPep01933,SH-SY5Y,,,CellTiter-Glo assay,0% Killing=64 µM,Not available,1
DCTPep01934,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTox cytotoxicity assay,5%Killing=100 µM,30 min,1
DCTPep01935,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTox cytotoxicity assay,25%Killing=100 µM,30 min,1
DCTPep01936,OCI-AML3,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,CellTox cytotoxicity assay,Not active up to 100 µM,30 min,1
DCTPep01937,HCT 116-/-p53,Colon carcinoma,Carcinoma,CellTox cytotoxicity assay,30%Killing=10 µM,30 min,1
DCTPep01938,OPM-2,Plasma cell myeloma; Multiple myeloma,Carcinoma,CellTox cytotoxicity assay,30%Killing=50 µM,30 min,1
DCTPep01939,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTox cytotoxicity assay,78%Killing=10 µM; 100%Killing=50 µM,30 min,1
DCTPep01940,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTox cytotoxicity assay,Not active up to 100 µM,30 min,1
DCTPep01941,OPM-2,Plasma cell myeloma; Multiple myeloma,Carcinoma,CellTox cytotoxicity assay,0%Killing=50 µM,30 min,1
DCTPep01942,OPM-2,Plasma cell myeloma; Multiple myeloma,Carcinoma,CellTox cytotoxicity assay,78%Killing=10 µM; 100%Killing=50 µM,30 min,1
DCTPep01943,HCT 116-/-p53,Colon carcinoma,Carcinoma,CellTox cytotoxicity assay,100%Killing=10 µM,30 min,1
DCTPep01944,HCT 116-/-p53,Colon carcinoma,Carcinoma,CellTox cytotoxicity assay,65%Killing=10 µM; 100%Killing=50 µM,30 min,1
DCTPep01945,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=8.6 μM,24 h,1
DCTPep01946,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=11.3 μM,24 h,1
DCTPep01947,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01948,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01949,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01950,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=10.7 μM,24 h,1
DCTPep01951,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01952,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01953,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01954,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01955,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=4.6 μM,24 h,1
DCTPep01956,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=36.3 μM,24 h,1
DCTPep01957,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01958,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01959,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01960,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01961,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01962,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24 h,1
DCTPep01963,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=2.9 µM,24 h,1
DCTPep01964,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=2.0 µM,24 h,1
DCTPep01965,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50>80 µM,Not available,1
DCTPep01966,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50>80 µM,Not available,1
DCTPep01967,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50=25 µM,Not available,1
DCTPep01968,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50>80 µM,Not available,1
DCTPep01969,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-1 assay,EC50=9.1±3 µM(pH=7.4),24 h,1
DCTPep01970,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-1 assay,EC50=14.7±0.6 µM(pH=7.4),24 h,1
DCTPep01971,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-1 assay,EC50=35.7±0.7 µM(pH=7.4),24 h,1
DCTPep01972,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-1 assay,EC50=55±1.8 µM(pH=7.4),24 h,1
DCTPep01973,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,WST-1 assay,EC50=61.4±1.7 µM(pH=7.4),24 h,1
DCTPep01974,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01975,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01976,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01977,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01978,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01979,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01980,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,50% Cytotoxicity>100 µg/ml,Not available,1
DCTPep01981,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=25 µM,24 h,1
DCTPep01982,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=23 µM,24 h,1
DCTPep01983,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=20 µM,24 h,1
DCTPep01984,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15 µM,24 h,1
DCTPep01985,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>40 µM,24 h,1
DCTPep01986,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>40 µM,24 h,1
DCTPep01987,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>40 µM,24 h,1
DCTPep01988,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15 µM,24 h,1
DCTPep01989,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=47±3 µM,Not available,1
DCTPep01990,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=56±3 µM,Not available,1
DCTPep01991,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=47±4 µM,Not available,1
DCTPep01992,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=95±4 µM,Not available,1
DCTPep01993,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=42±4 µM,Not available,1
DCTPep01994,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=34±4 µM,Not available,1
DCTPep01995,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=101±4 µM,Not available,1
DCTPep01996,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=45.5±0.8 µM,Not available,1
DCTPep01997,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=50±10 µM,Not available,1
DCTPep01998,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Not available,EC50=16.1±0.3 µM,Not available,1
DCTPep01999,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,IC50=74.43±1.91 µM,4 h,1
DCTPep02000,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,IC50=95.78±6.37 µM,4 h,1
DCTPep02001,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,IC50=171.55±1.23 µM,4 h,1
DCTPep02002,Hep-G2,Hepatoblastoma,Blastoma,MTT assay,IC50=59.64±6.17 µM,4 h,1
DCTPep02004,MDA-MB-435S,Amelanotic melanoma,Carcinoma,CellTox Green Dye assay,KV10.1 Expression Level: Moderate,Not available,1
DCTPep02005,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Promega CellTiter Blue assay,~95%Inhibition=100 µM,72 h,1
DCTPep02006,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Promega CellTiter Blue assay,~18%Inhibition=100 µM,72 h,1
DCTPep02007,DU145,Prostate carcinoma,Carcinoma,Not available,Sub peptide was internalized and directed to the intranuclear region.,Not available,1
DCTPep02008,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=23±3 µM,48 h,1
DCTPep02008,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02009,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=12±1 µM,48 h,1
DCTPep02009,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=34 µM,48 h,1
DCTPep02009,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=35±3 µM,48 h,1
DCTPep02010,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=12 µM,48 h,1
DCTPep02010,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep02011,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15±3 µM,48 h,1
DCTPep02011,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02012,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14±2 µM,48 h,1
DCTPep02012,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02013,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=16±4 µM,48 h,1
DCTPep02013,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02014,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=38±6 µM,48 h,1
DCTPep02014,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02015,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30±5 µM,48 h,1
DCTPep02015,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02016,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13±3 µM,48 h,1
DCTPep02016,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 60 µM,48 h,1
DCTPep02017,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=43±14 µM,48 h,1
DCTPep02017,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep02017,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50> 40 µM,48 h,1
DCTPep02018,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=22±3 µM,48 h,1
DCTPep02018,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50> 40 µM,48 h,1
DCTPep02018,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02019,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=44±5 µM,48 h,1
DCTPep02019,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9±1 µM,48 h,1
DCTPep02019,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50> 40 µM,48 h,1
DCTPep02020,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13±2 µM,48 h,1
DCTPep02020,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 60 µM,48 h,1
DCTPep02021,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15±1 µM,48 h,1
DCTPep02021,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep02022,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=11±2 µM,48 h,1
DCTPep02022,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=44±8 µM,48 h,1
DCTPep02022,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=49±9 µM,48 h,1
DCTPep02023,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15±3 µM,48 h,1
DCTPep02023,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 40 µM,48 h,1
DCTPep02024,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep02025,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50> 100 µM,48 h,1
DCTPep02026,CCRF-CEM,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=30±10 µM,48 h,1
DCTPep02026,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=9±1 µM,48 h,1
DCTPep02026,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50> 50 µM,48 h,1
DCTPep02027,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=18±2 µM,48 h,1
DCTPep02027,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=4±2 µM,48 h,1
DCTPep02028,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12.3 µM,24h,1
DCTPep02029,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep02030,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=15.8 µM,24h,1
DCTPep02031,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=10.0 µM,24h,1
DCTPep02032,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep02033,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16.8 µM,24h,1
DCTPep02034,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=12.0  µM,24h,1
DCTPep02035,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50 ≥ 65 µM,24h,1
DCTPep02036,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16.8 µM,24h,1
DCTPep02037,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,60.20% apoptotic=1.5 mg/mL; 48.12% apoptotic=0.75 mg/mL,Not available,1
DCTPep02038,MGC-803,Gastric mucinous adenocarcinoma,Carcinoma,MTT assay,Observed by scanning electronic microscopy,"24 h, 48 h",1
DCTPep02039,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,19 ± 2.82% Inhibition=160 μM,72 h,1
DCTPep02039,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,4.5 ± 0.1.4% Inhibition=160 μM,48 h,1
DCTPep02040,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,4 ± 1.4% Inhibition=160 μM,72 h,1
DCTPep02041,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,16.5 ± 2.12% Inhibition=160 μM,24 h,1
DCTPep02041,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,30 ± 2.82% Inhibition=160 μM,48 h,1
DCTPep02041,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,32.0 ± 4.2% Inhibition=160 μM,72 h,1
DCTPep02042,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,28 ± 5.5% Inhibition=160 μM,24 h,1
DCTPep02042,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,46 ± 4.2% Inhibition=160 μM,48 h,1
DCTPep02042,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,51 ± 1.4% Inhibition=160 μM,72 h,1
DCTPep02043,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,48.0 ± 2.82% Inhibition=160 μM,24 h,1
DCTPep02043,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,62.5 ± 4.9% Inhibition=160 μM,48 h,1
DCTPep02043,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,66.5 ± 2.12% Inhibition=160 μM,72 h,1
DCTPep02044,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,19 ± 4.2% Inhibition=160 μM,72 h,1
DCTPep02044,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,2 ± 1.5% Inhibition=160 μM,48 h,1
DCTPep02045,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,19 ± 4.2% Inhibition=160 μM,72 h,1
DCTPep02046,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,20 ± 1.4% Inhibition=160 μM,72 h,1
DCTPep02046,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Trypan blue assay,4.5 ± 2.13% Inhibition=160 μM,48 h,1
DCTPep02050,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,34% Cytotoxicity=10 µM,24 h,1
DCTPep02050,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 10 µM,24 h,1
DCTPep02064,HepG2,Hepatoblastoma,Blastoma,Not available,Not active  up to 400 µg/ml,Not available,1
DCTPep02066,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 256 µg/ml,24 h,1
DCTPep02067,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=45 µM,1 h,1
DCTPep02068,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=40 µM,1 h,1
DCTPep02069,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=55 µM,1 h,1
DCTPep02070,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=40 µM,1 h,1
DCTPep02071,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=25 µM,1 h,1
DCTPep02072,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=40 µM,1 h,1
DCTPep02073,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50>200 µM,1 h,1
DCTPep02074,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=22 µM,1 h,1
DCTPep02075,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=10 µM,1 h,1
DCTPep02076,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=75 µM,1 h,1
DCTPep02077,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=10 µM,1 h,1
DCTPep02078,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=90 µM,1 h,1
DCTPep02079,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=130 µM,1 h,1
DCTPep02080,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=404 µM,24 h,1
DCTPep02081,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50=46 µM,24 h,1
DCTPep02082,AGS,Gastric adenocarcinoma,Carcinoma,MTT assay,IC50>500 µM,24 h,1
DCTPep02083,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=2.22 µM,"24 h, 48 h",1
DCTPep02083,A549,Lung adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=4.2 µM,"24 h, 48 h",1
DCTPep02083,HT-1080,Fibrosarcoma,Sarcoma,MTT/MTS assay,IC50=5.58 µM,"24 h, 48 h",1
DCTPep02083,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=5.83 µM,"24 h, 48 h",1
DCTPep02084,A549,Lung adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=2.15 µM,"24 h, 48 h",1
DCTPep02084,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=2.17 µM,"24 h, 48 h",1
DCTPep02084,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=3.92 µM,"24 h, 48 h",1
DCTPep02084,HT-1080,Fibrosarcoma,Sarcoma,MTT/MTS assay,IC50=5.31 µM,"24 h, 48 h",1
DCTPep02085,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=17.5 µM,"24 h, 48 h",1
DCTPep02085,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=18.1 µM,"24 h, 48 h",1
DCTPep02085,A549,Lung adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=21.6 µM,"24 h, 48 h",1
DCTPep02085,HT-1080,Fibrosarcoma,Sarcoma,MTT/MTS assay,IC50=26.01 µM,"24 h, 48 h",1
DCTPep02086,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=1.97 µM,"24 h, 48 h",1
DCTPep02086,A549,Lung adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=2.99 µM,"24 h, 48 h",1
DCTPep02086,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT/MTS assay,IC50=5.25 µM,"24 h, 48 h",1
DCTPep02086,HT-1080,Fibrosarcoma,Sarcoma,MTT/MTS assay,IC50=5.52 µM,"24 h, 48 h",1
DCTPep02087,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=65 μM,24 h,1
DCTPep02087,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=80 μM,24 h,1
DCTPep02087,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=80 μM,24 h,1
DCTPep02087,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=85 μM,24 h,1
DCTPep02088,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=100 μM,24 h,1
DCTPep02089,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=35 μM,24 h,1
DCTPep02090,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50>100 μM,24 h,1
DCTPep02091,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=20 μM,24 h,1
DCTPep02092,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=28 μM,24 h,1
DCTPep02093,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=30 μM,24 h,1
DCTPep02094,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=13 μM,24 h,1
DCTPep02094,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=17 μM,24 h,1
DCTPep02094,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=18 μM,24 h,1
DCTPep02094,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=32 μM,24 h,1
DCTPep02095,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=125 μM,24 h,1
DCTPep02095,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=75 μM,24 h,1
DCTPep02095,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=80 μM,24 h,1
DCTPep02095,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=90 μM,24 h,1
DCTPep02096,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=20 μM,24 h,1
DCTPep02097,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=65 μM,24 h,1
DCTPep02098,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=10 μM,24 h,1
DCTPep02098,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=18 μM,24 h,1
DCTPep02098,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6 μM,24 h,1
DCTPep02098,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=8 μM,24 h,1
DCTPep02099,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=15 μM,24 h,1
DCTPep02099,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=20 μM,24 h,1
DCTPep02099,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=26 μM,24 h,1
DCTPep02099,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=28 μM,24 h,1
DCTPep02100,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=12 μM,24 h,1
DCTPep02101,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=21 μM,24 h,1
DCTPep02102,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=7 μM,24 h,1
DCTPep02103,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=17 μM,24 h,1
DCTPep02104,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6 μM,24 h,1
DCTPep02105,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=20 μM,24 h,1
DCTPep02106,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=17 μM,24 h,1
DCTPep02107,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02108,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02109,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02110,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02111,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02112,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,4 ± 0.11% Growth inhibition=40 μM,48 h,1
DCTPep02113,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02114,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,4 ± 0.07% Growth inhibition=40 μM,48 h,1
DCTPep02115,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,2 ± 0.08% Growth inhibition=40 μM,48 h,1
DCTPep02116,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,22 ± 0.08% Growth inhibition=40 μM,48 h,1
DCTPep02117,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,14 ± 0.05% Growth inhibition=40 μM,48 h,1
DCTPep02118,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,13 ± 0.05% Growth inhibition=40 μM,48 h,1
DCTPep02119,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,9 ± 0.11% Growth inhibition=40 μM,48 h,1
DCTPep02120,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,25 ± 0.03% Growth inhibition=40 μM,48 h,1
DCTPep02121,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,27 ± 0.11% Growth inhibition=40 μM,48 h,1
DCTPep02122,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,8 ± 0.21% Growth inhibition=40 μM,48 h,1
DCTPep02123,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,6 ± 0.10% Growth inhibition=40 μM,48 h,1
DCTPep02124,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,23 ± 0.08% Growth inhibition=40 μM,48 h,1
DCTPep02125,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,11 ± 0.08% Growth inhibition=40 μM,48 h,1
DCTPep02126,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,17 ± 0.10% Growth inhibition=40 μM,48 h,1
DCTPep02127,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,9 ± 0.09% Growth inhibition=40 μM,48 h,1
DCTPep02128,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,14 ± 0.15% Growth inhibition=40 μM,48 h,1
DCTPep02129,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,9 ± 0.06% Growth inhibition=40 μM,48 h,1
DCTPep02130,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,17 ± 0.05% Growth inhibition=40 μM,48 h,1
DCTPep02131,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,5 ± 0.24% Growth inhibition=40 μM,48 h,1
DCTPep02132,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,19 ± 0.01% Growth inhibition=40 μM,48 h,1
DCTPep02133,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,12 ± 0.02% Growth inhibition=40 μM,48 h,1
DCTPep02134,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,7 ± 0.08% Growth inhibition=40 μM,48 h,1
DCTPep02135,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,4 ± 0.07% Growth inhibition=40 μM,48 h,1
DCTPep02136,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,8 ± 0.03% Growth inhibition=40 μM,48 h,1
DCTPep02137,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,22 ± 0.06% Growth inhibition=40 μM,48 h,1
DCTPep02138,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,15 ± 0.20% Growth inhibition=40 μM,48 h,1
DCTPep02139,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,18 ± 0.18% Growth inhibition=40 μM,48 h,1
DCTPep02140,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,3 ± 0.15% Growth inhibition=40 μM,48 h,1
DCTPep02141,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,29 ± 0.05% Growth inhibition=40 μM,48 h,1
DCTPep02142,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02143,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02144,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02145,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,7 ± 0.17% Growth inhibition=40 μM,48 h,1
DCTPep02146,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,12 ± 0.19% Growth inhibition=40 μM,48 h,1
DCTPep02147,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,19 ± 0.09% Growth inhibition=40 μM,48 h,1
DCTPep02148,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,11 ± 0.22% Growth inhibition=40 μM,48 h,1
DCTPep02149,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02150,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,28 ± 0.05% Growth inhibition=40 μM,48 h,1
DCTPep02151,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,1 ± 0.26% Growth inhibition=40 μM,48 h,1
DCTPep02152,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,2 ± 0.13% Growth inhibition=40 μM,48 h,1
DCTPep02153,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,20 ± 0.26% Growth inhibition=40 μM,48 h,1
DCTPep02154,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,16 ± 0.31% Growth inhibition=40 μM,48 h,1
DCTPep02155,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,16 ± 0.15% Growth inhibition=40 μM,48 h,1
DCTPep02156,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,5 ± 0.24% Growth inhibition=40 μM,48 h,1
DCTPep02157,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,50 ± 0.10% Growth inhibition=40 μM; IC50=31.2 ± 5 μM,48 h,1
DCTPep02157,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=22.5 ± 0 μM,48 h,1
DCTPep02157,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=28.0 ± 3 μM,48 h,1
DCTPep02157,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=32.5 ± 11 μM,48 h,1
DCTPep02157,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=32.5 ± 4 μM,48 h,1
DCTPep02158,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,23 ± 0.17% Growth inhibition=40 μM,48 h,1
DCTPep02159,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,13 ± 0.08% Growth inhibition=40 μM,48 h,1
DCTPep02160,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,95 ± 0.01% Growth inhibition=40 μM; IC50=22.0 ± 0 μM,48 h,1
DCTPep02160,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=18.5 ± 8 μM,48 h,1
DCTPep02160,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=20.5 ± 6 μM,48 h,1
DCTPep02160,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=21.5 ± 8 μM,48 h,1
DCTPep02160,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=23.0 ± 3 μM,48 h,1
DCTPep02161,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,59 ± 0.08% Growth inhibition=40 μM; IC50=40.0 ± 7 μM,48 h,1
DCTPep02161,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=24.5 ± 0.7 μM,48 h,1
DCTPep02161,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=34.5 ± 2 μM,48 h,1
DCTPep02161,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=35.0 ± 7 μM,48 h,1
DCTPep02161,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=51.0 ± 6 μM,48 h,1
DCTPep02162,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,60 ± 0.07% Growth inhibition=40 μM; IC50=40.7 ± 3 μM,48 h,1
DCTPep02162,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.5 ± 4 μM,48 h,1
DCTPep02162,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=44.0 ± 3 μM,48 h,1
DCTPep02162,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=44.5 ± 0.7 μM,48 h,1
DCTPep02162,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=47.5 ± 4 μM,48 h,1
DCTPep02163,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,88 ± 0.01% Growth inhibition=40 μM; IC50=32.2 ± 7 μM,48 h,1
DCTPep02163,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=24.5 ± 0.7	 μM,48 h,1
DCTPep02163,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30.5 ± 12 μM,48 h,1
DCTPep02163,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=41.5 ± 11 μM,48 h,1
DCTPep02163,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=42.2 ± 2 μM,48 h,1
DCTPep02164,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,22 ± 0.09% Growth inhibition=40 μM,48 h,1
DCTPep02165,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,14 ± 0.01% Growth inhibition=40 μM,48 h,1
DCTPep02166,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 40 μM,48 h,1
DCTPep02167,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,20 ± 0.05% Growth inhibition=40 μM,48 h,1
DCTPep02168,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,70 ± 0.01% Growth inhibition=40 μM; IC50=32.5 ± 0.5 μM,48 h,1
DCTPep02168,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=29.5 ± 2 μM,48 h,1
DCTPep02168,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=40.0 ± 3 μM,48 h,1
DCTPep02168,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=46.0 ± 3 μM,48 h,1
DCTPep02168,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=50.0 ± 10 μM,48 h,1
DCTPep02169,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,18 ± 0.09% Growth inhibition=40 μM,48 h,1
DCTPep02170,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,56 ± 0.06% Growth inhibition=40 μM; IC50=53.2 ± 13 μM,48 h,1
DCTPep02170,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=35.0 ± 1 μM,48 h,1
DCTPep02170,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=49.5 ± 6 μM,48 h,1
DCTPep02170,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=57.5 ± 6 μM,48 h,1
DCTPep02170,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>60 μM,48 h,1
DCTPep02171,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,11 ± 0.27% Growth inhibition=40 μM,48 h,1
DCTPep02172,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,63 ± 0.02% Growth inhibition=40 μM; IC50=40.5 ± 9 μM,48 h,1
DCTPep02172,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,IC50=35.5 ± 2 μM,48 h,1
DCTPep02172,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=43.5 ± 0.7 μM,48 h,1
DCTPep02172,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=46.0 ± 8 μM,48 h,1
DCTPep02172,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=54.0 ± 6 μM,48 h,1
DCTPep02173,Human nasopharyngeal carcinoma,Nasopharyngeal carcinoma,Carcinoma,Methylene Blue colourimetric assay,IC50=0.06 µM,72h,1
DCTPep02174,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=35 µM,3 days,1
DCTPep02174,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=47 µM,3 days,1
DCTPep02175,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=19 µM,3 days,1
DCTPep02175,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=28 µM,3 days,1
DCTPep02176,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=20 µM,3 days,1
DCTPep02176,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=30 µM,3 days,1
DCTPep02177,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=29 µM,3 days,1
DCTPep02177,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=39 µM,3 days,1
DCTPep02178,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=23 µM,3 days,1
DCTPep02178,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=37 µM,3 days,1
DCTPep02179,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=16 µM,3 days,1
DCTPep02179,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=21 µM,3 days,1
DCTPep02180,SNU-601,Gastric signet ring cell adenocarcinoma,Carcinoma,MTT assay,IC50=10 µM,3 days,1
DCTPep02180,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=11 µM,3 days,1
DCTPep02181,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,3 days,1
DCTPep02181,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>100 µM,3 days,1
DCTPep02181,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50>100 µM,3 days,1
DCTPep02182,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=20 µM,3 days,1
DCTPep02182,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=25 µM,3 days,1
DCTPep02182,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=34 µM,3 days,1
DCTPep02183,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=66 µM,3 days,1
DCTPep02183,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=85 µM,3 days,1
DCTPep02183,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=88 µM,3 days,1
DCTPep02184,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=100 µM,3 days,1
DCTPep02184,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50=78 µM,3 days,1
DCTPep02184,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=93 µM,3 days,1
DCTPep02185,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,3 days,1
DCTPep02185,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,IC50>100 µM,3 days,1
DCTPep02185,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50>100 µM,3 days,1
DCTPep02186,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>256 µM,1 h,1
DCTPep02189,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>256 µM,1 h,1
DCTPep02190,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=64 µM,1 h,1
DCTPep02191,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=16 µM,1 h,1
DCTPep02196,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=128 µM,1 h,1
DCTPep02197,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=16 µM,1 h,1
DCTPep02198,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=8 µM,1 h,1
DCTPep02201,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11±1 μM,24/72 h,1
DCTPep02201,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=21±1 μM,24/72 h,1
DCTPep02201,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=39±1 μM,24/72 h,1
DCTPep02201,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=9±1 μM,24/72 h,1
DCTPep02202,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=14±1 μM,24/72 h,1
DCTPep02202,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=25±1 μM,24/72 h,1
DCTPep02202,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=7±1 μM,24/72 h,1
DCTPep02202,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=9±1 μM,24/72 h,1
DCTPep02203,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11±1 μM,24/72 h,1
DCTPep02203,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=16±1 μM,24/72 h,1
DCTPep02203,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=22±1 μM,24/72 h,1
DCTPep02203,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=25±1 μM,24/72 h,1
DCTPep02204,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=13±1 μM,24/72 h,1
DCTPep02204,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=14±1 μM,24/72 h,1
DCTPep02204,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=22±1 μM,24/72 h,1
DCTPep02204,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=29±1 μM,24/72 h,1
DCTPep02205,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=14±1 μM,24/72 h,1
DCTPep02205,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=16±1 μM,24/72 h,1
DCTPep02205,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=27±1 μM,24/72 h,1
DCTPep02205,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=27±1 μM,24/72 h,1
DCTPep02206,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=21±1 μM,24/72 h,1
DCTPep02206,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=22±1 μM,24/72 h,1
DCTPep02206,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=29±1 μM,24/72 h,1
DCTPep02206,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=35±1 μM,24/72 h,1
DCTPep02207,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=24±1 μM,24/72 h,1
DCTPep02207,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=33±1 μM,24/72 h,1
DCTPep02207,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=33±1 μM,24/72 h,1
DCTPep02207,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=46±1 μM,24/72 h,1
DCTPep02208,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=16±1 μM,24/72 h,1
DCTPep02208,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=31±1 μM,24/72 h,1
DCTPep02208,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=31±1 μM,24/72 h,1
DCTPep02208,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=58±1 μM,24/72 h,1
DCTPep02209,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=38±1 μM,24/72 h,1
DCTPep02209,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=53±1 μM,24/72 h,1
DCTPep02209,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=60±1 μM,24/72 h,1
DCTPep02209,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=75±1 μM,24/72 h,1
DCTPep02210,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=39±1 μM,24/72 h,1
DCTPep02210,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=50-100 μM,24/72 h,1
DCTPep02210,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=54±1 μM,24/72 h,1
DCTPep02210,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=69±1 μM,24/72 h,1
DCTPep02211,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=29±1 μM,24/72 h,1
DCTPep02211,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=50-100 μM,24/72 h,1
DCTPep02211,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=58±1 μM,24/72 h,1
DCTPep02211,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=61±1 μM,24/72 h,1
DCTPep02212,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=10±1 μM,24/72 h,1
DCTPep02212,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=12±1 μM,24/72 h,1
DCTPep02212,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=30±1 μM,24/72 h,1
DCTPep02212,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=53±1 μM,24/72 h,1
DCTPep02213,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=16±1 μM,24/72 h,1
DCTPep02213,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=30±1 μM,24/72 h,1
DCTPep02213,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=38±1 μM,24/72 h,1
DCTPep02213,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=79±1 μM,24/72 h,1
DCTPep02214,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=18±1 μM,24/72 h,1
DCTPep02214,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=24±1 μM,24/72 h,1
DCTPep02214,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=35±1 μM,24/72 h,1
DCTPep02214,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=40±1 μM,24/72 h,1
DCTPep02215,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=25±1 μM,24/72 h,1
DCTPep02215,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=48±1 μM,24/72 h,1
DCTPep02215,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=50±1 μM,24/72 h,1
DCTPep02215,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02216,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50=39±1 μM,24/72 h,1
DCTPep02216,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=44±1 μM,24/72 h,1
DCTPep02216,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=63±1 μM,24/72 h,1
DCTPep02216,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02217,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=53±1 μM,24/72 h,1
DCTPep02217,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=77±1 μM,24/72 h,1
DCTPep02217,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02217,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02218,1205Lu,Melanoma,Carcinoma,MTT assay,EC50=76±1 μM,24/72 h,1
DCTPep02218,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02218,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02218,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 μM,24/72 h,1
DCTPep02219,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=24.3 µM,72 h,2
DCTPep02220,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=25.2 µM,72 h,1
DCTPep02221,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=56.4 µM,72 h,1
DCTPep02222,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=73 µM,72 h,1
DCTPep02223,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=47.3 µM,72 h,1
DCTPep02224,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=79.2 µM,72 h,2
DCTPep02225,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=152.6 µM,72 h,1
DCTPep02226,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=173.9 µM,72 h,1
DCTPep02227,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=87 µM,72 h,1
DCTPep02228,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=90.4 µM,72 h,1
DCTPep02229,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=182.5 µM,72 h,1
DCTPep02230,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=48 µM,72 h,1
DCTPep02231,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=147.5 µM,72 h,1
DCTPep02232,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=166.7 µM,72 h,1
DCTPep02233,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=84.4 µM,72 h,1
DCTPep02234,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=179.1 µM,72 h,1
DCTPep02235,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=189.3 µM,72 h,1
DCTPep02236,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=49 µM,72 h,1
DCTPep02237,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=59.1 µM,72 h,1
DCTPep02238,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=167.2 µM,72 h,1
DCTPep02239,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=171.5 µM,72 h,1
DCTPep02240,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=131.7 µM,72 h,1
DCTPep02241,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=186.7 µM,72 h,1
DCTPep02242,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=190.2 µM,72 h,1
DCTPep02243,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=192.8 µM,72 h,1
DCTPep02244,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=195.1 µM,72 h,1
DCTPep02245,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=190.8 µM,72 h,1
DCTPep02246,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=219 µM,72 h,1
DCTPep02247,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=177.3 µM,72 h,1
DCTPep02248,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=181 µM,72 h,1
DCTPep02249,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=181.8 µM,72 h,1
DCTPep02250,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=94 µM,72 h,1
DCTPep02251,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=189.1 µM,72 h,1
DCTPep02252,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=190.2 µM,72 h,1
DCTPep02253,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=186 µM,72 h,1
DCTPep02254,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=197.2 µM,72 h,1
DCTPep02255,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=197.2 µM,72 h,1
DCTPep02256,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=132.3 µM,72 h,1
DCTPep02257,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=138.4 µM,72 h,1
DCTPep02258,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=158.8 µM,72 h,1
DCTPep02259,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=40.2 µM,72 h,1
DCTPep02260,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=176.9 µM,72 h,1
DCTPep02261,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=183.8 µM,72 h,1
DCTPep02262,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=191.9 µM,72 h,1
DCTPep02263,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=206 µM,72 h,1
DCTPep02264,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=208.3 µM,72 h,1
DCTPep02265,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=174.9 µM,72 h,1
DCTPep02266,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=173.3 µM,72 h,1
DCTPep02267,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Resazurin assay,IC50=188 µM,72 h,1
DCTPep02268,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=14 µM,24 h,1
DCTPep02268,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=21 µM,24 h,1
DCTPep02269,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=12 µM,24 h,1
DCTPep02269,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=15 µM,24 h,1
DCTPep02270,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=12 µM,24 h,1
DCTPep02270,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=17 µM,24 h,1
DCTPep02271,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=24 µM,24 h,1
DCTPep02271,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=28 µM,24 h,1
DCTPep02272,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=12 µM,24 h,1
DCTPep02272,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=13 µM,24 h,1
DCTPep02273,A549,Lung adenocarcinoma,Carcinoma,Resazurin assay,LC50=12 µM,24 h,1
DCTPep02273,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,LC50=16 µM,24 h,1
DCTPep02276,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=14.2 µM,24 h,1
DCTPep02276,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=15.8 µM,24 h,1
DCTPep02276,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=17.5 µM,24 h,1
DCTPep02277,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,12.5 µM,24 h,1
DCTPep02278,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,>100 µM,24 h,1
DCTPep02279,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,>100 µM,24 h,1
DCTPep02280,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,>100 µM,24 h,1
DCTPep02281,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,12.5 µM,24 h,1
DCTPep02282,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,12.5 µM,24 h,1
DCTPep02283,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,6.3 µM,24 h,1
DCTPep02284,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,6.3 µM,24 h,1
DCTPep02285,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50=50 μM,Not available,1
DCTPep02285,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,MTS assay,LC50=65 μM,Not available,1
DCTPep02286,4T1,Malignant neoplasms of the mouse mammary gland,Carcinoma,MTS assay,LC50=80 μM,Not available,1
DCTPep02286,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,LC50>80 μM,Not available,1
DCTPep02287,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,IC50=28.5 ± 1.0 μM,24 h,1
DCTPep02287,DU145,Prostate carcinoma,Carcinoma,MTS assay,IC50=47.5 ± 2.0 μM,24 h,1
DCTPep02288,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,IC50=12.5 ± 1.0 μM,24 h,1
DCTPep02288,DU145,Prostate carcinoma,Carcinoma,MTS assay,IC50=16.5 ± 1.0 μM,24 h,1
DCTPep02289,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,IC50=13.5 ± 2.0 μM,24 h,1
DCTPep02289,DU145,Prostate carcinoma,Carcinoma,MTS assay,IC50=17.3 ± 1.0 μM,24 h,1
DCTPep02290,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=6 μM ,1 h,1
DCTPep02290,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=9 μM ,"24, 48 h",1
DCTPep02291,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=4 μM ,1 h,1
DCTPep02291,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=7 μM ,"24, 48 h",1
DCTPep02293,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=10 μM ,1 h,1
DCTPep02293,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=13 μM ,"24, 48 h",1
DCTPep02295,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=12.76±0.43 μM,96 h,2
DCTPep02295,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=15.22±0.21 μM,96 h,2
DCTPep02295,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=8.07±0.21 μM,96 h,2
DCTPep02295,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=2.5 ± 0.2 μM ,24 h,1
DCTPep02295,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=22.5 ± 1.4 μM,24 h,1
DCTPep02295,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=9.0 ± 0.3 μM,24 h,1
DCTPep02295,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=9.7 ± 0.2 μM,24 h,1
DCTPep02296,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=14.6 ± 0.6 μM,24 h,1
DCTPep02296,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=17.7 ± 1.2 μM,24 h,1
DCTPep02296,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=31.3 ± 1.9 μM,24 h,1
DCTPep02296,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6.9 ± 0.4 μM ,24 h,1
DCTPep02297,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=21.2 ± 2.0 μM,24 h,1
DCTPep02297,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=33.0 ± 2.2 μM,24 h,1
DCTPep02297,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=47.9 ± 1.8 μM,24 h,1
DCTPep02297,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=8.8 ± 0.7 μM ,24 h,1
DCTPep02298,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=11.0 ± 1.7 μM,24 h,1
DCTPep02298,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=14.8 ± 2.0 μM,24 h,1
DCTPep02298,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=28.4 ± 0.4 μM,24 h,1
DCTPep02298,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=5.9 ± 0.6 μM,24 h,1
DCTPep02299,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.35±0.31 μM,96 h,2
DCTPep02299,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=4.28±0.38 μM,96 h,2
DCTPep02299,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=8.09±0.40 μM,96 h,2
DCTPep02299,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.4 ± 0.2 μM,24 h,1
DCTPep02300,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.2 ± 0.1 μM,24 h,1
DCTPep02301,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=1.82±0.23 μM,96 h,2
DCTPep02301,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=4.96±0.43 μM,96 h,2
DCTPep02301,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=6.50±0.32  μM,96 h,2
DCTPep02301,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.1 ± 0.1 μM,24 h,1
DCTPep02301,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=2.9 ± 0.5 μM,24 h,1
DCTPep02301,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=3.9 ± 0.1 μM,24 h,1
DCTPep02301,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=6.5 ± 1.2 μM,24 h,1
DCTPep02302,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.1 ± 0.1 μM,24 h,1
DCTPep02303,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=1.17±0.23 μM,96 h,2
DCTPep02303,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=4.28±0.38 μM,96 h,2
DCTPep02303,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=4.93±0.51  μM,96 h,2
DCTPep02303,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.3 ± 0.2 μM,24 h,1
DCTPep02304,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.0 ± 0.1 μM,24 h,1
DCTPep02305,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=1.8 ± 0.1 μM,24 h,1
DCTPep02305,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=10.6 ± 0.4 μM,24 h,1
DCTPep02305,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=4.5 ± 0.5 μM,24 h,1
DCTPep02305,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=5.5 ± 0.5 μM,24 h,1
DCTPep02306,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=14.9 ± 1.0 μM,24 h,1
DCTPep02306,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=2.9 ± 0.2 μM,24 h,1
DCTPep02306,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=21.0 ± 3.1 μM,24 h,1
DCTPep02306,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=7.8 ± 1.9 μM,24 h,1
DCTPep02307,HT-29,Colon adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=15.1 ± 0.5 μM,24 h,1
DCTPep02307,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=2.1 ± 0.1 μM,24 h,1
DCTPep02307,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=4.1 ± 0.7 μM,24 h,1
DCTPep02307,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=5.2 ± 0.3 μM,24 h,1
DCTPep02308,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,90% Cell death=20 µM,4 h,1
DCTPep02309,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,Not active at 20 µM,4 h,1
DCTPep02310,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,Not active at 20 µM,4 h,1
DCTPep02311,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,Not active at 20 µM,4 h,1
DCTPep02312,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,20% Cell death=20 µM,4 h,1
DCTPep02313,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,Not active at 20 µM,4 h,1
DCTPep02314,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,50% Cell death=20 µM,4 h,1
DCTPep02315,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI assay,Not active at 20 µM,4 h,1
DCTPep02316,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,Not active at 150 µM,24 h,1
DCTPep02316,PC-3,Prostate carcinoma,Carcinoma,MTT assay,Not active at 150 µM,24 h,1
DCTPep02316,U251 ,Astrocytoma,Carcinoma,MTT assay,Not active at 150 µM,24 h,1
DCTPep02317,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,Not active at 150 µM,24 h,1
DCTPep02317,PC-3,Prostate carcinoma,Carcinoma,MTT assay,Not active at 150 µM,24 h,1
DCTPep02317,U251 ,Astrocytoma,Carcinoma,MTT assay,Not active at 150 µM,24 h,1
DCTPep02318,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,IC50=25.58 µM,24 h,1
DCTPep02318,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=28 µM,24 h,1
DCTPep02318,U251 ,Astrocytoma,Carcinoma,MTT assay,IC50=29.23 µM,24 h,1
DCTPep02319,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=23 µM,72 h,1
DCTPep02320,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=22.5 µM,72 h,1
DCTPep02321,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=23 µM,72 h,1
DCTPep02322,T98G,Glioblastoma,Blastoma,CellTiter 96 AQueous One Solution Cell Proliferation Assay,IC50=125 µM,72 h,1
DCTPep02323,NCI-N87,Gastric tubular adenocarcinoma,Carcinoma,XTT assay,50% Cytotoxicity=1.7 µM,24 h,1
DCTPep02324,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=0.82±0.14 µM,24 h,1
DCTPep02325,BFTC-905,Bladder carcinoma ,Carcinoma,MTT assay,~40% Cell death=40 µg/ml,24 h,1
DCTPep02325,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,~40% Cell death=40 µg/ml,24 h,1
DCTPep02325,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=40 µg/ml,24 h,1
DCTPep02326,BFTC-905,Bladder carcinoma ,Carcinoma,MTT assay,~40% Cell death=40 µg/ml,24 h,1
DCTPep02326,CaCo-3,Colon adenocarcinoma,Carcinoma,MTT assay,~40% Cell death=40 µg/ml,24 h,1
DCTPep02326,SW480,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=40 µg/ml,24 h,1
DCTPep02327,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,PI staining assay,LD50=2.11 µM,Not available,1
DCTPep02327,LNCaP,Prostate carcinoma,Carcinoma,PI staining assay,LD50=3.98 µM,Not available,1
DCTPep02327,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,PI staining assay,LD50=4.22 µM,Not available,1
DCTPep02329,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=40 µM,48 h,1
DCTPep02329,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=46 µM,48 h,1
DCTPep02330,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=57 µM,48 h,1
DCTPep02330,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=58 µM,48 h,1
DCTPep02331,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,Low active up to 100 µg/ml,24 h,1
DCTPep02332,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,Low active up to 100 µg/ml,24 h,1
DCTPep02333,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,~80% Killing=40 µg/ml,24 h,1
DCTPep02334,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,~80% Killing=22 µg/ml,24 h,1
DCTPep02335,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,Low active up to 100 µg/ml,24 h,1
DCTPep02336,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=10 μM ,24 h,1
DCTPep02337,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=3 μM ,24 h,1
DCTPep02338,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=26 μM ,24 h,1
DCTPep02339,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50>100 μM ,24 h,1
DCTPep02340,DU145,Prostate carcinoma,Carcinoma,MTT assay,~25% Cell death=10 µM,72 h,1
DCTPep02340,PC-3,Prostate carcinoma,Carcinoma,MTT assay,~25% Cell death=10 µM,72 h,1
DCTPep02340,LNCaP,Prostate carcinoma,Carcinoma,MTT assay,~50% Cell death=10 µM,72 h,1
DCTPep02341,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.73 µM ,72 h,1
DCTPep02342,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.7 µM ,72 h,1
DCTPep02343,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.78 µM ,72 h,1
DCTPep02344,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9.59 µM ,72 h,1
DCTPep02345,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>10 µM ,72 h,1
DCTPep02346,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Fluorescent dye SYTOX Green assay,Low active up to 10 µM ,Not available,1
DCTPep02347,Jurkat,Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia,Leukemia,Fluorescent dye SYTOX Green assay,Low active up to 10 µM ,Not available,1
DCTPep02348,Clinical isolate 22B,Human head tumor,Carcinoma,MTT assay,LC50<50 μM ,3 h,1
DCTPep02348,Clinical isolate 4129,Human neck tumor,Carcinoma,MTT assay,LC50<50 μM ,3 h,1
DCTPep02348,MCA 205,Mouse fibrosarcoma,Carcinoma,MTT assay,LC50<50 μM ,3 h,1
DCTPep02355,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CellTox cytotoxicity assay,82% Killing=10 µM	; 100% Killing=50 µM,30 min,1
DCTPep02356,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,LD50>256 µg/ml; 12% Killing=250 µg/ml,48 h,1
DCTPep02357,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,LD50>256 µg/ml; 32% Killing=250 µg/ml,48 h,1
DCTPep02358,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,LD50=192 µg/ml,48 h,1
DCTPep02359,H157,Buccal mucosa squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,IC50=1.74 μM,24 h,1
DCTPep02359,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=17.86 μM,24 h,1
DCTPep02359,NCI-H838,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=5.38 μM,24 h,1
DCTPep02359,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=6.6 μM ,24 h,1
DCTPep02360,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=128.89 μM,24 h,1
DCTPep02360,NCI-H838,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=25.25 μM,24 h,1
DCTPep02360,U-251MG,Astrocytoma,Carcinoma,MTT assay,IC50=40.58 μM,24 h,1
DCTPep02360,H157,Buccal mucosa squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,IC50=9.36 μM,24 h,1
DCTPep02361,CHO-K1,Ovary tumor,Carcinoma,MTT assay,IC50=5 µM,24 h,1
DCTPep02362,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTS assay,IC50=35 µM,72 h,1
DCTPep02362,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTS assay,IC50=50 µM,72 h,1
DCTPep02362,HepG2,Hepatoblastoma,Blastoma,MTS assay,IC50=92 µM,72 h,1
DCTPep02363,A549,Lung adenocarcinoma,Carcinoma,"CellTiter-Glo Luminescent
Cell Viability assay",LC50>100 µM,24 h,1
DCTPep02364,B16-F10,Mouse melanoma,Carcinoma,MTT assay,IC50=25.7 µM,Not available,1
DCTPep02365,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50=4.1 µM,48 h,1
DCTPep02366,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50=6 µM,48 h,1
DCTPep02367,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50>10 µM,48 h,1
DCTPep02368,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50>10 µM,48 h,1
DCTPep02369,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50=10 µM,48 h,1
DCTPep02370,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50=5.7 µM,48 h,1
DCTPep02371,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50=7.7 µM,48 h,1
DCTPep02372,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue cell viability reagent,IC50>10 µM,48 h,1
DCTPep02373,HeLa 229,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PI and Annexin-V-FITC double-staining,Not active up to 50 µM,48 h,1
DCTPep02374,HeLa 229,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PI and Annexin-V-FITC double-staining,Not active up to 50 µM,48 h,1
DCTPep02377,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50>120 μM ,2 h,1
DCTPep02377,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>160 μM ,2 h,1
DCTPep02378,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9 μM ,2 h,1
DCTPep02378,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=9 μM ,2 h,1
DCTPep02379,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=22 μM ,2 h,1
DCTPep02379,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=39 μM ,2 h,1
DCTPep02380,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=31 μM ,2 h,1
DCTPep02380,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50=54 μM ,2 h,1
DCTPep02381,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=59 μM ,2 h,1
DCTPep02381,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,IC50>120 μM ,2 h,1
DCTPep02382,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,LDH cytotoxicity assay,EC50=14.4±3.3 μM ,24 h,2
DCTPep02383,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,LDH cytotoxicity assay,EC50=17.9±1.7 μM ,24 h,2
DCTPep02383,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=2.44 ± 0.43 μM ,4 h,1
DCTPep02384,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,LDH cytotoxicity assay,EC50=31.9±9.5 μM ,24 h,2
DCTPep02384,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=5.23 ± 0.35 μM ,4 h,1
DCTPep02385,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=3.11 ± 0.57 μM ,4 h,1
DCTPep02385,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,LDH cytotoxicity assay,EC50=32.1±4.8 μM ,24 h,2
DCTPep02386,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,LDH cytotoxicity assay,EC50=32.2±5.5 μM ,24 h,2
DCTPep02386,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=4.54 ± 0.30 μM ,4 h,1
DCTPep02387,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=2.21 ± 0.63 μM ,4 h,1
DCTPep02387,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,LDH cytotoxicity assay,EC50=32.3±4.7 μM ,24 h,2
DCTPep02388,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=6.50 ± 0.37 μM ,4 h,1
DCTPep02389,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=7.58 ± 0.42 μM ,4 h,1
DCTPep02390,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=19 ± 3 μM(pH=7.4); IC50=10 ± 2 μM(pH=5.5),2 h,1
DCTPep02391,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12 ± 2 μM(pH=7.4); IC50=7 ± 2 μM(pH=5.5),2 h,1
DCTPep02392,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50>80 μM(pH=7.4); IC50=12 ± 2 μM(pH=5.5),2 h,1
DCTPep02393,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=56±3 μM(pH=7.4); IC50=44±3 μM(pH=5.5),2 h,1
DCTPep02394,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=97 ± 4 μM(pH=7.4); IC50=61±3 μM(pH=5.5),2 h,1
DCTPep02395,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=156 ± 7 μM(pH=7.4); IC50=36 ± 2 μM(pH=5.5),2 h,1
DCTPep02396,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=31.48 µM,24 h,1
DCTPep02396,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=36.31 µM,24 h,2
DCTPep02396,BCaP-37,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=37.52 µM,24 h,1
DCTPep02396,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.98 µM,24 h,2
DCTPep02396,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=50.32 µM,24 h,2
DCTPep02396,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=53.31 µM,24 h,2
DCTPep02396,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=61.63 µM,24 h,2
DCTPep02396,LK-2,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=63.4 µM,24 h,2
DCTPep02396,HO-8910,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=64.75 µM,24 h,2
DCTPep02396,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=65.42 µM,24 h,1
DCTPep02396,NCI-H446,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,IC50=67.66 µM,24 h,2
DCTPep02396,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50>100 µM,24 h,2
DCTPep02397,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,Trypan blue assay,Not active up to 120 µg/ml,"24, 48, 72 h",1
DCTPep02398,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=61.5 μM ,48 h,1
DCTPep02399,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50>60 μM ,72 h,Patent
DCTPep02399,HepG2,Hepatoblastoma,Blastoma,MTT assay,LC50=560 μM ,72 h,Patent
DCTPep02400,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=48 μM ,72 h,Patent
DCTPep02400,HepG2,Hepatoblastoma,Blastoma,MTT assay,LC50=358 μM ,72 h,Patent
DCTPep02402,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=55 μM ,72 h,Patent
DCTPep02403,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=60 μM ,72 h,Patent
DCTPep02404,HepG2,Hepatoblastoma,Blastoma,MTT assay,LC50=376 μM ,72 h,Patent
DCTPep02405,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=51 μM ,72 h,Patent
DCTPep02405,HepG2,Hepatoblastoma,Blastoma,MTT assay,LC50=295 μM ,72 h,Patent
DCTPep02407,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM ,2 h,1
DCTPep02408,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM ,2 h,1
DCTPep02409,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02410,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02411,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02412,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02413,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50=36 µm,2 h,1
DCTPep02414,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02415,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02416,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50=58 µM,2 h,1
DCTPep02417,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02418,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02419,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02420,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02421,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50=61 µM,2 h,1
DCTPep02422,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02423,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02424,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02425,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02426,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02427,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02428,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02429,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02430,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02431,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02432,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02433,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02434,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02435,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02436,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02437,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02438,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02439,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02440,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02441,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02442,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02443,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02444,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02445,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02446,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02447,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02448,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02449,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02450,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CytoTox 96 non-radiactive cytotoxicity assay ,LD50>64 µM,2 h,1
DCTPep02451,T67,Astrocytoma,Carcinoma,MTT assay,EC50=2 μM,24 h,1
DCTPep02451,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=8 μM,24 h,1
DCTPep02452,T67,Astrocytoma,Carcinoma,MTT assay,EC50=1 μM,24 h,1
DCTPep02452,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=3 μM,24 h,1
DCTPep02453,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=2 μM,24 h,1
DCTPep02453,T67,Astrocytoma,Carcinoma,MTT assay,EC50=4 μM,24 h,1
DCTPep02454,T67,Astrocytoma,Carcinoma,MTT assay,EC50=1 μM,24 h,1
DCTPep02454,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=3 μM,24 h,1
DCTPep02455,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=4 μM,24 h,1
DCTPep02455,T67,Astrocytoma,Carcinoma,MTT assay,EC50=8 μM,24 h,1
DCTPep02456,T67,Astrocytoma,Carcinoma,MTT assay,EC50=8 μM,24 h,1
DCTPep02456,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=9 μM,24 h,1
DCTPep02457,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=5 μM,24 h,1
DCTPep02457,T67,Astrocytoma,Carcinoma,MTT assay,EC50=8 μM,24 h,1
DCTPep02458,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=10 μM,24 h,1
DCTPep02458,T67,Astrocytoma,Carcinoma,MTT assay,EC50=7 μM,24 h,1
DCTPep02459,T67,Astrocytoma,Carcinoma,MTT assay,EC50=10 μM,24 h,1
DCTPep02459,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,EC50=6 μM,24 h,1
DCTPep02460,T67,Astrocytoma,Carcinoma,MTT assay,EC50=8 μM,24 h,1
DCTPep02460,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02461,T67,Astrocytoma,Carcinoma,MTT assay,EC50=13 μM,24 h,1
DCTPep02461,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02462,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02462,T67,Astrocytoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02463,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02463,T67,Astrocytoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02464,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02464,T67,Astrocytoma,Carcinoma,MTT assay,Not active up to 20 μM,24 h,1
DCTPep02465,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=20 µM,1 h,1
DCTPep02466,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=12 µM,1 h,1
DCTPep02467,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=8 µM,1 h,1
DCTPep02468,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50>200 µM,1 h,1
DCTPep02469,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=200 µM,1 h,1
DCTPep02470,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=200 µM,1 h,1
DCTPep02471,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=22 µM,1 h,1
DCTPep02472,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=15 µM,1 h,1
DCTPep02473,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50>200 µM,1 h,1
DCTPep02474,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50>200 µM,1 h,1
DCTPep02475,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=140 µM,1 h,1
DCTPep02476,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=9 µM,1 h,1
DCTPep02477,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=75 µM,1 h,1
DCTPep02478,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=230 µM,1 h,1
DCTPep02479,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=170 µM,1 h,1
DCTPep02480,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=14 µM,1 h,1
DCTPep02481,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=65 µM,1 h,1
DCTPep02482,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=24 µM,1 h,1
DCTPep02483,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=22 µM,1 h,1
DCTPep02484,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=10 µM,1 h,1
DCTPep02485,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=5 µM,1 h,1
DCTPep02486,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=6 µM,1 h,1
DCTPep02515,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02516,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02517,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02518,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02519,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02520,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02521,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,21.1 ± 4.0% Cytotoxicity=100 μg/ml,24 h,1
DCTPep02522,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02523,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,6.6 ± 7.9% Cytotoxicity=100 μg/ml,24 h,1
DCTPep02524,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02525,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02526,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,6.4 ± 3.0% Cytotoxicity=100 μg/ml,24 h,1
DCTPep02527,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02528,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 100μg/ml,24 h,1
DCTPep02529,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=129.0 ± 35.5 µM,48 h,1
DCTPep02529,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=73.7 ± 4.5 µM,48 h,1
DCTPep02530,CAPAN-1,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50>200 µM,48 h,1
DCTPep02530,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50>200 µM,48 h,1
DCTPep02531,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=0.6 µM,3 days,1
DCTPep02531,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,SRB assay,IC50=0.6 µM,3 days,1
DCTPep02531,SK-MEL-2,Melanoma,Carcinoma,SRB assay,IC50=0.7 µM,3 days,1
DCTPep02532,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,SRB assay,IC50=1.7 µM,3 days,1
DCTPep02532,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=2 µM,3 days,1
DCTPep02532,SK-MEL-2,Melanoma,Carcinoma,SRB assay,IC50=2.1 µM,3 days,1
DCTPep02533,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,SRB assay,IC50=0.9 µM,3 days,1
DCTPep02533,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=1 µM,3 days,1
DCTPep02533,SK-MEL-2,Melanoma,Carcinoma,SRB assay,IC50=1.3 µM,3 days,1
DCTPep02534,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,SRB assay,IC50=0.5 µM,3 days,1
DCTPep02534,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=0.6 µM,3 days,1
DCTPep02534,SK-MEL-2,Melanoma,Carcinoma,SRB assay,IC50=0.6 µM,3 days,1
DCTPep02535,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,SRB assay,IC50=31.9 µM,3 days,1
DCTPep02535,SK-MEL-2,Melanoma,Carcinoma,SRB assay,IC50=38.7 µM,3 days,1
DCTPep02535,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=75.5 µM,3 days,1
DCTPep02536,SK-OV-3,Ovarian serous cystadenocarcinoma,Carcinoma,SRB assay,IC50=0.7 µM,3 days,1
DCTPep02536,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=1 µM,3 days,1
DCTPep02536,SK-MEL-2,Melanoma,Carcinoma,SRB assay,IC50=1.1 µM,3 days,1
DCTPep02537,M21,Melanoma,Carcinoma,Lysosomal hexosaminidase quantitative assay,IC50 (Cilengitide inhibited integrin-mediated binding to vitronectin) =0.4 µM,Not available,1
DCTPep02537,UCLA-P3,Lung squamous cell carcinoma,Carcinoma,Lysosomal hexosaminidase quantitative assay,IC50 (Cilengitide inhibited integrin-mediated binding to vitronectin) =0.4 µM,Not available,1
DCTPep02539,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=36 ± 3.6 μM ,1 h,1
DCTPep02540,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity>1000 μM ,1 h,1
DCTPep02541,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity>1000 μM ,1 h,1
DCTPep02542,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity>1000 μM ,1 h,1
DCTPep02543,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=36 ± 5.7 μM ,1 h,1
DCTPep02544,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity= μM ,1 h,1
DCTPep02545,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity= μM ,1 h,1
DCTPep02546,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=17 ± 1.2 μM ,1 h,1
DCTPep02547,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=9 ± 0.9 μM ,1 h,1
DCTPep02548,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=33 ± 8.5 μM ,1 h,1
DCTPep02549,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=5 ± 0.2 μM ,1 h,1
DCTPep02550,HeLa WT,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,50% Cytotoxicity=442 ± 66.7 μM ,1 h,1
DCTPep02551,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=1.9 μM ,72 h,1
DCTPep02551,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=2 μM ,72 h,1
DCTPep02551,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50=2.6 μM ,72 h,1
DCTPep02551,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50=3 μM ,72 h,1
DCTPep02551,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=5.4 μM ,72 h,1
DCTPep02551,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50=6.2 μM ,72 h,1
DCTPep02551,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=7.2 μM ,72 h,1
DCTPep02551,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=7.3 μM ,72 h,1
DCTPep02551,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02551,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02551,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02551,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02552,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=1.1 μM ,72 h,1
DCTPep02552,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=2 μM ,72 h,1
DCTPep02552,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50=2.6 μM ,72 h,1
DCTPep02552,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=5 μM ,72 h,1
DCTPep02552,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50=5.6 μM ,72 h,1
DCTPep02552,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50=6 μM ,72 h,1
DCTPep02552,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.4 μM ,72 h,1
DCTPep02552,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.4 μM ,72 h,1
DCTPep02552,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50=6.4 μM ,72 h,1
DCTPep02552,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.6 μM ,72 h,1
DCTPep02552,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50=7 μM ,72 h,1
DCTPep02552,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50=7.4 μM ,72 h,1
DCTPep02553,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=1.7 μM,72 h,1
DCTPep02553,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=2.5 μM,72 h,1
DCTPep02553,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50=3.1 μM,72 h,1
DCTPep02553,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=3.2 μM,72 h,1
DCTPep02553,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=3.6 μM,72 h,1
DCTPep02553,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50=4.6 μM,72 h,1
DCTPep02553,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50=4.7 μM,72 h,1
DCTPep02553,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50=5.4 μM,72 h,1
DCTPep02553,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50=5.9 μM ,72 h,1
DCTPep02553,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.2 μM,72 h,1
DCTPep02553,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.5 μM,72 h,1
DCTPep02553,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50=7.5 μM,72 h,1
DCTPep02554,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=1.5 μM,72 h,1
DCTPep02554,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=1.7 μM,72 h,1
DCTPep02554,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50=1.9 μM,72 h,1
DCTPep02554,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50=2.1 μM,72 h,1
DCTPep02554,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50=2.3 μM,72 h,1
DCTPep02554,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=2.4 μM,72 h,1
DCTPep02554,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=2.6 μM,72 h,1
DCTPep02554,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50=2.7 μM,72 h,1
DCTPep02554,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50=3 μM,72 h,1
DCTPep02554,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=4.4 μM,72 h,1
DCTPep02554,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.4 μM,72 h,1
DCTPep02554,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.5 μM,72 h,1
DCTPep02556,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02556,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM ,72 h,1
DCTPep02557,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=3.7 μM,72 h,1
DCTPep02557,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=7.1 μM,72 h,1
DCTPep02557,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02557,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=6.8 μM,72 h,1
DCTPep02558,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02558,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=6.7 μM,72 h,1
DCTPep02559,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02559,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=5.9 μM,72 h,1
DCTPep02560,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=6.7 μM,72 h,1
DCTPep02560,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02560,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02561,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,CellTiter-Glo assay,IC50=2.2 μM,72 h,1
DCTPep02561,RL,Diffuse large B-cell lymphoma,Lymphoma,CellTiter-Glo assay,IC50=3.7 μM,72 h,1
DCTPep02561,A498,Renal cell carcinoma,Carcinoma,CellTiter-Glo assay,IC50=4.2 μM,72 h,1
DCTPep02561,UACC-62,Melanoma,Carcinoma,CellTiter-Glo assay,IC50=6.4 μM,72 h,1
DCTPep02561,COLO 205,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=6.7 μM,72 h,1
DCTPep02561,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50=7.2 μM,72 h,1
DCTPep02561,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CellTiter-Glo assay,IC50=7.3 μM,72 h,1
DCTPep02561,CFPAC-1,Cystic fibrosis; Pancreatic ductal adenocarcinoma; Cystic fibrosis ,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02561,DLD-1,Colon adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02561,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02561,Mia PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02561,PC-3,Prostate carcinoma,Carcinoma,CellTiter-Glo assay,IC50>7.5 μM,72 h,1
DCTPep02567,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=31.0 ± 1.0 µM,4 h,1
DCTPep02567,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=37.3 ± 1.5 µM,4 h,1
DCTPep02568,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=36.7 ± 9.5 µM,4 h,1
DCTPep02568,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=51.7 ± 6.5 µM,4 h,1
DCTPep02569,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=24.7 ± 2.3 µM,4 h,1
DCTPep02569,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=25.7 ± 0.6 µM,4 h,1
DCTPep02570,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=12.3 ± 1.5 µM,4 h,1
DCTPep02570,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=25.3 ± 4.2 µM,4 h,1
DCTPep02571,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=12 µM,4 h,1
DCTPep02571,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=15.0 ± 1.0 µM,4 h,1
DCTPep02572,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=18.7 ± 1.5 µM,4 h,1
DCTPep02572,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=27.3 ± 5.1 µM,4 h,1
DCTPep02573,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=24.0 ± 1.0 µM,4 h,1
DCTPep02573,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=26.3 ± 7.1 µM,4 h,1
DCTPep02574,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=26.0 ± 1.7 µM,4 h,1
DCTPep02574,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=29.3 ± 7.8 µM,4 h,1
DCTPep02575,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=11.0 ± 1.0 µM,4 h,1
DCTPep02575,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=9.3 ± 1.2 µM,4 h,1
DCTPep02576,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=13.0 ± 1.0 µM,4 h,1
DCTPep02576,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=13.4 ± 1.6 µM,4 h,1
DCTPep02576,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=17.7 ± 3.1 µM,4 h,1
DCTPep02576,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=6.1 ± 1.8 µM,4 h,1
DCTPep02576,IGROV-1/CDDP,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=6.6 ± 2.6 µM,4 h,1
DCTPep02576,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=6.8 ± 2.8 µM,4 h,1
DCTPep02576,HL-60/ADR,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=7.0 ± 3.7 µM,4 h,1
DCTPep02576,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.2 ± 0.4 µM,4 h,1
DCTPep02576,K562/Gleevec,"Blast phase chronic myelogenous leukemia, BCR-ABL3 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.9 ± 2.9 µM,4 h,1
DCTPep02576,MCF-7/mdr,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.4 ± 2.7 µM,4 h,1
DCTPep02577,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=11.3 ± 1.2 µM,4 h,1
DCTPep02577,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=14.3 ± 5.3 µM,4 h,1
DCTPep02577,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.6 ± 1.1 µM,4 h,1
DCTPep02577,MCF-7/mdr,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.9 ± 1.6 µM,4 h,1
DCTPep02577,HL-60/ADR,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=4.9 ± 3.7 µM,4 h,1
DCTPep02577,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=6.1 ± 3.4 µM,4 h,1
DCTPep02577,IGROV-1/CDDP,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=6.6 ± 2.7 µM,4 h,1
DCTPep02577,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.4 ± 0.1 µM,4 h,1
DCTPep02577,K562/Gleevec,"Blast phase chronic myelogenous leukemia, BCR-ABL4 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.6 ± 1.3 µM,4 h,1
DCTPep02577,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=8.3 ± 1.5 µM,4 h,1
DCTPep02578,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=14.3 ± 1.2 µM,4 h,1
DCTPep02578,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=8.3 ± 0.6 µM,4 h,1
DCTPep02579,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=154 ± 29 µM,4 h,1
DCTPep02579,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=67.7 ± 13.2 µM,4 h,1
DCTPep02580,IGROV-1,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=11.1 ± 3.4 µM,4 h,1
DCTPep02580,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=11.3 ± 2.1 µM,4 h,1
DCTPep02580,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=5.5 ± 0.9 µM,4 h,1
DCTPep02580,IGROV-1/CDDP,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=5.5 ± 2.2 µM,4 h,1
DCTPep02580,HL-60/ADR,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=6.0 ± 4.5 µM,4 h,1
DCTPep02580,MCF-7/mdr,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=6.6 ± 2.8 µM,4 h,1
DCTPep02580,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=6.7 ± 1.2 µM,4 h,1
DCTPep02580,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,IC50=6.7 ± 3.7 µM,4 h,1
DCTPep02580,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.0 ± 0.8 µM,4 h,1
DCTPep02580,K562/Gleevec,"Blast phase chronic myelogenous leukemia, BCR-ABL5 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=7.7 ± 1.6 µM,4 h,1
DCTPep02581,AT84,Murine squamous cell carcinoma,Carcinoma,MTT assay,IC50=113 ± 10 µM,4 h,1
DCTPep02581,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=134 ± 13 µM,4 h,1
DCTPep02582,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=13.5 ± 0.9 µM,4 h,1
DCTPep02583,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=20.3 ± 2.9 µM,4 h,1
DCTPep02584,A20,Murine B cell lymphoma,Lymphoma,MTT assay,IC50=247 ± 13 µM,4 h,1
DCTPep02585,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50=12.3±0.6 μM,"2, 24 h",1
DCTPep02585,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=3.2±0.1 μM,"2, 24 h",1
DCTPep02585,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=8.1±0.4 μM,"2, 24 h",1
DCTPep02586,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02586,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02586,MM96L,Melanoma,Carcinoma,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02587,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02587,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02587,MM96L,Melanoma,Carcinoma,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02588,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=43.8±0.5 μM,"2, 24 h",1
DCTPep02589,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02589,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02589,MM96L,Melanoma,Carcinoma,Resazurin assay,Not active up to 60 µM,"2, 24 h",1
DCTPep02590,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50=12.2±0.6 μM,"2, 24 h",1
DCTPep02590,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,CC50=9.8±0.5 μM,"2, 24 h",1
DCTPep02592,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter-Blue assay,21% Cytotoxicity=15 µM,24 h,1
DCTPep02593,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter-Blue assay,52% Cytotoxicity=15 µM,24 h,1
DCTPep02594,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter-Blue assay,52% Cytotoxicity=15 µM,24 h,1
DCTPep02595,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter-Blue assay,8% Cytotoxicity=15 µM,24 h,1
DCTPep02596,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CellTiter-Blue assay,12% Cytotoxicity=15 µM,24 h,1
DCTPep02597,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02597,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02598,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02598,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02599,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02599,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02600,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02600,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02601,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02601,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02602,HepG2,Hepatoblastoma,Blastoma,CellTiter-Glo assay,IC50=56 µM,Not available,2
DCTPep02602,NCI-H460,Lung large cell carcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02602,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,Not active up to 30 µM,68 h,1
DCTPep02603,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2 h,1
DCTPep02605,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2 h,1
DCTPep02606,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=16 µg/ml,2 h,1
DCTPep02607,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=128 µg/ml,2 h,1
DCTPep02608,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=16 µg/ml,2 h,1
DCTPep02609,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=32 µg/ml,2 h,1
DCTPep02610,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=32 µg/ml,2 h,1
DCTPep02611,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=64 µg/ml,2 h,1
DCTPep02612,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death>128 µg/ml,2 h,1
DCTPep02613,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,50% Cell death=8 µg/ml,2 h,1
DCTPep02614,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=80 ± 6 μM ,24 h,1
DCTPep02615,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50=65 ± 5 μM ,24 h,1
DCTPep02616,A549,Lung adenocarcinoma,Carcinoma,CellTiter-Glo Luminescent Cell Viability assay,LC50>100 μM ,24 h,1
DCTPep02620,PC-3,Prostate carcinoma,Carcinoma,SBR assay,IC50=10.8 µg/mL,48 h,1
DCTPep02620,NCI-H23,Lung adenocarcinoma,Carcinoma,SBR assay,IC50=11.2 µg/mL,48 h,1
DCTPep02620,HCT 15,Colon adenocarcinoma,Carcinoma,SBR assay,IC50=11.4 µg/mL,48 h,1
DCTPep02620,ACHN,Papillary renal cell carcinoma,Carcinoma,SBR assay,IC50=11.5 µg/mL,48 h,1
DCTPep02620,NUGC-3,Gastric adenocarcinoma ,Carcinoma,SBR assay,IC50=11.8 µg/mL,48 h,1
DCTPep02620,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SBR assay,IC50=14.9 µg/mL,48 h,1
DCTPep02621,NCI-H23,Lung adenocarcinoma,Carcinoma,SBR assay,IC50=11.7 µg/mL,48 h,1
DCTPep02621,NUGC-3,Gastric adenocarcinoma ,Carcinoma,SBR assay,IC50=13.9 µg/mL,48 h,1
DCTPep02621,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SBR assay,IC50=16.1 µg/mL,48 h,1
DCTPep02621,HCT 15,Colon adenocarcinoma,Carcinoma,SBR assay,IC50=18.3 µg/mL,48 h,1
DCTPep02621,ACHN,Papillary renal cell carcinoma,Carcinoma,SBR assay,IC50=18.4 µg/mL,48 h,1
DCTPep02621,PC-3,Prostate carcinoma,Carcinoma,SBR assay,IC50=19.4 µg/mL,48 h,1
DCTPep02622,NUGC-3,Gastric adenocarcinoma ,Carcinoma,SBR assay,IC50=10.5 µg/mL,48 h,1
DCTPep02622,NCI-H23,Lung adenocarcinoma,Carcinoma,SBR assay,IC50=10.9 µg/mL,48 h,1
DCTPep02622,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SBR assay,IC50=11.2 µg/mL,48 h,1
DCTPep02622,PC-3,Prostate carcinoma,Carcinoma,SBR assay,IC50=11.7 µg/mL,48 h,1
DCTPep02622,ACHN,Papillary renal cell carcinoma,Carcinoma,SBR assay,IC50=12.3 µg/mL,48 h,1
DCTPep02622,HCT 15,Colon adenocarcinoma,Carcinoma,SBR assay,IC50=23.2 µg/mL,48 h,1
DCTPep02623,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=30 µM ,1 h,1
DCTPep02624,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=4 µM ,1 h,1
DCTPep02625,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=4 µM ,1 h,1
DCTPep02626,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=6 µM ,1 h,1
DCTPep02627,HepG2,Hepatoblastoma,Blastoma,CytoTox 96 non-radiactive cytotoxicity assay ,LC50=7 µM ,1 h,1
DCTPep02628,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.5 ± 1.3 µM,48 h,1
DCTPep02628,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=11.0 ± 1.1 µM,48 h,1
DCTPep02628,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL11 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=11.7 ± 0.7 µM,48 h,1
DCTPep02628,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=9.1 ± 0.7 µM ,48 h,1
DCTPep02629,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL12 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=10.0 ± 0.8 µM,48 h,1
DCTPep02629,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL2 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=11.5 ± 0.9 µM,48 h,1
DCTPep02629,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=8.8 ± 0.5 µM ,48 h,1
DCTPep02629,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=9.5 ± 1.1 µM,48 h,1
DCTPep02630,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.2 ± 0.2 µM,48 h,1
DCTPep02630,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.2 ± 0.4 µM,48 h,1
DCTPep02630,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL13 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=4.9 ± 0.1 µM,48 h,1
DCTPep02630,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL3 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=6.6 ± 0.3 µM,48 h,1
DCTPep02631,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=1.9 ± 0.2 µM,48 h,1
DCTPep02631,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.0 ± 0.3 µM,48 h,1
DCTPep02631,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL14 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.4 ± 0.3 µM,48 h,1
DCTPep02631,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL4 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.8 ± 0.1 µM,48 h,1
DCTPep02632,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.0 ± 0.1 µM,48 h,1
DCTPep02632,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.3 ± 0.1 µM,48 h,1
DCTPep02632,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL5 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.9 ± 0.2 µM,48 h,1
DCTPep02632,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL15 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=4.2 ± 0.5 µM,48 h,1
DCTPep02633,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.5 ± 0.9 µM,48 h,1
DCTPep02633,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=11.5 ± 0.8 µM,48 h,1
DCTPep02633,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL16 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=9.2 ± 1.1 µM,48 h,1
DCTPep02633,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL6 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=9.7 ± 0.7 µM,48 h,1
DCTPep02634,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL7 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=10.2 ± 1.1 µM,48 h,1
DCTPep02634,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL17 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=10.5 ± 1.3 µM,48 h,1
DCTPep02634,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10.7 ± 1.0 µM,48 h,1
DCTPep02634,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=9.6 ± 0.4 µM,48 h,1
DCTPep02635,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.5 ± 0.1 µM,48 h,1
DCTPep02635,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL8 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.8 ± 0.2 µM,48 h,1
DCTPep02635,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=4.3 ± 0.2 µM,48 h,1
DCTPep02635,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL18 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=4.6 ± 0.3 µM,48 h,1
DCTPep02636,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.7 ± 0.3 µM,48 h,1
DCTPep02636,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.2 ± 0.2 µM,48 h,1
DCTPep02636,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL19 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.4 ± 0.1 µM,48 h,1
DCTPep02636,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL9 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.4 ± 0.3 µM,48 h,1
DCTPep02637,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=2.5 ± 0.2 µM,48 h,1
DCTPep02637,MCF-7/Taxol,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.2 ± 0.1 µM,48 h,1
DCTPep02637,K562/ADM,"Blast phase chronic myelogenous leukemia, BCR-ABL20 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.3 ± 0.3 µM,48 h,1
DCTPep02637,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL10 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=3.4 ± 0.1 µM,48 h,1
DCTPep02648,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=10 µM,20 h,2
DCTPep02648,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=45.92 μM,4 h,1
DCTPep02649,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=95.46 μM,4 h,1
DCTPep02650,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=80.40 μM,4 h,1
DCTPep02651,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=9.44 μM,4 h,1
DCTPep02652,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=13.95 μM,4 h,1
DCTPep02653,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50>100 μM,4 h,1
DCTPep02654,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=67.15 μM,4 h,1
DCTPep02655,U-373MG,Astrocytoma,Carcinoma,MTT assay,LD50=28.67 μM,4 h,1
DCTPep02656,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=5 µM,20 h,1
DCTPep02657,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=13 µM,20 h,1
DCTPep02686,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,30% Cytotoxicity=10 µM,24 h,1
DCTPep02686,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 10 µM,24 h,1
DCTPep02687,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,<10% Cytotoxicity=10 µM,24 h,1
DCTPep02687,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 10 µM,24 h,1
DCTPep02688,A431,Skin squamous cell carcinoma,Carcinoma,MTT assay,<10% Cytotoxicity=10 µM,24 h,1
DCTPep02688,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,Not active up to 10 µM,24 h,1
DCTPep02689,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02689,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02689,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02690,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,<5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02690,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,25% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02690,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02691,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02691,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20-25% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02691,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02692,HepG2,Hepatoblastoma,Blastoma,MTT assay,<5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02692,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20-25% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02692,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02693,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,<5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02693,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20-25% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02693,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02694,HepG2,Hepatoblastoma,Blastoma,MTT assay,<10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02694,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,10-20% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02694,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02695,HepG2,Hepatoblastoma,Blastoma,MTT assay,<5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02695,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02695,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,10-20% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02696,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,10-20% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02696,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02696,HepG2,Hepatoblastoma,Blastoma,MTT assay,Not active up to 600 µg/ml,24 h,1
DCTPep02697,HepG2,Hepatoblastoma,Blastoma,MTT assay,<10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02697,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,<5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02697,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,10-20% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02698,HepG2,Hepatoblastoma,Blastoma,MTT assay,<5% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02698,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02698,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50-60% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02699,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,<10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02699,HepG2,Hepatoblastoma,Blastoma,MTT assay,10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02699,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,40% Cytotoxicity=601 µg/ml,24 h,1
DCTPep02700,HepG2,Hepatoblastoma,Blastoma,MTT assay,<10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02700,SH-SY5Y,Neuroblastoma,Blastoma,MTT assay,10% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02700,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50-60% Cytotoxicity=600 µg/ml,24 h,1
DCTPep02725,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=12 µg/ml,24 h,1
DCTPep02725,LNCaP C4-2,Prostate carcinoma,Carcinoma,MTT assay,IC50=16 µg/ml,24 h,1
DCTPep02725,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=18 µg/ml,24 h,1
DCTPep02725,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30 µg/ml,24 h,1
DCTPep02726,LNCaP C4-2,Prostate carcinoma,Carcinoma,MTT assay,IC50=13 µg/ml,24 h,1
DCTPep02726,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=13 µg/ml,24 h,1
DCTPep02726,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=15 µg/ml,24 h,1
DCTPep02726,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=22 µg/ml,24 h,1
DCTPep02727,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=10 µg/ml,24 h,1
DCTPep02727,LNCaP C4-2,Prostate carcinoma,Carcinoma,MTT assay,IC50=15 µg/ml,24 h,1
DCTPep02727,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=19 µg/ml,24 h,1
DCTPep02727,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30 µg/ml,24 h,1
DCTPep02728,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=17 µg/ml,24 h,1
DCTPep02728,LNCaP C4-2,Prostate carcinoma,Carcinoma,MTT assay,IC50=20 µg/ml,24 h,1
DCTPep02728,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30 µg/ml,24 h,1
DCTPep02728,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=32 µg/ml,24 h,1
DCTPep02729,LNCaP C4-2,Prostate carcinoma,Carcinoma,MTT assay,IC50=35 µg/ml,24 h,1
DCTPep02729,MEC-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=35 µg/ml,24 h,1
DCTPep02729,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=36 µg/ml,24 h,1
DCTPep02729,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=48 µg/ml,24 h,1
DCTPep02730,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02730,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,70% Killing=50 µM,24 h,1
DCTPep02731,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02731,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,60% Killing=50 µM,24 h,1
DCTPep02732,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,<10% Killing=50 µM,24 h,1
DCTPep02732,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02733,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02733,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02734,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02734,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02735,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02735,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,>80% Killing=50 µM,24 h,1
DCTPep02741,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50=2.38±0.9 µM ,48 h,1
DCTPep02742,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50=74.5±6.8 µM ,48 h,1
DCTPep02743,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02744,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50=19.8±1.6 µM ,48 h,1
DCTPep02745,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50=4.04±0.4 µM ,48 h,1
DCTPep02746,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50=88.8±28 µM ,48 h,1
DCTPep02747,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02748,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02749,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02750,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02751,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50=4.54±0.6 µM ,48 h,1
DCTPep02752,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02753,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 µM ,48 h,1
DCTPep02758,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=4.4 ± 1.3 µM ,24 h,1
DCTPep02758,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=8.3 ± 2.0 µM,24 h,1
DCTPep02759,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02759,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02760,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02760,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02761,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM,24 h,1
DCTPep02761,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02762,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=18.4 ± 0.7 µM,24 h,1
DCTPep02762,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=7.0 ± 0.5 µM,24 h,1
DCTPep02763,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=5.7 ± 0.7 µM,24 h,1
DCTPep02763,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=9.3 ± 1.5 µM,24 h,1
DCTPep02764,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02764,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02765,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02765,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02766,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM,24 h,1
DCTPep02766,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02767,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=19.0 ± 1.8 µM,24 h,1
DCTPep02767,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM,24 h,1
DCTPep02768,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM,24 h,1
DCTPep02768,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02769,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>50 µM,24 h,1
DCTPep02769,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>50 µM ,24 h,1
DCTPep02770,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=27.4 ± 0.5 µM,24 h,1
DCTPep02770,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=49 ± 2 µM,24 h,1
DCTPep02771,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=10 ± 2 µM,24 h,1
DCTPep02771,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=17.0 ± 0.6 µM,24 h,1
DCTPep02772,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=10 ± 1 µM,24 h,1
DCTPep02772,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=14 ± 3 µM,24 h,1
DCTPep02773,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11 ± 2 µM,24 h,1
DCTPep02773,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=15.0 ± 0.1 µM,24 h,1
DCTPep02774,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=12.4 ± 0.4 µM,24 h,1
DCTPep02774,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=17.4 ± 0.1 µM,24 h,1
DCTPep02775,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=12 ± 3 µM,24 h,1
DCTPep02775,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=18 ± 2 µM,24 h,1
DCTPep02776,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=39 ± 3 µM,24 h,1
DCTPep02776,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=52 ± 2 µM,24 h,1
DCTPep02777,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11.9 ± 0.1 µM,24 h,1
DCTPep02777,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=17 ± 4 µM,24 h,1
DCTPep02778,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=18.9 ± 0.2 µM,24 h,1
DCTPep02778,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=22 ± 4 µM,24 h,1
DCTPep02779,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=56 ± 5 µM,24 h,1
DCTPep02779,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=83 ± 11 µM,24 h,1
DCTPep02780,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=91 ± 2 µM,24 h,1
DCTPep02780,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02781,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11.6 ± 0.8 µM,24 h,1
DCTPep02781,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=20 ± 1 µM,24 h,1
DCTPep02782,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=65 ± 3 µM,24 h,1
DCTPep02782,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02783,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02783,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02784,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=10.4 ± 0.8 µM,24 h,1
DCTPep02784,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=14.8 ± 0.7 µM,24 h,1
DCTPep02785,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=12.4 ± 0.1 µM,24 h,1
DCTPep02785,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=9.3 ± 0.2 µM,24 h,1
DCTPep02786,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11.2 ± 0.7 µM,24 h,1
DCTPep02786,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=15 ± 1 µM,24 h,1
DCTPep02787,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02787,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02788,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02788,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02789,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=28.6 ± 0.1 µM,24 h,1
DCTPep02789,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=40 ± 2 µM,24 h,1
DCTPep02790,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=76 ± 15 µM,24 h,1
DCTPep02790,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50>100 µM,24 h,1
DCTPep02791,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=13 ± 1 µM,24 h,1
DCTPep02791,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=20 ± 2 µM,24 h,1
DCTPep02792,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=7 ± 1 µM,24 h,1
DCTPep02792,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=9 ± 1 µM,24 h,1
DCTPep02793,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=68 ± 5 µM,24 h,1
DCTPep02794,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=16 ± 2 µM,24 h,1
DCTPep02794,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=29.3 ± 0.9 µM,24 h,1
DCTPep02795,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=10.6 ± 0.8 µM,24 h,1
DCTPep02795,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=6.5 ± 0.2 µM,24 h,1
DCTPep02796,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=12 ± 2 µM,24 h,1
DCTPep02796,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=8 ± 1 µM,24 h,1
DCTPep02797,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=11.0 ± 0.2 µM,24 h,1
DCTPep02797,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=16.5 ± 0.2 µM,24 h,1
DCTPep02798,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=13 ± 1 µM,24 h,1
DCTPep02798,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=28 ± 3 µM,24 h,1
DCTPep02799,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=16.9 ± 0.8 µM,24 h,1
DCTPep02799,A549,Lung adenocarcinoma,Carcinoma,MTT assay,EC50=36 ± 7 µM,24 h,1
DCTPep02800,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=190 µg/ml,24 h,1
DCTPep02800,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=212 µg/ml,24 h,1
DCTPep02801,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=15.5 ± 0.3 μM,overnight,1
DCTPep02801,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=8.1 ± 0.4 μM,overnight,1
DCTPep02802,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=12.9 ± 0.3 μM,overnight,1
DCTPep02802,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=24.4 ± 4.0 μM,overnight,1
DCTPep02803,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=4.5 ± 1.6 μM,overnight,1
DCTPep02803,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=8.4 ± 1.1 μM,overnight,1
DCTPep02804,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=16.5 ± 1.3 μM,overnight,1
DCTPep02804,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=9.8 ± 0.5 μM,overnight,1
DCTPep02805,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=20.0 ± 3.4 μM,overnight,1
DCTPep02805,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=3.2 ± 0.4 μM,overnight,1
DCTPep02806,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=13.7 ± 2.3 μM,overnight,1
DCTPep02806,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=4.1 ± 0.3 μM,overnight,1
DCTPep02807,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=11.5 ± 0.5 μM,overnight,1
DCTPep02807,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=25.0 ± 3.5 μM,overnight,1
DCTPep02808,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50=17.0 ± 1.1 μM,overnight,1
DCTPep02808,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=39.4 ± 2.3 μM,overnight,1
DCTPep02809,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=28.0 ± 6.5 μM,overnight,1
DCTPep02809,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50>64 μM,overnight,1
DCTPep02810,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=33.6 ± 4.1 μM,overnight,1
DCTPep02810,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50>64 μM,overnight,1
DCTPep02811,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=39.4 ± 6.6 μM,overnight,1
DCTPep02811,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,IC50>64 μM,overnight,1
DCTPep02812,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM ,24 h,1
DCTPep02813,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50=200 μM ,24 h,1
DCTPep02814,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50=12.5 μM,24 h,1
DCTPep02814,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,CC50=25 μM,24 h,1
DCTPep02815,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM,24 h,1
DCTPep02816,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50=50 μM,24 h,1
DCTPep02817,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50=200 μM,24 h,1
DCTPep02818,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM,24 h,1
DCTPep02819,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,CC50=12.5 μM,24 h,1
DCTPep02819,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50=25 μM,24 h,1
DCTPep02820,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM,24 h,1
DCTPep02821,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM,24 h,1
DCTPep02822,A549,Lung adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM,24 h,1
DCTPep02822,CaCo-2,Colon adenocarcinoma,Carcinoma,MTT assay,CC50>200 μM,24 h,1
DCTPep02823,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=3.9 ± 1.1 μg/mL,24 h,1
DCTPep02824,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=17.9 ± 2.1 μg/mL,24 h,1
DCTPep02825,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=3.0 ± 0.6 μg/mL,24 h,1
DCTPep02826,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=27.5 ± 3.4 μg/mL,24 h,1
DCTPep02827,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=3.0 ± 0.4 μg/mL,24 h,1
DCTPep02828,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS assay,IC50=20.9 ± 2.1 μg/mL,24 h,1
DCTPep02829,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>250 μg/mL,24 h,1
DCTPep02830,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=32 μg/mL,24 h,1
DCTPep02831,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>250 μg/mL,24 h,1
DCTPep02832,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=250 μg/mL,24 h,1
DCTPep02833,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=32 μg/mL,24 h,1
DCTPep02834,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=125 μg/mL,24 h,1
DCTPep02835,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>250 μg/mL,24 h,1
DCTPep02836,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>250 μg/mL,24 h,1
DCTPep02837,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=250 μg/mL,24 h,1
DCTPep02838,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=125 μg/mL,24 h,1
DCTPep02839,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=250 μg/mL,24 h,1
DCTPep02840,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=250 μg/mL,24 h,1
DCTPep02841,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=125 μg/mL,24 h,1
DCTPep02842,C666-1,Nasopharyngeal carcinoma,Carcinoma,MTT assay,IC50=18.27 μM ,24 h,1
DCTPep02842,MGC-803,Gastric mucinous adenocarcinoma,Carcinoma,MTT assay,IC50=31.55 μM ,24 h,1
DCTPep02842,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=40.83 μM ,24 h,1
DCTPep02843,MDA-MB-231,Breast adenocarcinoma,Carcinoma,Resazurin assay,CC50=15.9 ± 2.3 μM,26 h,1
DCTPep02843,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50=16.0 ± 0.5 μM,26 h,1
DCTPep02843,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50=5.4 ± 0.3 μM ,26 h,1
DCTPep02843,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=5.7 ± 0.4 μM ,26 h,1
DCTPep02843,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=8.2 ± 0.4 μM,26 h,1
DCTPep02844,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50=5.3 ± 0.5 μM ,26 h,1
DCTPep02844,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50=7.1 ± 0.6 μM ,26 h,1
DCTPep02845,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02845,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02845,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02845,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02846,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,Resazurin assay,CC50=36.7 ± 1.9 μM,26 h,1
DCTPep02846,MDA-MB-435S,Amelanotic melanoma,Carcinoma,Resazurin assay,CC50>32 μM,26 h,1
DCTPep02846,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02846,MDA-MB-231,Breast adenocarcinoma,Carcinoma,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02846,MM96L,Melanoma,Carcinoma,Resazurin assay,CC50>64 μM,26 h,1
DCTPep02847,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02848,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02849,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50=299 μg/ml,24 h,1
DCTPep02850,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02851,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02852,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02853,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02854,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02855,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02856,HepG2,Hepatoblastoma,Blastoma,Resazurin assay,CC50>300 μg/ml,24 h,1
DCTPep02857,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,9% Killing=16-32 µM,24 h,1
DCTPep02858,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,8% Killing=16 µM,24 h,1
DCTPep02859,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,19% Killing=128 µM,24 h,1
DCTPep02860,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,24% Killing=1 µM,24 h,1
DCTPep02861,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,28% Killing=2-4 µM,24 h,1
DCTPep02862,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,19% Killing=2 µM,24 h,1
DCTPep02863,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,27% Killing=128 µM,24 h,1
DCTPep02864,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,28% Killing=128 µM,24 h,1
DCTPep02865,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,13% Killing=128 µM,24 h,1
DCTPep02866,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,3% Killing=128 µM,24 h,1
DCTPep02867,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,15% Killing=128 µM,24 h,1
DCTPep02868,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=33.7 μg/ml,24 h,1
DCTPep02869,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=29.8 μg/ml,24 h,1
DCTPep02870,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3.9 μg/ml,24 h,1
DCTPep02871,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=10.7 μg/ml,24 h,1
DCTPep02872,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=56 μg/ml,24 h,1
DCTPep02873,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12.5 μg/ml,24 h,1
DCTPep02874,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=145.1 μg/ml,24 h,1
DCTPep02875,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=18.9 μg/ml,24 h,1
DCTPep02876,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=13.9 μg/ml,24 h,1
DCTPep02877,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=75 μg/ml,24 h,1
DCTPep02878,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=45.5 μg/ml,24 h,1
DCTPep02879,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=20 μg/ml,24 h,1
DCTPep02880,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12.9 μg/ml,24 h,1
DCTPep02881,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=12.8 μg/ml,24 h,1
DCTPep02882,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=9.8 μg/ml,24 h,1
DCTPep02883,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=19.2 μg/ml,24 h,1
DCTPep02884,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=29.2 μg/ml,24 h,1
DCTPep02885,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,50% Killing=100 mg/L,6 h,1
DCTPep02886,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,Weak active up to 125 mg/L,6 h,1
DCTPep02887,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,Weak active up to 125 mg/L,6 h,1
DCTPep02888,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,Weak active up to 125 mg/L,6 h,1
DCTPep02889,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=1.60±0.24 μM,96 h,1
DCTPep02889,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=3.54±0.72  μM,96 h,1
DCTPep02889,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.26±0.52 μM ,96 h,1
DCTPep02890,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=2.82±0.23 μM,96 h,1
DCTPep02890,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=4.16±0.21 μM,96 h,1
DCTPep02890,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=4.26±0.52 μM ,96 h,1
DCTPep02891,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=1.50±0.21 μM,96 h,1
DCTPep02891,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=3.51±0.37  μM,96 h,1
DCTPep02891,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3.59±0.12 μM,96 h,1
DCTPep02892,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.98±0.11 μM,96 h,1
DCTPep02892,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.841±0.34 μM,96 h,1
DCTPep02892,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=4.54±0.25 μM,96 h,1
DCTPep02893,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=2.20±0.27 μM,96 h,1
DCTPep02893,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.26±0.24 μM,96 h,1
DCTPep02893,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=2.95±0.25  μM,96 h,1
DCTPep02894,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=1.85±0.31 μM,96 h,1
DCTPep02894,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=2.65±0.35  μM,96 h,1
DCTPep02894,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=3.14±0.46 μM,96 h,1
DCTPep02895,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.96±0.33  μM,96 h,1
DCTPep02895,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.49±0.45  μM,96 h,1
DCTPep02895,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=1.64±0.47 μM,96 h,1
DCTPep02896,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.89±0.21 μM,96 h,1
DCTPep02896,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.11±0.21  μM,96 h,1
DCTPep02896,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=1.61±0.21 μM,96 h,1
DCTPep02897,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=1.00±0.36 μM,96 h,1
DCTPep02897,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=1.64±0.36 μM,96 h,1
DCTPep02897,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.78±0.35  μM,96 h,1
DCTPep02898,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=2.10±0.32 μM,96 h,1
DCTPep02898,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=2.63±0.35 μM,96 h,1
DCTPep02898,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=4.93±0.53 μM,96 h,1
DCTPep02899,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=1.50±0.28 μM,96 h,1
DCTPep02899,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=3.05±0.21 μM,96 h,1
DCTPep02899,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=3.26±0.36 μM,96 h,1
DCTPep02900,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=1.10±0.31 μM,96 h,1
DCTPep02900,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.65±0.28 μM,96 h,1
DCTPep02900,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=2.71±0.05 μM,96 h,1
DCTPep02901,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.62±0.12 μM,96 h,1
DCTPep02901,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=1.29±0.08  μM,96 h,1
DCTPep02901,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=2.13±0.07 μM,96 h,1
DCTPep02902,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,42.19±24.29% Cytotoxicity=256 µg/ml,3h,1
DCTPep02903,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,71.48±4.81% Cytotoxicity=256 µg/ml,3h,1
DCTPep02904,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,66.21±20.07% Cytotoxicity=256 µg/ml,3h,1
DCTPep02905,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,54.02±3.37% Cytotoxicity=256 µg/ml,3h,1
DCTPep02906,SW620,Colon adenocarcinoma,Carcinoma,MTT assay,35.72±18.49% Cytotoxicity=256 µg/ml,3h,1
DCTPep02907,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,<20% Killing=40 µM,24 h,1
DCTPep02907,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,Not active up to 40 µM,24 h,1
DCTPep02908,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,Not active up to 40 µM,24 h,1
DCTPep02908,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,Not active up to 40 µM,24 h,1
DCTPep02909,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,<10% Killing=40 µM,24 h,1
DCTPep02909,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,<20% Killing=40 µM,24 h,1
DCTPep02910,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,60% Killing=40 µM,24 h,1
DCTPep02910,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,75% Killing=40 µM,24 h,1
DCTPep02911,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,>50% Killing=40 µM,24 h,1
DCTPep02911,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,40% Killing=40 µM,24 h,1
DCTPep02912,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,40% Killing=40 µM,24 h,1
DCTPep02912,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,80% Killing=40 µM,24 h,1
DCTPep02913,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,>80% Killing=40 µM,24 h,1
DCTPep02913,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,80% Killing=40 µM,24 h,1
DCTPep02914,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,<10% Killing=40 µM,24 h,1
DCTPep02914,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,35% Killing=40 µM,24 h,1
DCTPep02915,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,<10% Killing=40 µM,24 h,1
DCTPep02915,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,>90% Killing=40 µM,24 h,1
DCTPep02916,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,>80% Killing=40 µM,24 h,1
DCTPep02916,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,>90% Killing=40 µM,24 h,1
DCTPep02917,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,>80% Killing=40 µM,24 h,1
DCTPep02917,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,>90% Killing=40 µM,24 h,1
DCTPep02918,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,Resazurin assay,>80% Killing=40 µM,24 h,1
DCTPep02918,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,Resazurin assay,>90% Killing=40 µM,24 h,1
DCTPep02919,P388,Mouse lymphoma,Lymphoma,MTT assay,IC50=8.5 μM,48 h,1
DCTPep02920,BEL-7402,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=14.3 μM,48 h,1
DCTPep02920,P388,Mouse lymphoma,Lymphoma,MTT assay,IC50=5.4 μM,48 h,1
DCTPep02921,P388,Mouse lymphoma,Lymphoma,MTT assay,Not active up to 100 µg/ml,48 h,1
DCTPep02922,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=3.9 μM ,Not available,2
DCTPep02922,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=33 μM,Not available,2
DCTPep02922,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=37 μM,Not available,2
DCTPep02922,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=6.7 μM ,Not available,2
DCTPep02922,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=7.7 μM,Not available,2
DCTPep02922,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=9.1 μM,Not available,2
DCTPep02922,P388,Mouse lymphoma,Lymphoma,MTT assay,Not active up to 100 µg/ml,48 h,1
DCTPep02923,A549,Lung adenocarcinoma,Carcinoma,MTT assay,IC50=0.44 µM,8 h,1
DCTPep02923,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=0.462 µM,8 h,1
DCTPep02923,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTT assay,IC50=0.515 µM,8 h,1
DCTPep02924,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=11 µM,Not available,1
DCTPep02924,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=12 µM,Not available,1
DCTPep02924,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=12 µM,Not available,1
DCTPep02924,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=12 µM,Not available,1
DCTPep02924,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=13 µM,Not available,1
DCTPep02924,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=15 µM,Not available,1
DCTPep02925,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=0.041 µM,Not available,1
DCTPep02925,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=0.14 µM,Not available,1
DCTPep02925,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=0.16 µM,Not available,1
DCTPep02925,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=0.17 µM,Not available,1
DCTPep02925,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=0.19 µM,Not available,1
DCTPep02925,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=0.4 µM,Not available,1
DCTPep02926,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=0.01 µM,Not available,1
DCTPep02926,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=0.011 µM,Not available,1
DCTPep02926,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=0.014 µM,Not available,1
DCTPep02926,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=0.021 µM,Not available,1
DCTPep02926,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=0.023 µM,Not available,1
DCTPep02926,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=0.35 µM,Not available,1
DCTPep02927,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=0.66 µM,Not available,2
DCTPep02927,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=0.71 µM,Not available,2
DCTPep02927,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=0.77 µM,Not available,2
DCTPep02927,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=1.3 µM,Not available,2
DCTPep02927,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=1.6 µM,Not available,2
DCTPep02927,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,SRB assay,IC50=28.27 µg/ml (DMSO); IC50=2.72 µg/ml (MeOH),Not available,1
DCTPep02927,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=3.2 µM,Not available,2
DCTPep02928,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=10 µM,Not available,1
DCTPep02928,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=24 µM,Not available,1
DCTPep02928,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=30 µM,Not available,1
DCTPep02928,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=4.5 µM,Not available,1
DCTPep02928,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=7.2 µM,Not available,1
DCTPep02928,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=7.4 µM,Not available,1
DCTPep02929,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=1 µM,Not available,1
DCTPep02929,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=1.1 µM,Not available,1
DCTPep02929,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=1.4 µM,Not available,1
DCTPep02929,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=12 µM,Not available,1
DCTPep02929,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=2.2 µM,Not available,1
DCTPep02929,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=8.6 µM,Not available,1
DCTPep02930,P388,Mouse lymphoma,Lymphoma,Not available,ED50=0.2 µg/ml,Not available,2
DCTPep02930,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=1.6 µM,Not available,1
DCTPep02930,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=1.7 µM,Not available,1
DCTPep02930,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=2.8 µM,Not available,1
DCTPep02930,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=3.2 µM,Not available,1
DCTPep02930,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=5.6 µM,Not available,1
DCTPep02930,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=6.9 µM,Not available,1
DCTPep02931,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=0.1 µM,Not available,1
DCTPep02931,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=0.29 µM,Not available,1
DCTPep02931,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=0.54 µM,Not available,1
DCTPep02931,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=1.7 µM,Not available,1
DCTPep02931,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=2.3 µM,Not available,1
DCTPep02931,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=2.5 µM,Not available,1
DCTPep02932,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02932,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02932,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>50 µM,3 days,2
DCTPep02932,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50>50 µM,Not available,1
DCTPep02932,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02932,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02932,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02933,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02933,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02933,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50>50 µM,Not available,1
DCTPep02933,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02933,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02933,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02934,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=1.3 µM,3 days,2
DCTPep02934,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50=11 µM,Not available,1
DCTPep02934,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50=11 µM,Not available,1
DCTPep02934,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50=17 µM,Not available,1
DCTPep02934,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50=19 µM,Not available,1
DCTPep02934,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50=3.9 µM,Not available,1
DCTPep02934,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50=6.2 µM,Not available,1
DCTPep02935,A549,Lung adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02935,HCT 116,Colon carcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02935,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>50 µM,3 days,2
DCTPep02935,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,SRB assay,IC50>50 µM,Not available,1
DCTPep02935,MDA-MB-231,Breast adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02935,SK-HEP-1,Liver and intrahepatic bile duct epithelial neoplasm,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02935,SNU-638,Gastric adenocarcinoma,Carcinoma,SRB assay,IC50>50 µM,Not available,1
DCTPep02936,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=25 µM,3 days,1
DCTPep02936,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50=5 µM,3 days,1
DCTPep02937,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,Not available,IC50 = 17 μg/mL,Not available,1
DCTPep02937,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15 µM,3 days,2
DCTPep02937,HCT 116,Colon carcinoma,Carcinoma,MTT assay,IC50>50 µM,3 days,2
DCTPep02938,P388,Mouse lymphoma,Lymphoma,Not available,ED50=2.1 µg/ml,Not available,1
DCTPep02939,DU145,Prostate carcinoma,Carcinoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02939,KM20L2,Colon adenocarcinoma ,Carcinoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02939,NCI-H460,Lung large cell carcinoma,Carcinoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02939,OVCAR-3,High grade ovarian serous adenocarcinoma,Carcinoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02939,P388,Mouse lymphoma,Lymphoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02939,SF295,Glioblastoma,Blastoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02939,SK-MEL-5,Cutaneous melanoma,Carcinoma,Not available,GI50=0.14-0.74 μg/mL,Not available,1
DCTPep02940,P388,Mouse lymphoma,Lymphoma,Not available,ED50=7.5 μg/mL,Not available,1
DCTPep02941,P388,Mouse lymphoma,Lymphoma,Not available,ED50=0.33 μg/mL,Not available,1
DCTPep02942,P388,Mouse lymphoma,Lymphoma,Not available,ED50=0.18 μg/mL,Not available,1
DCTPep02943,P388,Mouse lymphoma,Lymphoma,Not available,ED50=3.2 μg/mL,Not available,1
DCTPep02944,P388,Mouse lymphoma,Lymphoma,Not available,ED50=2.8 μg/mL,Not available,1
DCTPep02945,P388,Mouse lymphoma,Lymphoma,Not available,ED50=0.0042 μg/mL,Not available,1
DCTPep02946,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=21.1 μM,72 h,1
DCTPep02946,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=82.8 μM,72 h,1
DCTPep02946,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=85.9 μM,72 h,1
DCTPep02947,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=16.7 μM,72 h,1
DCTPep02947,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=82.4 μM,72 h,1
DCTPep02947,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=85.2 μM,72 h,1
DCTPep02948,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=30.1 μM,72 h,1
DCTPep02948,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=75 μM,72 h,1
DCTPep02948,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=92.6 μM,72 h,1
DCTPep02949,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=29.8 μM,72 h,1
DCTPep02949,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=80.8 μM,72 h,1
DCTPep02949,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=89.7 μM,72 h,1
DCTPep02950,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=31.6 μM,72 h,1
DCTPep02950,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=83.3 μM,72 h,1
DCTPep02950,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=89.8 μM,72 h,1
DCTPep02951,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=70.4 μM,72 h,1
DCTPep02951,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=81.6 μM,72 h,1
DCTPep02951,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=87 μM,72 h,1
DCTPep02952,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=106 μM,72 h,1
DCTPep02952,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=34.7 μM,72 h,1
DCTPep02952,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=92 μM,72 h,1
DCTPep02953,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=100 μM,72 h,1
DCTPep02953,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=40.4 μM,72 h,1
DCTPep02953,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=87.8 μM,72 h,1
DCTPep02954,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=30.9 μM,72 h,1
DCTPep02954,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=85.6 μM,72 h,1
DCTPep02954,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=93.1 μM,72 h,1
DCTPep02955,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=35.2 μM,72 h,1
DCTPep02955,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=82.2 μM,72 h,1
DCTPep02955,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=89.8 μM,72 h,1
DCTPep02956,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=34.5 μM,72 h,1
DCTPep02956,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=77 μM,72 h,1
DCTPep02956,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=77.2 μM,72 h,1
DCTPep02957,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=34.7 μM,72 h,1
DCTPep02957,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=81.1 μM,72 h,1
DCTPep02957,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=85 μM,72 h,1
DCTPep02958,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=35.3 μM,72 h,1
DCTPep02958,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=84.3 μM,72 h,1
DCTPep02958,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=86.2 μM,72 h,1
DCTPep02959,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,IC50=32.2 μM,72 h,1
DCTPep02959,A2780-cisR,Ovarian endometrioid adenocarcinoma,Carcinoma,MTT assay,IC50=91.7 μM,72 h,1
DCTPep02959,A2780,Ovarian endometrioid adenocarcinoma; Endometrioid carcinoma of ovary,Carcinoma,MTT assay,IC50=91.8 μM,72 h,1
DCTPep02960,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,12.58±1.23% Inhibition=10 µM ; 28.64 ± 1.51% Inhibition=100 µM ,48 h,1
DCTPep02960,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,19.50 ± 1.34% Inhibition=10 µM; 27.49 ± 2.68% Inhibition=100 µM,48 h,1
DCTPep02960,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,21.55 ± 1.93% Inhibition=10 µM; 17.25 ± 1.66% Inhibition=100 µM,48 h,1
DCTPep02961,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,12.56 ± 1.03% Inhibition=10 µM; 23.58 ± 1.70% Inhibition=100 µM,48 h,1
DCTPep02961,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,21.33 ± 1.83% Inhibition=10 µM ; 28.45 ± 2.05% Inhibition=100 µM ,48 h,1
DCTPep02961,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,8.62 ± 0.78% Inhibition=10 µM; 26.74 ± 1.38% Inhibition=100 µM,48 h,1
DCTPep02962,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,12.58 ± 1.23% Inhibition=10 µM ; 23.46 ± 2.04% Inhibition=100 µM,48 h,1
DCTPep02962,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,6.87 ± 0.67% Inhibition=10 µM; 23.90 ± 2.25% Inhibition=100 µM,48 h,1
DCTPep02962,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,7.00 ± 0.56% Inhibition=10 µM; 21.19 ± 2.04% Inhibition=100 µM,48 h,1
DCTPep02963,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,14.29 ± 1.40% Inhibition=10 µM; 16.78 ± 1.65% Inhibition=100 µM,48 h,1
DCTPep02963,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,19.61 ± 0.82% Inhibition=10 µM ; 20.55 ± 2.03% Inhibition=100 µM,48 h,1
DCTPep02963,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,19.78 ± 1.86% Inhibition=10 µM; 21.94 ± 2.17% Inhibition=100 µM,48 h,1
DCTPep02964,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,30.56 ± 0.03% Inhibition=10 µM; 51.29 ± 0.01% Inhibition=100 µM,48 h,1
DCTPep02964,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,36.49 ± 0.02% Inhibition=10 µM; 56.08 ± 0.01% Inhibition=100 µM,48 h,1
DCTPep02964,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,43.92 ± 0.02% Inhibition=10 µM ; 57.79 ± 0.02% Inhibition=100 µM,48 h,1
DCTPep02965,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,32.41 ± 0.03% Inhibition=10 µM; 52.27 ± 0.02% Inhibition=100 µM,48 h,1
DCTPep02965,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,35.15 ± 0.01% Inhibition=10 µM; 56.08 ± 0.01% Inhibition=100 µM,48 h,1
DCTPep02965,HeLa ,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,54.61 ± 0.02% Inhibition=10 µM ; 57.79 ± 0.02% Inhibition=100 µM,48 h,1
DCTPep02966,HepG2,Hepatoblastoma,Blastoma,MTT assay,40% Killing=600 µg/ml,20 h,1
DCTPep02967,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02968,HepG2,Hepatoblastoma,Blastoma,MTT assay,50% Killing=600 µg/ml,20 h,1
DCTPep02969,HepG2,Hepatoblastoma,Blastoma,MTT assay,39% Killing=600 µg/ml,20 h,1
DCTPep02970,HepG2,Hepatoblastoma,Blastoma,MTT assay,30% Killing=600 µg/ml,20 h,1
DCTPep02971,HepG2,Hepatoblastoma,Blastoma,MTT assay,34% Killing=600 µg/ml,20 h,1
DCTPep02972,HepG2,Hepatoblastoma,Blastoma,MTT assay,35% Killing=600 µg/ml,20 h,1
DCTPep02973,HepG2,Hepatoblastoma,Blastoma,MTT assay,34% Killing=600 µg/ml,20 h,1
DCTPep02974,HepG2,Hepatoblastoma,Blastoma,MTT assay,40% Killing=600 µg/ml,20 h,1
DCTPep02975,HepG2,Hepatoblastoma,Blastoma,MTT assay,34% Killing=600 µg/ml,20 h,1
DCTPep02976,HepG2,Hepatoblastoma,Blastoma,MTT assay,44% Killing=600 µg/ml,20 h,1
DCTPep02977,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02978,HepG2,Hepatoblastoma,Blastoma,MTT assay,58% Killing=600 µg/ml,20 h,1
DCTPep02979,HepG2,Hepatoblastoma,Blastoma,MTT assay,54% Killing=600 µg/ml,20 h,1
DCTPep02980,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02981,HepG2,Hepatoblastoma,Blastoma,MTT assay,43% Killing=600 µg/ml,20 h,1
DCTPep02982,HepG2,Hepatoblastoma,Blastoma,MTT assay,42% Killing=600 µg/ml,20 h,1
DCTPep02983,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02984,HepG2,Hepatoblastoma,Blastoma,MTT assay,32% Killing=600 µg/ml,20 h,1
DCTPep02985,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02986,HepG2,Hepatoblastoma,Blastoma,MTT assay,44% Killing=600 µg/ml,20 h,1
DCTPep02987,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02988,HepG2,Hepatoblastoma,Blastoma,MTT assay,58% Killing=600 µg/ml,20 h,1
DCTPep02989,HepG2,Hepatoblastoma,Blastoma,MTT assay,50% Killing=600 µg/ml,20 h,1
DCTPep02990,HepG2,Hepatoblastoma,Blastoma,MTT assay,43% Killing=600 µg/ml,20 h,1
DCTPep02991,HepG2,Hepatoblastoma,Blastoma,MTT assay,38% Killing=600 µg/ml,20 h,1
DCTPep02992,HepG2,Hepatoblastoma,Blastoma,MTT assay,38% Killing=600 µg/ml,20 h,1
DCTPep02993,HepG2,Hepatoblastoma,Blastoma,MTT assay,38% Killing=600 µg/ml,20 h,1
DCTPep02994,HepG2,Hepatoblastoma,Blastoma,MTT assay,46% Killing=600 µg/ml,20 h,1
DCTPep02995,HepG2,Hepatoblastoma,Blastoma,MTT assay,43% Killing=600 µg/ml,20 h,1
DCTPep02996,HepG2,Hepatoblastoma,Blastoma,MTT assay,64% Killing=600 µg/ml,20 h,1
DCTPep02997,HepG2,Hepatoblastoma,Blastoma,MTT assay,48% Killing=600 µg/ml,20 h,1
DCTPep02998,HepG2,Hepatoblastoma,Blastoma,MTT assay,51% Killing=600 µg/ml,20 h,1
DCTPep02999,HepG2,Hepatoblastoma,Blastoma,MTT assay,56% Killing=600 µg/ml,20 h,1
DCTPep03000,HepG2,Hepatoblastoma,Blastoma,MTT assay,61% Killing=600 µg/ml,20 h,1
DCTPep03001,HepG2,Hepatoblastoma,Blastoma,MTT assay,50% Killing=600 µg/ml,20 h,1
DCTPep03002,HepG2,Hepatoblastoma,Blastoma,MTT assay,48% Killing=600 µg/ml,20 h,1
DCTPep03003,HepG2,Hepatoblastoma,Blastoma,MTT assay,54% Killing=600 µg/ml,20 h,1
DCTPep03004,HepG2,Hepatoblastoma,Blastoma,MTT assay,25% Killing=600 µg/ml,20 h,1
DCTPep03005,HepG2,Hepatoblastoma,Blastoma,MTT assay,27% Killing=600 µg/ml,20 h,1
DCTPep03006,HepG2,Hepatoblastoma,Blastoma,MTT assay,38% Killing=600 µg/ml,20 h,1
DCTPep03007,HepG2,Hepatoblastoma,Blastoma,MTT assay,41% Killing=600 µg/ml,20 h,1
DCTPep03008,HepG2,Hepatoblastoma,Blastoma,MTT assay,30% Killing=600 µg/ml,20 h,1
DCTPep03009,HepG2,Hepatoblastoma,Blastoma,MTT assay,28% Killing=600 µg/ml,20 h,1
DCTPep03010,HepG2,Hepatoblastoma,Blastoma,MTT assay,22% Killing=600 µg/ml,20 h,1
DCTPep03011,HepG2,Hepatoblastoma,Blastoma,MTT assay,34% Killing=600 µg/ml,20 h,1
DCTPep03012,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=12.22 μM,24 h,1
DCTPep03012,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=6.38 μM ,24 h,1
DCTPep03013,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=38.64 μM,24 h,1
DCTPep03013,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=38.92 μM ,24 h,1
DCTPep03014,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=40.46 μM,24 h,1
DCTPep03014,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=47.37 μM,24 h,1
DCTPep03015,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=31.84 μM,24 h,1
DCTPep03015,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=47.37 μM,24 h,1
DCTPep03016,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=42.81 μM,24 h,1
DCTPep03016,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03017,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=29.8 μM,24 h,1
DCTPep03017,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03018,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=36.08 μM,24 h,1
DCTPep03018,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=55.61 μM,24 h,1
DCTPep03019,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=39.37 μM,24 h,1
DCTPep03019,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=48.48 μM,24 h,1
DCTPep03020,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=29.94 μM,24 h,1
DCTPep03020,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=29.95 μM,24 h,1
DCTPep03021,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=51.72 μM,24 h,1
DCTPep03021,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=73.93 μM,24 h,1
DCTPep03022,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03022,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03023,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03023,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03024,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03024,SMMC-7721,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50>100 μM,24 h,1
DCTPep03025,MDA-MB-231 (Bc1-xL dependent),Breast adenocarcinoma,Carcinoma,Not available,EC50=1.006 ± 0.337 μM,Not available,1
DCTPep03025,OCI-Ly1 (Bcl-2 dependent),Diffuse large B-cell lymphoma,Lymphoma,Not available,EC50=1.967 ± 0.48 μM,Not available,1
DCTPep03026,OCI-Ly1 (Bcl-2 dependent),Diffuse large B-cell lymphoma,Lymphoma,Not available,EC50=228 ± 56 nM,Not available,1
DCTPep03026,MDA-MB-231 (Bc1-xL dependent),Breast adenocarcinoma,Carcinoma,Not available,EC50=50 ± 16 nM,Not available,1
DCTPep03029,MDA-MB-231 (Bc1-xL dependent),Breast adenocarcinoma,Carcinoma,Not available,EC50=12 ± 4 nM,Not available,1
DCTPep03029,OCI-Ly1 (Bcl-2 dependent),Diffuse large B-cell lymphoma,Lymphoma,Not available,EC50=37 ± 9 nM,Not available,1
DCTPep03032,MDA-MB-231 (Bc1-xL dependent),Breast adenocarcinoma,Carcinoma,Not available,EC50=82 ± 27 nM,Not available,1
DCTPep03032,OCI-Ly1 (Bcl-2 dependent),Diffuse large B-cell lymphoma,Lymphoma,Not available,EC50=911 ± 222 nM,Not available,1
DCTPep03033,OCI-Ly1 (Bcl-2 dependent),Diffuse large B-cell lymphoma,Lymphoma,Not available,EC50=3.325 ± 0.812 μM,Not available,1
DCTPep03033,MDA-MB-231 (Bc1-xL dependent),Breast adenocarcinoma,Carcinoma,Not available,EC50=847 ± 284 nM,Not available,1
DCTPep03034,MDA-MB-231 (Bc1-xL dependent),Breast adenocarcinoma,Carcinoma,Not available,EC50=159 ± 53 nM,Not available,1
DCTPep03034,OCI-Ly1 (Bcl-2 dependent),Diffuse large B-cell lymphoma,Lymphoma,Not available,EC50=3.435 ± 0.839 μM,Not available,1
DCTPep03047,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,18% Killing= 50 μM,48 h,1
DCTPep03047,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,23% Killing= 50 μM,48 h,1
DCTPep03047,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,25% Killing= 50 μM,48 h,1
DCTPep03051,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,21% Killing= 50 μM,48 h,1
DCTPep03051,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,26% Killing= 50 μM,48 h,1
DCTPep03051,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,40% Killing= 50 μM,48 h,1
DCTPep03052,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,MTT assay,20% Killing= 50 μM,48 h,1
DCTPep03052,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,23% Killing= 50 μM,48 h,1
DCTPep03052,U-937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,MTT assay,45% Killing= 50 μM,48 h,1
DCTPep03479,Calu-3,Lung adenocarcinoma,Carcinoma,XTT assay,IC50=41.9 ± 1.8 μg/ml,120 h,1
DCTPep03479,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,IC50=47.1 ± 2.1 μg/ml,120 h,1
DCTPep03479,A549,Lung adenocarcinoma,Carcinoma,XTT assay,IC50=79.3 ± 7.2 μg/ml,120 h,1
DCTPep03511,TZM-bl,Human papillomavirus-related cervical adenocarcinoma,adenocarcinoma,CellTiter 96 AQueous One Solution cell proliferation assay,CC50=148.73μM,2 h,1
DCTPep03512,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=30µM,18h,2
DCTPep03671,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=15.6 ± 4.1μM ,24h,1
DCTPep03671,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=17.9 ± 2.3μM,24h,1
DCTPep03671,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=20.0 ± 0.8μM,24h,1
DCTPep03671,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=7.2 ± 5.2μM,24h,1
DCTPep03672,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=22.4 ± 2.3μM,24h,1
DCTPep03672,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=25.5 ± 0.5	μM,24h,1
DCTPep03672,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=30.6 ± 0.5μM ,24h,1
DCTPep03672,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=41.3 ± 2.6μM,24h,1
DCTPep03673,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=22.5 ± 0.5μM,24h,1
DCTPep03673,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=24.1 ± 5.5μM,24h,1
DCTPep03673,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=31.6 ± 2.1μM,24h,1
DCTPep03673,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=47.1 ± 5.3μM,24h,1
DCTPep03674,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=41.1 ± 0.5μM,24h,1
DCTPep03674,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=45.5 ± 5.6μM,24h,1
DCTPep03674,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=54.2 ± 1.2μM,24h,1
DCTPep03674,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=56.8 ± 3.3μM,24h,1
DCTPep03675,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=15.5 ± 1.7μM,24h,1
DCTPep03675,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=28.8 ± 0.8	μM,24h,1
DCTPep03675,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=29.9 ± 4.8μM,24h,1
DCTPep03675,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=45.1 ± 1.0μM,24h,1
DCTPep03676,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=125.0 ± 3.7μM,24h,1
DCTPep03676,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=38.8 ± 2.9	μM,24h,1
DCTPep03676,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=42.4 ± 3.0μM,24h,1
DCTPep03676,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=59.8 ± 0.5μM,24h,1
DCTPep03677,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=125.0 ± 5.9μM,24h,1
DCTPep03677,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=41.4 ± 1.4μM,24h,1
DCTPep03677,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=46.2 ± 3.0μM,24h,1
DCTPep03677,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=60.1 ± 1.2μM,24h,1
DCTPep03678,Bxpc-3,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=125.0 ± 1.8μM,24h,1
DCTPep03678,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=125.0 ± 3.4μM,24h,1
DCTPep03678,MIA PaCa-2,Pancreatic ductal adenocarcinoma,Carcinoma,MTT assay,IC50=57.9 ± 2.8μM,24h,1
DCTPep03678,HPAC,Pancreatic adenocarcinoma,Carcinoma,MTT assay,IC50=95.6 ± 1.8μM,24h,1
DCTPep03697,L5178Y,Mouse thymic lymphoma,Lymphoma,MTT assay,IC50=5.71μM,72h,1
DCTPep03697,PC12,Rat brain cancer cell lines,Carcinoma,MTT assay,IC50=9.55μM,72h,1
DCTPep03700,PLC-PRF-5,Human hepatoma cells,Carcinoma,MTT assay,30-50% loss of viability=20μM,30min,1
DCTPep03700,PLC-PRF-5,Human hepatoma cells,Carcinoma,MTT assay,30-50% loss of viability=8μM,30min,1
DCTPep03701,Rous II,Human osteosarcoma cells,Sarcoma,MTT assay,>=50% loss of viability=20μM,30min,1
DCTPep03701,Rous II,Human osteosarcoma cells,Sarcoma,MTT assay,>=50% loss of viability=8μM,30min,1
DCTPep03710,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=3.21μM,24h,1
DCTPep03710,H157,Buccal mucosa squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,IC50=8.43μM,24h,1
DCTPep03712,H157,Buccal mucosa squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,IC50=21.6μM,24h,1
DCTPep03712,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=6.75μM,24h,1
DCTPep03756,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,2.4±1.75% Cytotoxicity=100µM,48h,1
DCTPep03756,HCT 116,Colon carcinoma,Carcinoma,MTT assay,5.8±3.21% Cytotoxicity=100µM,48h,1
DCTPep03802,HepG2,Hepatoblastoma,Blastoma,MTS/PMS assay,IC50=355µM,21-25h,1
DCTPep03803,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,IC50=462µM,21-25h,1
DCTPep03804,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTS/PMS assay,IC50=783µM,21-25h,1
DCTPep03833,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,PrestoBlue,EC50=22.5 ± 0.7μM,30min,1
DCTPep03833,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,PrestoBlue,EC50=29.8 ± 1μM,30min,1
DCTPep03844,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,15% loss of viability=600μg/mL,4h,1
DCTPep03845,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,15% loss of viability=600μg/mL,4h,1
DCTPep03846,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,15% loss of viability=600μg/mL,4h,1
DCTPep03861,H157,Buccal mucosa squamous cell carcinoma; Squamous cell carcinoma of the oral cavity,Carcinoma,MTT assay,50% viability=100μM,Not available,1
DCTPep03861,H460,Lung large cell carcinoma,Carcinoma,MTT assay,50% viability=100μM,Not available,1
DCTPep03899,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=24μM,24h,1
DCTPep03961,PANC-1,Pancreatic ductal adenocarcinoma ,Carcinoma,MTT assay,14% Inhibition=20µM,Not available,1
DCTPep03961,HeLa S3,Breast cancer,Carcinoma,MTT assay,41% Inhibition=20µM,Not available,1
DCTPep03961,Eca 109,Esophageal squamous cell carcinoma; Squamous cell carcinoma of the esophagus,Carcinoma,MTT assay,55% Inhibition=20µM,Not available,1
DCTPep03971,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=26.6µM,Not available,1
DCTPep03971,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=34.7µM,Not available,1
DCTPep03972,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=38.2µM,Not available,1
DCTPep03972,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,IC50=46.1µM,Not available,1
DCTPep03973,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,10% Killing=100µM,24h,1
DCTPep03974,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,80% Killing=100µM,24h,1
DCTPep03975,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,0% Killing=100µM,24h,1
DCTPep03976,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,85% Killing=100µM,24h,1
DCTPep03993,Calu-3,Lung adenocarcinoma,Carcinoma,CCK-8 assay,CC50>100 μM,48 h,1
DCTPep03993,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 μM,48 h,1
DCTPep03994,Calu-3,Lung adenocarcinoma,Carcinoma,CCK-8 assay,CC50>100 μM,48 h,1
DCTPep03994,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 μM,48 h,1
DCTPep03995,Calu-3,Lung adenocarcinoma,Carcinoma,CCK-8 assay,CC50>100 μM,48 h,1
DCTPep03995,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,CC50>100 μM,48 h,1
DCTPep04183,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=25.2µM,18h,2
DCTPep04184,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,50% Cytotoxicity=18.9µM,18h,2
DCTPep04381,A549/ACE2,Lung adenocarcinoma,Carcinoma,MTS assay,CC50>27.7 μM,24 h,1
DCTPep04381,HT1080/ACE2,Fibrosarcoma,Sarcoma,MTS assay,CC50>27.7 μM,24 h,1
DCTPep04382,A549/ACE2,Lung adenocarcinoma,Carcinoma,MTS assay,CC50>27.5 μM,24 h,1
DCTPep04382,HT1080/ACE2,Fibrosarcoma,Sarcoma,MTS assay,CC50>27.5 μM,24 h,1
DCTPep04383,A549/ACE2,Lung adenocarcinoma,Carcinoma,MTS assay,CC50>26.8 μM,24 h,1
DCTPep04383,HT1080/ACE2,Fibrosarcoma,Sarcoma,MTS assay,CC50>26.8 μM,24 h,1
DCTPep04384,A549/ACE2,Lung adenocarcinoma,Carcinoma,MTS assay,CC50>27.6 μM,24 h,1
DCTPep04384,HT1080/ACE2,Fibrosarcoma,Sarcoma,MTS assay,CC50>27.6 μM,24 h,1
DCTPep04385,A549/ACE2,Lung adenocarcinoma,Carcinoma,MTS assay,CC50>26.6 μM,24 h,1
DCTPep04385,HT1080/ACE2,Fibrosarcoma,Sarcoma,MTS assay,CC50>26.6 μM,24 h,1
DCTPep04576,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,IC50=30.7 ± 2.6 μg/ml,120 h,1
DCTPep04577,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,IC50=25.3 ± 2.2 μg/ml,120 h,1
DCTPep04577,Calu-3,Lung adenocarcinoma,Carcinoma,XTT assay,IC50=39.1 ± 1.8 μg/ml,120 h,1
DCTPep04577,A549,Lung adenocarcinoma,Carcinoma,XTT assay,IC50=56.5 ± 4.5 μg/ml,120 h,1
DCTPep04578,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,IC50>400 μg/ml,120 h,1
DCTPep04579,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,XTT assay,IC50=198.2 ± 10.2 μg/ml,120 h,1
DCTPep04579,A549,Lung adenocarcinoma,Carcinoma,XTT assay,IC50>250 μg/ml,120 h,1
DCTPep04579,Calu-3,Lung adenocarcinoma,Carcinoma,XTT assay,IC50>250 μg/ml,120 h,1
DCTPep04685,1321N1,Astrocytoma,Carcinoma,MTS assay,IC50 =1.25mM,72h,1
DCTPep04685,U87MG,Astrocytoma,Carcinoma,MTS assay,IC50=1.85mM,72h,1
DCTPep04746,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,"Trypan
blue dye assay",IC50=36(32-40)μM,24h,1
DCTPep04791,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,"Trypan
blue dye assay",IC50=2.3(2.0-2.5)μM,24h,1
DCTPep04875,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,"Trypan
blue dye assay",IC50=0.95(0.82-1.1)μM,24h,1
DCTPep04876,U-937/GTB,Adult acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,"Trypan
blue dye assay",IC50=5.1(4.8-5.5)μM,24h,1
DCTPep05876,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CCK-8 assay,IC50=1.6μM,72h,Patent
DCTPep05876,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=3.6±1.0 μM,72 h,1
DCTPep05876,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=4.9±0.91 μM,72 h,1
DCTPep05876,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=9.8±0.11 μM,72 h,1
DCTPep05877,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=10.9±2.7 μM,72 h,1
DCTPep05877,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CCK-8 assay,IC50=3.6μM,72h,Patent
DCTPep05877,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=5.2±0.68 μM,72 h,1
DCTPep05877,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=5.8±0.80 μM,72 h,1
DCTPep05878,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CCK-8 assay,IC50=0.86μM,72h,Patent
DCTPep05878,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=0.99±0.21 μM,72 h,1
DCTPep05878,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=2.8±0.90 μM,72 h,1
DCTPep05878,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=3.9±0.010 μM,72 h,1
DCTPep05879,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=10.1±1.6 μM,72 h,1
DCTPep05879,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=11.6±2.2 μM,72 h,1
DCTPep05879,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=8.5±1.4 μM,72 h,1
DCTPep05879,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CCK-8 assay,IC50=9.2μM,72h,Patent
DCTPep05880,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=5.2±0.91 μM,72 h,1
DCTPep05880,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=8.4±1.8 μM,72 h,1
DCTPep05880,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=9.5±2.0 μM,72 h,1
DCTPep05881,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=12.24±1.23 μM,48 h,1
DCTPep05881,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=13.87±1.25 μM,48 h,1
DCTPep05881,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=15.89±0.92 μM,48 h,1
DCTPep05882,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=6.18±0.63 μM,48 h,1
DCTPep05882,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=6.591±0.42 μM,48 h,1
DCTPep05882,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=8.86±1.43 μM,48 h,1
DCTPep05883,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=3.59±1.20 μM,48 h,1
DCTPep05883,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=5.478±0.89 μM,48 h,1
DCTPep05883,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=5.96±0.54 μM,48 h,1
DCTPep05884,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=13.41±1.92 μM,48 h,1
DCTPep05884,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=15.20±1.02 μM,48 h,1
DCTPep05884,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=17.91±3.23 μM,48 h,1
DCTPep05885,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=13.84±1.53 μM,48 h,1
DCTPep05885,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=13.99±0.73 μM,48 h,1
DCTPep05885,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=14.33±2.35 μM,48 h,1
DCTPep05886,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=4.58±0.93 μM,48 h,1
DCTPep05886,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=5.152±1.04 μM,48 h,1
DCTPep05886,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=5.89±0.43 μM,48 h,1
DCTPep05887,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=12.70±1.63 μM,48 h,1
DCTPep05887,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=13.36±1.22 μM,48 h,1
DCTPep05887,Huh-7,Adult hepatocellular carcinoma; Adult hepatocellular carcinoma,Carcinoma,CCK-8 assay,IC50=7.49±1.2 μM,48 h,1
DCTPep05888,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=11.26 μM,96 h,1
DCTPep05888,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=11.88 μM,96 h,1
DCTPep05888,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=35.84 μM,96 h,1
DCTPep05888,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=8.94 μM,96 h,1
DCTPep05889,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=10.14 μM,96 h,1
DCTPep05889,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=12.55 μM,96 h,1
DCTPep05889,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=12.65 μM,96 h,1
DCTPep05889,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=14.76 μM,96 h,1
DCTPep05890,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=11.92 μM,96 h,1
DCTPep05890,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=11.93 μM,96 h,1
DCTPep05890,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=12.11 μM,96 h,1
DCTPep05890,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=17.89 μM,96 h,1
DCTPep05891,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=10.49 μM,96 h,1
DCTPep05891,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=10.51 μM,96 h,1
DCTPep05891,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=7.277 μM,96 h,1
DCTPep05891,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=8.90 μM,96 h,1
DCTPep05892,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=11.90 μM,96 h,1
DCTPep05892,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=12.42 μM,96 h,1
DCTPep05892,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=8.229 μM,96 h,1
DCTPep05892,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=9.899 μM,96 h,1
DCTPep05893,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=23.78 μM,96 h,1
DCTPep05893,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=30.19 μM,96 h,1
DCTPep05893,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=34.49 μM,96 h,1
DCTPep05893,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=35.84 μM,96 h,1
DCTPep05894,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=12.1 μM,96 h,1
DCTPep05894,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=14.72 μM,96 h,1
DCTPep05894,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=16.37 μM,96 h,1
DCTPep05894,C4-2B,Prostate carcinoma,Carcinoma,CCK-8 assay,IC50=35.84 μM,96 h,1
DCTPep05897,U87,Glioblastoma,Blastoma,MTT assay,IC50>10 μM,72 h,1
DCTPep05898,U87,Glioblastoma,Blastoma,MTT assay,IC50=2.5 μM,72 h,1
DCTPep05899,U87,Glioblastoma,Blastoma,MTT assay,IC50=900 nM,72 h,1
DCTPep05900,M109S,DOX-sensitive-M109 murine lung carcinoma ,Carcinoma,MTT assay,IC50=1.2 μM,72 h,1
DCTPep05900,U87,Glioblastoma,Blastoma,MTT assay,IC50=400 nM,72 h,1
DCTPep05900,M109R,Subline of DOX-sensitive-M109 murine lung carcinoma (M109S) cells,Carcinoma,MTT assay,IC50=9 μM,72 h,1
DCTPep05908,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05908,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05909,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05909,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05910,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05910,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05911,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=82.1 μM,72 h,1
DCTPep05911,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05912,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=85.1 μM,72 h,1
DCTPep05912,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05913,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=57.7 μM,72 h,1
DCTPep05913,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05914,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=6.7 μM,72 h,1
DCTPep05914,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05915,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=10.8 μM,72 h,1
DCTPep05915,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05916,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=15.2 μM,72 h,1
DCTPep05916,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05917,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05917,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05918,HCT 116 p53+/+,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=28.4 μM,72 h,1
DCTPep05918,HCT 116 p53-/-,Colon carcinoma,Carcinoma,CCK-8 assay,IC50>100 μM,72 h,1
DCTPep05919,A549,Lung adenocarcinoma,Carcinoma,Crystal violet dye,50% Killing=10 μM,"24, 48 or 72 h",1
DCTPep05919,PC-9,Lung adenocarcinoma,Carcinoma,Crystal violet dye,80% Killing=10 μM,"24, 48 or 72 h",1
DCTPep05919,NCI-H358,Minimally invasive lung adenocarcinoma,Carcinoma,Crystal violet dye,98% Killing=10 μM,"24, 48 or 72 h",1
DCTPep05921,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=271.59 ± 76.41 μM,24 h,1
DCTPep05926,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=37.21 ± 2.66 μM,24 h,1
DCTPep05930,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=3.71 ± 0.21 μM,24 h,1
DCTPep05931,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=18.69 ± 1.27 μM,24 h,1
DCTPep05932,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=33.79 ± 2.34 μM,24 h,1
DCTPep05933,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=52.33 ± 3.75 μM,24 h,1
DCTPep06002,H22,Hepatocellular carcinoma of the mouse,Carcinoma,MTT assay,45.93% Survival=160 μg/ml,24 h,Patent
DCTPep06003,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,45±5.3% Survival=100 μΜ,24 h,Patent
DCTPep06004,U87,Glioblastoma,Blastoma,CCK-8 assay,IC50=15.85±0.38 μM,24 h,Patent
DCTPep06004,T98G,Glioblastoma,Blastoma,CCK-8 assay,IC50=23.37±2.03 μM,24 h,Patent
DCTPep06004,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=25.68±0.74 μM,24 h,Patent
DCTPep06005,THP-1,Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia,Leukemia,CCK-8 assay,IC50=10.25μM,48h,Patent
DCTPep06005,HepG2,Hepatoblastoma,Blastoma,CCK-8 assy,IC50=10.82μM,48h,Patent
DCTPep06005,BGC-823,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=13.61μM,48h,Patent
DCTPep06005,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=13.98μM,48h,Patent
DCTPep06005,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,CCK-8 assay,IC50=8.345μM,48h,Patent
DCTPep06007,SK-MEL-103,Melanoma ,Carcinoma,CCK-8 assay,48% Survival=10 μg/ml,72h,Patent
DCTPep06007,HeLa S3,Breast cancer,Carcinoma,CCK-8 assay,48% Survival=25 μg/ml,72h,Patent
DCTPep06007,A549,Lung adenocarcinoma,Carcinoma,CCK-8 assay,62% Survival=10 μg/ml,24h,Patent
DCTPep06008,A549,Lung adenocarcinoma,Carcinoma,MTT assay,38% Survival=100 μg/ml,24h,Patent
DCTPep06009,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=2.3μM,24h,Patent
DCTPep06009,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=3.8μM,24h,Patent
DCTPep06009,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=4.5μM,24h,Patent
DCTPep06009,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=8.3μM,24h,Patent
DCTPep06010,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=0.84μM,24h,Patent
DCTPep06010,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=1.7μM,24h,Patent
DCTPep06010,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=2.4μM,24h,Patent
DCTPep06010,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=3.6μM,24h,Patent
DCTPep06011,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=10.1μM,24h,Patent
DCTPep06011,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=12.2μM,24h,Patent
DCTPep06011,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=13.9μM,24h,Patent
DCTPep06011,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=8.6μM,24h,Patent
DCTPep06012,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=0.57μM,24h,Patent
DCTPep06012,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=0.95μM,24h,Patent
DCTPep06012,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=1.2μM,24h,Patent
DCTPep06012,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=1.4μM,24h,Patent
DCTPep06013,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=2.7μM,24h,Patent
DCTPep06013,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=5.6μM,24h,Patent
DCTPep06013,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=7.1μM,24h,Patent
DCTPep06013,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=8.5μM,24h,Patent
DCTPep06014,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=0.58μM,24h,Patent
DCTPep06014,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=0.77μM,24h,Patent
DCTPep06014,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=3.6μM,24h,Patent
DCTPep06014,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=5.3μM,24h,Patent
DCTPep06015,K562,"Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia",Leukemia,CCK-8 assay,IC50=1.35μM,24h,Patent
DCTPep06015,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=1.5μM,24h,Patent
DCTPep06015,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=3.8μM,24h,Patent
DCTPep06015,U251,Astrocytoma,Carcinoma,CCK-8 assay,IC50=4.7μM,24h,Patent
DCTPep06016,PC-3,Prostate carcinoma,Carcinoma,MTT assay,10% Survival=200 μg/ml,24h,Patent
DCTPep06017,HepG2,Hepatoblastoma,Blastoma,MTT assay,44.68% Survival=16 μg/ml,24h,Patent
DCTPep06018,LN-18,Glioblastoma,Blastoma,MTT assay,38% Survival=500 μg/ml,48h,Patent
DCTPep06019,NCI-H1299,Lung large cell carcinoma,Carcinoma,MTS assay,IC50=14.09μM,48h,Patent
DCTPep06019,MDA-MB-231,Breast adenocarcinoma,Carcinoma,MTS assay,IC50=16.07μM,48h,Patent
DCTPep06019,HepG2,Hepatoblastoma,Blastoma,MTS assay,IC50=16.24μM,48h,Patent
DCTPep06019,T47D,Invasive breast carcinoma of no special type,Carcinoma,MTS assay,IC50=20.3μM,48h,Patent
DCTPep06019,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTS assay,IC50=7.69μM,48h,Patent
DCTPep06020,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=18.94μM,96h,Patent
DCTPep06021,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=22.46μM,96h,Patent
DCTPep06022,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=9.45μM,96h,Patent
DCTPep06023,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=25.91μM,96h,Patent
DCTPep06024,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=14.22μM,96h,Patent
DCTPep06025,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=4.22μM,96h,Patent
DCTPep06026,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=27.46μM,96h,Patent
DCTPep06027,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=26.36μM,96h,Patent
DCTPep06028,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=7.93μM,96h,Patent
DCTPep06029,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=11.82μM,96h,Patent
DCTPep06030,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=3.55μM,96h,Patent
DCTPep06031,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=33.20μM,96h,Patent
DCTPep06032,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=4.08μM,96h,Patent
DCTPep06033,PC-9,Lung adenocarcinoma,Carcinoma,CCK-8 assay,IC50=10.1μM,72h,Patent
DCTPep06033,HGC-27,Gastric carcinoma,Carcinoma,CCK-8 assay,IC50=3.2μM,72h,Patent
DCTPep06033,MDA-MB-231,Breast adenocarcinoma,Carcinoma,CCK-8 assay,IC50=4.1μM,72h,Patent
DCTPep06033,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=4.8μM,72h,Patent
DCTPep06033,HCT 8,Colon adenocarcinoma,Carcinoma,CCK-8 assay,IC50=6.6μM,72h,Patent
DCTPep06035,HepG2,Hepatoblastoma,Blastoma,MTT assay,23% cellular inhibition rate=0.6mM,24h,Patent
DCTPep06036,HepG2,Hepatoblastoma,Blastoma,MTT assay,15% cellular inhibition rate=0.6mM,24h,Patent
DCTPep06037,NCI-H157,Lung squamous cell carcinoma,Carcinoma,MTT assay,IC50=11.54μM,24h,Patent
DCTPep06037,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=2.444μM,24h,Patent
DCTPep06037,U251MG,Astrocytoma,Carcinoma,MTT assay,IC50=26.7μM,24h,Patent
DCTPep06038,HepG2,Hepatoblastoma,Blastoma,MTT assay,38% cellular inhibition rate=0.6mM,24h,Patent
DCTPep06039,A20,Mouse reticulum cell sarcoma,Sarcoma,CCK-8 assay,IC50=1.887±0.389μM,24h,Patent
DCTPep06039,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=2.241±0.941 μM,24h,Patent
DCTPep06039,U937,Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia,Leukemia,CCK-8 assay,IC50=2.241±0.941μM,24h,Patent
DCTPep06039,Daudi,EBV-related Burkitt lymphoma,Lymphoma,CCK-8 assay,IC50=2.308±0.241μM,24h,Patent
DCTPep06039,ES-2,Ovarian clear cell adenocarcinoma,Carcinoma,MTT assay,IC50=2.570±0.658 μM,24h,Patent
DCTPep06041,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=91.15μg/ml,Not available,Patent
DCTPep06042,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=96.64μg/ml,Not available,Patent
DCTPep06043,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=111.07μg/ml,Not available,Patent
DCTPep06044,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=51.50μg/ml,Not available,Patent
DCTPep06046,HepG2,Hepatoblastoma,Blastoma,CCK-8 assay,IC50=54.19μg/ml,Not available,Patent
DCTPep06047,NCI-H460,Lung large cell carcinoma,Carcinoma,CCK-8 assay,Survival rate=60% ,24h,Patent
DCTPep06064,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,20% Survival=20μM,24h,Patent
DCTPep06065,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,60% Survival=20μM,24h,Patent
DCTPep06066,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,60% Survival=20μM,24h,Patent
DCTPep06067,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,70% Survival=20μM,24h,Patent
DCTPep06112,NCI-H526,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=10μM,24h,Patent
DCTPep06113,NCI-H524,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=9μM,24h,Patent
DCTPep06114,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50=14μM,24h,Patent
DCTPep06114,GBM-18,Glioblastoma,Blastoma,MTT assay,EC50=4μM,24h,Patent
DCTPep06114,GBM-27,Glioblastoma,Blastoma,MTT assay,EC50=5μM,24h,Patent
DCTPep06114,NCI-H69,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7μM,24h,Patent
DCTPep06114,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=9μM,24h,Patent
DCTPep06115,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06115,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06115,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06116,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=2.5μM,24h,Patent
DCTPep06116,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06116,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06116,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06117,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=2.5μM,24h,Patent
DCTPep06117,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06117,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06117,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06118,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06118,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06118,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06118,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06119,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=2.5μM,24h,Patent
DCTPep06119,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06119,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06119,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06120,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=12.5μM,24h,Patent
DCTPep06120,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06120,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06120,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06121,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=12.5μM,24h,Patent
DCTPep06122,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=12.5μM,24h,Patent
DCTPep06122,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06122,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06122,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC507.5μM,24h,Patent
DCTPep06123,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06123,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06123,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC507.5μM,24h,Patent
DCTPep06123,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC507.5μM,24h,Patent
DCTPep06124,H-5B,Lung cancer,Carcinoma,MTT assay,EC50=2.5μM,24h,Patent
DCTPep06124,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06124,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06124,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μM,24h,Patent
DCTPep06156,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50=5μm,24h,Patent
DCTPep06156,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50=6μm,24h,Patent
DCTPep06156,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100μm,24h,Patent
DCTPep06156,U266,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50>100μm,24h,Patent
DCTPep06157,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50=10μm,24h,Patent
DCTPep06157,U266,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50=10μm,24h,Patent
DCTPep06157,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50=7μm,24h,Patent
DCTPep06157,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50=9μm,24h,Patent
DCTPep06158,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50=7μm,24h,Patent
DCTPep06158,U266,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50=8μm,24h,Patent
DCTPep06158,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100μm,24h,Patent
DCTPep06158,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100μm,24h,Patent
DCTPep06159,U266,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50=10μm,24h,Patent
DCTPep06159,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50=15μm,24h,Patent
DCTPep06159,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100μm,24h,Patent
DCTPep06159,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100μm,24h,Patent
DCTPep06160,RPMI,Human multiple myeloma,Carcinoma,MTT assay,EC50=10μm,24h,Patent
DCTPep06160,U266,Plasma cell myeloma; Multiple myeloma,Carcinoma,MTT assay,EC50=16μm,24h,Patent
DCTPep06160,HL-60,Adult acute myeloid leukemia; Acute myeloid leukemia,Leukemia,MTT assay,EC50>100μm,24h,Patent
DCTPep06160,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,EC50>100μm,24h,Patent
DCTPep06161,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=12.5μm,24h,Patent
DCTPep06161,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=22.5μm,24h,Patent
DCTPep06161,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=22.5μm,24h,Patent
DCTPep06162,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=15μm,24h,Patent
DCTPep06162,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=22.5μm,24h,Patent
DCTPep06162,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μm,24h,Patent
DCTPep06163,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=15μm,24h,Patent
DCTPep06163,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=22.5μm,24h,Patent
DCTPep06163,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=5μm,24h,Patent
DCTPep06164,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=12.5μm,24h,Patent
DCTPep06164,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50>30μm,24h,Patent
DCTPep06164,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50>30μm,24h,Patent
DCTPep06165,NCI-H187,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=10μm,24h,Patent
DCTPep06165,NCI-H510A,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=12.5μm,24h,Patent
DCTPep06165,NCI-H82,Lung small cell carcinoma; Small cell lung cancer,Carcinoma,MTT assay,EC50=7.5μm,24h,Patent
DCTPep06828,HeLa,Human papillomavirus-related endocervical adenocarcinoma,Carcinoma,MTT assay,65% Inhibition=100μg/ml,24h,1
DCTPep06829,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=29.06μM,48h,1
DCTPep06829,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=35.34μM,24h,1
DCTPep06831,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=11.53µg/mL,48h,1
DCTPep06831,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=15.73µg/mL,48h,1
DCTPep06831,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,IC50=17.84µg/mL,48h,1
DCTPep06831,A375,Amelanotic Amelanotic melanoma,Carcinoma,MTT assay,IC50=69.87µg/mL,48h,1
DCTPep06832,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.92µg/mL,48h,1
DCTPep06832,HEp-2,Human papillomavirus-related endocervical adenocarcinoma ,Carcinoma,MTT assay,IC50=11.38µg/mL,48h,1
DCTPep06832,MCF-7 ,Invasive breast carcinoma of no special type,Carcinoma,MTT assay,IC50=38.53µg/mL,48h,1
DCTPep06832,A375,Amelanotic Amelanotic melanoma,Carcinoma,MTT assay,IC50=91.28µg/mL,48h,1
DCTPep06833,HepG2,Hepatoblastoma,Blastoma,MTT assay,10% viability=75μM,48h,1
DCTPep06834,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=175µg/mL,24h,1
DCTPep06835,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=41µg/mL,24h,1
DCTPep06836,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=115µg/mL,24h,1
DCTPep06837,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=10µg/mL,24h,1
DCTPep06838,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=15µg/mL,24h,1
DCTPep06839,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=14µg/mL,24h,1
DCTPep06840,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=12µg/mL,24h,1
DCTPep06841,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=25µg/mL,24h,1
DCTPep06842,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=44µg/mL,24h,1
DCTPep06843,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=10µg/mL,24h,1
DCTPep06844,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=25µg/mL,24h,1
DCTPep06845,C26,Murine colon carcinoma,Carcinoma,MTT assay,IC50=22µg/mL,24h,1
DCTPep06874,H838,Human non-small cell lung cancer cells,Carcinoma,MTT assay,IC50=32.15µM,24h,1
DCTPep06874,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=33.46µM,24h,1
DCTPep06874,U251MG,Human glioblastoma/astrocytoma cancer cells,Blastoma,MTT assay,IC50=33.56µM,24h,1
DCTPep06875,U251MG,Human glioblastoma/astrocytoma cancer cells,Blastoma,MTT assay,IC50=3.86µM,24h,1
DCTPep06875,PC-3,Prostate carcinoma,Carcinoma,MTT assay,IC50=4.283µM,24h,1
DCTPep06875,H838,Human non-small cell lung cancer cells,Carcinoma,MTT assay,IC50=5.15µM,24h,1
DCTPep06876,MDA361,Human breast cancer,Carcinoma,MTT assay,IC50=6.4µM,24h,1
DCTPep06876,A549,Human lung cancer,Carcinoma,MTT assay,IC50=7.1µM,24h,1
DCTPep06877,H358 ,Minimally invasive lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=34nM,1h,1
DCTPep06877,H1993 ,Lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=37nM,1h,1
DCTPep06877,H1299,Lung large cell carcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=38nM,1h,1
DCTPep06877,H2009 ,Lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=38nM,1h,1
DCTPep06878,H358 ,Minimally invasive lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=3.9nM,1h,1
DCTPep06878,H1993 ,Lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=4nM,1h,1
DCTPep06878,H1299,Lung large cell carcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=5.8nM,1h,1
DCTPep06878,H2009 ,Lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=6.8nM,1h,1
DCTPep06879,H1993 ,Lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=1.5nM,1h,1
DCTPep06879,H1299,Lung large cell carcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=2.5nM,1h,1
DCTPep06879,H2009 ,Lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=3.4nM,1h,1
DCTPep06879,H358 ,Minimally invasive lung adenocarcinoma,Carcinoma,Streptavidin-R-phycoerythrin or streptavidin-Alexa Fluor 647,EC50=3.5nM,1h,1
DCTPep06880,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,55.3 ± 2.7% cell viability=200µM,24h,1
DCTPep06880,A549 ,Lung adenocarcinoma,Carcinoma,MTT assay,59.7 ± 1.1% cell viability=200µM,24h,1
DCTPep06881,SNU449,Adult hepatocellular carcinoma,Carcinoma,MTT assay,4.8% viability=162 μM,24h,1
DCTPep06881,SNU449,Adult hepatocellular carcinoma,Carcinoma,MTT assay,52.8% viability=71 μM,24h,1
DCTPep06882,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=11.44µM,24h,1
DCTPep06882,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=12.47µM,24h,1
DCTPep06882,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=13.93µM,24h,1
DCTPep06883,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=105.5µM,24h,1
DCTPep06883,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=54.74µM,24h,1
DCTPep06883,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=57.82µM,24h,1
DCTPep06884,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=229.8µM,24h,1
DCTPep06884,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=52.98µM,24h,1
DCTPep06884,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=54.08µM,24h,1
DCTPep06885,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=2.75µM,24h,1
DCTPep06885,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=2.8µM,24h,1
DCTPep06885,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=5.04µM,24h,1
DCTPep06886,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=11.75µM,24h,1
DCTPep06886,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=8.23µM,24h,1
DCTPep06886,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=9.25µM,24h,1
DCTPep06887,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=11.83µM,24h,1
DCTPep06887,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=12.77µM,24h,1
DCTPep06887,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=12.93µM,24h,1
DCTPep06888,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=5.86µM,24h,1
DCTPep06888,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=6.27µM,24h,1
DCTPep06888,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=6.58µM,24h,1
DCTPep06889,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=10.55µM,24h,1
DCTPep06889,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=13.58µM,24h,1
DCTPep06889,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=14.31µM,24h,1
DCTPep06890,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=13.39µM,24h,1
DCTPep06890,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=15.58µM,24h,1
DCTPep06890,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=15.67µM,24h,1
DCTPep06891,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=7.94µM,24h,1
DCTPep06891,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=8.42µM,24h,1
DCTPep06891,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=8.68µM,24h,1
DCTPep06892,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=10.65µM,24h,1
DCTPep06892,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=11µM,24h,1
DCTPep06892,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=8.34µM,24h,1
DCTPep06893,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=114.2µM,24h,1
DCTPep06893,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=25.89µM,24h,1
DCTPep06893,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=32.06µM,24h,1
DCTPep06894,HCT 116,Colon carcinoma,Carcinoma,CCK-8 assay,IC50=7.44µM,24h,1
DCTPep06894,MCF-7,Invasive breast carcinoma of no special type,Carcinoma,CCK-8 assay,IC50=7.47µM,24h,1
DCTPep06894,U-87MG ATCC,Glioblastoma,Blastoma,CCK-8 assay,IC50=9.2µM,24h,1
DCTPep03656,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.66 ± 0.0007 μg/mL,24 h,1
DCTPep03729,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=8.76 ± 0.0035 μg/mL,24 h,1
DCTPep04589,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.77 ± 0.0007 μg/mL,24 h,1
DCTPep04590,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.53 ± 0.0014 μg/mL,24 h,1
DCTPep04591,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=8.99 ± 0.0014 μg/mL,24 h,1
DCTPep04592,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.98 ± 0.0014 μg/mL,24 h,1
DCTPep04593,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.6 ± 0.0007 μg/mL,24 h,1
DCTPep04594,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.35 ± 0.0014 μg/mL,24 h,1
DCTPep04595,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.33 ± 0.0007 μg/mL,24 h,1
DCTPep04596,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.5 ± 0.0014 μg/mL,24 h,1
DCTPep04597,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.56 ± 0.0021 μg/mL,24 h,1
DCTPep04598,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=11.32 ± 0.0014 μg/mL,24 h,1
DCTPep04599,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.26 ± 0.0028 μg/mL,24 h,1
DCTPep04600,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.67 ± 0.0007 μg/mL,24 h,1
DCTPep04601,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.44 ± 0 μg/mL,24 h,1
DCTPep04602,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=11.1 ± 0.0007 μg/mL,24 h,1
DCTPep04603,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.33 ± 0.0007 μg/mL,24 h,1
DCTPep04604,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.33 ± 0.0007 μg/mL,24 h,1
DCTPep04605,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.18 ± 0.0014 μg/mL,24 h,1
DCTPep06895,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.2 ± 0.0007 μg/mL,24 h,1
DCTPep06896,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.4 ± 0.0014 μg/mL,24 h,1
DCTPep06897,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.5 ± 0.0056 μg/mL,24 h,1
DCTPep06898,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.77 ± 0.0007 μg/mL,24 h,1
DCTPep06899,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.45 ± 0.0056 μg/mL,24 h,1
DCTPep06900,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=17.34 ± 0.0014 μg/mL,24 h,1
DCTPep06901,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.21 ± 0.0056 μg/mL,24 h,1
DCTPep06902,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.12 ± 0.0007 μg/mL,24 h,1
DCTPep06903,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.67 ± 0 μg/mL,24 h,1
DCTPep06904,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.28 ± 0 μg/mL,24 h,1
DCTPep06905,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.36 ± 0 μg/mL,24 h,1
DCTPep06906,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=12.37 ± 0.0014 μg/mL,24 h,1
DCTPep06907,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.44 ± 0.0014 μg/mL,24 h,1
DCTPep06908,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.46 ± 0.0028 μg/mL,24 h,1
DCTPep06909,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.33 ± 0 μg/mL,24 h,1
DCTPep06910,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=12.1 ± 0.0007 μg/mL,24 h,1
DCTPep06911,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.4 ± 0.0014 μg/mL,24 h,1
DCTPep06912,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=9.68 ± 0.0014 μg/mL,24 h,1
DCTPep06913,HepG2,Hepatoblastoma,Blastoma,MTT assay,IC50=10.45 ± 0.0042 μg/mL,24 h,1
DCTPep03656,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.45 ± 0.0042 μg/mL,24 h,1
DCTPep03729,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.33 ± 0 μg/mL,24 h,1
DCTPep04589,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.4 ± 0 μg/mL,24 h,1
DCTPep04590,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.78 ± 0.0021 μg/mL,24 h,1
DCTPep04591,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.97 ± 0.0049 μg/mL,24 h,1
DCTPep04592,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.31 ± 0.0063 μg/mL,24 h,1
DCTPep04593,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.78 ± 0.0212 μg/mL,24 h,1
DCTPep04594,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.88 ± 0.0014 μg/mL,24 h,1
DCTPep04595,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.44 ± 0.5536 μg/mL,24 h,1
DCTPep04596,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.5 ± 0.0007 μg/mL,24 h,1
DCTPep04597,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.67 ± 0.0014 μg/mL,24 h,1
DCTPep04598,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=14.2 ± 0.0014 μg/mL,24 h,1
DCTPep04599,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=17.2 ± 0.0014 μg/mL,24 h,1
DCTPep04600,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.12 ± 0.0042 μg/mL,24 h,1
DCTPep04601,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.55 ± 0.0989 μg/mL,24 h,1
DCTPep04602,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.11 ± 0.0056 μg/mL,24 h,1
DCTPep04603,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.33 ± 0.0035 μg/mL,24 h,1
DCTPep04604,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.2 ± 0.0014 μg/mL,24 h,1
DCTPep04605,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.61 ± 0.0007 μg/mL,24 h,1
DCTPep06895,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.4 ± 0.0028 μg/mL,24 h,1
DCTPep06896,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.09 ± 0.0014 μg/mL,24 h,1
DCTPep06897,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.28 ± 0.0063 μg/mL,24 h,1
DCTPep06898,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.33 ± 0.0035 μg/mL,24 h,1
DCTPep06899,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.98 ± 0.4256 μg/mL,24 h,1
DCTPep06900,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.2 ± 0.0021 μg/mL,24 h,1
DCTPep06901,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.11 ± 0.0035 μg/mL,24 h,1
DCTPep06902,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=12.67 ± 0.0028 μg/mL,24 h,1
DCTPep06903,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.7 ± 0.0056 μg/mL,24 h,1
DCTPep06904,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.56 ± 0.0028 μg/mL,24 h,1
DCTPep06905,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.61 ± 0.0007 μg/mL,24 h,1
DCTPep06906,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=13.2 ± 0 μg/mL,24 h,1
DCTPep06907,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.08 ± 0.0007 μg/mL,24 h,1
DCTPep06908,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.92 ± 0.0021 μg/mL,24 h,1
DCTPep06909,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.23 ± 0.0007 μg/mL,24 h,1
DCTPep06910,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=10.4 ± 0.0028 μg/mL,24 h,1
DCTPep06911,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.2 ± 0.0007 μg/mL,24 h,1
DCTPep06912,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=9.06 ± 0.0014 μg/mL,24 h,1
DCTPep06913,HT-29,Colon adenocarcinoma,Carcinoma,MTT assay,IC50=11.87 ± 0.0021 μg/mL,24 h,1
